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SUMMARY 
In recent years, various modelling approaches in systems biology have been applied for 
the study and analysis of signal transduction networks. However, each modelling 
approach has its inherent advantages and disadvantages, so the choice has to be made 
based on research objectives and types of data. In this PhD dissertation, we propose 
probabilistic Boolean network (PBN) as one of the suitable modelling approaches for 
studying signal transduction networks with steady-state data. The steady-state distribution 
of molecular states in PBN can be correlated to the steady-state proteomic profiles 
generated from wet-lab experiments. In addition, the relevance of interactions within 
signalling networks can be assessed through the optimised selection probabilities. These 
features make PBNs ideal for describing the properties of signal transduction networks at 
steady-state with some uncertainty on network topologies. 
 
To investigate the applicability of PBNs for the study of signal transduction networks, we 
developed optPBN, an optimisation and analysis toolbox in the PBN framework. We 
demonstrated that optPBN can be applied to optimise a large-scale apoptotic network with 
96 nodes and 105 interactions. Also, it allows for network contextualisation in a 
physiological context of primary hepatocytes through the analysis on optimised selection 
probabilities. Similarly, we also applied optPBN to study deregulated signal transduction 
networks in pathological contexts, i.e. the PDGF signalling in gastrointestinal stromal 
tumour (GIST) and the L-plastin signalling in breast cancer cell lines. By integrating prior 
information on network topology from literature with context-specific experimental data, 
contextualised PBNs can be derived which in turn provide additional insights into 
biological systems such as the importance of certain crosstalk interactions and the 
comparative signal flows at steady-state in non-metastatic versus metastatic cancer           
cell lines. 
 
In addition to the applications on fundamental research, we also explored the applications 
of PBNs in a pharmaceutical setting where detailed mechanistic models are usually used. 
Here, we applied optPBN as a tool for network contextualisation. A proof-of-concept 
example on a small model demonstrated that optPBN helped to pre-select the suitable 
network structure according to the provided experimental data prior to the building and 
optimisation of detailed mechanistic models. Such application is foreseen to be applied in 
a pharmaceutical setting and to explore additional applications such as combinatorial 
drugs’ effect and toxicity screening. 
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Chapter 1 
INTRODUCTION 
1.1. Cellular signal transduction networks 
 The cell is a basic building block of life. Higher-level complex organisations among 
different types of cells lead to the formation of tissues and organs with specialised 
functions that work systematically to maintain the well-being of an organism. On another 
view, complex and diverse regulatory mechanisms within the cells also operate on 
multiple cellular components in an orchestrated fashion to preserve the proper 
functionalities and integrity of each cell. 
 
 In eukaryotes, from yeast to human, multi-level cellular organisations and 
regulations have been established and they are well-conserved through evolution. To 
shortly recall on the information processing between cellular components within central 
dogma of molecular biology, the functional genetic components in deoxyribonucleic acid 
(DNA) are transcribed into messenger ribonucleic acid (mRNA) which are subsequently 
translated into proteins in diverse forms including structural proteins, transcription factors, 
signalling proteins and enzymes (Crick, 1970). Each form of these protein has designated 
functions, i.e. providing structural support and protect the cells from external environment, 
binding to DNA and regulating transcription, transducing signals from internal and external 
cues to regulate cellular phenotypes, and catalysing biochemical reactions within the cell, 
respectively. These diverse effector units are built to supply the need of cells to survive 
and to undergo through particular cellular events such as cell division or apoptosis 
according to the incoming changes and perturbations in the environment. 
 
Among the information transfer within central dogma, it is noteworthy that each 
step is governed by multiple regulatory processes. This includes epigenetic regulations 
such as chromatin remodelling or DNA methylation, regulation of transcription machinery 
by various transcription factors, post-transcriptional regulation, e.g. by endogenous 
microRNAs (miRs), and post-translational modifications of proteins such as 
phosphorylation or glycosylation. Such regulatory processes modulate and contextualise 
the information from the genome to create diversified cellular units with specialised 
properties that function on particular biochemical reactions. Over decades, these 
regulatory mechanisms were increasingly studied as networks, which depict the 
interactions or relationships between cellular components. Some of the most well-studied 
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cellular networks are gene regulatory networks which represent the interactions among 
genes within genomes, metabolic networks which illustrate the pathways of biochemical 
reactions of metabolites, and signal transduction networks where the information 
processing between signalling molecules are rendered (Ryll et al., 2014). 
 
 The signal transduction network is one of the core functional layers in a cell. Upon 
perturbations, it is the first system which receives and integrates information from internal 
and external stimuli before passing them to various effectors such as transcription factors 
and metabolic enzymes to further regulate other functional layers including gene 
regulatory and metabolic networks. In terms of organisation, a signal transduction network 
comprises multiple cascades of signalling molecules which are classified into several 
intracellular signalling pathways. Some of the major intracellular signalling pathways are 
for instance mitogen-activated protein kinases (MAPK), phosphoinositide-3-kinases 
(PI3K)/AKT (a.k.a. protein kinase B, PKB)/mammalian target of rapamycin (mTOR), 
phospholipase C gamma/protein kinase C (PLCγ/PKC), Janus kinase and signal 
transducer and activator of transcription (JAK/STAT) and Caspase pathways (Bos, 2000). 
Each of these pathways supports various cellular functions such as promoting 
proliferation, differentiation, senescence, or activating apoptotic machinery depending on 
the cell types. 
  
 In a physiological state, signal transduction networks maintain an optimal signal 
flow towards effector units. Multiple cues from stimuli such as growth and death factors, 
cytokines, hormones, and cell-to-cell contacts are sensed by the corresponding receptors 
including receptor tyrosine kinases (RTKs), cytokine receptors, transmembrane and 
hormonal receptors, as well as integrins and E-cadherins which in turn pass the signals 
towards intracellular signalling pathways. The most common route to transduce signals is 
mediated via the phosphorylation and dephosphorylation of signalling molecules by kinase 
and phosphatase enzymes. To modulate the signals within the signal transduction 
processes, a large number of natural regulatory mechanisms are taking place such as the 
dephosphorylation by cytoplasmic phosphatases or by target-specific phosphatase 
enzymes, e.g. phosphatidylinositol-3,4,5-triphosphate 3-phosphatase (PTEN), 
proteosomal degradation following ubiquitination, and the formation of inactive protein 
complexes, e.g. inhibitor of kappa B (IκB) and nuclear factor kappa B (NFκB) complex. 
Apart from these regulatory mechanisms, increasing evidence in literature also reports the 
importance of regulatory effects from crosstalk interactions between intracellular signalling 
pathways (Su, Mei, & Sinha, 2013; Xia & Storm, 2012). It was shown that crosstalk 
interactions play a major role in the fine-tuning of signals and they are also involved in the 
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compensatory mechanism once the signal flows within the canonical pathways are 
disturbed (Mendoza, Er, & Blenis, 2011). 
 
 Generally, the regulatory and compensatory mechanisms are able to cope with 
small and transient perturbations within signal transduction network. However, for certain 
perturbations, e.g. the mutations of key signalling molecules such as Ras in MAPK 
pathway or PTEN in PI3K/AKT/mTOR pathway, the signal flows are deregulated and 
inappropriate signals were transduced to the effector units which in turn leads to 
pathological phenotypes of cells. The abnormality in cellular phenotypes subsequently 
serves as the etiology in many types of diseases including neurodegenerative diseases, 
metabolic diseases as well as cancers (E. K. Kim & Choi, 2010; Lawrence et al., 2008). 
 
1.2. Deregulation of signalling pathways in cancers 
 Cancer is one of the major causes of death in human worldwide since decades 
(Jemal et al., 2011). It is often characterised by the over-proliferation of cancerous cells 
which invade tissues and cause the failure of homeostatic regulation in the human body. 
To date, there is no simple treatment which can eradicate all types of cancer due to the 
high complexity of cellular and tissue organisations within tumours. Thus, a deeper and 
more comprehensive understanding in the field of cancer research is required to decipher 
the pathogenesis of cancers and to develop more advanced therapeutic treatments. 
 
In 2000, Hanahan and Weinberg introduced six hallmarks of cancers which hold 
true still today (Hanahan & Weinberg, 2000). These hallmarks, which are considered to be 
the common phenotypes in almost all types of cancers, include self-sufficiency in growth 
signals, insensitivity to anti-growth signals, limitless replication potency, evasion of 
apoptosis, sustained angiogenesis, and tissue invasion and metastasis. Interestingly, the 
molecular mechanisms which give rise to the six cancerous phenotypes can be explained 
by the deregulation of normal physiology in signal transduction networks. A few examples 
are as follows: the independence of growth signals for cell proliferation can be due to the 
over-expression of receptor tyrosine kinases, the reduction of apoptotic machinery can be 
caused by the up-regulation of anti-apoptotic oncogenes such as bcl-2, and the changes 
in integrin and E-cadherin expressions could lead to more invasive cellular phenotypes. 
From this perspective, it was proposed that the deregulation of signal transduction 
networks is the central mechanism that drives carcinogenic transformation. The integrated 
circuit of signal transduction networks comprising multiple intracellular signalling cascades 
are depicted in Figure 1. 
4 | P a g e   Chapter 1: Introduction 
 
Changes  
in gene 
expression 
Cell 
proliferation 
(Cell Cycle) 
Cell death 
(Apoptosis) PI3K AKT 
PKC 
RTKs 
7-TMR 
RTKs 
Integrins 
E-cadherin 
Frizzled 
TGFβR 
Fas 
Decoy R 
Cytokine R 
Akkα 
NF-kB NF-kB 
JAKs 
STATs 
STATs 
Bcl-XL 
IkB 
PTEN 
Bad Mitochondria 
Abnormality 
sensor Bim, etc 
Bid 
Bcl-2 
Cytochrome C 
Caspase 9 
Caspase 8 
Death 
factors 
Bax 
FADD 
FAP 
ARF MDM2 
TP53 
p21 
DNA damage 
sensor 
Cyclin E 
p27 
p15 
p16 
Cyclin D 
RB 
E2F 
HPV-E7 
Smads 
Disheveled 
GSK-3β 
APC 
ProteaseR 
β-catenin 
β-catenin: 
TCF4 
TCF4 
Growth 
factors 
Proliferation 
Circuits 
Motility Circuits 
Viability Circuits 
Cytostasis and 
differentiation 
Circuits 
Proteases 
Adjacent 
cells 
Extracellular 
matrix 
Hormones 
G-Prot Ad-Cycl PKA CREB 
Grb2
SOS 
Mos 
MEK MAPK MAPK ELK Fos 
MEKK 
MKKs JNKs Jun 
CdC42 Rac Rho 
Myc 
Mad 
Abl 
Fyn
Shc NF1 
Ras 
FAK
Src Cas Crk 
CdC42 PI3K Rac 
WNT 
HormoneR 
Activation 
Legend: 
Inhibition 
Anti-
growth 
factors 
Cytokines  
Figure 1. Integrated circuit of a cellular signal transduction network. Multiple intracellular 
signalling cascades were depicted together with the points of signal integration via 
crosstalk interactions. Adapted from (Hanahan & Weinberg, 2000) under licensing number 
3585911018186 and (Hanahan & Weinberg, 2011). 
 
Since the hallmarks of cancer were established, the body of cancer research 
based on this conceptual work was largely expanded over the last decade. In 2011, two 
new cancer hallmarks which are deregulating cellular energetics and avoiding immune 
destruction together with two enabling characteristics which are tumour-promoting 
inflammation and genome instability and mutations were additionally proposed to 
participate along the carcinogenic progression of cancer cells (Hanahan & Weinberg, 
2011). It was shown that the reprogramming of glucose metabolism via aerobic glycolysis 
(Warburg, 1956) could divert glycolytic intermediates towards other biosynthetic pathways 
(Vander Heiden, Cantley, & Thompson, 2009) and the by-product lactate can also be re-
utilised within the lactic cycle (Feron, 2009). In addition, the role of innate immune system-
driven inflammation during tumour progression (DeNardo, Andreu, & Coussens, 2010) 
and the mechanistic details of epithelial-mesenchymal transition (EMT) mediated by a set 
of transcription factors, e.g. Snail, Slug, Twist, and Zeb1/2 (Klymkowsky & Savagner, 
2009) were also illustrated. These advances on identifying additional cancer etiology 
opened up a new possibility for discovering novel cancer therapeutic treatments such as 
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metabolic and immunological therapies which were not concretely focused for treating 
malignancies in the past. 
 
Apart from investigating the molecular transformations of normal cells into cancer 
cells as a basis to understand carcinogenesis progression, the focus on the tumour 
microenvironment was also recently emphasised as an important rudimentary unit which 
allows cancer cells to survive and to further spread to adjacent and distant tissues 
(Egeblad, Nakasone, & Werb, 2010). The composition of each tumour microenvironment 
generally comprises cancerous cells together with supporting structures such as cancer-
associates fibroblasts, vascular endothelium, pericytes, inflammatory immune cells as well 
as cancer stem cells. These cells elicit a heterotypic signalling among different cell types 
to foster their local expansion and invasiveness. In parallel, they also establish a 
reciprocal interaction with surrounding supporting structures such as stromal reservoirs to 
exploit the source of nutrients before moving to a distant site. In a causal view, the 
deregulation of signalling pathways was shown to be one of the principal contributors to 
the formation of the tumour environment (Hanahan & Weinberg, 2011). For instance, 
cancer cells up-regulate the expression of vascular endothelial growth factor (VEGF) and 
its receptors to promote the proliferation of endothelial cells and angiogenesis (Ferrara & 
Davis-Smyth, 1997). Another example is an over-expressed platelet-derived growth factor 
(PDGF) and its receptors mediated by tumour cells leading to the recruitment of 
mesenchymal cells such as fibroblasts to tumour sites which in turn secrete hepatocyte 
growth factor (HGF) in order to promote tumour metastasis (Hanahan & Weinberg, 2011). 
At the molecular level, these growth factors serve as ligands for RTKs which activate 
downstream signalling cascades to transform cellular phenotypes in favour of malignancy. 
Such line of arguments additionally highlights the importance of deregulated signal 
transduction networks, both at the levels of receptors and downstream intracellular 
signalling pathways, which largely contribute to cancer advancement. 
 
To further illustrate the role of major intracellular signalling pathways and their 
contributions to cancer pathogenesis as summarised in Figure 1, I shortly review the 
components and their roles in cancer signalling in the scope of this dissertation as follows: 
 
 1.2.1. Mitogen-activated protein kinases (MAPK) pathway family 
 The MAPK pathway comprises a cascade of three or more protein kinases which 
are MAPK kinase kinases (MAP3Ks), MAPK kinases (MAP2Ks) and MAPKs. The series 
of molecular activation are modulated by phosphorylation on serine, threonine and 
tyrosine residues. The mammalian MAPK family consists of 3 downstream effectors which 
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are extracellular signal-regulated kinase (ERK), p38 and c-Jun NH2-terminal kinase (JNK) 
which exist in several forms, i.e. ERK1 to ERK8, p38-α, -β, -γ, -δ, and JNK1 to JNK3. The 
activation within the MAPK pathway are moderated by either one-to-one interaction 
between kinase components or by the guidance of scaffold proteins, e.g. kinase 
suppressor of Ras-1 (KSR), JNK-interacting protein (JIPs) and β-Arrestin (E. K. Kim & 
Choi, 2010). 
 
 On signal processing, the three different MAPK pathways respond to different 
stimuli with a designated set of molecular players. The JNK pathway responses to cellular 
stress and inflammatory cytokines by activating apoptosis signal-regulating kinase 1 
(ASK1) or transforming growth factor-β-activated kinase 1 (TAK1) which pass the signals 
towards mitogen-activated protein kinase kinase (MKK) 6 and MKK3 that in turn trigger 
JNK activity. In parallel, the p38 pathway responds to the same set of stimuli as JNK 
pathway and it shares the activation on ASK1 and TAK1 downstream. However, this 
pathway further activates another set of MKK which are MKK4 and MKK7 before eliciting 
the function of p38. Lastly, the ERK pathway, which is usually activated in response to the 
activation of the RTK-Growth factor receptor bound protein 2 (Grb2)-Son of Sevenless 
(SOS) cascade via the members of the Ras family proteins including K-Ras, H-Ras and 
N-Ras, processes the information through Raf isoforms such as A-Raf, B-Raf or C-Raf 
(Raf-1), MEK1/2 (MKK1/2) and ERK1/2 successively. Subsequently, the activated MAPKs 
from each pathway phosphorylate various substrates proteins such as ELK-1, activating 
transcription factor 2 (ATF2) and TP53 (E. K. Kim & Choi, 2010; Lawrence et al., 2008). 
 
 Physiologically, each MAPK pathway is optimally triggered to maintain proper 
functions in response to corresponding stimuli while pathologic deregulation of MAPK 
pathways leads to the destabilisation of homeostatic regulation that eventually results in 
disease. The alterations in MAPK signalling cascades were shown to be the cause of 
multiple diseases including neurodegenerative diseases such as Alzheimer’s disease and 
Parkinson’s disease, chronic and genetic diseases such as Crohn’s disease and 
polycystic kidney disease, and also many types of cancers (E. K. Kim & Choi, 2010). Even 
though it was shown that the anomalies in JNK and p38 pathways are also the etiology of 
many diseases, only the aberration in ERK pathway, on which we will further focus in this 
dissertation, was clearly demonstrated to be the promotor of carcinogenesis (see Fig. 1). 
 
 Among the evidence from literature in early years of cancer research, ERK1/2 
activity was identified as a crucial contributor to the pathogenesis of cancers (Land, 
Parada, & Weinberg, 1983). Cancer-associated mutations of the components in ERK 
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pathway, especially of Ras and Raf, often up-regulate signal flows in this pathway and 
facilitate the cells to obtain cancerous phenotypes. For instance, the mutations of K-Ras 
were often found in many human cancers such as lung and colon cancers (Schubbert, 
Shannon, & Bollag, 2007) while the mutations of B-Raf gene were discovered in more 
than half of malignant melanomas (Calcagno et al., 2008). Looking at the hallmarks of 
cancer at molecular level, it was shown that the ERK pathway plays a major role in many 
steps of tumour development. The key role of this pathway is to transduce growth signals 
from RTKs into the cells in order to initiate cellular proliferation. Hence, the abnormality of 
upstream signalling components, such as the over-expression of ligands and RTKs, also 
contributes to the clonal expansion of cancer cells as well as their supporting structures 
(Hynes & MacDonald, 2009). In addition, the ERK pathway was also found to contribute to 
other cancer hallmarks such as increasing cell invasion by inducing the expression of 
matrix metalloproteinases (Chakraborti, Mandal, & Das, 2003) and promoting survival of 
cancer cells by regulating the activities of Bcl-2 family proteins (Balmanno & Cook, 2009). 
Given the broad role of the ERK pathway in different stages of carcinogenesis, it has been 
now one of the most targeted signalling pathways for the treatment of cancers. 
 
 1.2.2. PI3K/AKT/mTOR pathway 
 The PI3K/AKT/mTOR pathway is highly conserved in mammalian signalling 
networks and its activation is tightly controlled in multiple steps. Class-I PI3Ks are 
heterodimers composed of two subunits, a catalytic subunit (p110) and a regulatory 
subunit (p85). The Class-I PI3Ks are also classified into subclasses, i.e. subclass IA which 
interacts with RTKs and subclass IB which is activated by receptors coupled with G-
protein. Upon the activation of these receptors, the p85 subunit of PI3K binds to the 
receptor by recognising the phospho-tyrosine residue on the receptors with SH2 domain 
and activates the enzymatic activity of the p110 subunit which in turn converts 
phosphatidylinositol (3,4)-bis-phosphate (PIP2) into phosphatidylinositol (3,4,5)-tris-
phosphate (PIP3) on cell membrane. Active PIP3 at the cell membrane then recruits AKT 
to bind, allowing 3-phosphoinositide-dependent protein kinase 1 (PDK1) to access and 
phosphorylate threonine 308 (T308) residue of AKT which leads to partial AKT activation. 
Subsequently, partially activated AKT activates the mTOR complex 1/2 (mTORC1/2) and 
inhibits tuberous sclerosis protein 2 (TSC2) which inhibits the activity of mTORC1/2. The 
unleashed mTORC1/2 then reciprocally phosphorylates the second regulatory 
phosphorylation site serine 473 (S473) on the C-terminal tail of AKT which leads to the full 
activation of AKT activity. The activities of AKT can be counter-regulated by the 
dephosphorylation of T308 by protein phosphatase 2 (PP2A), the dephosphorylation of 
S473 by PH-domain leucine-rich-repeat-containing protein phosphatases (PHLPP1/2), 
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and the reconversion of PIP3 to PIP2 mediated by phosphatase and tensin homolog 
(PTEN).  (Fresno Vara et al., 2004; Hemmings & Restuccia, 2012) 
 
 Once the downstream signalling molecules of the PI3K/AKT/mTOR pathway, i.e. 
AKT and mTORC1/2 are fully activated via phosphorylation, they further interact with a 
large number of their downstream targets and regulate a variety of cellular functions (see 
Fig.1). To demonstrate some examples, AKT is involved in cell-death regulation by 
phosphorylating and inhibiting pro-apoptotic factor Bad and procaspase-9. In addition, it 
also activates an inhibitor of cyclic AMP response element-binding protein (CREB) and 
kappa-B kinase (IKK) in the NFκB pathway which results in the transcription of anti-
apoptotic genes. In parallel, it was shown that AKT also modulates cell cycle progression 
and cell growth by regulating the localisation of targeting proteins. For instance, Akt 
inhibits glycogen synthase kinase 3 (GSK3) by phosphorylation which in turn impedes the 
degradation of β-catenin. This results in the increase of β-catenin translocation into 
nucleus to bind transcription factors, e.g. TCF/LEF-1 to induce several genes that in turn 
induce cell cycle progression, e.g. cyclin-dependent kinase (CDK) 1 which inactivates 
retinoblastoma (RB) protein via hyperphosphorylation. In addition, AKT phosphorylates 
and inhibits the anti-proliferative proteins p21 and p27 by retaining them in the cytoplasm 
and it also facilitates nuclear translocation of Mouse double minute 2 homolog (Mdm2) to 
antagonise the effect of TP53 on cell cycle checkpoints. On the other path, the activated 
molecules downstream of the mTOR pathway further stimulate protein synthesis by 
phosphorylating p70 S6 kinase (p70S6K) and eIF4E binding proteins 1,2, and 3 (4E-BPs) 
where p70S6K increases translation of mRNAs via the phosphorylation of ribosomal 
protein S6 and 4E-BPs release the initiation factor eIF4E to promote translation of many 
proteins e.g. cyclin D1, Myc, and VEGF. (Altomare & Testa, 2005; Fresno Vara et al., 
2004). To summarize, both AKT and mTOR principally activate various cellular 
mechanisms to increase the total cell population.  
 
 In the pathological context, the deregulation of PI3K/AKT/mTOR pathway also 
leads to an abnormality in cellular phenotype which is the cause of multiple diseases such 
as metabolic diseases (Manning & Cantley, 2007) as well as cancers (Altomare & Testa, 
2005; Fresno Vara et al., 2004). As mentioned previously, both AKT and mTOR 
participate in the regulatory circuit of cell survival and cell cycle progression. Hence, this 
implies that both effector units could also promote cellular proliferation and evasion of 
apoptosis in cancerous cells. In addition, the by-products of mTOR, e.g. VEGF, also has 
an angiogenic effect which additionally reinforces the formation of tumours in local and 
distant sites. Based on the survey on prostate, breast and ovarian cancer, it was shown 
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that nearly 80% of tumours with activated AKT1 were high grade stage III/IV carcinomas 
(Sun et al., 2001) while 30-40% of pancreatic and ovarian cancers were found to have 
high activity of AKT2 (Altomare et al., 2005). In addition, the aberration of upstream 
signalling molecules of the PI3K/AKT/mTOR axis is also involved in multiple types of 
cancers. To name a few, the mutation of p110 subunit of PI3K was reported in ovarian 
carcinoma (Shayesteh et al., 1999) while the mutated gene that codes for the p85 
regulatory subunit of PI3K was also shown in a T-cell lymphoma cell line (Jucker et al., 
2002). The loss of PTEN function due to somatic mutation also elevates the signal flux in 
the PI3K/AKT/mTOR pathway via PIP3 elevation which occurs frequently in glioblastoma, 
melanoma and cancers of prostate and endometrium (Sansal & Sellers, 2004). Taken 
together, it appears that the deregulation of the PI3K/AKT/mTOR pathway also plays a 
central role in cancer progression by activating multiple cancer hallmarks. Hence, their 
components are worth to be further investigated together with the ones in the MAPK 
pathway to design more advanced targeted therapies. 
 
 1.2.3. PLCγ/PKC pathway  
 In mammalian cells, up to fourteen PLC-isozymes were characterised and 
classified into multiple subtypes (Hwang et al., 2005). Among them, one of the well-
studied isozymes is PLCγ-1 which has a strong implication in signal transduction. PLCγ-1 
has Src homology 2 and 3 (SH2 and SH3) domains, which interact with proteins via 
phosphotyrosine and proline-rich sequences, respectively. The classical signalling 
cascade of the PLCγ/PKC pathway starts from the interaction of extracellular signalling 
molecules such as hormone and growth factors with their receptors on cell surface which 
in turn triggers a rapid hydrolysis of membrane phospholipid PIP2 catalysed by PLCγ 
isozymes. The biochemical reaction leads to the generation of two intracellular 
messengers, diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) which further 
activate PKC and promote the release of calcium ion (Ca2+) from intracellular storage. The 
activated PKC and the gradient of increased Ca2+ concentration subsequently modulate 
the activities of signalling molecules which are the components of other intracellular 
signalling pathways with diverse functions (Choi, Ryu, & Suh, 2007; Putney, 2002). 
 
 The deregulation of the PLCγ/PKC pathway has been investigated for its potential 
role in promoting tumour formation and metastasis. In one study, PLCγ was shown to 
mediate together with epidermal growth factor receptor (EGFR) to promote tumour cell 
invasion in prostate cancer cell lines (Kassis et al., 1999). In other studies, it was shown 
that the expression level of PLCγ-1 is elevated in cancer tissues comparing to normal 
counterpart (Nanney et al., 1992) and it also plays an essential role in cellular proliferation 
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and anti-apoptosis in various cell types (M. J. Kim et al., 2000). Thus, the PLCγ/PKC 
pathway is one of the important intracellular signalling pathways with direct links to many 
hallmarks of cancers that needs to be considered and controlled in cancer treatment. 
 
 1.2.4. JAK/STAT pathway 
 The JAK/STAT pathway is known to be ubiquitous among vertebrates but it can 
also be found in other metazoans such as Drosophila (Hombría & Brown, 2002). In 
human, the JAK family consists of 4 cytoplasmic tyrosine kinases, i.e. JAK1-3 and Tyk2 
and 7 proteins were identified in the STAT family, i.e. STAT1-6 with STAT5a and STAT5b. 
Upon the activation of signalling receptors in response to extracellular growth factors and 
cytokines, multimerisations of receptor subunits are formed and lead to the activation of 
JAKs which are bound to receptors via phosphorylation. Subsequently, activated JAKs 
recruit, phosphorylate, and dimerise STATs which then translocate into nucleus to interact 
with various regulatory elements on the genome in order to modulate gene expression. 
The activities of STATs are controlled by negative regulators including tyrosine 
phosphatases such as SHP1/2, protein inhibitors of activated STATs (PIAS) and 
suppressors of cytokine signalling (SOCS) proteins (Furqan, Mukhi, Lee, & Liu, 2013; 
Rawlings, Rosler, & Harrison, 2004). 
 
 Various types of ligands such as erythropoietin (Epo), interleukin-6 (IL-6) and 
interferon-gamma (IFNγ) give rise to multiple combinations of JAK and STAT family 
activations (Schindler, 2002). The diversities of JAK/STAT organisation subsequently lead 
to complex regulations on multiple cellular functions including cell proliferation, 
differentiation, migration, and apoptosis (Rawlings et al., 2004). On disease pathology, the 
deregulation of JAK/STAT signalling was found to be the etiology for many types of 
haematological malignancies, such as leukaemia and lymphoma. Among the effector 
units, the anomaly of certain molecules, e.g. the constitutively active mutants of STAT3, 
has a key role in the regulation of proliferation as well as oncogenesis in several tissues 
(Levy & Lee, 2002). Such evidence inevitably points to the involvement of the JAK/STAT 
pathway in the cancerous signalling circuit. 
 
1.2.5. NFκB pathway 
 The NFκB pathway is one of the signalling cascades that is conserved through the 
evolution from Cnidaria to humans (Sullivan, Kalaitzidis, Gilmore, & Finnerty, 2007). In 
total, five members of NFκB family, which serve as transcription factors, were identified 
including RelA (p65), RelB, c-Rel, NFκB1 (p105) and NFκB2 (p100). In most quiescent 
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cells, dimers of NFκB family are bound to the inhibitory molecules of the IκB family. To 
activate the NFκB pathway, 3 routes have been proposed (Gilmore, 2006). In the 
canonical pathway, inflammatory-related ligands such as tumour necrosis factor alpha 
(TNFα), lipopolysaccharides (LPS) and interleukin-1 beta (IL-1β) bind to their receptors, 
i.e. TNF receptor (TNFR), toll-like receptor (TLR) and IL-1 receptor (IL-1R) which in turn 
activate IκB kinase (IKK) complexes and NFκB essential modulator (NEMO). IKKs 
subsequently phosphorylate IκBs which leads to proteasomal degradation of IκBs by 
ubiquitination, allowing the p65/p50 dimers to enter the nucleus and regulate the 
expression of up to thousand genes. In an alternative pathway, a different set of activated 
receptors, e.g. lymphotoxin beta-receptor (LTβR) and CD40 induce the activity of NFκB 
inducing kinase (NIK) which in turn leads to the ubiquitination and partial degradation of 
p100 into p52 that binds to RelB before entering nucleus. In an atypical pathway which is 
activated, e.g. by genotoxic stress, the signals are mediated via the signalling kinase 
ataxia telangiectasia mutated (ATM) which in turn activates NEMO and follows the route 
of the canonical pathway. The activity of NFκB is controlled by the IκB family as well as by 
specific NFκB pathway regulators such as A20 (Gilmore, 2006; Hoesel & Schmid, 2013). 
 
 In terms of cellular functions, the NFκB pathway is well-known for its involvement 
in the inflammatory responses mediated primarily by innate immunity. In addition, it was 
shown that chronic inflammation exerts a pro-tumorigenic effect rather than a protective 
one, e.g. by up-regulating the expression of anti-apoptotic genes (Dunn, Old, & Schreiber, 
2004). In addition, it was shown that the NFκB pathway also contributes to the EMT 
process (Huber et al., 2004) and neovascularization (Xie, Xia, Zhang, Gong, & Huang, 
2010). Even if it is far-fetched to speculate that solid tumours arise from the deregulation 
of this pathway alone, there is no counter-argument on its involvement in tumourigenesis.  
 
 1.2.6. Cell cycle signalling 
 In response to growth factors, the cell cycle signalling is initiated and drives the 
cells from the resting state (G0) through the interphase (G1/S/G2) and mitosis (M) cycle, 
resulting in cell division. The classical model of cell cycle in mammalian cells comprises 
several cyclin proteins and CDKs which are required at different phases. The most critical 
steps known as cell cycle checkpoints are G1/S and G2/M transitions where they are 
controlled by cyclin D:CDK4/6 with cyclin E:CDK2 and cyclin A/B:CDK1, respectively. The 
first checkpoint is controlled by the RB protein which binds to the E2F transcription factor 
that up-regulates the expression of cyclin E. Additionally, the signalling molecules at the 
checkpoints can also be regulated by a group of CDK inhibitor families with a broad range 
of regulatory effects. To mention a few, p15 specifically inhibits cyclin D:CDK4/6 complex 
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while p21 (CDKN1A gene) has wider targets and acts on multiple cyclins:CDKs 
complexes. The expression of these regulatory molecules can be up-regulated by the 
activation of anti-growth factors such as transforming growth factor beta (TGFβ) which 
transduces signals via Smads proteins. Also, TP53, as the chief guardian of genome 
integrity, can up-regulate p21 and it functions together with other DNA-damage sensor 
protein kinases such as ATM, ataxia and rad3 related (ATR), and Chk1/2 to ensure the 
finest quality of DNA sequence before proceeding to DNA replication and mitosis. 
(Vermeulen, Van Bockstaele, & Berneman, 2003) 
 
 Intuitively, the cell cycle signalling is highly involved in carcinogenesis with respect 
to the control of cell population. The deregulation or mutations of signalling molecules 
within this signalling pathway, e.g. the mutations of cyclin proteins, CDKs, p15, p21, RB 
protein, and especially TP53, lead to the alteration of signal flows toward cell cycle and 
also to the instability of the genomes in the progeny cells. Interestingly, recent studies 
revealed that CDK1 is the only essential element to drive cell cycle in most mammalian 
cells while the interphase CDKs, i.e. CDK2/4/6 are only essential in some specific cell 
types. Such evidence ignites a new line of cancer treatment on cell cycle signalling which 
can be applied to patients in a more personalised manner (Malumbres & Barbacid, 2009). 
 
 1.2.7. Apoptotic signalling 
 Apoptosis is one of the components in programmed cell death together with 
autophagy and programmed necrosis (Ouyang et al., 2012). The classical apoptotic 
pathway is divided into two parts: the extrinsic pathway and the intrinsic pathway where 
both involve a series of energy-dependent cysteine protease enzymes called caspases. 
The extrinsic pathway is triggered by the binding of death ligands, e.g. Fas or TNF 
ligands, to their corresponding death receptors. The ligand-receptor complex recruits 
adaptor proteins, e.g. Fas-associated protein with death domain (FADD) and forms a 
death-inducing signalling complex (DISC) which in turn activates caspase 8 and the 
executioners of apoptosis, i.e. caspases 3,6,7, successively. In parallel, the intrinsic 
pathway senses perturbations from external and internal stimuli and direct signals towards 
the Bcl-2 family proteins which are involved in the release of mitochondrial enzymes. Two 
distinct members of the Bcl-2 family are classified, the pro-apoptotic members such as 
BAD, BAX, BAK, BID, BIM and the anti-apoptotic members, e.g. Bcl-2, Bcl-xL, Mcl-1. The 
balancing of the two groups control the permeability of the inner membrane of 
mitochondria. The disruption of the mitochondrial membrane results in the release of 
cytochrome c which binds to apoptotic protease activating factor-1 (APAF-1). Activated 
APAF-1 then leads to the activation of caspase 9 that in turn activates effector caspases 
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3, 6, 7. Once the executors of apoptosis are activated, they further activate proteases 
which degrade nuclear and cytoskeleton proteins. The most important executioner is 
caspase 3 which specifically activates endonuclease caspase-activated DNAse (CAD) by 
cleaving inhibitor of CAD (ICAD), leading to chromatins breakage and condensation. 
Subsequently, apoptotic cells externalise phosphatidylserine on their cell surfaces as a 
marker to be engulfed by phagocytic cells to complete the apoptotic process (Elmore, 
2007; Ouyang et al., 2012). Another apoptotic pathway mediated by Perforin and 
Granzyme stimulated by cytotoxic T-cell is shortly reviewed in (Elmore, 2007). 
 
 In the view of cellular functions, the apoptotic pathway is a vital component of 
multiple cellular processes including embryonic development, normal cell turnover and 
chemical-induced cell death. The deregulation of this pathway therefore contributes to the 
pathogenesis of many diseases such as autoimmune diseases, neurodegenerative 
diseases, and cancer. In the carcinogenic process, evasion of apoptosis is one of the key 
cancer hallmarks that cancer cells need to acquire which can be achieved by perturbing 
the regulatory units of this pathway. Apart from the regulation by the Bcl-2 family proteins, 
there also exist other regulators in the group of inhibitor of apoptosis (IAP), e.g. X-linked 
IAP (XIAP) which binds to Apaf-1 and inhibits its activity in the intrinsic pathway. In 
addition, TP53 also plays an important role in sensing cellular threats and controlling the 
release of mitochondrial cytochrome c via BAX (Benchimol, 2001). The aberration of 
these regulators thus increases the survival chance of cancerous cells. Furthermore, there 
are increasing evidences that other signalling cascades also send crosstalk signals to 
regulate apoptosis, e.g. the PI3K/AKT/mTOR pathway could inhibit the activities of Bad 
via AKT (Vivanco & Sawyers, 2002) or the increased expression of pro-apoptotic genes 
can be mediated by NFκB (Karin & Greten, 2005). For that reason, new therapeutic 
targets in apoptotic signalling in cancers would not be effective if one simply targets only 
an individual gene or protein components (Ouyang et al., 2012). By contrast, one needs to 
integrate the interconnected signalling components as a network to unravel the complex 
regulations of this pathway and to prevent the activation of alternative pathways that 
contribute to the relapse phase of diseases via crosstalk interactions.  
 
 Apart from the short reviews of intracellular signalling pathways as demonstrated, 
short reviews for other signalling pathways, e.g. Integrin, Wnt/β-catenin, and Src signalling 
can be found in (Harburger & Calderwood, 2009), (Clevers & Nusse, 2012), and (Parsons 
& Parsons, 2004), respectively. To further illustrate the connections between aberrant 
carcinogenic signals and the deregulation of intracellular signalling cascades, we 
introduce two examples of aberrant signal transduction networks arising from mutated 
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receptor tyrosine kinases which in turn contribute to the pathogeneses of cancers focused 
within this dissertation as follows: 
 
 1.2.8. Deregulated PDGF signalling in gastrointestinal stromal tumours 
(GISTs) 
 Gastrointestinal stromal tumours (GISTs) are the most common primary 
mesenchymal neoplasia of gastrointestinal tract. These tumours commonly arise from the 
mutations of either KIT (85-95%) or PDGFRα (5-7%) where the respective mutation sites 
can be located in extracellular domain, juxtamembrane domain, split kinase domain, or 
activation loop domain (Tan, Zhi, Shahzad, & Mustacchia, 2012).  The first-line therapy for 
GISTs is surgical resection combined with the administration of Imatinib mesylate 
(Gleevec®), a tyrosine kinase inhibitor with activities against ABL, BCR-ABL, KIT, and 
PDGFRα/β. The clinical outcome of the first-line therapy is mostly satisfactory with 35%-
49% 9-year survival (Rammohan et al., 2013). However, certain point mutations, e.g. 
aspartate (D) to valine (V) mutation at amino acid 842 in the PDGFRA gene in exon 18 
(activation loop domain) are usually associated with drug resistance (Markku & Jerzy, 
2006) while the other similar mutations such as aspartate (D) to tyrosine (Y) at the same 
amino acid or valine (V) to aspartate (D) at amino acid 561 on the PDGFRA gene still 
have good therapeutic outcomes. Such observation requires further investigation at the 
molecular level to understand how the signals are processed mechanistically. 
 
 Once amino acids at the regulatory sites of PDGFRα are mutated in GISTs, these 
mutations render constitutively active signalling towards downstream intracellular 
signalling pathways including Ras/Raf/MAPK and PI3K/AKT/mTOR pathways (Gramza, 
Corless, & Heinrich, 2009). These two main signalling pathways largely contribute to the 
acquisition of multiple hallmarks of cancers, notably on cell proliferation and cell survival 
circuits. In addition, PDGFRα was also reported to activate other signalling pathways such 
as the PLCγ-PKC pathway as well as the tyrosine kinases of the Src family (Heldin, 2014). 
Both of these pathways have numerous interaction partners within the intracellular 
signalling circuits, leading to the increase in complexity for further analysis. To add up the 
challenge, a number of crosstalk interactions between intracellular signalling pathways 
were proposed to be involved in the regulations within the generic mammalian signal 
transduction network (Grammer & Blenis, 1997; Lynch & Daly, 2002) as well as within the 
PDGF-signalling-specific context (C.-C. Wang, Cirit, & Haugh, 2009). At this level of 
complexity, it seems that only the analyses performed by computational means in the field 
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of bioinformatics or systems biology sound plausible to derive a global conclusion on the 
properties of deregulated PDGF signalling pathway at steady-state. 
 
 Recently, (Bahlawane et al., 2015) applied a bioinformatics approach to study the 
deregulated PDGF signalling in GISTs. In their study, they discovered that constitutive 
signalling via the oncogenic PDGFRα mutants in GISTs leads to the mislocalisation of the 
receptors which in turn modifies the signalling characteristics via STAT factors in the 
endoplasmic reticulum. Apart from this work, the importance of crosstalk interactions 
within the deregulated PDGF signalling in GISTs was investigated and analysed with a 
systems biology approach in parallel as presented in this dissertation. 
 
 1.2.9. Deregulated EGFR and L-plastin signalling in breast cancers 
 Breast cancer is one of most common forms of malignancy in female worldwide 
(Tinoco, Warsch, Glück, Avancha, & Montero, 2013) where complex interactions between 
multiple signalling pathways predominantly contribute to the course of pathogenesis. The 
three most common signalling receptors which have been characterised to be involved in 
breast cancer are oestrogen receptor alpha, progesterone receptor, and ErbB2 receptor, 
while EGFR was thought to be minimally associated. However, recent evidence in 
literature report that EGFR signalling might play a major role in triple-negative breast 
tumours as 50%-70% of them exhibit EGFR expression without the presence of the three 
most common receptors (Burness, Grushko, & Olopade, 2010). Hence, the molecular 
mechanisms of deregulated EGFR signalling was gaining interests to be further 
investigated and developed into therapeutic targets in pharmaceutical industry (Foley et 
al., 2010). 
 
 Generally, the deregulation of EGFR signalling is well-characterised as the 
etiology of epithelial tumours such as colorectal, lung, and skin tumours (Scaltriti, 2006). 
Besides, the pathological regulations of this signalling pathway in breast cancer were also 
increasingly reported over years (Foley et al., 2010). Apart from the induction of classical 
downstream intracellular signalling pathways such as Ras/Raf/MAPK, PI3K/AKT/mTOR, 
PLCγ/PKC and JAK/STAT pathways which promote the acquisition of cancer hallmarks, it 
was demonstrated that EGFR can also be directly shunted into nucleus as a 
transcriptional regulator (Lo, Hsu, & Hung, 2006).  Furthermore, the elevated expression 
levels of EGFR and ErbB2 were associated with bone metastasis and they are considered 
as markers for disseminated breast tumour cells (Braun et al., 2001). As it is not yet clear 
why bone is the preferred metastatic site for breast cancer, this observation still needs 
further investigations to clarify the regulatory mechanism of such cancer phenotypes. 
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 Regarding the role of EGFR signalling in cell invasion and metastasis, it was 
proposed that downstream targets of this signalling pathway, e.g. ERK1/2 in the MAPK 
cascade, leads to a more invasive behaviour (Foley et al., 2010). In parallel, the effective 
cytoskeleton units of the metastatic process might also be mediated by the deregulation of 
actin-binding proteins such as cofilin, filamin, or Lymphocyte cytosolic protein 1 (L-plastin) 
(Samstag, Eibert, Klemke, & Wabnitz, 2002). Within the framework of collaboration 
between the Cytoskeleton and Cell plasticity lab and the Systems Biology lab at the Life 
Sciences Research Unit of the University of Luxembourg, we applied a systems biology 
approach to investigate the interconnection between signalling components in MAPK 
pathways and the surrounding signalling molecules of L-plastin in order to unravel the 
regulatory mechanisms of cell invasiveness in 4 breast cancer cell lines as presented in 
this dissertation. 
 
1.3. Model-based data integration approaches in 
systems biology 
 Biology is the science of life where its ultimate goal is to understand the structures 
and dynamics of living species from the molecular to the organism levels. Biological 
research in the early years focused primarily on identifying and characterising individual 
cellular components and their distinctive functions with the hope to understand physiology 
and pathology of life with simplistic causal relationships. However, advanced research 
revealed that, even if there exist high-throughput technologies which allow for discovering 
components and functions of individual cellular components at the omics scale, it is 
usually insufficient to explain the pathophysiology of many diseases as these components 
function together as a system with underlying regulatory mechanisms. Hence, biological 
sciences in the 21st century are moving towards the study of biological processes as a 
network which comprises an ensemble of biological components that perform particular 
functions (Kitano, 2002). 
 
 In order to assemble biological components as a functional system, one needs to 
integrate information on network structures and interactions derived from literature to 
experimental data in the context of the study. With this respect, mathematical models, 
which represent the essential components of the systems in a mathematical form, can be 
applied as a mean for data integration which allows for illustrating network topology as 
well as representing the dynamics of the systems depending on the modelling framework. 
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To date, a large number of modelling approaches were applied to study and analyse 
biological systems. Some examples of these approaches with their key characteristics are 
presented in Figure 2. 
 
 
Figure 2. Mathematical models in biology and their characteristics. A large number of 
modelling approaches in statistics and systems biology were applied to model biological 
systems. Each of them has certain requirements and features with a trade-off on their 
advantages. (Adapted from “Spectrum of biological modelling method” by Peter Sorger and 
(Aldridge, Saez-Rodriguez, Muhlich, Sorger, & Lauffenburger, 2009)) 
 
 According to the examples in Figure 2, one could classify the modelling 
approaches into two groups: statistical models and mechanistic models in systems 
biology. Statistical models such as principal component analysis (PCA) or partial least 
square regression only provide the information on the connections and influences 
between biological components without details on causal relationships nor on the 
mechanisms of regulation. Bayesian networks, a statistical model which could account for 
causal relationships in terms of conditional probabilities, were extensively used to model 
biological networks such as gene regulatory networks (Friedman, 2004) and signalling 
networks (Sachs, Perez, Pe’er, Lauffenburger, & Nolan, 2005). Nevertheless, this 
modelling approach is still unable to depict the regulatory mechanisms of biological 
processes which are naturally embedded within the systems. 
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 In contrast to statistical models, the models in systems biology aim to account and 
represent the interconnections between biological components mechanistically with a set 
of rules, functions or mathematical equations. In this dissertation, I briefly review several 
modelling approaches in systems biology and their applications to biological systems 
followed by a comparison of their advantages and disadvantages. 
 
1.3.1. Qualitative modelling approaches 
 Qualitative modelling refers to the modelling class which contains qualitative 
variables within the framework. In systems biology, there exist many qualitative modelling 
approaches including Boolean networks, Petri net, process algebra and constraint-based 
modelling. A short review of these approaches can be found in (Machado et al., 2011) and 
I will shortly introduce the first two approaches in this dissertation. 
 
 Boolean networks (BNs) were introduced by Kauffman as a model for gene 
regulatory networks (Kauffman, 1969). A Boolean model comprises a graph of molecules 
with binary states which are updated synchronously in each time step following a set of 
defined Boolean rules. Simple molecular mechanisms such as the formation of protein 
complex or the redundancy of protein functions can be represented by the Boolean logic 
gates ‘AND’ and ‘OR’, respectively. The steady-state properties of Boolean networks can 
be derived from attractors where they can also be correlated to the molecular states of 
biological entities in the network. As the description of this modelling framework is rather 
simple, multiple variants of Boolean networks were established, e.g. multi-state BN, 
asynchronous BN, and BN with perturbations, with an intent to capture more realistic 
biological phenomena (Albert, Thakar, Li, Zhang, & Albert, 2008; Chai et al., 2014; R.-S. 
Wang, Saadatpour, & Albert, 2012).  
 
 Petri nets were originally created to model and analyse concurrent systems (Petri, 
1962). The network consists of a graph with two types of nodes, i.e. ‘places’ which hold 
‘tokens’ connected by ‘transitions’ which ‘fire’ the execution. In biology, the concepts of 
place and token were correlated to the availability of substrates while the concept of 
transition and firing was correlated to the execution of biochemical reactions. Of note, the 
firing of transition is not deterministic hence stochasticity is inherited in this approach. 
Similar to BNs, there exist several Petri net extensions, e.g. coloured, timed, and 
functional, which allow for more detailed descriptions and analyses of the systems (Mura 
& Csikász-Nagy, 2008).  
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1.3.2. Quantitative modelling approaches 
 In contrast to qualitative models, quantitative modelling approaches take 
continuous variables into account. The most commonly used quantitative framework in 
systems biology is the group of differential equation approaches which describe the rates 
of changes over continuous variables. Therefore, these methods are suitable for the 
modelling of dynamical systems. Some examples of this framework are ordinary 
differential equation (ODE)-based models and partial differential equation (PDE)-based 
models. 
 
ODE-based models contain a set of differential equations which describe the 
change of dependent variables as a function of one independent variable such as time. 
This framework can be applied to study many types of biological systems in order to 
depict detailed quantitative changes of molecular entities after perturbations over the 
course of an experiment (Chassagnole, Noisommit-Rizzi, Schmid, Mauch, & Reuss, 
2002). Also, detailed mechanistic regulations of biochemical reactions can be accounted 
in this framework by integrating additional formula such as the Hill equation into 
differential equations to capture complex dynamical properties of biological phenomena. 
 
Once quantitative changes of molecular entities need to be accounted based on 
more than one variable, PDE-based models which describe the changes of dependent 
variables as a function of multiple independent variables can be applied. An example of 
the application of a PDE-based model is the description of changing chemotherapeutic 
drug concentrations which are varied as a function of time and also as of the radial 
distance from the core tumour mass. More examples on the applications of PDE-based 
models in biology can be found in (Rangamani & Iyengar, 2007; Turing, 1952).  
 
1.3.3. Applications of modelling in systems biology on signalling 
networks 
 Over recent years, both qualitative and quantitative models in systems biology 
were applied to study and analyse various biological systems including signal transduction 
networks. Boolean networks were applied to analyse, e.g. the cell cycle of budding yeast 
(F. Li, Long, Lu, Ouyang, & Tang, 2004), the signalling properties mediated by T-cell 
receptor (Saez-Rodriguez et al., 2007), and the crosstalk regulations of apoptotic network 
in hepatocytes (Schlatter et al., 2009) while Petri nets were applied to examine, e.g. the 
Ca2+/calmodulin-dependent protein kinase II (CaMKII) regulatory network (Hardy & 
Robillard, 2008) and also the execution of apoptotic pathways (C. Li, Ge, Nakata, 
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Matsuno, & Miyano, 2007). Coarse-grained mechanistic insights such as robustness and 
steady-state properties can be derived from these qualitative networks where some 
models, e.g. (Schlatter et al., 2009), also serve as a well-established starting topology for 
further modelling of detailed mechanistic networks (Schmich et al., 2011). 
 
 The applications of quantitative ODE-based models on signalling networks cover, 
e.g. the oscillation and variability in the p53 system (Geva-Zatorsky et al., 2006), the 
dynamic regulations of NFkB pathways via IkBs (Hoffmann, Levchenko, Scott, & 
Baltimore, 2002) and the time-course activation of MAPK pathway following EGFR 
stimulation (Schoeberl, Eichler-Jonsson, Gilles, & Müller, 2002). These models capture 
quantitative changes of molecular entities over time and thereby offer quantitative 
analyses and predictions. The mechanistic model of EGFR signalling was also 
subsequently used in pharmaceutical industry, e.g. to explore the mechanism of drug 
resistance in breast cancers via the PI3K/AKT/mTOR pathway after inhibition of ErbB2 
(Schoeberl et al., 2009) which in turn lead to the discovery of novel therapeutic targets. 
 
1.3.4. Advantages and disadvantages of applying different modelling 
approaches 
 According to the characteristics and requirements of qualitative and quantitative 
models in systems biology as depicted in Figure 2, one could observe a trade-off among 
the size of the model, the challenge on model calibration, the amount of required prior 
knowledge and experimental data, and the amount of mechanistic insights which could be 
derived from the models. Qualitative models such as Boolean networks allows for 
describing large size networks with minimal calibration. For instance, the Boolean model 
of (Schlatter et al., 2009) comprising 86 nodes and 125 interaction functions could 
comprehensively cover a large array of molecular players involved in the apoptotic 
pathway. Also, this model allows for a very fast computation of the logical steady-state, 
thereby allowing to compare and predict the effect of combinatorial treatments on 
apoptosis. However, this approach failed to provide quantitative predictions such as the 
proportion of apoptotic cells in the different experimental settings because of its inherited 
qualitative nature of state and time. 
 
 On the other hand, quantitative approaches such as ODE-based models grant 
detailed mechanistic insights from the network such as the precise prediction of molecular 
concentrations beyond the observed time-course or the sensitivity of molecules upon 
quantitative perturbations. Nevertheless, ODE-based models require prior knowledge on 
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biochemical reactions to determine the suitable formula, i.e. the rate laws of differential 
equations (Machado et al., 2011). In parallel, an extensive set of experimental data is 
required in order to estimate the unknown kinetic parameters where one could also 
encounter problems with unidentifiability in case the available datasets are not rich 
enough. These constraints therefore limit the scale of dynamical models in practice and it 
is consequently applicable to investigate only small subsets of reactions in the pathways 
(Blair, Trichler, & Gaille, 2012). 
 
 Given the advantages and disadvantages of each modelling approach, one always 
has to balance between the simplicity of the frameworks versus the expressiveness that 
the models could offer (Machado et al., 2011). Several factors should be considered, e.g. 
the research objective, the scope of the model, and the type and availability of data. In 
certain scenario, one might need to perform a quantitative mechanistic analysis on a 
large-scale biological network based on a limited amount of dataset, e.g. steady-state 
data where neither traditional qualitative nor quantitative models are suitable to be 
applied. With this regard, a class of quantitative mechanistic modelling approach with 
minimal parameterisation such as probabilistic Boolean networks (PBNs) could be a 
promising approach in such experimental setting. 
 
1.4. Probabilistic Boolean networks  
PBNs were introduced by Shmulevich et al. to model gene regulatory networks in 
the context of uncertainty (Shmulevich, Dougherty, Kim, & Zhang, 2002). To provide a 
comprehensive overview on the PBN approach, we reviewed the recent development and 
biomedical applications of PBNs from 2002 to the middle of 2013 (Trairatphisan et al., 
2013). The review article covers a broad range of topics including the dynamic, inference, 
and intervention on PBNs. The relationship between PBNs and dynamic Bayesian 
networks (DBNs) were also discussed. Furthermore, the applications of PBNs on 
biological and physiological networks were collected and summarised.  
 
On the study of signal transduction networks in the PBN framework, the steady-
state distribution of molecular states in PBN can be correlated to the steady-state 
proteomic profiles generated from wet-lab experiments. Also, the relevance of interactions 
within the signalling networks can be accounted in terms of selection probabilities. These 
features make PBN ideal for describing the properties of signal transduction networks at 
steady-state with some uncertainty on network topologies derived from literature. 
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Abstract
Probabilistic Boolean network (PBN) modelling is a semi-quantitative approach widely used for the study of the
topology and dynamic aspects of biological systems. The combined use of rule-based representation and probability
makes PBN appealing for large-scale modelling of biological networks where degrees of uncertainty need to be
considered.
A considerable expansion of our knowledge in the field of theoretical research on PBN can be observed over the past
few years, with a focus on network inference, network intervention and control. With respect to areas of applications,
PBN is mainly used for the study of gene regulatory networks though with an increasing emergence in signal
transduction, metabolic, and also physiological networks. At the same time, a number of computational tools,
facilitating the modelling and analysis of PBNs, are continuously developed.
A concise yet comprehensive review of the state-of-the-art on PBN modelling is offered in this article, including a
comparative discussion on PBN versus similar models with respect to concepts and biomedical applications. Due to
their many advantages, we consider PBN to stand as a suitable modelling framework for the description and analysis
of complex biological systems, ranging from molecular to physiological levels.
Keywords: Probabilistic Boolean networks, Probabilistic graphical models, Qualitative modelling, Systems biology
Background
A large number of formal representation types that exist
in Systems Biology are used to construct distinctive math-
ematical models, each with their own strengths and
weaknesses. On one hand, deciphering the complexity
of biological systems by quantitative methods, such as
ordinary differential equation (ODE) based mathemat-
ical models, yields detailed representations with high
predictive power. Such an approach is however often
hampered by the low availability and/or identifiability
of kinetic parameters and experimental data [1]. These
limitations often result in the generation of relatively
small quantitative network models. On the other hand,
qualitative modelling frameworks such as the Boolean
Networks (BNs), allow for describing large biological net-
works while still preserving important properties of the
systems [2]. The models pertaining to this latter class
*Correspondence: panuwat.trairatphisan@uni.lu
1 Life Sciences Research Unit,University of Luxembourg, Luxembourg
Full list of author information is available at the end of the article
fail nevertheless to offer a quantitative determination of
the system’s dynamics due to their inherent qualitative
nature.
Probabilistic Boolean networks (PBNs) were introduced
in 2002 by Shmulevich et al. as an extension of the
Boolean Network concept and as an alternative for mod-
elling gene regulatory networks [3]. PBNs combine the
rule-based modelling of a BN, as introduced by Kauff-
man [4-7], with uncertainty principles, e.g., as described
by a Markov chain [8]. In terms of applications, anal-
ogously to the case of traditional BNs, the qualitative
nature of state and time in a PBN framework allows
for modelling of large-scale networks. The integrated
stochastic properties of PBNs additionally enable semi-
quantitative properties to be extracted. Existing analytic
methods on PBNs allow for gaining a better under-
standing of how biological systems behave, and offer
in addition the means to compare to traditional BNs.
Examples are the calculation of influences which rep-
resent the quantitative strength of interaction between
certain genes [3], or the determination of steady-state
© 2013 Trairatphisan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
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distributions to quantitatively predict the activity of cer-
tain genes in steady state [8].
It has been shown in the past years that the use of
PBNs in the biological field is not limited to the molecu-
lar level, but also can potentially be linked to applications
in clinic. To name a few, Tay et al. constructed a PBN
to demonstrate the interplay between dengue virus and
different cytokines which mediate the course of disease
in dengue haemorrhagic fever (DHF) [9]. Ma et al. pro-
cessed functional Magnetic Resonance Imaging (fMRI)
signals to infer a brain connectivity network comparing
between Parkinson’s disease patients and healthy subjects
[10]. Even though the research efforts on PBNs in this
direction are just sprouting, the results from such PBN
studies can provide a first clue on a disease’s etiology and
progression. As PBNs are highly flexible for data integra-
tion and as there exist a number of computational tools
for PBN analysis, PBN is a suitable modelling approach
to integrate information and derive knowledge from omic
scale data which should in turn facilitate a physician’s
decision-making process in clinic.
For the past decade, PBNs were the object of extensive
studies, both theoretical and applied. Among theoretical
topics, there are steady-state distribution, e.g., [11-13],
network construction and inference, e.g., [14-16], net-
work intervention and control, e.g., [17-19]. Several minor
topics were investigated as well, including reachability
analysis [20] or sensitivity analysis [21]. Other studies
dealt with PBNs in biological systems at multi-level such
as gene regulatory networks [22-24], signal transduction
networks [25], metabolic networks [26], and also physi-
ological networks [9,10] which could potentially link to
medicine as previously mentioned. In parallel, a number
of computational tools which facilitate the modelling and
analysis of PBNs are also continuously developed [27-29].
Given the continuous development in this area due to
the broad on-going range of research on PBNs, we offer
a state-of-the-art overview on this modelling framework.
A comparison of PBN to other graphical probabilistic
modelling approaches is also enclosed, specifically with
respect to Bayesian networks. Last but not least, a view
of the theoretical and applied research on PBNs as mod-
els for the study of multi-level biomedical networks is
included.
In order to provide a coherent overview of the recent
advances on PBN, we start with several theoretical
aspects, organised as follows: an introduction to PBNs and
associated dynamics are given in Section ‘Introduction to
probabilistic Boolean networks and their dynamics’, the
construction and inference of PBNs as models for gene
regulatory networks are presented in Section ‘Construc-
tion and inference of PBNs as models of gene regulatory
networks’, structural intervention and external control are
discussed in Section ‘Structural intervention and con-
trol of PBNs’, ending with the relationship between PBNs
and other probabilistic graphical models in Section ‘Rela-
tionship between PBNs and other probabilistic graphical
models’. Later, in Section ‘PBN applications in biological
and biomedical studies’ we present a broad summary of
PBN applications as a representation of biological net-
works followed by a discussion on the future applications
of PBN in Systems Biology and Systems Biomedicine. A
short conclusion is given in Section ‘Conclusion’.
Introduction to probabilistic Boolean networks
and their dynamics
Boolean networks
A Boolean Network (BN)G(V , F), as originally introduced
by Kauffman [4-7], is defined as a set of binary-valued
variables (nodes) V = {x1, x2, . . . , xn} and a vector of
Boolean functions f = (f1, . . . , fn). At each updating
epoch, referred to as time point t (t = 0, 1, 2, . . .), the
state of the network is defined by the vector x(t) =
(x1(t), x2(t), . . . , xn(t)), where xi(t) is the value of variable
xi at time t, i.e., xi(t) ∈ {0, 1} (i = 1, 2, . . . , n). For each
variable xi there exists a predictor set {xi1 , xi2 , . . . , xik(i)}
and a Boolean predictor function (or simply predictor) fi
being the i-th element of f that determines the value of xi
at the next time point, i.e.,
xi(t + 1) = fi(xi1(t), xi2(t), . . . , xik(i) (t)), (1)
where 1 ≤ i1 < i2 < · · · < ik(i) ≤ n. Since
the predictor functions of f are time-homogenous, the
notation can be simplified by writing fi(xi1 , xi2 , . . . , xik(i) ).
Without loss of generality, k(i) can be defined to be
a constant equal to n for all i by introducing ficti-
tious variables in each function: the variable xi is ficti-
tious for a function f if f (x1, . . . , xi−1, 0, xi+1, . . . , xn) =
f (x1, . . . , xi−1, 1, xi+1, . . . , xn) for all possible values of
x1, . . . , xi−1, xi+1, . . . , xn. A variable that is not fictitious is
referred to as essential. The k(i) elements of the predictor
set {xi1 , xi2 , . . . , xik(i)} are referred to as the essential pre-
dictors of variable xi. The vector f of predictor functions
constitutes the network transition function (or simply the
network function). The network function f determines the
time evolution of the states of the Boolean network, i.e.,
x(t + 1) = f (x(t)). Thus, the BN’s dynamics is determin-
istic. The only potential uncertainty is in the selection of
the initial starting state of the network.
Given an initial state, within a finite number of steps,
the BN will transition into a fixed state or a set of states
through which it will repeatedly cycle forever. In the first
case, each such fixed state is called a singleton attractor,
whereas in the second case, the set of states is referred to
as a cyclic attractor. An attractor is either a singleton or  
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a cyclic attractor. The number of transitions required to
return to a given state in an attractor is the cycle length of
that attractor. The attractor structure of the BN is deter-
mined by the particular combination of singleton and
cyclic attractors, and by the cycle lengths of the cyclic
attractors. The states within an attractor are called attrac-
tor states. Non-attractor states are called transient and are
visited at most once on any network trajectory. The states
that lead into an attractor constitute its basin of attrac-
tion. The basins form a partition of the state space of the
BN. For example, in Figure 1 the state transition diagrams
of four different Boolean networks with three variables
are given (in fact all these Boolean networks constitute a
probabilistic Boolean network — the framework of prob-
abilistic Boolean networks is presented in Section ‘5’). For
each of these networks attractor states and transient states
are indicated and the cyclic- and singleton attractors are
given.
A Boolean Network with perturbations (BNp) is a BN
with an introduced positive probability for which, at any
transition, the network can depart from its current tra-
jectory into a randomly chosen state, which becomes an
initial state of a new trajectory. Formally, the perturba-
tion mechanism is modelled by introducing a parameter
p, 0 < p < 1, and a so-called perturbation vector γ =
(γ1, γ2, . . . , γn), where γ1, γ2, . . . , γn are independent and
identically distributed (i.i.d.) binary-valued random vari-
ables a such that Pr{γi = 1} = p, and Pr{γi = 0} = 1 − p,
for all i = 1, 2, . . . , n. For every transition step of the net-
work a new realisation of the perturbation vector is given.
If x(t) ∈ {0, 1}n is the state of the network at time t, then
the next state x(t + 1) is given by either f (x(t)) or by
(a)
101
100
111
110
011
001000
010
(b)
101
100
111
110
011
001000
010
(c)
101
100
111
110
011
001000
010
(d)
101
100
111
110
011
001000
010
Figure 1 State transition diagrams of the four constituent Boolean networks of the PBN in Figure 2. For each constituent BN the attractor
states and the transitions between them are indicated with solid circles and arrows, respectively. The remaining transitions and transient states are
indicated with dashed arrows and circles, respectively. (a) The constituent BN of the PBN in Figure 2corresponding to transition function f 1. There is
only one attractor, i.e., {011, 111}, which is a cyclic attractor. (b) The constituent BN of the PBN in Figure 2 corresponding to transition function f 2.
There are two cyclic attractors: {011, 111}, {001, 101} and one singleton attractor: {110}. (c) The constituent BN of the PBN in Figure 2 corresponding
to transition function f 3. {001, 110, 111} is the cyclic attractor. (d) The constituent BN of the PBN in Figure 2corresponding to transition function f 4.
There are two attractors: a cyclic one, i.e., {001, 111} and a singleton one, i.e., {110}.
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x(t)⊕ γ (t), where⊕ is component-wise addition modulo
2 and γ (t) ∈ {0, 1}n is the realisation of the perturbation
vector for the current transition. The choice of the state
transition rule depends on the current realisation of the
perturbation vector. Two cases are distinguished: either
γ (t) = 0 or at least one component of γ (t) is 1, i.e.,
γ (t) ̸= 0. In the first case, which happens with probability
(1 − p)n, the next state is given by f (x(t)). In the second
case, given with probability 1 − (1 − p)n, the next state
is determined as x(t) ⊕ γ (t): if γi = 1, then xi changes
its value; otherwise it does not (i = 1, 2, . . . , n). Since
γ (t) ̸= 0, at least one of the nodes flips its value.
The attractors of a Boolean network characterise its
long-run behaviour [8]. However, if random perturbations
are incorporated, the network can escape the attractors.
In particular, perturbations allow the system to reach
any of its states from any current state in one transi-
tion. In consequence, the dynamics of the BNp is given
by an ergodic Markov chain [30], b having a unique sta-
tionary distribution which simultaneously is its steady-
state (limiting) distribution. The steady-state probability
distribution, where each state is assigned a non-zero
probability, characterises the long-run behaviour of the
BNp. Nevertheless, if perturbation probability is very
small, the network will remain in the attractors of the orig-
inal network for most of the time, meaning that attractor
states will carry most of the steady-state probability mass
[8]. In this way the attractor states remain significant for
the description of the long-run behaviour of a Boolean
network after adding perturbations. Thus, a BNp inherits
the attractor-basin structure from the original BN; how-
ever, once an attractor has been reached, the network
remains in it until a perturbation occurs that throws the
network out of it [31].
Probabilistic Boolean networks
PBNs were introduced in order to overcome the deter-
ministic rigidity of BNs [3,32,33], originally as a model for
gene regulatory networks. A PBN consists of a finite col-
lection of BNs, each defined by a fixed network function,
and a probability distribution that governs the switching
between these BNs.
Formally, a probabilistic Boolean network G(V ,F) is
defined by a set of binary-valued variables (nodes)c V =
{x1, x2, . . . , xn} and a list of sets F = (F1, F2, . . . , Fn). For
i = 1, 2, . . . , n the set Fi is given as {f (i)1 , f (i)2 , . . . , f (i)l(i)},
where f (i)j , 1 ≤ j ≤ l(i), is a possible Boolean predictor
function for the variable xi, with l(i) the number of pos-
sible predictors for xi. In general, each node xi can have
l(i) different sets of essential predictors, each specified for
a particular predictor function in Fi. A realisation of the
PBN at a given instant of time is determined by a vec-
tor of predictor functions, where the ith element of that
vector contains the function selected at that time point
for xi. For a PBN with N realisations there are N possible
network transition functions f 1, f 2, . . . , f N of the form
f l = (f (1)l1 , f
(2)
l2 , . . . , f
(n)
ln ), l = 1, 2, . . . ,N , 1 ≤ lj ≤ l(j),
f (j)lj ∈ Fj, and j = 1, 2, . . . , n. Each network function f l
defines a constituent Boolean network, or context, of the
PBN.
Let f = (f (1), f (2), . . . , f (n)) be a random vector taking
values in F1× F2× · · ·× Fn; in other words, f is a random
vector that acquires as value any of the realisations of the
PBN. The probability that the predictor f (i)j , 1 ≤ j ≤ l(i),
is selected to determine the value of xi is given by
c(i)j = Pr{f (i) = f (i)j } =
∑
l:f (i)li =f
(i)
j
Pr{f = f l}. (2)
It follows that ∑l(i)j=1 c(i)j = 1. The PBN is said to be
independent if the random variables f (1), f (2), . . . , f (n) are
independent. Assuming independence, there are N =∏n
i=1 l(i) realisations (constituent BNs) of the PBN and the
probability distribution on f governing the selection of a
particular realisation is given by Pr{f = f l} =
∏n
i=1 c
(i)
li .An example of a PBN with three nodes is given in
Figure2.
At each time point of the PBN’s evolution, a decision
is made whether to switch the constituent network. This
is modelled with a binary random variable ξ : if ξ =
0, then the current constituent network is preserved; if
ξ = 1, then a context is randomly selected from all the
constituent networks in accordance with the probability
distribution of f . Notice that this definition implies that
there are twomutually exclusive ways in which the context
may remain unchanged: 1) either ξ = 0 or 2) ξ = 1 and
the current network is reselected. The functional switch-
ing probability q = Pr(ξ = 1) is a system parameter. Two
cases are distinguished in the literature: if q = 1, then
a switch is made at each updating epoch; if q < 1, then
the PBN’s evolution in consecutive time points proceeds
in accordance with a given constituent BN until the ran-
dom variable ξ calls for a switch. If q = 1, as originally
introduced in [32], the PBN is said to be instantaneously
random; if q < 1, it is said to be context-sensitive. The
former models uncertainty in model selection, the lat-
ter models the situation where the model is affected by
latent variables outside the model [34]. As an example let
us consider the PBN given in Figure 2. Let the PBN be
instantaneously random, i.e., q = 1. The four constituent
BNs associated with the four transition functions f 1, f 2,
f 3, and f 4, are given in Figure 1. Further, let us assume
that the initial state is the state 101 and that the con-
secutive realisations are f 1, f 2, f 4, f 3, f 2, f 2, f 3, f 4, f 4, . . ..  
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x 1x 2x 3 f (1)1 f (2)1 f (2)2 f (3)1 f (3)2
000 0 1 0 1 1
001 1 0 1 0 1
010 1 0 0 1 0
011 1 1 1 1 1
100 0 0 1 0 1
101 0 0 1 1 1
110 1 1 1 1 0
111 0 1 0 1 1
c
( i )
j 1 0.3 0.7 0.4 0.6
101
100
111
110
011
001000
010
A =
0 c3 + c4 0 c1 + c2 0 0 0 0
0 0 0 0 c1 c2 c3 c4
0 0 0 0 c2 + c4 c1 + c3 0 0
0 0 0 0 0 0 0 1
c1 c2 c3 c4 0 0 0 0
0 c1 + c2 0 c3 + c4 0 0 0 0
0 0 0 0 0 0 c2 + c4 c1 + c3
0 c3 + c4 0 c1 + c2 0 0 0 0
Figure 2 An example of truth table, state transition diagram, and transition probability matrix of a PBN. The truth table, the state transition
diagram, and the transition probability matrix A of a PBN without perturbations consisting of three variables V = {x1, x2, x3} andF = (F1, F2, F3),
where F1 = {f (1)1 }, F2 = {f (2)1 , f (2)2 }, and F3 = {f (3)1 , f (3)2 }. Since there is one predictor function for node x1 and two predictors for nodes x2 and x3,
there are 1 · 2 · 2 = 4 realisations of the PBN given by four network transition functions f 1 = (f (1)1 , f (2)1 , f (3)1 ), f 2 = (f (1)1 , f (2)1 , f (3)2 ),
f 3 = (f (1)1 , f (2)2 , f (3)1 ), and f 4 = (f (1)1 , f (2)2 , f (3)2 ) with associated probabilities c1 = 0.12, c2 = 0.18, c3 = 0.28, and c4 = 0.42, respectively. For example,
c3 = c(1)1 · c(2)2 · c(3)1 = 1 · 0.7 · 0.4 = 0.28. The edges in the state transition diagram are labelled with the transition probabilities. As can be seen from
the state transition diagram, the underlying Markov chain is irreducible and aperiodic, thus ergodic. The steady-state (limiting) distribution for the
chosen ci values, i = 1..4, is given by [ 71609 , 364014481 , 494827 , 7164827 , 1754827 , 2384827 , 254814481 , 469614481 ] (the states are considered in the lexicographical order from 000
to 111).
Then, the corresponding time evolution of the PBN (tra-
jectory) is given by the following sequence of state tran-
sitions: 101 → 001 → 110 → 110 → 111 → 011 →
111 → 001 → 100 → 011 → . . .. Irrespective of which
constituent network (realisation) is selected next, the con-
secutive state in the trajectory is going to be 111 as the
probability of moving from 011 to 111 is c1+c2+c3+c4=1.
A Probabilistic Boolean Network with perturbations
(PBNp) is the variant of the PBN framework in which
each constituent network is a BNp with a common per-
turbation probability parameter p, 0 < p < 1, and a
perturbation vector γ . If x(t) ∈ {0, 1}n is the current state
of the network and γ (t) = 0, then the next state of the
network is determined according to the current network
function f l, i.e., x(t + 1) = f l(x(t)). If x(t) ∈ {0, 1}n is
the current state and γ (t) ̸= 0, then x(t + 1) = x(t) ⊕
γ (t). Whereas a context switch in a PBNp corresponds
to a change in latent variables, resulting in a structural
change in the functions that govern the PBNp, a random
perturbation reflects a transient value change that leaves
the network wiring unmodified, as for example in the
case of gene activation or inactivation caused by external
stimuli such as stress conditions or small molecule
inhibitors [8].
The relationship between the four frameworks, i.e.,
Boolean networks, Boolean networks with perturbations,
probabilistic Boolean networks, and probabilistic Boolean
networks with perturbations is schematically depicted in
Figure 3.
Dynamics of PBNs
A Boolean network with perturbations can be viewed as
a homogenous irreducible Markov chain Xt , with state
space X = {0, 1}n, where n is the number of nodes in the
BNp. Let Py(x) = Pr[Xt0+1 = x|Xt0 = y] be the Markov
chain transition probability from state y to state x at any
instant t0. This probability is a weighted sum of two tran-
sition probabilities, one for the BN, with probability (1 −
p)n, and the other for the perturbations, with probability
1− (1− p)n, i.e.,
Py(x) = 1[f (y)=x](1−p)n+(1−1[x=y])pη(x,y)(1−p)n−η(x,y),
(3)
where p is the perturbation probability, 1 is the indicator
function (1[P] = 1 if the proposition P is true, and 1[P] = 0
otherwise), and η(x, y) is the Hamming distance between
the binary vectors x and y.
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Figure 3 Relationships between the frameworks of Boolean and
probabilistic Boolean networks. A Boolean network (BN) can be
converted to a Boolean network with perturbations (BNp) by
introducing a probability parameter p, 0 < p < 1, and a perturbation
vector (γ ). A probabilistic Boolean network (PBN) is built upon a
number of constituent BNs and a probability distribution governing
the choice of the Boolean network in accordance with which the next
transition is made. Analogically, a PBN can be converted to a
probabilistic Boolean network with perturbations (PBNp) by
introducing a probability parameter p, 0 < p < 1, and a perturbation
vector (γ ). A probabilistic Boolean network (PBN) is built upon a
number of constituent BNps and a probability distribution governing
the choice of the BNp in accordance with which the next transition is
made.
The Markov chain Xt is ergodic, which follows from
the fact that it is aperiodic, irreducible, and defined on
a finite state space. In other words, it possesses a unique
stationary distribution, being simultaneously its steady-
state (limiting) distribution. If P(t)y (x) is the probability
that the system transitions from y to x in t time steps, i.e.,
P(t)y (x) = Pr[Xt0+t = x|Xt0 = y], then the steady-state
distribution π of Xt is defined by π(x) = limt→∞ P(t)k (x)
for any initial state k ∈ X . For a set of states B ⊆ X the
steady-state probability is given by π(B) = ∑x∈B π(x) =
limt→∞ P(t)k (B) for any initial state k ∈ X . For exam-
ple, the steady-state distribution of the Markov chain
given by the transition probability matrix in Figure 2 is
[ 71609 , 364014481 , 494827 , 7164827 , 1754827 , 2384827 , 254814481 , 469614481 ] (the states
are considered in the lexicographical order from 000 to
111).
In the case of a probabilistic Boolean network, the tran-
sition probabilities Py(x) of the underlying Markov chain
Xt depend on the probability of selecting a network tran-
sition function f k , k = 1, 2, . . . ,N , that determines the
transition from y to x i.e.,
Py(x) = Pr[Xt+1 = x|Xt = y]=
N∑
k=1
1[f k(y)=x]·Pr{f = f k},
(4)
whereN, as before, is the number of constituent BNs and f
is a random vector determining the PBN’s realisation. Let-
ting x and y range all states inX , the transition probability
matrix A of size 2n × 2n can be formed and expressed as
A =
N∑
k=1
Ak · Pr{f = f k}, (5)
where Ak is the transition matrix corresponding to the
k-th constituent BN.
Now, adding perturbations with probability p makes
the underlying finite-space Markov chain Xt of the PBNp
aperiodic and irreducible, hence ergodic. This allows the
network dynamics of a PBNp to be studied with the use
of the rich theory of ergodic Markov chains [30]. In par-
ticular, in the case of instantaneously random PBNps, the
transition probability matrix A˜ is given by
A˜ = (1− p)n · A+ P˜, (6)
where P˜ is the perturbation matrix of the form
P˜y,x = (1− 1[x=y])pη(x,y)(1− p)n−η(x,y), (7)
where, as before, 1 is the indicator function and η is the
Hamming distance. As in the case of BNps, the ergod-
icy of the underlying Markov chain ensures the existence
of the unique stationary distribution being the limiting
distribution of the chain.
By definition, the set of attractors of a PBN is the union
of the sets of attractors of the constituent networks [8].
Notice that whereas in a BN two attractors cannot inter-
sect, attractors from different contexts can intersect in
the case of a PBN. Similarly as in the case of Boolean
networks, attractors play a major role in the characterisa-
tion of the long-run behaviour of a probabilistic Boolean
network. If, however, perturbations are incorporated, the
long-run behaviour of the network is characterised by its
steady-state distribution. Nevertheless, if both the switch-
ing and perturbation probabilities are very small, then the
attractors still carry most of the steady-state probability
mass [8]. From a biological point of view attractors of such
networks are interesting as they can be given a clear bio-
logical interpretation: they can be used to model cellular
states [31]. For example, in the context of gene regulatory
networks, it is believed that attractors can be interpreted
as cellular phenotypes [7,8]. Thus, the long-run behaviour
of the network given by its steady-state probabilities is
of a special interest. Specifically, the attractor steady-
state probabilities, i.e., π(A), where A is an attractor, are
important. There are a number of approaches towards the
determination and analysis of the steady-state distribution
of a PBNp. We review them shortly.
First, one approach to the steady-state analysis is to con-
struct the state transition matrix in some form or another
and then apply some numerical methods, e.g., iterative,
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decompositional or projection methods [35]. A transi-
tion matrix based approach in which the sparse transition
matrix is constructed in an efficient way and the so-
called power method, which is applied to compute the
steady-state probability distribution, is proposed in [36].
Unfortunately, the size of the state space grows expo-
nentially in the number of nodes (genes) and becomes
prohibitive for matrix-based numerical analysis of larger
networks [11]. In [12], an approximation method for com-
puting the steady-state probability distribution of a PBNp
is derived from the approach of [36]. Thismethod neglects
some constituent BNps with very small probabilities dur-
ing the construction of the transition probability matrix.
An error analysis is given to demonstrate the effective-
ness of this approach. Further, in [13] and [37] a matrix
perturbation method for computing the steady-state
probability distribution of PBNps is proposed together
with its approximation variant. The proposed meth-
ods make use of certain properties of the perturbation
matrix, P˜.
Second, Markov chain Monte Carlo methods [38] rep-
resent a feasible alternative to numerical matrix-based
methods for obtaining steady-state distributions. Given an
ergodic Markov chain, a Monte Carlo simulation method
has been proposed: the probability of being in state x in
the long run can be estimated empirically by simulating
the network for a sufficiently long time and by count-
ing the percentage of time the chain spends in that state
regardless of the starting state [8]. A set of examples of
Monte Carlo simulations from the PBN example in Figure
2 is shown in Figure 4. However, the question that remains
is how to judge whether the simulation time is sufficiently
long? The key factor here is the convergence, which in the
case of a PBNp is known to depend to a large extent on
the perturbation probability p [11]. Several approaches for
determining the number of iterations necessary to achieve
convergence were developed. A typical class consists of
methods based on the second-largest eigenvalue of the
transitions probability matrix, but due to reasons already
mentioned above, these approaches can be impractical
for larger networks. Another method utilises the so-called
minorisation condition for Markov chains [39] to provide
a priori bounds on the number of iterations. However, the
usefulness of this approach is also limited (see [11] for
details). There exist a number of methods for empirically
diagnosing convergence to the steady-state distribution
[40,41]. In [11] two of them are considered: one, based
on the Kolmogorov-Smirnov test, a nonparametric test
for the equality of continuous, one-dimensional proba-
bility distributions, and, second, the approach proposed
in [42] which reduces the study of convergence of the
chain to the investigation of the convergence of a two-
state Markov chain. For illustration of application of these
approaches to PBNs, we refer to [11] where the joint
steady-state probabilities of combinations between two
genes in human glioma gene expression data set were
analysed.
Finally, as shown in [31], analytical expressions for the
attractor steady-state probabilities can be derived both
for BNps and PBNps. The obtained formulas are fur-
ther exploited to propose an approximate steady-state
computation algorithm.
We just shortly mention here that in the case of
probabilistic Boolean networks without perturbations the
dynamics is given by a Markov chain that does not nec-
essarily be ergodic, specifically the Markov chain may
contain more than one so-called ergodic set of states, also
referred to as a closed, irreducible set of states in the lit-
erature. An ergodic set of states C in a Markov chain
is defined as a set of states where all states communi-
cate and no state outside C is reachable from any state
in Cd. The notion of an ergodic set of the correspond-
ing Markov chain in probabilistic Boolean networks is the
stochastic analogue of the notion of an attractor in stan-
dard Boolean networks [32]. Notice, however, that the
ergodic sets and the attractors of a PBN or PBNp may dif-
fer. In the case of probabilistic Boolean networks without
perturbations where the underlying Markov chain con-
tains more than one ergodic set, considering the ergodic
sets rather than the attractors may be more significant
for understanding the long-run behaviour of the net-
work. For example, in the context of modelling biolog-
ical processes with PBNs, cellular phenotypes may in
fact be represented by the ergodic sets. For more details
see [32,43,44].
A number of other issues related to probabilistic
Boolean network dynamics have been considered in the
literature. We briefly list them here. In [45,46], the
ordering of network switching and state transitions in
context-sensitive PBNs are considered and its influence on
the steady-state probability distributions is investigated.
Algorithms for enumeration of attractors in probabilistic
Boolean networks are discussed in [47]. Stability and sta-
bilisation issues of PBNs are covered in [48]. Further, net-
work transformations from one to another without losing
some crucial properties, e.g., the steady-state probability
distribution, are considered in [49]. For this purpose the
concepts of homomorphisms and ϵ-homomorphisms for
probabilistic regulatory networks, in particular PBNs, are
developed.
Construction and inference of PBNs as models of
gene regulatory networks
One approach to the dynamical modelling of gene regula-
tion is based on the construction and analysis of network
models. Generally, in the study of dynamical systems,
long-run behaviour characteristics are of utter impor-
tance and their determination is a main aspect of system
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Figure 4 Dynamical simulations of node x2 of the example network in Figure 2, with initial state k = 000. (a) Dynamics of x2 governed by
the constituent BN corresponding to the transition function f 1, where c1 = 1, c2 = c3 = c4 = 0. Starting from 000 the periodic attractor {011, 111}
is reached. The probability of {x2 = 1} given by the stationary distribution is 1. (b) Dynamics of x2 governed by the constituent BN corresponding to
the transition function f 4, where c4 = 1, c1 = c2 = c3 = 0. Starting from 000 the periodic attractor {001, 111} is reached. The probability of {x2 = 1}
given by the stationary distribution related to the reached attractor, i.e., [ 0, 12 , 0, 0, 0, 0, 0,
1
2 ] (the states are considered in the lexicographical order), is
0.5. (c,d) Examples of x2 dynamics in the full PBN as given in Figure 2. Starting from 000 different trajectories are obtained for different simulation
runs. The underlying Markov chain is ergodic and a unique stationary distribution, being the steady state (limiting) distribution, exists therefore. The
steady state probability of {x2 = 1} is 0.66.
analysis. Reversely, the task of constructing a network
possessing a specific set of properties is a subject of sys-
tem synthesis. However, this inverse problem is usually
ill-posed, i.e., there may be many models, or none, with
the given properties [50]. Here we concentrate on the
problem of inference from data in the framework of prob-
abilistic Boolean networks, an inverse problem in which
a network is constructed relative to some relationship
with the available data. An outline of the workflow in
network inference in the PBN framework is shown in
Figure 5.
A data-driven approach for model construction con-
sists of inferring the model structure and model param-
eters from measurement data, which in the case of gene
regulation most commonly are gene expression measure-
ments obtained with microarray technology. However,
such data are continuous in nature. Thus, prior to the
inference of Boolean or other discrete-type models (e.g.,
ternary) the measurements are usually discretised. The
most common discretisation is binary (0 or 1) or ternary
(usually -1, 0, 1) [8]. Discretisation is often justified as
biological systems commonly exhibit switch-like on/off
behaviour. Moreover, there are also a number of prag-
matic reasons for quantising the measurements, e.g., it
reduces the level of model complexity implying less com-
putation and lower data requirements for model identi-
fication, provides a certain level of robustness to noise
in the data, and has been shown to substantially reduce
error rates in microarray-based classification [8,51-53]. A
number of methods for discretisation of gene expression
data exist, many of them having their origin in signal pro-
cessing. One approach to quantisation was proposed in
[54]: given some thresholds τ1 < τ2 < . . . (e.g., cor-
responding to limiting cases of a sigmoidal response), a
multilevel discrete variable x is defined as x = ϕ(x) = rk
for τk < x ≤ τk+1. As mentioned in [8], the thresh-
olds can either come from prior knowledge or be chosen
automatically from the data. In fact, there are various
ways for optimal selection of the thresholds τk . One of
the most popular methods is the Lloyd-Max quantizer,
which amounts to minimising a so-called mean square
quantisation error, see [55] for details. Approaches spe-
cific to binarising gene expression data can be found
in [56-58]. Recently, Hopfensitz et al. [58] proposed a
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Figure 5 An outline of the workflow in network inference and control in the PBN framework.Microarray data, either from steady-state or
time-course measurements, are typically binarised or discretised into discrete values. A heuristic approach, such as using genetic algorithms, is
generally applied to identify constituent Boolean networks of the inferred PBN. Regularisation methods can be further applied to improve the
accuracy of the inference with use of prior information on the network structure or dynamical rules. A number of well-established methods are
subsequently applied to determine the predictor probability of each constituent Boolean network, thus the PBN is inferred. The inferred PBN can
subsequently be perturbed with the methods on structural intervention or external control. The goal of network control is to increase the
probability of reaching desirable states in the corresponding PBN.
new approach to binarisation which incorporates mea-
surements at multiple resolutions. The method, called
Binarization across Multiple Scales, is based on the com-
putation of a series of step functions, detection of the
strongest discontinuity in each step function and the esti-
mation of the location and variation of the strongest
discontinuities. Two variants of the method are proposed
which differ in the approach towards the calculation of
the series of step functions. The proposed method allows
thresholds determination even with limited number of
samples and simultaneously provides a measure of thresh-
old validity – the latter can further be used to restrict
network inference only to measurements yielding rele-
vant thresholds. An example of application of binarisation
to real data in the context of modelling with PBNs can
be found in [10], where a brain connectivity network of
Parkinson’s disease is analysed. Binarisation is performed
on fMRI real-valued data along the method recently
proposed in [59].
One of the most straightforward inferential approaches
is the consistency problem (also referred to as the extension
problem), that entails a search for a rule from experimental
data [8,60-62]. The problem amounts to finding in a spec-
ified class of Boolean functions one that complies with
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two given sets of “true" and “false" Boolean vectors, i.e.,
a function that takes the value 1 for each of the “true"
vectors and 0 for each of the “false" vectors.
In the case of real experimental data, a consistent exten-
sion may not exist either due to measurement noise or
due to some underlying latent factors or other external
influences not considered in the model [8]. In such case
instead of searching for a consistent extension a Boolean
function that minimises the number of misclassifications
(errors) is considered. This problem is known as the
best-fit extension problem [61] and is computationally
more difficult than the consistency problem, since the
latter is a special case of the former.
The application of PBN for modelling of large-scale
networks is often impeded by limited sample sizes of
experimental data. As mentioned in [63], main challenges
in automated network reconstruction arise from the expo-
nential growth of possible model topologies for increasing
network size, the high level of variability in measured
data often characterised by low signal to noise ratios, and
the usually large number of different components that
are measured versus relatively small number of differ-
ent observations under changing conditions, e.g., number
of time points or perturbations of the biological system.
Together these problems lead to non-identifiability and
over-fitting of models [63]. In such cases any prior infor-
mation on the network structure or dynamical rules is
likely to improve the accuracy of the inference [8,64].
This information usually pertains to model complexity
and is used to penalise excessively complex models. For
this purpose, the so-called regularisation methods can
be employed. The most popular regularisation assump-
tion in gene regulatory modelling is that the inferred
models should be sparse, i.e., the number of regulators
acting on a gene is low [65-68] or that the node degree
in biological networks is often power law distributed,
with only few highly-connected genes, and most genes
having small number of interaction partners [63,69]. Reg-
ularisation is a well-established inference approach in the
framework of Bayesian networks (see, e.g., [63,70,71]) and
can be also used in the framework of BNs and PBNs.
For example, in the case of inference of Boolean net-
works, the so-called sensitivity regularisation method has
been proposed [64]. Due to limited sets of data, the
estimates of the errors of a given model in the best-
fit extension problem, which themselves depend on the
measurements, may be highly variable [64]. The regu-
larisation is built on the observation that the expecta-
tion of the state transition error generally depends on
a number of terms, among others the sensitivity devi-
ation which is a difference in the sensitivities of the
original and the inferred networks. In consequence, as
argued in [64], the sensitivity deviation can be incorpo-
rated as an additional penalty term to the best-fit objective
function, reflecting the hypothesis that the best inference
should have a small error in both state transition and
sensitivity.
In order to infer a PBN, strong candidates for regu-
lar Boolean networks need to be identified first. This
can be performed with generic methods mentioned in
[72] such as literature data compilation, the gene associ-
ation networks approach [73,74] or by applying a heuris-
tic approach, e.g., a genetic algorithm, which searches
through the model space to find good candidates for
the network structure with respect to a specified fitness
function. Next, the candidates’ predictor functions are
combined into a set of network transition functions for the
PBN. An example of PBNmodel selection using heuristics
can be found in [75].
A common strategy for determining the predictor prob-
abilities relies on the coefficient of determination (CoD)
between target and predictor genes [8,32,72,76]. The CoD
is a measure of relative decrease in error from estimat-
ing transcriptional levels of a target gene via the levels
of its predictor genes rather than the best possible pre-
diction in the absence of predictor genes [8]. The CoDs
can be then translated to the predictor probabilities. How-
ever, as pointed out in [77], for each gene, the maximum
number of possible predictors as well as the number of
their corresponding probabilities is equal to 22n , where
n is the number of nodes. This implies that the number
of parameters in the PBN model is O(n22n)e. Therefore,
the applicability of the CoD approach is significantly lim-
ited due to the model complexity or imprecisions owing
to insufficient data sample size. This hindrance is often
surpassed by imposing some constraints on the maximum
size of admissible predictors for each gene.
In [50] the authors consider the attractor inverse prob-
lem, that involves designing Boolean networks given
attractor and connectivity information. Two algorithms
for solving this problem are proposed. They are based
on two assumptions on the biological reality: first, the
biological stability, i.e., that most of the steady-state prob-
ability mass is concentrated in the attractors and, second,
the biological tendency to stably occupy a given state,
i.e., attractors are singleton attractor cycles consisting of
a single state. The first algorithm operates directly on the
truth table, while taking into account simultaneously the
information on the attractors and predictor sets. There is
however no control on the level-set structure. The sec-
ond algorithm works on the state transition diagram that
satisfies the design requirements on attractor and level-
set structures and checks whether the associated truth
table has predictor sets that agree with the design goals.
The proposed algorithms can be further used in a pro-
cedure for designing PBN from data. In the approach
described in [50], a collection of BNs is generated by
the first algorithm, then some of the BNs are selected
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based on the basin sizes criterion and combined in a
PBN whose steady-state distribution closely matches the
observed data frequency distribution. This design pro-
cedure has been applied to gene-expression profiles in a
study of 31 malignant melanoma samples in [50].
An inverse PBN construction approach is also described
in [78]. This work relies on expressing the probabil-
ity transition matrix as a weighted sum of Boolean
network matrices. A heuristic algorithm with O(m2n)
complexity is proposed, where n, m stand for the
number of genes, respectively the number of non-zero
entries in the transition matrix. The authors also intro-
duce an entropy based probabilistic extension, both
algorithms being analysed against random transition
matrices.
Usually, the optimal predictor for a gene will not be
perfect as there will be inconsistencies in the data. In
[79] it is proposed to model these inconsistencies in
a way that mimics context changes in genomic regu-
lation, with the intention to view data inconsistencies
as caused by latent variables. The inference procedure
of [79] results in PBNs whose contexts model the data
in such a way that they are consistent within each
context. The key criterion for network design is that
the distribution of data states agrees with the distribu-
tion of expected long-term state observations for the
system.
The probabilities of the system being in a particular
context and the number of constituent networks are deter-
mined by the data. The approach of [79] can be seen as
imposing a structure on a probabilistic Boolean network
that resolves inconsistencies in the data arising from mix-
ing of data from several contexts. It should be noted that
in this approach the contexts are determined directly by
the data, whereas in [32] and [80] constituent networks
depend on the number of high-CoD predictor sets or
high Bayes-score predictor sets, respectively, and these
in turn depend on the designer’s choice of a threshold.
Moreover, the number of constituent networks is deter-
mined by how inconsistencies appear in the data, not
the number of states appearing in the data (see [8] for
an example). The contextual-design method of [79] has
been applied to expression profiles for melanoma genetic
network.
We just mention here that also information theoretic
approaches were considered for inference of PBN from
data. Probably the most widely studied methods are based
on the minimum description length (MDL) principle [81].
Descriptions of inference algorithms that utilise this prin-
ciple can be found, e.g., in [8,82,83].
The manner of inference depends on the kind of exper-
imental data available. There are two cases: 1) time-series
data and 2) steady-state data. We proceed with presenting
them briefly.
Time-course measurements
It is assumed that the available data are a single temporal
sequence of network states. In this case, given a suffi-
ciently long sequence of observations, the goal is to infer
a PBN that is one of plausible candidates to have gener-
ated the data. Usually, an inference procedure for this type
of problem constructs a network that is to some extent
consistent with the observed sequence.
In [84,85], the inference in case of context-sensitive
PBNs with perturbations is considered, where the proba-
bility of switching from the current constituent Boolean
network to a different one is assumed to be small. The
proposed inference procedure consists of three main
steps: first, identification of subsequences in the tempo-
ral data sequence that correspond to constituent Boolean
networks with use of so-called ‘purity functions’; sec-
ond, determination of essential predictors for each subse-
quence by applying an inference procedure based on the
transition counting matrix and a proposed cost function;
finally, inference of perturbation, switching, and selec-
tion probabilities. However, the amount of temporal data
needed for inference with this approach is huge, especially
due to the perturbation and switching probabilities: if they
are very small, then long periods of time are needed to
escape attractors and if they are large, estimation accu-
racy is harmed. As stated in [85], if one does not wish to
infer the perturbation, switching, and selection probabili-
ties, then constituent-network connectivity can be discov-
ered with decent accuracy for relatively small time-course
sequences.
A more practical way of inferring PBN parameters
from time-course measurements is presented in [77]. The
authors propose a multivariate Markov chain model to
infer the genetic network, develop techniques for esti-
mating the model parameters and provide an efficient
method of estimating PBN parameters from their multi-
variate Markov chain model. The proposed technique has
been tested with synthetic data as well as applied to gene
expression data of yeast.
Further, in [86] the problem of PBN context estimation
from time-course data is considered. The inference is con-
sidered with respect to minimising both the conditional
and unconditional mean-square error (MSE). The author
proposes a novel state-space signal model for discrete-
time Boolean dynamical systems, which includes as spe-
cial cases distinct Boolean models, one of them being
the PBN model. A Boolean Kalman Filter algorithm is
employed to provide the optimal PBN context switch-
ing inference procedure in accordance to minimisation of
MSE.
Steady-state data
Here we consider a long-run inverse problem in the
context of probabilistic Boolean networks as models for
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gene regulation. On one hand, in the case of microarray-
based gene-expression studies it is often assumed that
the data are obtained by sampling from a steady state.
On the other hand, attractors represent the essential
long-run behaviour of the modelled system [31]. Thus,
in the modelling framework of Boolean networks it is
expected that the observed data states are mostly the
attractor states of amodel network. In consequence, much
of the steady-state distribution mass of the model net-
work should lie in the states observed in the sample
data [50,80,87]. In the case of Boolean networks with
perturbations or probabilistic Boolean networks with per-
turbations, the underlying dynamical system is an ergodic
Markov chain, hence possesses a steady-state distribution.
However, by imposing somemild stability constraints that
reflect biological state stability, also in these frameworks
most of the steady-state probability mass is carried by the
attractors [31].
There are however inherent limitations to the con-
struction of dynamical systems from steady-state data.
Although the steady-state behaviour restricts the net-
work dynamics, it does not determine the steady-state
behaviour: there may be a collection of compatible net-
works with a given attractor structure. In particular, it
does not determine the Boolean network’s basin structure.
As a consequence, obtaining good inference relative to the
attractor structure does not necessary entail valid infer-
ence with respect to the steady-state distribution as the
steady-state probabilities of attractor states depend on the
basin structure [50,80]. In fact building a dynamical model
from steady-state data is a kind of over-fitting [88].
Although the CoD has been used for inference of PBNs
from steady-state data in [32], a fundamental problem is
that the CoD cannot provide information on the direc-
tion of prediction without time-course data. The resulting
bidirectional relationships can affect the inferred graph
topology by introducing spurious connections. Moreover,
they can lead to inference of spurious attractor cycles that
do not correspond to any biological state [8]. As a conse-
quence, this suppressed the use of the CoD as a inference
method for steady-state data.
The inference methods that replaced the CoD approach
are primarily based on the attractor structure [50,79] or
graph topology [89]. In the former case, the key concern
is to infer an attractor structure close to that of the true
network. In the latter case, the focus is on the agree-
ment between graph connections, e.g., as measured by
the Hamming distance between the regulatory graphs [8].
In [16], an approach that achieves both preservation of
attractor structure and connectivity based on strong gene
prediction has been proposed.
Another approach to the problem of constructing gene
regulatory networks from expression data using the PBNs
framework is proposed in [90]. The key element of this
method is a non-linear regression technique based on
reversible-jump Markov chain Monte Carlo (MCMC)
annealing for predictor design. The network construc-
tion algorithm consists of the following stages. First, for
each target gene xi (i = 1, 2, . . . , n) in the network of
n genes a collection of predictor sets is determined by
applying a clustering technique based on mutual informa-
tion minimisation. Optimisation f is performed with use
of the simulated annealing procedure. This step reduces
the class of different predictor functions available for
each target gene. Next, each predictor set is used to
model a predictor function f (i)k by a perceptron con-
sisting of both a linear and a nonlinear term, where
k = 1, 2, . . . , l(i), with l(i) the number of predictor sets
found in the previous step for target gene xi. A reversible
MCMC technique is used to calculate the model order
and the parameters. Finally, the CoD is used to compute
the probability of selecting different predictors for each
gene. For a detailed description of this algorithm and its
application to data on transcription levels in the context
of investigating responsiveness to genotoxic stresses see
[90]. It should be noticed that the proposed reversible-
jump MCMC model for predictor design extends the
binary nature of PBNs allowing for a more general model
containing non-Boolean predictor functions that operate
on variables with any finite number of possible discrete
values [72].
As an alternative to the technique of [90], a fully
Bayesian approach (without the use of CoD) for con-
structing probabilistic gene regulatory networks, with an
emphasis for network topology, is proposed in [80]. In
this approach, the predictor sets of each target gene are
computed, the corresponding predictors are determined,
and the associated probabilities, based on the nonlinear
perceptron model of [90], are calculated by relying on
a reversible jump MCMC. Then, a MCMC method is
used to search for the network configurations that max-
imise the Bayesian scores to construct the network. As
stated in [8], this method produces models whose steady-
state distribution contains attractors that are either iden-
tical or very similar to the states observed in the data.
Moreover, many of the attractors are singleton attractors,
which reflect the biological propensity to stably occupy
a given state. The approach of [90] has been applied to
gene-expression profiles resulting from the study of 31
malignant melanoma samples presented in [91].
In [92] the inverse problem of constructing instanta-
neously randomPBNs from a given stationary distribution
and a set of given Boolean networks is considered. Due
to large size of this problem, it is formulated in terms of
constrained least squares and a heuristic method based on
Conjugate Gradient is proposed as a solution.
In [93], the inverse problem of PBNs with perturba-
tions is considered, where a modified Newton method is
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proposed for computing the perturbation probability p
where the transition probability matrix A˜ and the steady-
state probability of the PBNp x˜ are known. The new
algorithm makes use of certain properties of the set of
steady-state nonlinear equations, i.e., A˜x˜ − x˜ = 0, with
p as the unknown variable. Considering these proper-
ties improves the computational efficiency with respect
to a direct approach in which every of the 2n equations
(n being the number of nodes) is solved and common
solutions are reported.
Structural intervention and control of PBNs
Using PBNs for the modelling and analysis of biological
systems can lead to a deeper understanding of the dynam-
ics and behaviour of these systems (see Section ‘Dynamics
of PBNs’), paving the way for different methods used for
system structure inference and data measurement (see
Section ‘Construction and inference of PBNs as models
of gene regulatory networks’). Another major objective of
such studies is to predict the effect a perturbation or an
intervention has on the system structure, e.g., allowing to
identify potential targets for therapeutic intervention in
diseases such as cancer. Intervention strategies in PBNs,
e.g., as to change the long-run behavior of networks in
order to decrease the probability of entering some unde-
sired state, rely on two different kinds of direction –
structural intervention [8,33] and external control [8,18].
While the first approach can alter the underlying network
structure permanently, the second one uses external con-
trol to modulate the network dynamics. A classification of
network control methods in the PBN framework is shown
in Figure 5.
Structural intervention
The problem of performing a structural intervention in
a PBN looks at how the steady-state probability of cer-
tain states can be changed with only minimal structural
modifications [8,33]. A more formal description is offered
in the following. Given a PBN and two subsets A and
B of its states, the associated steady-state probabilities
π(A), π(B), have to be modified such as to approach some
given values λA, respectively λB. This can be achieved by
replacing the predictor function fik (of gene i in context
k) with a new function gik , while keeping all other net-
work parameters unchanged. We denote the steady-state
distribution of the resulting PBN as µ. Then, it is possi-
ble to interpret the problem as an optimisation one: given
the state sets A, B, and two values λA ≥ 0, λB ≥ 0,
with λA + λB ≤ 1, find a context k, a gene i, and a func-
tion gik to replace fik , such as to minimises ϵ(A,B) =|
µ(A)− λA | + | µ(B)− λB |, with respect to all contexts,
genes, and predictor functions. Note that A and B can
be used to represent both desirable as well as undesirable
states. While this approach allows changing one predictor
function at a time, a generalisation can be made by allow-
ing a number of predictor functions or by adding more
constraints on the selected functions, only to give a few
examples.
Shmulevich et al. [33] proposed using genetic algo-
rithms to deal with the above optimisation problem.
Later, Xiao and Dougherty [94] provided a construc-
tive algorithm for structural intervention and applied it
to a WNT5A network. The proposed algorithm focuses
on the impact one-bit predictor function perturbations
have on state transitions and attractors. Their approach,
however, does not directly characterise the steady-
state distribution changes that result from (structural)
perturbations of a given probability. In order to solve this
problem, Qian and Dougherty [95] derived a formal char-
acterisation of optimal structural intervention, based on
the general perturbation theory in finite Markov chains.
Specifically, they gave an analytical solution for comput-
ing the perturbed steady-state distribution by looking at
function perturbations. Their work mainly focused on
one-bit function (or rank-1 matrix) perturbations, imply-
ing that for more general perturbations, one needs to
consider an iterative approach. The associated complexity
of such an approach is of O(23n), where n is the num-
ber of genes in the network. Their results have been
applied to a WNT5A network and a mammalian cell
cycle related network, respectively. More recently, Qian
et al. [96] extended their previous result in [95] to a
more efficient solution that uses the Sherman-Morrison-
Woodury (SMW) formula [97] to deal with rank-k matrix
perturbations. Thus, they managed to reduce the com-
putational complexity of the approach from O(23n) to
O(k3), where k ≪ 2n (k is much smaller than 2n).
The application of the derived structural intervention
method to a mutated mammalian cell cycle network
shows that the intervention strategy can identify the
main targets to stop uncontrolled cell growth in the
network.
Qian and Dougherty [98] also looked at how long-run
sensitivity analysis can be used in PBNs, in terms of
difference between steady-state distributions before and
after perturbation, and with respect to different elements
of the network, e.g., probabilistic parameters, regulatory
functions, etc.
External control
While structural intervention focuses on a permanent
change in the network dynamics, external control relies on
Markov decision processes theory for driving a network
out of an undesired state, i.e. as to reach a more desirable
one [8,18].
The first approach to deal with PBNs was proposed by
Shmulevich et al. [18]. They studied the impact of ran-
dom gene perturbations g on the long-run behavior of a
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network. The main idea of Shmulevich et al. [18] is to
construct a formulation of the state-transition probability
that relies on the probability of a gene perturbation and on
Boolean functions for finding bounds for the steady-state
probability. Their particularly interesting finding is that
these states (which in terms of mean first-passage times
(MFPT) are easy to reach from other states) are more sta-
ble with respect to random gene perturbations. In gene
regulatory networks, it is important to identify what genes
are more likely to lead the network into a desirable state
when perturbed. MFPT naturally captures this idea – a
few other methods developed by Shmulevich et al. [18]
work, for example, by maximising the probability to enter
some particular state in some fixed maximum amount
of time, or by minimising the time needed to reach
that state.
Gene perturbation works by single flips of a gene’s
state, providing a natural platform for external interven-
tion control via auxiliary input variables. It makes sense
from a biological perspective, for example, to model aux-
iliary treatments in cancer such as radiation. The value
of these variables can be thus chosen such as to make
the probabilistic distribution vector of the PBN evolve in
some desired manner.
More formally, given a PBN with n genes and k
control inputs, u1,u2, . . . ,uk , the vector u(t) =
(u1(t),u2(t), . . . ,uk(t)) is used to denote the values of all
control inputs at a given time step t. Let P denote the tran-
sition probability matrix of the PBN, evolving according
tow(t+1) = w(t)·P(u(t)). It is obvious to see that, at each
time step t, P depends not only on the initial probability
distribution vector, but also on the values of the control
inputs. External control is essentially about making the
network evolve in some desired manner by choosing, at
each time step, input control values. The sequence of con-
trol inputs, referred to as a control policy or strategy, can
be associated to a cost function which has to beminimised
over the entire class of allowed policies. Such functions
capture the cost and benefit of using interventions, and
are normally application dependent. For the sake of sim-
plicity, we use Jω(z(0)) to denote the cost with respect to
a control policy ω and an initial state z(0). Then, an opti-
mal PBN control problem can be defined as a search for a
control policy ω that minimises the cost Jω(z(0)). External
control in PBNs can be classified into the following two
groups.
Finite-horizon external control
The finite-horizon external control problem is about mod-
ifying over a transient period of time the network dynam-
ics of some given PBN, without changing its steady-state
distribution. In other words, external control is only
applied over a finite number of M time steps, using
policies of the form ω = (µ0,µ1, . . . ,µM−1). The first
optimal finite control formulation in PBNs, and a solu-
tion based on Dynamic Programming [99], were given by
Datta et al. [100]. Working assumptions implied known
transition probabilities and horizon length, later removed
in [101] by making use of measurements, thought to be
related to the underlying Markov chain states of the PBN.
Pal et al. [17] extended the results of Datta et al. [100,101]
to context-sensitive PBNs with perturbation. The results
have been used to devise a control strategy that
reduces the WNT5A gene’s action in affecting biological
regulation.
Optimal finite-horizon dynamic programming based
control, assuming a fixed number of time steps M and
a fixed number of controls k, has a computational com-
plexity of O(22n), where n is the number of genes in the
network. Namely, the problem is limited by the size of
the network as one needs to compute the transition prob-
ability matrix. In particular, Akutsu et al. [102] proved
that the problem is NP-hard.h Chen and Ching [103] used
dynamic programming in conjunction with state reduc-
tion techniques [104,105] to find an optimal control policy
for large PBNs. They managed to reduce the computation
complexity to O(| R |), where | R | is the number of states
after state reduction.
Kobayashi and Hiraishi [106] proposed an integer pro-
gramming based approach that avoids computing the
probability matrix in optimal finite-horizon control. Later,
they extended their work to context-sensitive PBNs
[107,108], focusing on the lower and upper bounds of the
cost function. Furthermore, Kobayashi and Hiraishi [109]
proposed a polynomial optimisation approach where a
PBN is first transformed into a polynomial system, sub-
sequently allowing to reduce the optimal control to a
polynomial optimisation problem. In the above papers,
only small examples are used to illustrate the proposed
approaches.
Ching et al. [110] looked at hard constraints for an upper
bound on the number of controls, and proposed a novel
approach that requires minimising the distance between
terminal and desirable states. They also gave a method to
reduce the computational cost of the problem by using
an approximation technique [12]. Cong et al. [111] made
one step further by considering the case of multiple hard
constraints, i.e., the maximum numbers of times each
control method can be applied, developing an algorithm
capable of finding all optimal control policies. A heuris-
tic approach was developed by the same authors in order
to deal with large size networks [111]. A different and
more efficient algorithm, using integer linear program-
ming with hard constraints, was presented later by Chen
et al. [112]. The WNT5A network is a typical example
used in [111,112].
Instead of minimising the cost, Liu et al. [113] investi-
gated the problem of how control can be used to reach
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desirable network states, with maximal probability and
within a certain time. Later, Liu [19] imposed another
new criterion for the optimal design of PBN control
policies, namely the expected average time required to
transform undesired states into desirable ones. In both
papers, the optimal control problem can be solved by
minimising the MFPT of discrete-time Markov decision
processes.
The controllability problem of PBNs was studied by
Li and Sun [114]. A semi-tensor product of matrices, as
described in their work, allows to convert a probabilistic
Boolean control network into a discrete time system. They
provided some conditions for the controllability of PBNs
via either open or closed loop control.
Infinite-horizon external control
Infinite-horizon external control implies working with
external auxiliary variables, over an infinite period of time,
the steady-state distribution being also changed. Policies
in this case have the form of ω = (µ0,µ1, . . .).
In the finite-horizon case, the optimal control policy
is calculated by (essentially) using a backward dynamic
programming algorithm, ending once the initial state is
reached. However, this approach cannot be applied to
infinite-horizon control directly due to the non-existence
of a termination state in the finite-horizon case, poten-
tially leading to an infinite total cost. Pal et al. [115]
extended the earlier finite-horizon results to the infinite-
horizon case for context-sensitive PBNs. They solved
the above two problems by using the theory of average
expected costs and expected discounted cost criteria in
Markov decision processes. For applications, they consid-
ered a gene network containing the genes WNT5A, pirin,
S100P, RET1, MART1, HADHB, and STC2.
A robust control policy can be found in Pal et al.
[116], devised via a minimisation of the worst-case
cost over the uncertainty set, with uncertainty defined
with respect to the entries of the transition probability
matrix.
Due to the computational complexity of O(22n), sev-
eral greedy algorithms have been proposed in the lit-
erature. Vahedi et al. [117] developed a greedy control
policy that uses MFPT. Their main idea is to reduce
the risk of entering undesirable states by increasing (or
decreasing) the time needed to enter such a state (or,
respectively a desirable state). Performance of the MFPT-
based algorithm was studied on a few synthetic PBNs
and a PBN obtained from a melanoma gene-expression
dataset, where the abundance of messenger RNA for
the gene WNT5A was found to be highly discriminating
between cells with properties associated with high or low
metastatic competence. Later, three different greedy con-
trol policies were proposed by Qian et al. [118], using the
steady-state probability mass. The first one explores the
structural information of a basin of attractors in order
to reduce the steady-state probability mass for undesir-
able states, while the remaining two policies regard the
shift in the steady-state probability mass of undesirable
states as a criterion when applying control. The identi-
fied three policies, together with the one based on MFPT
[117], were evaluated on a large number (around 1000) of
randomly generated networks and a mammalian cell cycle
network [119].
Some types of cancer therapies like chemotherapy, are
given in cycles with each treatment being followed by a
recovery period. Vahedi et al. [120] showed how an opti-
mal cyclic control policy can be devised for PBNs. Yousefi
et al. [121] extended the results in [120] to obtain opti-
mal control policies for the class of cyclic therapeutic
methods where interventions have a fixed-length dura-
tion of effectiveness. Both of the two approaches [120,121]
were applied to derive optimal cyclic policies to control
the behavior of regulatory models of the mammalian cell
cycle network [119]. While the goal of control policies
is to reduce the steady-state probability mass of unde-
sirable states, in practice it is also important to limit
collateral damage, to consider when designing control
policies. Based on this observation, Qian and Dougherty
[122] developed two new phenotypically-constrained con-
trol policies by investigating their effects on the long-run
behaviour of the network. The newly proposed policies
were examined on a reduced network of 10 nodes. The
network was obtained from gene expression data collected
for the study of metastatic melanoma (e.g, see [91]).
Relationship between PBNs and other probabilistic
graphical models
Probabilistic graphical models, commonly applied in com-
putational biology for network reconstruction, provide
the means for representing complex joint distributions.
Examples include PBNs, Bayesian networks and their vari-
ants, e.g., dynamic and hierarchical Bayesian networks,
hidden Markov models, factor graphs, Markov random
fields, conditional random fields, Markov logic networks,
etc. In this section we discuss the relationship between
the two of them which are usually employed to deal with
system dynamics: the PBNs and the dynamic Bayesian
networks, the latter generalising hidden Markov models.
A Bayesian network is essentially a graphical, com-
pact representation of a joint probability distribution.
The Bayesian network consists of two elements. First, a
directed acyclic graph (DAG) where the vertices of the
graph represent random variables and the directed edges
or lack thereof encodes the so-called Markovian assump-
tion, which states that each variable is independent of its
non-descendants, given its parents [8,123]. Second, a set
of local conditional probability distributions for each ver-
tex, given its parents in the graph. By the chain rule of
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probabilities, the joint probability distribution on the ran-
dom variables in the graph can be decomposed into a
product of the local conditional probabilities, i.e., if there
are n random variables Xi, i = 1, 2, . . . , n and Pa(Xi)
denotes the parents of Xi in the graph, then the joint
probability distribution factors as
Pr(X1,X2, . . . ,Xn) =
n∏
i=1
Pr(Xi|Pa(Xi)). (8)
Two different Bayesian networks can encode the same
set of independencies. Such networks are said to be equiv-
alent. Equivalent networks cannot be distinguished when
inferring the network from measurement data. One way
to bypass this difficulty is to perform targeted interven-
tion experiments which can narrow the range of possible
network architectures.
Dynamic Bayesian networks (DBNs) are extensions of
Bayesian networks to the temporal domain and can be
used to model stochastic processes [70]. DBNs generalise
hidden Markov models and linear dynamical systems by
representing the conditional dependencies and indepen-
dencies between variables over time. Contrary to Bayesian
networks, DBNs can be used to model feedback rela-
tionships, a ubiquitous element in genetic regulation. In
comparison to PBNs, dynamic Bayesian networks support
the assignment of quantitative state values, making this
modelling approach more flexible to handle various types
of data. DBNs are broadly applied to represent biologi-
cal networks such as gene regulatory networks [124-127],
signal transduction networks, e.g., [128-130], metabolic
networks [131], as well as networks in physiology and
medicine [132-136].
As shown in [137], PBNs and binary-valued DBNs
whose initial and transition Bayesian networks are
assumed to have only within and between consecutive
slice connections, respectively, can represent the same
joint probability distribution over their common variables.
This is true both for independent as well as dependent
variants of PBNs. However, there are many statistically
equivalent PBNs that correspond to a DBN. On one hand,
the PBN framework can be considered as redundant from
the probabilistic point of view. On the other hand, it is
richer from the functional point of view because it models
the regulatory roles of different gene sets in more detail
than the conditional probabilities in DBNs [137]. The
conversion algorithms between the two modelling for-
malism are presented in [137], both for independent and
dependent PBNs. Also the extensions of standard PBNs
to context-sensitive PBNp is discussed. The perturbations
and context switching can be introduced in the DBN for-
malism by adding additional hidden nodes to the dynamic
Bayesian network, as shown in [137].
In terms of applications, it has been shown that both
the PBN and the DBN approaches principally have good
performance on the inference of gene regulatory networks
from microarray data [138]. In addition, the connection
between PBNs and DBNs makes it possible to apply the
advancedDBNs to PBNs tools and vice versa. For example,
an abundant collection of learning theory and algorithms
for DBNs already exists and methods for the analysis
of temporal behaviour of DBNs are already established.
These techniques can be tailored to be applied directly in
the context of PBNs. Conversely, the tool for controlling
the steady-state behaviour of the networks, tools for net-
work projection, node adjunction, resolution reduction as
well as efficient learning schemes can be applied to DBNs.
As presented in [139], PBNs and dynamic Bayesian
networks can be viewed as consisting of a probabilis-
tic (Markov chain) and of a (Boolean) logic component.
In the case of a dynamic Bayesian network, the proba-
bilistic component is defined by a conditional probability
chain rule and a Markov chain while the logic component
is given by propositional logic with structural require-
ments. As shown in [139], Bayesian networks, with their
hierarchical and dynamic variants, as well as probabilis-
tic Boolean networks, are all generalised by Markov logic
networks. The same separation of components applies.
For a Markov logic network, the probabilistic compo-
nent is a Markov random field and the logic compo-
nent is the first order logic. We refer to [139] for more
details on this framework, its applications in biology and
medicine as well as the relationship with Bayesian net-
works.
PBN applications in biological and biomedical
studies
PBNmodels for the representation of biological networks
Even though a significant part of the research on PBNs is
theoretical, a large number of applied studies on the use
of PBNs for various biological systems can be found in
the literature. This is particularly the case with inference
of models for molecular and physiological networks (from
prior knowledge or data), with subsequent model analysis
that leads to novel knowledge in biology and medicine.
PBNs asmodels of gene regulatory networks
PBNs were originally developed as models for Gene Reg-
ulatory Networks (GRNs) [3,8]. As stated in [32], PBNs
1) incorporate rule-based dependencies between genes;
2) allow the systematic study of global network dynam-
ics; 3) are able to cope with uncertainty, both in the
data and model selection; and 4) permit the quantifica-
tion of the relative influence and sensitivity of genes in
their interactions with other genes. In the PBN modelling
framework, gene expression is quantised to two levels: ON
and OFF.
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The dynamical behaviour of PBNs can be used to model
many biologically meaningful phenomena, such as cellular
state dynamics possessing switch-like behaviour, hystere-
sis, stability, and etc. [32,140]. Often, the attractor cycles
are interpreted as functional states on physiological time
scales or as cellular phenotypes on developmental time-
scales [7,8]. This interpretation is fairly reasonable asmost
cell types are characterised by stable recurrent patterns of
gene expression [31].
In the past years, there were several studies which suc-
cessfully applied PBNs for the construction of GRNs from
high-throughput gene expression microarray experiment
data. In 2006, Yu et al. inferred a GRN of the inter-
feron pathway in macrophages using time-course gene
expression data [22]. The optimal network was identi-
fied applying the CoD approach. It was shown that the
respective selection probabilities are varying for different
biological conditions, e.g., after interferon treatment or
after viral infection on macrophage, while the structure of
the constituent network, i.e., predictor functions, remains
stable. With a similar approach, Nguyen et al. inferred a
GRN of hepatocellular carcinoma from microarray data
and compared it to a network derived from control non-
cancerous samples [141]. They indicated that certain
genes in tumour samples show activity in steady-state
periods while there is no activity for these genes in the
control (non-cancerous) samples. This allowed to distin-
guish different gene regulatory processes being realized
with the same set of genes.
Hashimoto et al. modelled the cell cycle of budding
yeast by using context-sensitive PBNs [23]. They showed
that the switching behaviour from stationary G1 phase
to excited G1 phase in the PBN model is more frequent,
when compared to the stochastic model of Zhang et al.
[142]. Recently, Todd et al. identified the ergodic sets of
states in PBNs that correspond to each phase of the bud-
ding yeast cell cycle, which in turn correspond to the
cellular phenotypes [44]. The analysis of the dynamical
behaviour gave additional insights on yeast cell cycle regu-
lation, e.g., the yeast cell cycle network showed robustness
both to external variable environments and to certain per-
turbations such as nitrogen deprivation, where yeast cells
proceeded through one round of division and arrest at G1
phase without appreciable growth.
In 2011, Flöttmann et al. modelled the regulatory pro-
cesses that govern the production of induced Pluripotent
Stem (iPS) cells by considering the interplay between gene
expression, chromatin modification, and DNA methyla-
tion [24]. As there is no clear guideline on how to assign
Boolean functions to represent the interactions of each
gene, their PBN model was designed to work by repre-
senting uncertainty via two assignments. First, a number
of possible functions were assigned to the corresponding
nodes with different probabilities. Second, the influences
of certain nodes were split into separated Boolean func-
tions with varied selection probabilities. A flexibility was
thus allowed for choosing Boolean functions that fit the
experimental data. With their PBN model, an extensive
analysis was performed, allowing to demonstrate epige-
netic landscape changes from differentiated cells to iPS
cells as a function of time step. In addition, by looking at
model variants of the core iPS regulation, it was shown
that an increased chromatin modification rate could
improve reprogramming efficiency while faster changes in
DNA methylation could provide an enhanced rate though
at the price of trading-off efficiency.
PBNwithin signal transduction network andmetabolic
networkmodelling
To date, there is no study which specifically applied
PBN as a stand-alone framework for modelling sig-
nal transduction or metabolic networks. Nevertheless,
PBN was combined with other algorithms or modelling
frameworks. Fertig et al. presented GESSA, Graphically
Extended Stochastic Simulation Algorithm, a mechanis-
tic hybrid model which integrates the network model
of cell signalling with pooled PBN to a differential
equation-based model of transcription and translation
computed by a stochastic simulation algorithm [25].
The cell signalling PBN model is generated by simu-
lating individual protein copies with the correspond-
ing state transitions updated according to the rules in
the PBN. The sum of the resulting molecular states
across copies, i.e., of each individual species, is com-
pared to the initial state, the difference being afterwards
returned and the cellular state being updated. GESSA
was applied to the study of the cell fate decision of val-
val precursor cells in C. elegans, where model predic-
tions matched the experimental results even for mini-
mal parameterisations of the PBN. It was thus shown
that PBN could be an essential component when flexi-
bility is needed in multi-level data integration and model
construction.
In metabolic modelling, Chandrasekaran et al. pre-
sented an automated algorithm for the Probabilistic Reg-
ulation of Metabolism (PROM), allowing to reconstruct
a probabilistic GRN integrated with a metabolic net-
work from high-throughput data[26]. PROMmakes use of
conditional probabilities to model transcriptional regula-
tion, similar to the CoD concept in PBN inference. This
formalism permits the strength of transcription factor
(TF)-gene regulation as well as gene states to be rep-
resented in terms of probabilities. PROM was used to
generate a genome-scale integrative transcriptomic and
metabolomic network of Escherichia coli, where PROM
surpassed the state-of-the-art methods such as the regu-
latory flux balance analysis. PROM was also used to gen-
erate an integrative model ofMycobacterium tuberculosis.  
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The results from the model analysis offered additional
details on known regulatory mechanisms and also helped
to uncover the function of less studied genes on metabolic
regulation.
Apart from these two studies, several other works also
made use of a probabilistic framework for analysing sig-
nal transduction and metabolic networks. Kaderali et al.,
for instance, developed an algorithm that reconstructs
signalling pathways from gene knockdown data (RNAi
data) [143]. In this work, pathway topologies are inferred
by using Bayesian networks with probabilistic Boolean
threshold functions. The algorithm was used to study
the Janus Kinase and Signal Transducers and Activators
of Transcription (JAK/STAT) pathway, correctly recon-
structing the core topology of the pathway along with
model variants. Similarly, Sauer et al. [144] used prob-
abilistic equations to determine flux ratios, allowing to
express the relative contribution of certain metabolites or
pathways as modulators in the network. This assignment
is more realistic than using flux absolute integer numbers,
given that the flux of each source can relatively contribute
to the production of certain metabolites.
PBN applications in the context of physiology
PBNs were also used in the recent years for studying net-
works in physiology, with a close link to medicine. Tay
et al. described a dengue hemorrhagic fever (DHF) infec-
tion model which contains the interplay between dengue
virus and different cytokines which are cross-regulated in
T-helper 1 (Th1) and Th2 cells [9]. In their work, a sin-
gle probabilistic Karnaugh-Map is generated, modelling
the inducement probability of each cell as to define the
overall influence of inducing nodes. Simulation results
matched clinical data for both synchronous and asyn-
chronous updating, with respect to the form and the
average duration-based attractors, respectively. In addi-
tion, by applying a genetic algorithm [145] to modulate
the DHF attractor basins to dengue fever (DF) basins (a
less severe form of DHF), Tay et al. also identified the
tumour growth factor beta (TGFβ), interleukine-8 (IL-8)
and IL-13, as sensitive intervention points.
Another example in this field can be found in the study
of Ma et al., where, based on functional Magnetic Reso-
nance Imaging (fMRI) data, the authors developed a brain
connectivity network model for Parkinson’s disease [10].
A method similar to the one of Yu et al. [22] was used
for probability inference selection, i.e., the calculation of
CoDs. Then the CoDs were subsequently used to gener-
ate an influence matrix representation of the brain sig-
nal connectivity among brain components. The obtained
results showed that a significant difference in connec-
tivity exists for many paired brain-components com-
paring between normal, Parkinson’s disease with drug,
and Parkinson’s disease with drug withdrawal conditions,
and this difference was expressed in terms of estimated
range of coefficient mean activity. This particular infor-
mation may allow to construct a new screening procedure
for Parkinson’s disease diagnose and to determine drug
trial responsiveness based on a non-invasive, fMRI-based
investigation in the future.
A certain number of the previously described (applied
research) articles on PBN have applications not only in
molecular biology, but also in physiology or medicine.
Only to name a few examples, being able to distinguish
among the regulatory networks of cancer and healthy
cells, as presented by Nguyen et al., could contribute to an
early detection of cancerous genes in susceptible popula-
tions [141]. A better understanding of dynamic processes
and the control of somatic cell programming, as proposed
by Fertig et al., may lead to a future use of iPS cells in cell
or tissue replacement therapies [25]. Last but not least,
the PROM algorithm, as introduced by Chandrasekaran
et al., is capable of predicting transcription factor drug
targets which are major hubs in the cellular network of
pathogenic organism such asMycobacterium tuberculosis
[26]. A further development of drugs in this direction may
help in the treatment of different infectious diseases. This
new line of treatment could have a strong impact for third-
world countries where infectious diseases still remain a
major cause of death.
PBN for Systems Biology and Systems Biomedicine?
As previously discussed, the PBN framework is a topic of
intensive and continuous theoretical research with suc-
cessful applications in the biomedical area. To describe
and extend a vision on future PBNs’ applications, we sum-
marise additional arguments to support why this mod-
elling approach is suitable for future research in Systems
Biology and Systems Biomedicine.
Data integration
Different types of biological and clinical investigation
datasets, ranging from qualitative to high-throughput
quantitative experimental data, were successfully applied
in PBN inference and analysis. Yu et al. [22] and Nyugen et
al. [141], for instance, inferred GRNs of macrophages and
hepatocellular carcinoma using microarray gene expres-
sion data. Flöttmann et al. [24] built a comprehensive
epigenetic regulatory network of iPS cells based on gene
expression, chromatin modification and DNA methyla-
tion data generated frommultiple high-throughput exper-
iments. Ma et al. applied voxel selection on fMRI clinical
data to capture the activities of each brain’s compartment
as the inputs for learning a functional brain connectivity
network [10].
We have recently shown that the normalised activity of
signalling proteins from quantitative western blot exper-
iment can be compared to the steady-state probability
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of certain molecule to be ON in instantaneously-random
PBNs. In an ergodic model, the activities of signalling
proteins, usually given by their phosphorylated forms nor-
malised to the maximal signal, could be correlated with
the steady-state probability distribution on the state space
of the PBN model. With this regard, PBN could support
the integration of semi-quantitative experimental data.
Apart from quantitative western blot data, the profiles
of signalling proteins from alternative experiments such
as enzyme-link immunosorbent assay (ELISA) and high-
throughput protein array data are also compatible with
this framework (publication submitted).
The PBN framework also allows for the description
and analysis of large-scale models, for instance as in
the case of a Boolean model of apoptosis of Schlatter
et al. [146]. Therein, a PBN model was derived from
the original literature-based BN consisting of 86 nodes
and 125 Boolean interactions. Quantitative experimental
data in this study were normalised to the maximal sig-
nals across experiments and were used as input data for
the PBN model. We analysed the strengths of canoni-
cal pathways and crosstalk interactions between different
signalling components among apoptotic and related sig-
nalling pathways through the identification of selection
probability. It was possible to obtain these via optimi-
sation. Thereby a curated signal transduction network
topology was derived. The resulting PBN demonstrates
the correlation between UVB irradiation, NFκB, caspase
3, and apoptotic activities in a semi-quantitative manner
which could not be demonstrated by the original BN. The
analysis pointed at an inconsistent caspase 3 measure-
ment, which shows no activity for high UVB irradiation
while significant apoptosis is measured (see Figure 6,
publication submitted).
Furthermore, the PBN framework has a good poten-
tial to describe cellular dynamics at multiple levels.
Hybrid PBN-related models could be applied, as previ-
ously described, e.g., in the studies of Fertig et al. and
Chandrasekaran et al. [25,26]. As reviewed in detail by
Gonçalves et al. [147], bridging layers towards an inte-
gration of signal transduction, regulation and metabolism
into mathematical models still posts many challenges as
each of the biological layer has their own distinct char-
acteristics and therefore is suitable for only a subset of
modelling approaches. To address such challenges, an
integrative hybridmodel for flux balance analysis was pro-
posed, combining BN modelling for the gene regulatory
part, ODE modelling for the signal transduction part and
Normalised experimental data
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Figure 6 A comparative study of apoptotic signalling in the context of Boolean and probabilistic Boolean networks. Background
subtracted and normalised experimental data derived from Schlatter et al. is shown in the top box. The experimental data compare the activities of
downstream signalling molecules and apoptotic activity in the control setting (no stimulation) versus two intensities of UVB irradiation (UVB_low,
300 J/m2 and UVB_high, 600 J/m2). The activities of caspase 3 refer to the high caspase 3 activities of the original publication. The steady-state
values from the original BN and the steady-state probability of the molecules to be ON from the optimised PBN of one exemplifying run are shown
in brackets. (Note: The interactions between each node in the actual network are much more complex than the simplified diagram as shown.).
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flux balance analysis for the metabolic part. With this
regard, PBN could also be integrated as part of such a
hybrid model to describe GRNs and/or signalling net-
works to provide more details on modelling analysis and
interpretation comparing to traditional BNs.
Computational tools for PBNmodelling and analysis
Several PBN modelling and analysis tools were continu-
ously developed over the past recent years. The BN/PBN
MATLAB-based toolbox, introduced by Lähdesmäki and
Shmulevich in 2003 [27], deals with the simulation, analy-
sis (network statistics, state transitions and distributions),
visualisation and intervention analysis of both BN and
PBN models. The toolbox was specifically designed for
GRN inference and it makes use of CoD calculations.
State transition probabilities and influence values (the
indicators for interactive effect for each pair of genes)
are subsequently calculated based on these calculated
CoDs. Ma et al. successfully applied the BN/PBN tool-
box to infer and analyse the brain connectivity network
of Parkinson’s disease patients, as previously described in
Section ‘PBN applications in the context of physiology’.
Hinkelmann et al. introduced ADAM (Analysis of
Discrete Models of biological systems using computer
Algebra) [28], a web-based tool for rapid steady-state
identification in various discrete model types. The tool
automatically converts discrete models into polynomial
dynamic systems, allowing to run computer-based alge-
bra analysis. For probabilistic networks, ADAM generates
a graph of all possible (local rule) updates, thus being
capable to build an enumeration of all steady states. Bool-
net, as introduced by Müssel et al., is an R-package for
the generation, modelling, reconstruction and analysis
of both synchronous and asynchronous BNs or PBNs
[29]. The toolbox features time-series (experimental data)
based network inference, e.g., making use ofMarkov chain
simulations for attractor identification with subsequent
visualisation and robustness analysis via network pertur-
bation or heuristic search and random walks. We have
recently developed optPBN, a MATLAB-based toolbox
for PBN optimisation based on the BN/PBN toolbox.
PBNs can easily be constructed from Boolean rule-based
models. The toolbox also provides a flexible platform
for data integration (e.g., to integrate data from multi-
ple experiments). Different algorithms can be used to
address the resulting optimisation problem. Thus, based
on normalised protein activity at steady-state data, one
can identify a curated model structure from different can-
didate models. Subsequent analysis on the curated PBN
can be performed in the BN/PBN toolbox (publication
submitted).
We also discuss a few different algorithms and tools
which are not specifically designed for PBN but with
a high potential for the analysis of PBNs. PROM, for
example, offers a mean to calculate the flux activities
of a metabolic network in a probabilistic manner based
on gene expression data [26]. Specifically, this gives rise
to the applicability of the PBN framework for metabolic
models. Recently, Terfve et al. introduced CellNOptR, a
flexible toolkit for training protein signalling networks
based on a multiple logic formalism [148]. CellNOptR
offers support for optimisation with respect to multiple
modelling frameworks, ranging from logical to ODE (logic
rule derived) models. Extending CellNOptR towards a
probabilistic modelling framework is also foreseen for
future work.
A perspective on potential applications of PBNs in a clinical
setting
It has been a decade since the completion of the Human
Genome Project in 2003 that initiated the era of bio-
logical and medical investigation in omic scales [149].
Due to technology advancements, the costs of genome
sequencing and high throughput biomedical investiga-
tions are exponentially decreased and they might become
part of the routine medical investigations in a fore-
seeable time frame [150]. Datasets from omics exper-
iments usually consist of large lists of numbers that
represent genes, transcripts, proteins, or metabolites
depending on the method applied. In the near future
all these methodologies might be applied together rou-
tinely, even in time series examinations. The major
problem with such data is their high complexity and
the need to make them interpretable by the medical
staff. Therefore, there is a strong demand for reason-
able computational approaches to integrate multidimen-
sional “big data" [151]. In addition, given the rich sets
of information from individual patients that physicians
will acquire, smart approaches are mandatory to trans-
late and simplify these large-scale biomedical data. Such
approaches should facilitate a physician’s decision-making
process to provide more accurate diagnosis and optimal
treatment.
For these fields we identify the PBN framework as
a powerful tool. Recent applications of PBN modelling
of gene regulatory and signalling networks have been
described in the previous section. As previously sum-
marised, PBNs allow an effective visualisation of GRN
models [9,10], allowing to represent gene function and
activity [152]. These efforts foster the understanding of
gene-gene interactions, consequences of aberrant gene
function and targeted perturbations of such networks,
as well as finding out the least adverse effects of per-
turbations [9,153]. PBNs allow for the integration of
information from large data sets and for inferring log-
ical relationships between genes/networks. This feature
is of particular benefit as many relationships and struc-
tural connections among genes are not known. Unknown
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relationships between transcripts and proteins can also
be assessed. In a therapeutic perspective PBNs could be
used in a disease-relevant context because many, fore-
most chronic diseases, share probably common under-
lying mechanisms that are not elucidated so far [154].
Using PBNs in the study of disease-related networks could
enable us to take genetic interactions into account and
associations could be generated to identify comorbidities
sharing common causative factors. Skahanenko et al. for
instance have applied Markov logic networks, a proba-
bilistic logic modelling approach in the same category as
PBN, to explore gene-phenotype associations. Whereas
traditional statistical methods are employed to identify
the marker that associates the most with an observed phe-
notype, Markov logic networks can be used to identify a
subset of markers that predicts the phenotype.Within this
method, the relationship between the genetic markers and
phenotype(s) can be hypothesised andmodelled. All mod-
els can then be tested and their respective probability can
be derived [139].
In the context of a single, yet complex disease, the
study on brain connectivity in Parkinson’s disease by Ma
et al. [10] is a good example showing how a probabilistic
model such as PBN could translate large-scale biomedical
data into a potential application in clinic. fMRI princi-
pally measures blood oxygen level-dependent signals that
are correlated to the blood flow into different regions
of the brain, which in turn give physicians information
on the functional activity of specific areas of the brain
[155]. For some neurological disorders, such as Parkin-
son’s disease, the lesions mainly affect a specific area of
the brain such as basal ganglia, but have consequences
on the overall integrity of brain connectivity, especially
on the dopaminergic pathway-dependent motor and cog-
nitive control [156]. Therefore, considering the aetiology
and disease progression from only conventional MRI data
which demonstrate only structural information is cer-
tainly insufficient to yield a comprehensive understanding
on the course of disease. Considering diseases as net-
work perturbations [157], the PBN model from Ma et al.
demonstrated differences of brain connectivity networks
comparing healthy population and diseased cases with
and without medication. Such observations could pos-
sibly be further developed towards clinical biomarkers
which could then be added to physicians’ portfolio and in
turn facilitate diagnostic process, treatment design, and
follow-up strategy.
Generally, the incorporation of tentativeness and prob-
ability could be evolved into a valid concept in a clinical
setting, as routine medical investigation often provides no
conclusive data. Together with a comprehensive reduc-
tion and translation of large-scale and complex biomed-
ical data, the PBN framework might serve as a mean to
develop simplistic terms like a probability score for certain
condition, e.g., for having a disease or of being respon-
sive to treatment. Such a probabilistic score could serve
as a simple but powerful additional input for physicians
in order to improve their healthcare management. As a
whole, healthcare systems would benefit from reducing
costs related to unnecessary diagnostic investigations and
treatment failures.
Conclusion
Even though the concept of PBN for the modelling of
biological systems is still young compared to other mod-
elling approaches, a broad area of research activities on
this modelling approach such as network inference and
network control have been well-established and are con-
tinuously developed. For a meaningful comparison of dif-
ferent inference algorithms in the future, it is necessary
to quantify their performance. The prospective research
in the area of network inference is to develop a formal
framework for validation of network inference proce-
dures. Moreover, there is a demand for establishing the
properties of network inference procedures under vari-
ous conditions, e.g., model class, distance function, etc.
The current trend in structural intervention and exter-
nal control is to develop new methods to reduce their
computational complexity and to define the optimal con-
trol problems and find the corresponding optimal policies
for specific therapies. With its flexibility for data inte-
gration and the availability of supporting algorithms and
computational tools, PBN is one of the most suitable
modelling frameworks to describe and analyse complex
biological systems from molecular to physiological levels
with possible future application at clinical level.
Endnotes
aIn general, γ1, γ2, . . . , γn need not be independent and
identically distributed random variables, but for the
simplicity of presentation are assumed so.
bA state in a Markov chain is said to be ergodic if
returns to the state can occur at irregular times and the
state is positive recurrent. If all states in an (irreducible)
Markov chain are ergodic, then the chain itself is said to
be ergodic.
cIn a generalised PBN framework a network variable
can have any value in {0, 1, . . . , d − 1}, where d > 2.
dIn the graph-theoretical terminology the notion of an
ergodic set of states in a Markov chain corresponds to the
notion of a bottom strongly connected component in a
graph.
eIn computer science, the complexity of a function or
an algorithm is expressed or characterised using the big
O notation, namely, how the function or algorithm
responds to changes in its input size.
fOptimisation deals with a broad range of problems,
relying on, for example, convex programming, optimal
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control, combinatorial optimisation or evolutionary
computation paradigms; examples and additional
information can be found by referring to [158-165]
gA one-time gene perturbation changes the value of
one or more genes without modifying the rules or
probabilistic parameters of the network.
hIn computational complexity theory, NP-hard is
a class of problems that are at least as hard as the hardest
problems in NP (nondeterministic polynomial time).
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
PT wrote background, PBNs for the representation of biological networks,
PBNs for multi-level Systems Biology, computational tools, partly of a
perspective on potential applications of PBNs in clinic, and co-ordinate overall
writing. AM wrote theoretical and mathematics sections on introduction, PBNs
dynamic, inference and technical comparison between PBN to other
probabilistic graphical models. JP wrote theoretical and mathematics sections
on intervention and control of PBNs. AT wrote a part on the optimisation of
PBNs. JS shared a medical perspective on the application of PBNs and wrote a
perspective on potential applications of PBNs in clinic. TS supervised and
integrated the overall writing together with PT and revised the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
We acknowledge with thanks financial support from the Fonds National de la
Recherche (FNR) Luxembourg (grant 1233900). Andrzej Mizera is on leave of
absence from the Institute of Fundamental Technological Research, Polish
Academy of Sciences, Warsaw, Poland.
Author details
1 Life Sciences Research Unit,University of Luxembourg, Luxembourg. 2
Computer Science and Communications Research Unit, University of
Luxembourg, Luxembourg. 3 Luxembourg Centre for Systems Biomedicine,
University of Luxembourg, Luxembourg. 4Interdisciplinary Centre for Security,
Reliability and Trust, University of Luxembourg, Luxembourg. 5Saarland
University Medical Center, Department of Internal Medicine II, Homburg,
Saarland, Germany.
Received: 29 March 2013 Accepted: 22 June 2013
Published: 01 July 2013
References
1. Raue A, Kreutz C, Maiwald T, Klingmueller U, Timmer J: Addressing
parameter identifiability by model-based experimentation. IET Syst
Biol 2010, 5(2):120–130.
2. Jack J, Wambaugh J, Shah I: Simulating quantitative cellular
responses using asynchronous threshold Boolean network
ensembles. BMC Syst Biol 2011, 5(1):1–13.
3. Shmulevich I, Dougherty ER, Zhang W: From Boolean to probabilistic
Boolean networks as models of genetic regulatory networks.
Proc of the IEEE 2002, 90(11):1778–1792.
4. Kauffman SA:Metabolic stability and epigenesis in randomly
constructed genetic nets. J Theor Biol 1969, 22(3):437–467.
5. Kauffman SA: Homeostasis and differentiation in random genetic
control networks. Nature 1969, 224:177–178.
6. Kauffman SA: The large scale structure and dynamics of gene
control circuits: an ensemble approach. J Theor Biol 1974, 44:167–190.
7. Kauffman SA: The Origins of Order: Self-Organization and Selection in
Evolution. Oxford: Oxford University Press; 1993.
8. Shmulevich I, Dougherty ER: Probabilistic Boolean Networks: The Modeling
and Control of Gene Regulatory Networks. Philadelphia PA: SIAM Press;
2010.
9. Tay J, Tan P: Finding intervention points in the pathogenesis of
dengue viral infection. In Proc. 28th IEEE EMBS Annual International
Conference: 30 August - 3 September; New York City, NY, USA: IEEE
Computer Society; 2006:5315–5321.
10. Ma Z, Wang Z, McKeown M: Probabilistic Boolean network analysis
of brain connectivity in Parkinsons disease. IEEE J Selected Topics in
Signal Process 2008, 2(6):975–985.
11. Shmulevich I, Gluhovsky I, Hashimoto RF, Dougherty ER, Zhang W:
Steady-state analysis of genetic regulatory networks modelled by
probabilistic Boolean networks. Comp and Funct Genomics 2003,
4:601–608.
12. Ching W, Zhang S, Ng M, Akutsu T: An approximation method for
solving the steady-state probability distribution of probabilistic
Boolean networks. Bioinformatics 2007, 23(12):1511–1518.
13. Li W, Cui L, Ng MK: On computation of the steady-state probability
distribution of probabilistic Boolean networks with gene
perturbation. J Comput Appl Math 2012, 236:4067–4081.
14. Hashimoto R, Kim S, Shmulevich I, Zhang W, Bittner M, Dougherty E:
Growing genetic regulatory networks from seed genes.
Bioinformatics 2004, 20(8):1241–1247.
15. Ching W, Chen X, Tsing N: Generating probabilistic Boolean
networks from a prescribed transition probability matrix. IET Syst
Biol 2009, 3(6):453–464.
16. Vahedi G, Ivanov I, Dougherty E: Inference of Boolean networks under
constraint on bidirectional gene relationships. IET Syst Biol 2009,
3(3):191–202.
17. Pal R, Datta A, Bittner ML, Dougherty ER: Intervention in
context-sensitive probabilistic Boolean networks. Bioinformatics
2005, 21(7):1211–1218.
18. Shmulevich I, Dougherty ER, Zhang W: Gene perturbation and
intervention in probabilistic Boolean networks. Bioinformatics 2002,
18(10):1319–1331.
19. Liu Q: An optimal control approach to probabilistic Boolean
networks. Physica A 2012, 391:6682–6689.
20. Kobayashi K, Hiraishi K: Reachability analysis of probabilistic Boolean
networks using model checking. In Proc. SICE Annual Conference: 18-21
August; Taipei, Taiwan: IEEE Computer Society; 2010:829–832.
21. Qian X, Dougherty E: Comparative study on sensitivities of Boolean
networks. In Proc. IEEE International Workshop on Genomic Signal
Processing and Statistics (GENSIPS): 10-12 November; Cold Spring Harbor,
NY, USA: IEEE Computer Society; 2010:1–4.
22. Yu L, Marshall S, Forster T, Ghazal P:Modelling of macrophage gene
expression in the interferon pathway. In Proc. IEEE International
Workshop on Genomic Signal Processing and Statistics (GENSIPS): 28-30
May; College Station, Texas, USA: IEEE Computer Society; 2006:45–46.
23. Hashimoto R, Stagni H, Higa C: Budding yeast cell cycle modeled by
context-sensitive probabilistic Boolean network. Proc. IEEE
International Workshop on Genomic Signal Processing and Statistics
(GENSIPS): 17-21 May; Minneapolis, MN, USA 2009:1–4.
24. Flöttmann M, Scharp T, Klipp E: A stochastic model of epigenetic
dynamics in somatic cell reprogramming. Front Physiol 2012,
3(216):1–19.
25. Fertig E, Danilova L, Favorov A, Ochs M: Hybrid modeling of cell
signaling and transcriptional reprogramming and its application in
C.elegans development. Front Genet 2011, 2(77):1–9.
26. Chandrasekaran S, Price N: Probabilistic integrative modeling of
genome-scale metabolic and regulatory networks in Escherichia
coli and Mycobacterium tuberculosis. Proc Nat Acad Sci 2010,
107(41):17845–17850.
27. BN/PBN Toolbox. [http://code.google.com/p/pbn-matlab-toolbox]
28. Hinkelmann F, Brandon M, Guang B, McNeill R, Blekherman G, Veliz-Cuba
A, Laubenbacher R: ADAM: analysis of discrete models of biological
systems using computer algebra. BMC Bioinformatics 2011, 12:295
29. Müssel C, Hopfensitz M, Kestler H: Boolnet: an R package for
generation, reconstruction and analysis of Boolean networks.
Bioinformatics 2010, 20(10):1378–1380.
30. Norris JR:Markov Chains. Cambridge UK: Cambridge University Press;
1998.
31. Brun M, Dougherty ER, Shmulevich I: Steady-state probabilities for
attractors in probabilistic Boolean networks. Signal Process 2005,
85:1993–2013.
 
44 | P a g e       Chapter 1: Introduction 
 
Trairatphisan et al. Cell Communication and Signaling 2013, 11:46 Page 23 of 25
http://www.biosignaling.com/content/11/1/46
32. Shmulevich I, Dougherty ER, Kim S, Zhang W: Probabilistic Boolean
networks: a rule-based uncertainty model for gene regulatory
networks. Bioinformatics 2002, 18(2):261–274.
33. Shmulevich I, Dougherty ER, Zhang W: Control Of stationary behavior
in probabilistic Boolean networks by means Of structural
intervention. J Biol Syst 2002, 10(4):431–445.
34. Choudhary A, Datta A, Bittner ML, Dougherty ER: Intervention in a
family of Boolean networks. Bioinformatics 2006, 22(2):226–232.
35. Stewart WJ: Introduction to the Numerical Solution of Markov Chains.
Princeton NJ: Princeton University Press; 1994.
36. Zhang S, Ching W, Ng MK, Akutsu T: Simulation study in probabilistic
Boolean network models for genetic regulatory networks. Int J Data
Mining Bioinf 2007, 1(3):217–240.
37. Xu W, Ching W, Zhang S, Li W, Xiao-ShanChen: Amatrix perturbation
method for computing the steady-state probability distributions
of probabilistic Boolean networks with gene perturbations.
J Comput Appl Math 2011, 235:2242–2251.
38. Berg BA:Markov Chain Monte Carlo Simulations and Their Statistical
Analysis. Singapore: World Scientific Publishing; 2004.
39. Rosenthal JS:Minorization Conditions and Convergence Rates for
Markov Chain Monte Carlo. J Am Stat Assoc 1995, 90(430):558–566.
40. Robert CP: Convergence control techniques for Markov chain
Monte Carlo algorithms. Stat Sci 1995, 10(3):231–253.
41. Cowles MK, Carlin BP:Markov Chain Monte Carlo Convergence
Diagnostics: A Comparative Review. J Am Stat Assoc 1996,
91(434):883–904.
42. Raftery AE, Lewis S: HowMany Iterations in the Gibbs Sampler?
In Bayesian Statistics, Volume 4. Edited by Bernardo JM, Berger JO, Dawid
AP, Smith AFM. Oxford UK: Oxford University Press; 1992:763–773.
43. Ribeiro AS, Kauffman SA: Noisy attractors and ergodic sets in models
of gene regulatory networks. J Theor Biol 2007, 247(4):
743–755.
44. Todd R, Helikar T: Ergodic Sets as cell phenotype of budding yeast
cell cycle. PLOS One 2012, 7(10):e45780.
45. Pal R: Analyzing steady state probability distributions of context-
sensitive probabilistic Boolean networks. In Proc. IEEE, International
Workshop on Genomic Signal Processing and Statistics (GENSIPS): 17-21
May; Minneapolis, MN, USA: IEEE Computer Society; 2009:1–4.
46. Pal R: Context-Sensitive Probabilistic Boolean networks:
steady-state properties, reduction, and steady-state
approximation. IEEE Trans Signal Process 2010,
58(2):879–890.
47. Hayashida M, Tamura T, Akutsu T, Ching W, Cong Y: Distribution and
enumeration of attractors in probabilistic Boolean networks.
IET Syst Biol 2009, 3(6):465–474.
48. Li F, Sun J: Stability and Stabilization Issue of Probabilistic Boolean
Network. In Proc. 30th Chinese Control Conference: 22-24 July; Yantai,
China: IEEE Computer Society; 2011:6381–6385.
49. Avi nó M A: Homomorphisms of probabilistic gene regulatory
networks. In Proc. IEEE International Workshop on Genomic Signal
Processing and Statistics (GENSIPS): 28-30 May; College Station, Texas, USA:
IEEE Computer Society; 2006:85–86.
50. Pal R, Ivanov I, Datta A, Bittner ML, Dougherty ER: Generating Boolean
networks with a prescribed attractor structure. Bioinformatics 2005,
21(21):4021–4025.
51. Pfahringer B: Compression-based discretization of continuous
attributes. In Proc. 12th International Conference onMachine Learning:
9-12 July; Tahoe City, CA, USA: Morgan Kaufmann Publishers;
1995:456–463.
52. Dougherty J, Kohavi R, Sahami M: Supervised and unsupervised
discretization of continuous features. In Proc. 12th International
Conference onMachine Learning: 9-12 July; Tahoe City, CA, USA: Morgan
Kaufmann Publishers; 1995:194–202.
53. Mircean C, Tabus I, Astola J, Kobayashi T, Shiku H, Yamaguchi M, B Y,
Shmulevich I, Zhang W: Quantization and similarity measure
selection for discrimination of lymphoma subtypes under
k-nearest neighbor classification. InMicroarrays and Combinatorial
Techniques: Design, Fabrication, and Analysis, Volume 5328 of Proceedings
of the SPIE: January; San Jose, CA, USA; 2004:6–17. BiOS.
54. Snoussi EH: Qualitative dynamics of piecewise-linear differential
equations: a discrete mapping approach. Dyn and Stability Syst 1989,
4(3–4):189–207.
55. Gersho A, Gray RM: Vector Quantization and Signal Compression: Boston
Kluwer Academic Publishers; 1992.
56. Shmulevich I, Zhang W: Binary analysis and optimization-based
normalization of gene expression data. Bioinformatics 2002,
18(4):555–565.
57. Zhou X, Wang X, Dougherty ER: Binarization of microarray data on
the basis of a mixture model.Mol Cancer Ther 2003, 2(7):679–684.
58. Hopfensitz M, Müssel C, Wawra C, Maucher M, Kühl M, Neumann H,
Kestler HA:Multiscale binarization of gene expression data for
reconstructing Boolean networks. IEEE/ACM Trans Comput Biol Bioinf
2012, 9(2):487–498.
59. Duan R, Man H, Jiang W, Liu W: Activation detection on fMRI time
series using hidden Markov model. In Proc. 2nd International IEEE
EMBS Conference on Neural Engineering: 16-19 March; Arlington, VA, USA:
IEEE Computer Society; 2005:510–513.
60. Pitt L, Valiant LG: Computational limitations on learning from
examples. J ACM 1988, 35:965–984.
61. Boros E, Ibaraki T, Makino K: Error-free and best-fit extensions of
partially defined Boolean functions. Inf Comput 1998,
140(2):254–283.
62. Lähdesmäki H, Shmulevich I, Yli-Harja O: On learning gene regulatory
networks under the Boolean network model.Mach Learn 2003,
52:147–167.
63. Böck M, Ogishima S, Tanaka H, Kramer S, Kaderali L: Hub-centered gene
network reconstruction using automatic relevance determination.
PloS ONE 2012, 7(5):e35077.
64. Liu W, Lähdesmäki H, Dougherty ER, Shmulevich I: Inference of
Boolean networks using sensitivity regularization. EURASIP J Bioinf
Syst Biol 2008, 2008:780541.
65. Arnone MI, Davidson EH: The hardwiring of development:
organization and function of genomic regulatory systems.
Development 1997, 124(10):1851–1864.
66. Chen T, He HL, Church GM:Modeling gene expression with
differential equations. In Proceedings of the Pacific Symposium on
Biocomputing, Volume 4: 4-9 January; Hawaii, USA; 1999:29–40. World
Scientific Press.
67. Someren EPV, Wessels LFA, Reinders MJT, Backer E: Searching for
limited connectivity in genetic network models. In Proc. 2nd
International Conference on Systems Biology: 4-7 November; Pasadena, CA,
USA: Omnipress; 2001:222–230.
68. Guthke R, Möller U, Hoffmann M, Thies F, Töpfer S: Dynamic network
reconstruction from gene expression data applied to immune
response during bacterial infection. Bioinformatics 2005,
21(8):1626–1634.
69. Jeong H, Tombor B, Albert R, Oltvai ZN, Barabási A: The large-scale
organization of metabolic networks. Nature 2000, 407:651–654.
70. Murphy K, Mian S:ModellingGene expressionDataUsingDynamic Bayesian
Networks. Tech. Rep., Berkeley CA: University of California Press; 1999.
71. Perrin B, Ralaivola L, Mazurie A, Bottani S, Mallet J, d’Alché-Buc F: Gene
networks inference using dynamic Bayesian networks.
Bioinformatics 2003, 19(Suppl. 2):ii138–ii148.
72. Styczynski MP, Stephanopoulos G: Overview of computational
methods for the inference of gene regulatory networks.
Comput Chem Eng 2005, 29:519–534.
73. Lindlöf A, Olsson B: Could correlation-based methods be used to
derive genetic association networks? Inf Sci 2002,
146(1-4):103–113.
74. Maucher M, Kracher B, M Kühl M, Kestler HA: Inferring Boolean network
structure via correlation. Bioinformatics 2011, 27(11):1529–1536.
75. Xiao Y, Dougherty E: Optimizing consistency-based design of
context-sensitive gene regulatory networks. IEEE Trans Circuits and
Syst 2006, 53(11):2431–2437.
76. Dougherty ER, Kim S, Chen Y: Coeffcient of determination in
nonlinear signal processing. Signal Process 2000, 80:2219–2235.
77. Ching W, Ng MM, Fung ES, Akutsu T: On construction of stochastic
genetic networks based on gene expression sequences. Int J Neural
Syst 2005, 15(4):297–310.
 
Chapter 1: Introduction      45 | P a g e  
 
Trairatphisan et al. Cell Communication and Signaling 2013, 11:46 Page 24 of 25
http://www.biosignaling.com/content/11/1/46
78. Ching W, Chen X, Tsing N, Leung H: A heuristic method for
generating probabilistic Boolean networks from a Prescribed
Transition Probability Matrix. In Proc. 2nd Symposium on Optimization
and Systems Biology (OSB): 31 October - 3 November; Ligiang, China: World
Publishing Corporation; 2008:271–278.
79. Dougherty ER, Xiao Y: Design of probabilistic Boolean networks
under the requirement of contextual data consistency. IEEE Trans
Signal Process 2006, 54(9):3603–3613.
80. Zhou X, Wang X, Pal R, Ivanov I, Bittner M, Dougherty ER: A Bayesian
connectivity-based approach to constructing probabilistic gene
regulatory networks. Bioinformatics 2004, 20(17):2918–2927.
81. Rissanen J:Modelling by shortest data description. Automatica 1978,
14:465–471.
82. Zhao W, Serpedin E, Dougherty ER: Inferring gene regulatory
networks from time series data using the minimum description
length principle. Bioinformatics 2006, 22(17):2129–2135.
83. Dougherty J, Tabus I, Astola J: Inference of gene regulatory networks
based on a universal minimum description length. EURASIP J Bioinf
Syst Biol 2008, 2008:482090.
84. Marshall S, Yu L, Xiao Y, Dougherty ER: Temporal inference of
probabilistic Boolean networks. In Proc. IEEE International Workshop
on Genomic Signal Processing and Statistics (GENSIPS): 28-30 May; College
Station, Texas, USA: IEEE Computer Society; 2006:71–72.
85. Marshall S, Yu L, Xiao Y, Dougherty ER: Inference of a probabilistic
Boolean network from a single observed temporal sequence.
EURASIP J Bioinf Syst Biol 2007, 2007:32454.
86. Braga-Neto U: Optimal state estimation for Boolean dynamical
systems. In Proc. 45th Annual Asilomar Conference on Signals, Systems,
and Computers: 6-9 November; Pacific Grove, CA, USA: IEEE Computer
Society; 2011:MP8a4-5.
87. Kim S, Li H, Dougherty ER, Cao N, Chen Y, Bittner M, Suh EB: CanMarkov
chain models mimic biological regulation? J Biol Syst 2002,
10(4):337–357.
88. Shmulevich I, Dougherty ER:Modeling genetic regulatory networks
with probabilistic Boolean networks. In Genomic Signal Processing
and Statistics. Cairo Egypt: Hindawi Publishing Corporation; 2005.
89. Zhao W, Serpedin E, Dougherty ER: Inferring connectivity of genetic
regulatory networks using information-theoretic criteria. IEEE/ACM
Trans Comput Biol Bioinf 2008, 5(2):262–274.
90. Zhou X, Wang X, Dougherty ER: Construction of genomic networks
using mutual-information clustering and reversible-jump
Markov-chain-Monte-Carlo predictor design. Signal Process 2003,
83:745–761.
91. Bittner M, Meltzer P, Chen Y, Jiang Y, Sefftor E, Hendrix M, Radmacher M,
Simon R, Yakhini Z, Ben-Dor A:Molecular classification of cutaneous
malignant melanoma by gene expression profiling. Nature 2000,
406(6795):536–540.
92. Zhang S, Ching W, Chen X, Tsing NK: Generating probabilistic
Boolean networks from a prescribed stationary distribution. Inf Sci
2010, 180:2560–2570.
93. Li W, Ching W, Cui L: Amodified Newton’s method for inverse
problem of probabilistic Boolean networks with gene
perturbations. In Proc. IEEE International Conference on Systems Biology
(ISB): 28 August - 1 September; Heidelberg-Mannheim, Germany: Curran
Associates, Inc; 2011:167–172.
94. Xiao Y, Dougherty ER: The impact of function perturbations in
Boolean networks. Bioinformatics 2007, 23(10):1265–1273.
95. Qian X, Dougherty ER: Effect of function perturbation on the
steady-state distribution of genetic regulatory networks: Optimal
structural intervention. IEEE Trans Signal Process 2008, 56(10-1):4966–4975.
96. Qian X, Yoon B, Dougherty ER: Structural intervention of gene
regulatory networks by general rank-k matrix perturbation. In Proc.
2012 IEEE International Conference on Acoustics, Speech and Signal
Processing: 25-30 March 2013 Kyoto, Japan: IEEE Computer Society;
2012:729–732.
97. Sherman J, Morrison WJ: Adjustment of an inverse matrix
corresponding to a change in one element of a given matrix.
AnnMath Stat 1950, 21:124–127.
98. Qian X, Dougherty ER: On the long-run sensitivity of probabilistic
Boolean networks. J Theor Biol 2009, 257(4):560–577.
99. Bellman R: Dynamic Programming. Mineola NY: Dover Publications; 2004.
100. Datta A, Choudhary A, Bittner ML, Dougherty ER: External control in
Markovian genetic regulatory networks.Mach Learn 2003,
52(1-2):169–191.
101. Datta A, Choudhary A, Bittner ML, Dougherty ER: External control in
Markovian genetic regulatory networks: the imperfect information
case. Bioinformatics 2004, 20(6):924–930.
102. Akutsu T, Hayashida M, Ching W, Ng M: Control of Boolean networks
Haridness results and algorithms for tree structured networks.
J Theor Biol 2007, 244(4):670–679.
103. Chen X, Ching W: Finding optimal control policy by dynamic
programming in conjunction with state reduction. In Proc. IEEE
International Conference on Systems Biology: 2-4 September 2011; Zhuhai,
China: IEEE Computer Society; 2011:274–278.
104. Ghaffari N, Ivanov I, Qian X, Dougherty ER: A CoD-based reduction
algorithm for designing stationary control policies on Boolean
networks. Bioinformatics 2010, 26(12):1556–1563.
105. Qian X, Ghaffari N, Ivanov I, Dougherty ER: State reduction for network
intervention in probabilistic Boolean networks. Bioinformatics 2010,
26(24):3098–3104.
106. Kobayashi K, Hiraishi K: An integer programming approach to control
problems in probabilistic Boolean networks. In Proc. American
Control Conference (ACC): 30 June - 2 July; Baltimore, MD, USA: American
Automatic Control Council; 2010:6710–6715.
107. Kobayashi K, Hiraishi K: Optimal control of context-sensitive
probabilistic Boolean networks using integer programming.
In Proc. 49th IEEE Conference on Decision and Control (CDC): 15-17
December; Atlanta, Georgia, USA: IEEE; 2010:7507–7512.
108. Kobayashi K, Hiraishi K: An integer programming approach to
optimal control problems in context-sensitive probabilistic
Boolean networks. Automatica 2011, 47(6):1260–1264.
109. Kobayashi K, Hiraishi K: Optimal control of probabilistic Boolean
networks using polynomial optimization. IEICE Trans 2012,
95-A(9):1512–1517.
110. Ching W, Zhang S, Jiao Y, Akutsu T, Tsing N, Wong A: Optimal control
policy for probabilistic Boolean networks with hard constraints.
IET Syst Biol 2009, 3(2):90–99.
111. Cong Y, Ching W, Tsing N, Leung H: On finite-horizon control of
genetic regulatory networks with multiple hard-constraints.
BMC Syst Biol 2010, 4(Suppl 2). article S14.
112. Chen X, Akutsu T, Tamura T, Ching W: Proc. IEEE International
Conference on Bioinformatics and Biomedicine: 18-21 December;
Hong Kong, China. IEEE Computer Society; 2010:240–246.
113. Liu Q, Guo X, Zhou T: Optimal control for probabilistic Boolean
networks. IET Syst Biol 2010, 4(2):99–107.
114. Li F, Sun J: Controllability of probabilistic Boolean control networks.
Automatica 2011, 47(12):2765–2771.
115. Pal R, Datta A, Dougherty ER: Optimal infinite horizon control for
probabilistic Boolean networks. IEEE Trans Signal Process 2006,
54(6):2375–2387.
116. Pal R, Datta A, Dougherty ER: Robust intervention in probabilistic
Boolean networks. IEEE Trans Signal Process 2008, 56(3):
1280–1294.
117. Vahedi G, Faryabi B, Chamberland J, Datta A, Dougherty ER:
Intervention in gene regulatory networks via a stationary
mean-first-passage-time control policy. IEEE Trans Biomed Eng 2008,
55(10):2319–2331.
118. Qian X, Ivanov I, Ghaffari N, Dougherty ER: Intervention in gene
regulatory networks via greedy control polices based on long-run
behavior. BMC Syst Biol 2009, 3: article 61.
119. Faure A, Naldi A, Chaouiya C, Theiffry D: Dynamical analysis of a
generic Booleanmodel for the control of the mammalian cell cycle.
Bioinformatics 2006, 22(14):124–131.
120. Vahedi G, Faryabi B, Chamberland J, Datta A, Dougherty ER: Optimal
intervention strategies for cyclic therapeutic methods. IEEE Trans
Biomed Eng 2009, 56(2):281–291.
121. Yousefi MR, Datta A, Dougherty ER: Optimal intervention strategies
for therapeutic methods with fixed-length duration of drug
effectiveness. IEEE Trans Signal Process 2012, 60(9):
4930–4944.
46 | P a g e       Chapter 1: Introduction 
 
Trairatphisan et al. Cell Communication and Signaling 2013, 11:46 Page 25 of 25
http://www.biosignaling.com/content/11/1/46
122. Qian X, Dougherty ER: Intervention in gene regulatory networks via
phenotypically constrained control policies based on long-run
behavior. IEEE/ACM Trans Comput Biol Bioinf 2012, 9:123–136.
123. Friedman N, Linial M, Nachman I, Peér D: Using Bayesian networks to
analyze expression data. J Comput Biol 2000, 7(3–4):601–620.
124. Dojer N, Gambin A, Mizera A, Wilczyn´ski B, Tiuryn J: Applying dynamic
Bayesian networks to perturbed gene expression data.
BMC Bioinformatics 2006, 7:249.
125. Needham C, Manfield I, Bulpitt A, Gilmartin P, Westhead D: From gene
expression to gene regulatory networks in Arabidopsis thaliana.
BMC Syst Biol 2009, 3(85):1–17.
126. Ferrazzi F, Engel F, Wu E, Moseman A, Kohane I, Bellazzi R, Ramoni M:
Inferring cell cycle feedback regulation from gene expression data.
J Biomed Inf 2011, 44:565–575.
127. Yu H, Zhu S, Zhou B, Xue H, Han J: Inferring causal relationships
among different histone modifications and gene expression.
Genome Res 2008, 18:1314–1324.
128. Ciaccio M, Wagner J, Chuu C, Lauffenburger D, Jones R: Systems
analysis of EGF receptor signaling dynamics with Micro-Western
arrays. Nature Methods 2010, 7(2):148–155.
129. Cursons J, Hurley D, Angel C, Dunbar R, Crampin E, Jacobs M: Inference
of an in situ epidermal intracellular signaling cascade. In Proc. 32nd
Annual International Conference of the IEEE EMBS: 1-4 September; Buenos
Aires, Argentina: IEEE Computer Society; 2010:799–802.
130. Yoeruek E, Ochs M, Geman D, Younes L: A Comprehensive statistical
model for cell signaling. IEEE/ACM Trans Comput Biol Bioinf 2011,
8(3):592–606.
131. Elvitigala T, Singh A, Pakrasi H, Ghosh B: Bayesian Network approach
to understand regulation of biological processes in Cyanobacteria.
In Proc. Joint 48th IEEE Conference on Decision and Control and 28th
Chinese Control Conference: 15-18 December; Shanghai, China: IEEE
Computer Society; 2009:3739–3744.
132. Peelen L, De Keizer N, De Jonge E, Bosman R, Abu-Hanna A, Peek N:
Using hierarchical dynamic Bayesian networks to investigate
dynamics of organ failure in patients in the Intensive Care Unit.
J Biomed Inf 2010, 43:272–286.
133. Himes B, Dai Y, Kohane I, Weiss S, Ramoni M: Prediction of Chronic
Obstructive Pulmonary Disease (COPD) in Asthma Patients using
electronic medical records. J AmMed Inf Assoc 2009, 16(3):371–379.
134. Estabragh Z, Kashani M, Moghaddam F, Sari S, Oskooyee K: Bayesian
network model for diagnosis of social anxiety disorder. In Proc. IEEE
International Conference on Bioinformatics and BiomedicineWorkshops:
12-15 Noverber; Atlanta, GA, USA: IEEE Computer Society; 2011:639–640.
135. Adams L, Khare S, Lawhon S, Rossetti C, Lewin H, Lipton M, Turse J, Wylie
D, Bai Y, Drake K: Enhancing the role of veterinary vaccines reducing
zoonotic diseases of humans: Linking systems biology with
vaccine development. Vaccine 2011, 29:7197–7206.
136. Si S, Liu G, Cai Z, Xia P: Using Bayesian networks and importance
measures to indentify tumour markers for breast cancer. In Proc.
IEEE Conference on Industrial Engineering and Engineering Management
(IEEM): 6-9 December; Singapore: IEEE Computer Society; 2011:1826–1830.
137. Lähdesmäki H, Hautaniemi S, Shmulevich I, Yli-Harja O: Relationships
between probabilistic Boolean networks and dynamic Bayesian
networks as models of gene regulatory networks. Signal Process
2006, 86:814–834.
138. Li P, Zhang C, Perkins E, Gong P, Deng Y: Comparison of probabilistic
Boolean network and dynamic Bayesian network approaches for
inferring gene regulatory networks. BMC Bioinformatics 2007, 8
(Suppl 7):S13.
139. Sakhanenko N, Galas D: Probabilistic logic method and some
applications to biology andmedicine. J Comput Biol 2012,
19(3):316–336.
140. Huang S: Gene expression profiling, genetic networks, and cellular
states: an integrating concept for tumorigenesis and drug
discovery. J Mol Med 1999, 77(6):469–480.
141. Nguyen D, Azadivar F: Early detection of cancer by reguression
analysis and computer simulation of gene regulatory rules. In Proc.
IEEE International Conference on Biomedical Engineering (ICoBE): 27-28
February; Penang, Malaysia: IEEE Computer Society; 2012:144–148.
142. Zhang Y, Quian M, Ouyang Q, Deng M, Li F, Tang C: Stochastic model
of yeast cell-cycle network. Physica D 2006, 209:35–39.
143. Kaderali L, Dazert E, Zeuge U, Frese M, Bartenschlager R: Reconstructing
signaling pathways from RNAi data using Probabilistic Boolean
threshold networks. Bioinformatics 2009, 25(17):2229–2235.
144. Sauer U:Metabolic networks in motion: 13C-based flux analysis.
Mol Syst Biol 2006, 62:1–10.
145. Holland J: Adaptation in Natural and Artificial Systems. Cambridge MA:
MIT Press; 1992.
146. Schlatter R, Schmich K, Vizcarra IA, Scheurich R, Sauter R, Borner C, Ederer
M, Merfort I, Sawodny O: ON/OFF and beyond - a Boolean model of
Apoptosis. PLOS Comput Biol 2009, 5(12):e1000595.
147. Gonçalves E, Bucher J, Ryll A, Niklas J, Mauch K, Klamt S, Rocha M,
Saez-Rodriguez J: Bridging the layers: towards integration of signal
transduction, regulation andmetabolism into mathematical
models.Mol Biosyst 2013, 9(7):1576-83.
148. Terfve C, Cokelaer T, Henriques D, MacNamara A, Goncalves E, Morris M,
Van Lersel M, Lauffenburger D, Saez-Rodriguez J: BMC Syst Biol.
Volume 6; 2012:133.
149. Collins F, Morgan M, Patrinos A: The human genome project: lesson
from large-scale biology. Science 2003, 300(5617):286–290.
150. Dewey F, Pan S, Wheeler M, Quake S, Ashley E: DNA sequencing -
clinical applications of new DNA sequencing technologies.
Circulation 2012, 125:931–944.
151. Sethi P, Theodos K: Translational bioinformatics and healthcare
informatics: computational and ethical challenges. Perspect in Health
Inf Manage 2009, 6:. 1h.
152. Rzhetsky A, Koike T, Kalachikov S, Gomez SM, Krauthammer M, Kaplan
SH, Kra P, Russo JJ, Friedman C: A knowledge model for analysis and
simulation of regulatory networks. Bioinformatics 2000,
16(12):1120–1128.
153. Faryabi B, Vahedi G, Chamberland J, Datta A, Dougherty E: Optimal
constrained stationary intervention in gene regulatory networks.
EURASIP J Bioinf Syst Biol 2008, 620767:1–10.
154. Goh K, Cusick ME, Valle D, Childs B, Vidal M, Barabási AL: The human
disease network. Proc Nat Acad Sci 2007, 104(21):8685–8690.
155. Gore J: Principles and practice of function MRI of the human brain.
J Clin Invest 2003, 112(1):4–9.
156. Davie C: A review of Parkinson’s disease. British Med Bull 2008,
86(1):109–127.
157. Del Sol A, Balling R, Hood L, Galas D: Diseases as network
perturbations. Curr Opin Biotechnol 2010, 21:566–571.
158. Del Moral P: Feynman-Kac Formulae: Genealogical and Interacting Particle
Systems with Applications. Berlin Germany: Springer; 2004.
159. Moral PD, Kallel L, Rowe J:Modeling genetic algorithms with
interacting particle systems. In Theoretical Aspects of Evolutionary
Computing. Berlin Germany: Springer; 2001:10–67.
160. Moral P, Miclo L: Branching and interacting particle systems
approximations of feynman-kac formulae with applications to
non-linear filtering. In Seminaire de Probability XXXIV, Volume 1729 of
Lecture Notes in Mathematics. Berlin Germany: Springer; 2000:1–145.
161. Back T, Fogel DB: Handbook of Evolutionary Computation (Michalewicz
Z, ed.) London UK: IOP Publishing Ltd.; 1997.
162. Jong KAD: Evolutionary Computation: A Unified Approach. Cambridge MA:
MIT Press; 2006.
163. Eiben AE, Smith JE: Introduction to Evolutionary Computing. Berlin
Germany: Springer; 2003.
164. Ashlock DA: Evolutionary Computation for Modeling and Optimization.
Berlin Germany: Springer; 2006.
165. Spears W, Jong K, Bäck T, Fogel D, Garis H: An overview of evolutionary
computation. InMachine Learning: ECML-93, Volume 667 of Lecture Notes
in Computer Science. Berlin Germany: Springer; 1993:442–459.
doi:10.1186/1478-811X-11-46
Cite this article as: Trairatphisan et al.: Recent development and biomedi-
cal applications of probabilistic Boolean networks. Cell Communication and
Signaling 2013 11:46.
 
Chapter 1: Introduction      47 | P a g e  
 
1.4.7. Research activities on probabilistic Boolean networks in the 
past two years  
 In the course of two years after our review article was published (from mid-2013 to 
mid-2015), research activities on the PBN approach still continuously progressed. On the 
dynamics of PBNs, several novel PBN variants have been proposed. To mention a few, a 
semi-tensor product approach (a.k.a. probability structure matrix for simplicity) was 
applied to represent the state transitions in PBNs instead of applying transitional 
probability matrix as in the traditional approach (Cheng et al., 2014). Context-sensitive 
stochastic Boolean networks which apply the formulation of instantaneously random PBNs 
were shown to decrease computational complexity on simulations compared to the ones 
performed on the whole collection of context-sensitive PBNs (Zhu, Liang, & Han, 2014). In 
another study, stochastic multiple-valued networks were extended from multiple-valued 
PBNs to enhance the computational speed on the state transition matrix calculation. Two 
small applications on TP53-Mdm2 interaction and WNT5A network were also 
demonstrated in this article (Zhu & Han, 2014). On top of the advancement on 
computational frameworks, several properties of PBNs’ dynamics such as partial stability 
upon disturbance of the initial states (Z. Li, Song, & Yang, 2014) and the fluctuations of 
steady-state distributions according to internal noise (Gao, Xu, Wang, & Liu, 2013) were 
also explored. The outcome of these studies revealed additional properties of the 
networks that are essential to be considered for the inference and control of PBNs. 
 
 In mid-2013, we commented in our review article that it is necessary to quantify the 
performance of the multiple existing BN and PBN inference algorithms. Following this 
perspective, Qian and Dougherty proposed a method to evaluate the inference algorithms 
for gene regulatory networks based on controllability which is considered to be a better 
objected-based measure compared to the assessment on the goodness-of-fit alone (Qian 
& Dougherty, 2013). This study compared several inference algorithms such as REVEAL, 
BIC, MDL and Best-Fit where it was shown that certain algorithm with poorer performance 
on network inference can inversely have a better performance in controllability. On 
another perspective, we stated in the conclusion of our review article that novel 
approaches with lesser computational complexity are required for designing the optimal 
control of PBNs. This outlook was realised by several studies using new computational 
pipelines such as the application of hard constraints integrated with integer and dynamic 
programming (X. C. X. Chen, Akutsu, Tamura, & Ching, 2013), the introduction of control-
fixed point designed based on reachability and stability analyses (Zhao & Cheng, 2014), 
and the application of the semi-tensor product technique combined with optimisation 
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applying genetic algorithms (Yang, Li, & Chu, 2014). Furthermore, several existing 
computational software and methods such as PRISM and polynomial optimisation were 
also shown to be applicable for the verification and control of PBNs (Kobayashi & Hiraishi, 
2014). These advancements allow scientists to design and apply optimal control on PBNs 
in a more effective and efficient way. 
 
 Browsing through the applications of PBNs and related frameworks in biomedicine, 
only a few studies were reported. For example, exact likelihood computation in Boolean 
networks with probabilistic exponential time delays was applied to infer regulatory signals 
in the gene network during embryonic stem cell development based on RNA interference 
dataset (Dümcke et al., 2014). In another study, single-cell RNA profiling data and the 
structure of the cell-lineage tree were applied to infer cell-fate controlling gene regulatory 
networks during mouse early development in the PBN framework (H. Chen et al., 2014). 
On the study related to signalling networks, Kiani and Kaderali introduced dynamic 
probabilistic threshold networks which utilise dynamic Bayesian network with probabilistic 
Boolean threshold function to describe the activated state of signalling proteins (Kiani & 
Kaderali, 2014). Together with the integration of RNA interference data and prior 
knowledge introduced as posterior distribution, a series of candidate signalling networks 
with certain probability distributions were inferred. This approach was successfully applied 
to study the ErbB signalling network where a large portion of known interactions were 
recovered and novel regulatory mechanisms between signalling molecules were derived. 
 
 To summarise, the research activities on the PBN approach in the past two years 
were still mainly performed on the theoretical surface with very few proof-of-concept 
examples. Biomedical applications of PBNs, even if a few existed, mainly focused on the 
inference and analysis of gene regulatory networks. Only the applications from the group 
of Kaderali (Kaderali, Dazert, Zeuge, Frese, & Bartenschlager, 2009; Kiani & Kaderali, 
2014) with probabilistic Boolean threshold functions were applied to signal transduction 
networks. Nevertheless, the original concept of PBN as initially introduced by the group of 
Shmulevich (Shmulevich et al., 2002) has not been applied to study the properties within 
this kind of network so far even if it has a high applicability to be applied to study and 
analyse many biological and physiological networks as shown in (Trairatphisan et al., 
2013). Hence, we take this opportunity to explore the application of the original PBN 
concept on signal transduction networks in order to unravel their complexity as presented 
in this dissertation. 
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Chapter 2 
SCOPE AND AIMS OF THESIS 
 
A large array of modelling approaches in systems biology has been applied to 
study and analyse signal transduction networks in order to gain improved mechanistic 
insights. Each modelling approach has its inherent advantages and disadvantages. For 
instance, qualitative models such as Boolean networks allow the description of large-scale 
networks but they fail to provide quantitative insights. On the other hand, quantitative 
approaches such as ODE-based models are able to depict the quantitative changes of 
molecular species over continuous time. However, they require detailed prior knowledge 
on molecular interactions as well as an extensive set of experimental data to infer kinetic 
parameters. Such demanding requirements limit the scalability of these approaches to 
only small to medium-size networks. 
 
Given the trade-off between different modelling approaches, one always has to 
balance between the simplicity of the frameworks versus their expressiveness. To choose 
an appropriate modelling approach, several factors should therefore be considered, e.g. 
the research objective, the scope of the model, and the type and availability of data. For 
the modelling of signal transduction networks where a quantitative mechanistic analysis 
on a large-scale biological network needs to be derived based on a limited amount of 
dataset, e.g. steady-state data, we identify probabilistic Boolean networks (PBNs), a class 
of quantitative mechanistic modelling approaches with minimal parameterisation, as a 
promising approach due to their capability in describing quantitative changes of signalling 
molecules at steady-state in large-scale models. 
 
In this dissertation, our global aim is to apply the PBN approach for the study of 
signal transduction networks with steady-state measurements. To perform the analysis of 
signalling networks in the PBN framework, a specific tool for building, optimising and 
analysing the PBN models based on the integration of prior knowledge and contextualised 
experimental data was so far not yet available. In addition, the application of probabilistic 
Boolean networks to signal transduction networks was not investigated. Furthermore, the 
potential applications of the PBN approach in a pharmaceutical setting which link 
biological sciences to clinical medicine were not yet explored either. 
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In order to account for these challenges in applying the PBN approach for the 
study of signal transduction networks, we formulate three specific aims of this dissertation 
as follows: 
 
1. To develop a computational tool for the optimisation and analysis of PBNs. 
 
2. To apply the PBN approach to analyse cellular signal transduction networks. 
 
3. To explore potential applications of PBNs in a pharmaceutical setting. 
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Chapter 3 
MATERIALS AND METHODS 
 
Summarised workflow of the dissertation  
In this dissertation, we address the three specific aims as presented in the scope 
and aims of the thesis in a successive order. These aims include the development of a 
novel computational tool for PBNs, the application of PBNs for the analysis of cellular 
signal transduction networks, and the exploration of potential PBNs’ applications in a 
pharmaceutical setting, respectively. A brief summary of the applied methods can be 
found in Chapter 3.1 to 3.4 and a full description is contained in the respective 
publications and manuscripts in the results section (see Chapter 4). 
 
To account for the first specific aim which is to develop a novel computational tool 
for PBNs, we present optPBN which allows for the building of PBN models based on 
literature knowledge and for the optimisation of PBNs against steady-state experimental 
data. Once the optPBN pipeline is established, we account for the second specific aim 
which is to apply PBNs for the analysis of cellular signal transduction networks by 
subsequently applying optPBN to build and analyse a signal transduction network in a 
physiological condition. For this task, we analyse a large-scale apoptotic network of 
primary hepatocytes as a case study. We also consider the optimised selection 
probabilities in PBNs as weights of interaction together with their distributions which 
allows to assess the relevance of interactions within the context of the study. A detailed 
representation of optPBN and the case study on the apoptotic network are presented in 
Chapter 4.1. 
 
To further address the second specific aim, we also apply the PBN framework to 
study two deregulated signal transduction networks in a pathological context of cancer. In 
the first study, we apply optPBN to analyse a cancer-specific deregulated PDGF signalling 
network in gastrointestinal stromal tumour (GIST) presented in Chapter 4.2. Initially, we fit 
a literature-derived PDGF signalling network to single perturbation experiments including 
genetic point mutations or signalling inhibitors. Then, we analyse the importance of 
crosstalk interactions between intracellular signalling pathways and we perform an 
additional set of experiments to validate the modelling results. Subsequently, we revise 
the model structure based on the new findings from the additional experiments and we 
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apply the revised model to predict the signalling profiles of combined perturbation 
experiments to evaluate its predictive power. This study shows that optPBN can be 
applied to identify relevant crosstalk interactions in the context of GIST and the revised 
PBN model has an excellent performance to predict the signalling profiles of combinatorial 
treatments. 
 
In addition to the PBN study on deregulated PDGF signalling in GIST, we also 
apply an improved version of the optPBN toolbox to analyse the deregulated L-plastin 
signalling via the ERK/MAPK pathway in four breast cancer cell lines presented in 
Chapter 4.3. We firstly fit a literature-derived L-plastin signalling network to a large set of 
experimental data which include the profiles of signalling molecules after applying various 
activators and inhibitors. Then, we apply a knock-out study by removing specific 
interactions from the fitted model and re-perform the optimisation to observe new fitting 
costs which in turn allows to evaluate the relevance of the respective interactions in the 
network. In addition, we perform a bootstrapping study by optimising the fitted model 
against 100 newly generated experimental data derived from the distributions of the 
original dataset in order to assess the robustness of optimised parameters. This study 
shows that only 2 out of 5 investigated interactions are relevant within the context of 
breast cancer and the optimised parameters, which are considered as weights of 
interaction, are robust against variability within the observed dataset. 
 
Once we could demonstrate the applicability of the PBN framework for the analysis 
of signal transduction networks in physiological and pathological contexts, we explored if 
the PBN framework can also be applied in a pharmaceutical setting as stated in the third 
specific aim of this dissertation. Prior to this exploration, I present a part of my work during 
a 6-month internship at Merrimack Pharmaceuticals (Boston, MA, USA) in Chapter 4.4.1 
where I applied a mechanistic ODE-based modelling approach to analyse a deregulated 
c-MET signalling network in solid tumours. I fitted the ODE-based model to the time-
course data of downstream signalling molecules and I applied the fitted model to assess 
the effectiveness of a therapeutic agent OA-5D5. From the study, I learned that detailed 
mechanistic models such as ODE-based or PDE-based models are commonly used in a 
pharmaceutical setting and they often require high computational power to perform the 
optimisation and analysis.  
 
 As we previously demonstrated that the PBN framework can be applied to assess 
the relevance of network interactions which allows for network contextualisation, we 
foresee that we could also apply PBNs to pre-select a suitable network topology prior to 
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the modelling of mechanistic models which in turn helps to reduce the computational 
demand. We explored this potential application in Chapter 4.4.2 by applying optPBN to 
pre-select a suitable model structure from a small example model with 10 uncertain 
interactions within the network. In parallel, we systematically built a total of 1024 ODE-
based model variants based on the same network topology and evaluated their fitting 
costs and optimisation time. Then, we compared the results and subsequently found that 
the model topology pre-selected by optPBN matched the minimal model topology of ODE-
based model still fitting well to the data. 
 
 To summarise, we address the three specific aims of this dissertation by 1) 
developing optPBN as a novel optimisation and analytical tool for PBNs, 2) demonstrating 
the applications of the PBN framework on the study of cellular signal transduction 
networks both in physiological and pathological contexts, and 3) demonstrating a proof-of-
concept example showing that the pre-selected network topology by the PBN approach 
can be used as a promising model structure for the mechanistic modelling. 
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3.1. Summarised materials and methods for Chapter 4.1 
Manuscript title: optPBN: an Optimisation Toolbox for Probabilistic Boolean Networks 
 
In this software article, we developed the Matlab-based computational toolbox 
optPBN for the optimisation and analysis of probabilistic Boolean networks. The optPBN 
toolbox was written based on the BN/PBN toolbox by H. Lähdesmäki and I. Shmulevich 
(https://code.google.com/p/pbn-matlab-toolbox) which allows for the simulation and 
inference of BN and PBN models. We extended the functionalities of the toolbox by 
integrating a set of computational scripts which allows optPBN to determine selection 
probabilities in PBNs based on experimental data and prior knowledge and also to run on 
parallel computing infrastructure on a grid-based pipeline for faster computation. 
 
 To build and perform the optimisation of PBNs, we initially coded literature-derived 
model structures as a set of Boolean rules with corresponding selection probabilities. 
Then, steady-state measurements from multiple experimental conditions were integrated 
with the model into a single integrated optimisation problem which was subsequently 
solved by global optimisation algorithms. During the optimisation, we evaluated the quality 
of model fitting by comparing marginal stationary distributions of molecular states in PBNs 
to steady-state measurement data. The stationary distributions were approximated by 
applying the Two-State Markov-Chain (TSMC) approach following the methodology in 
(Shmulevich, Gluhovsky, Hashimoto, Dougherty, & Zhang, 2003) while the ergodicity of 
PBN’s underlying Markov chain was ensured by the introduction of a small perturbation 
parameter as introduced in (Miranda & Parga, 2007). Subsequent analysis on the 
distribution of optimised selection probabilities can be performed to derive novel biological 
insights. The summarised optimisation pipeline is shown in Figure 3 inside the article. 
 
 In parallel, we built a grid-based pipeline of the optPBN toolbox by compiling 
Matlab scripts into an executable C++ package and integrating it to the parallel computing 
optimisation platform ParadisEO (http://paradiseo.gforge.inria.fr). Two optimisation 
algorithms, i.e. differential evolution (DE) and evolutionary algorithm (EA) were applied to 
identify the best optimised parameters from the parallelised cluster on Grid’5000 
(https://www.grid5000.fr) in an effective and efficient manner. 
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3.2. Summarised materials and methods for Chapter 4.2 
Manuscript title: A Probabilistic Boolean Network Approach for the Analysis of Cancer-
specific Signalling: a Case Study of Deregulated PDGF Signalling in GIST 
 
 In this research article, we applied our optimisation toolbox optPBN (Trairatphisan, 
Mizera, Pang, Tantar, & Sauter, 2014) to perform model-based data integration which 
combines literature-based knowledge on the structure of PDGF signalling and steady-
state proteomic data in the context of gastrointestinal stromal tumour (GIST). 
 
On the biological part, three HEK cell-based containing PDGFRα mutants with 
D842V mutation found in GIST (kindly provided by Prof. S. Haan) treated with four 
signalling molecule inhibitors were investigated by Western blot experiments (partly 
performed by Dr. C. Bahlawane). Two D842V-PDGFRα mutants additionally contain 
Y720F or YY731/742FF mutations to abrogate the recruitment sites of SHP2 or PI3K in 
the MAPK or PI3K/AKT/mTOR pathways, respectively. The four signalling molecule 
inhibitors includes PI3K/PKC inhibitor Wortmannin, MEK1,2 inhibitor U0126, pan-PKC 
inhibitor GF109203X, and PKCα/β1-specific inhibitor Gö6976. After the cells were cultured 
under serum reduced (1%) condition for 14 hours, signalling inhibitors were applied (if 
applicable) under serum free (0%) condition for 3 hours. Then, the cells were lysed to 
obtain protein lysates which were subjected to SDS-PAGE and Western blotting. Seven 
downstream signalling molecules were probed, i.e. PDGFRα, pPDGFRα, pSTAT5, 
pPLCγ, pPKC substrates, pERK1,2, and pAKT together with alpha-tubulin as loading 
controls. The Western blot images were then quantified by Image Studio v.4.0. Quantified 
data after passing quality control were normalised against tubulin, calibrated against 
calibrator, and normalised to maximum signals across three biological replicates. 
 
On the modelling part, a literature-derived PDGF signalling network (reviewed by 
Dr. M. Wiesinger) was converted into a PBN model and combined with the quantified 
Western Blot data to generate integrated optimisation problems. The grid-based version of 
the optPBN toolbox was applied to perform the optimisation on Grid’5000 with 80 cores 
where the best results from DE algorithm were chosen for further analysis. A single knock-
in approach was used to investigate the influence of each crosstalk interaction on model 
fitting quality after integrating them into the core model topology without crosstalk. The 
core PBN model and variants were initially trained against a set of single perturbation 
conditions comprising PDGFRα mutants or signalling inhibitors to obtain optimised 
selection probabilities. The final refined PBN model was then evaluated with a validation 
dataset comprising combined perturbation conditions for its predictive power. 
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3.3. Summarised materials and methods for Chapter 4.3 (modelling part) 
Manuscript title: L-plastin Ser5 phosphorylation in breast cancer cells and in vitro is 
mediated by RSKs, the downstream effectors of the MAPK-ERK pathway 
 
 In this research article, we applied an improved version of the optPBN toolbox to 
build, optimise and analyse the signalling profile of L-plastin signalling via the ERK-MAPK 
pathway. This work was performed in collaboration with M. Lommel and Dr. E. Schaffner-
Reckinger from the Laboratory of Cytoskeleton and Cell Plasticity at the University of 
Luxembourg. 
 
 On the experimental part, a large panel of experimental conditions combining 
different treatments with activators and inhibitors of the L-plastin signalling pathway were 
investigated in three biological replicates (experiments performed by Maiti Lommel). Four 
breast cancer cell lines, i.e. the non-invasive MCF7 and SK-BR-3 cell lines and the 
invasive BT-20 and MDA-MB-435S cell lines were included in the study. The activators of 
the L-plastin signalling pathway includes PKC-activator phorbol 12-myristate 13-acetate 
(PMA), PKA-activator 8-Bromo-cAMP, and EGFR-activator EGF ligand, while the group of 
inhibitors consists of pan-PKC/RSK-inhibitor GF109203X (GF), PKA/RSK-inhibitor H89, 
Src-inhibitor PP2, MEK1,2-inhibitor PD98059 and RSK-inhibitor BI-D1870 (BI). Two 
downstream signalling molecules which are phosphorylated PKA (pPKA) substrates and 
phosphorylated L-plastin (pLPL) were detected where total L-plastin (tLPL) was used as a 
loading control. To prepare a normalised dataset for modelling, signals were normalised to 
a loading control to account for well-to-well differences and then to the mean per gel to 
account for gel-to-gel variability. Then, the normalised signals were calibrated to the 
signals from PMA conditions which serve as a calibrator condition from different sets of 
experiment. Subsequently, the calibrated data were pooled to generate the final mean and 
standard deviation values where were finally normalised against maximal mean value. 
 
On the modelling part, the model topology of L-plastin signalling was derived from 
literature and was integrated together with the experimental data up to 28 conditions from 
four cell lines applied as inputs (see Figure 5 in the article). The optimisation was 
performed on a stand-alone machine (Intel CPU Xeon @3.50GHz, 16GB Ram) for the 
four different model variants based on random initial conditions. Bootstrapping was 
performed by randomly sampling 100 artificial data sets based on mean and standard 
deviation as acquired from the wet-lab experiments. Optimisation was subsequently 
performed 100 times to identify the distribution of the identified selection probabilities. 
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3.4. Summarised materials and methods for Chapter 4.4 
Chapter title: Applications of quantitative modelling in pharmaceutical industry 
 
Chapter 4.4.1: Detailed mechanistic models and applications in pharmaceutical industry 
 
 From January to June 2013, I participated in an internship program at Merrimack 
Pharmaceuticals (Boston, MA, USA, http://www.merrimackpharma.com) as an intern 
modeller. I applied several data integration techniques which combined quantitative 
modelling approaches in systems biology and in-house experimental data to analyse the 
properties of therapeutic targets. In this dissertation, I present a part of my work which 
demonstrates the construction of a dynamical c-MET signalling model in ODE-based 
format that was in turn used for assessing the effectiveness of a therapeutic agent OA-
5D5 (formerly under development by Roche/Genentech as MetMab). 
 
 On the experimental part, two sets of in-house experiment were performed, one to 
generate a training dataset and another to generate a validation dataset which were used 
for building and validating the c-MET signalling model, respectively. The training dataset 
was generated by Emily Pace. In this set, ACHN (renal cancer) cell line was treated with 
hepatocyte growth factor (HGF) at concentrations from 0.037nM to 9nM over 2 hours 
where the phosphorylated form of 3 signalling molecules were measured as read-outs, i.e. 
phosphorylated c-MET (pMET), phosphorylated ERK1,2 (pERK1,2/pMAPK1,2), and 
phosphorylated AKT (pAKT). In parallel, the validation dataset was generated by Stephen 
Su. In this set, 3 cancer cell lines, i.e. A549 (adenocarcinomic alveolar epithelial cells), 
H2170 (squamous cell carcinoma of lung) and SW-620 (metastasised colorectal 
adenocarcinoma) were pre-treated with c-MET monoclonal antibody (mAb) OA-5D5 at 
concentrations from 1pM to 1µM for 2 hours followed by the treatment of HGF at 1nM for 
10 minutes where pAKT was measured as a read-out. 
 
 On the modelling part, a c-MET signalling model was built based on the network 
topology as proposed in literature (Schoeberl et al., 2009, 2002). The model was initially 
fitted to the training dataset and to additional soft constraints derived from literature in 
order to obtain optimised kinetic parameters. The optimisation was performed by applying 
a modified version of the particle swarm algorithms (confidential) on an in-house 
computational cluster. The inhibitory mechanism and kinetic parameters of the mAb OA-
5D5 were incorporated into the optimised c-Met signalling model and the integrated model 
was subsequently evaluated with the validation dataset. Once the integrated model fitted 
well to the validation data, it was used to perform in silico simulations to predict the 
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changes of molecular states of downstream signalling molecules within the c-MET 
signalling pathway in order to derive novel biological knowledge. 
 
Chapter 4.4.2: A PBN-based approach for network pre-selection 
 
 To demonstrate that the PBN framework can be applied to efficiently pre-select the 
network topology prior to the building of mechanistic ODE-based models which are often 
used in a pharmaceutical setting (see Chapter 4.4.1), we investigated a small example 
model with an artificial set of measurement data (see Figure 9). The model comprises 11 
nodes and 15 interactions where 5 interactions are assigned to be in the canonical 
pathway (core interactions) while the remaining 10 interactions are yet to be determined if 
they are relevant in the context of the study. We first applied optPBN to identify the 
weights and to determine the relevance of the interactions. The interactions with optimised 
weights close to zero are not essential to explain the experimental data and could 
therefore be removed. 
 
In parallel, we built multiple variants of ODE-based models from the same network 
topology. Starting from the initial model variant with only 5 canonical interactions, we 
added combinations of 0 to 10 interactions selected from the pool of all uncertain 
interactions. We derived 1024 ODE-based model variants applying the law of mass 
action. We then applied the Simplex algorithm in the Systems Biology Toolbox 2, 
SBtoolbox2, (Schmidt & Jirstrand, 2006) to perform the optimisation of the ODE-based 
models and recorded the fitting cost and the optimisation time for each model variant. 
Subsequently, we compared the results from optPBN and from SBtoolbox2 to assess 
whether the contextualised network topology identified by optPBN matches the minimal 
topology of the ODE-based model that fits well to the same set of measurement data.
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Chapter 4 
RESULTS 
 
Summarised main findings from all studies 
In Chapter 4.1, we built optPBN as an optimisation toolbox for probabilistic 
Boolean networks. In terms of functionality, optPBN is the first toolbox which explicitly 
allows the integration of candidate model structures and normalised experimental data in 
the PBN framework. Also, the optPBN pipeline can be operated on a large-scale 
computational resource such as a cluster-based or a grid-based infrastructure to optimise 
large-scale networks in a reasonable timeframe. We applied optPBN to analyse a large-
scale apoptotic network of (Schlatter et al., 2009) where we demonstrated that the 
apoptotic model in the PBN framework fitted much better to the normalised experimental 
data compared to the original study in the BN formalism. The optimisation time for such a 
large model is also very low on a cluster with 160 parallel computing cores, i.e. less than 5 
minutes. In addition, we successfully applied the fitted PBN model to evaluate the 
relevance of a missing interaction in the network which connects the activation of the 
apoptotic cascade by Fas ligand to the activation of NFκB. Furthermore, the optimised 
selection probabilities also provide an initial clue on the weight of interactions within the 
network and allow the comparison of weights for different interactions in a quantitative 
scale. 
 
 In Chapter 4.2, we applied optPBN to analyse a deregulated PDGF signalling 
network in GIST. We successfully built a literature-derived PDGF signalling network which 
fitted well to the training set of experimental data comprising single perturbation 
experiments. Then, we applied the fitted model to analyse the relevance of 9 crosstalk 
interactions proposed in literature and identified that only 3 crosstalk interactions from 
PI3K to Ras or to MEK1,2 in the MAPK pathway and from PKC to MEK1,2 are the most 
relevant interactions in the context of GIST. We subsequently performed an additional set 
of experiments to validate the modelling results and unexpectedly found that one of the 
assumptions in our model, i.e. the activation of PKC being depended on the activation of 
PDGFRα via PLCγ, is wrong. Therefore, we revised the model structure and re-performed 
the optimisation and analysis and learned that only the on-going crosstalk interactions 
from PI3K to the MAPK pathways are relevant. Lastly, we evaluated the predictive power 
of the revised model by predicting the signalling profiles of the combined perturbation 
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experiments in the validation dataset where our PBN showed an excellent performance to 
correctly predict 19 out of 20 data points for five downstream signalling molecules. 
 
 In Chapter 4.3, we applied an improved version of optPBN to analyse the 
deregulated L-plastin signalling in breast cancer cell lines. We managed to build a 
literature-derived L-plastin signalling network with a single model topology that fitted well 
to a broad set of steady-state protein data of four breast cancer cell lines. The results from 
a knock-out study revealed that fitting costs after removing the interactions from RSK to L-
plastin or from PKC to PKA are much higher compared to the fitted model. This finding 
implied that these two interactions are necessary to be included in the context of the 
study. In contrast, the removal of other investigated interactions, i.e. from PKC or PKA to 
L-plastin, and from PKA to PKC did not affect the fitting cost and can practically be 
removed from the model. These findings also correlate well to a subsequent bootstrapping 
study where we fitted the model to 100 newly generated datasets derived from the 
distribution of the original experimental data (see also Chapter 7.3). The identified weights 
of the two essential interactions (RSK -> L-plastin and PKC -> PKA) are much higher than 
the other 3 investigated interactions. Also, the distributions of these identified parameters 
are low. This implied that the identified parameters are robust against variation within the 
observed dataset. 
 
 Besides the main results of the dissertation in Chapter 4.1, 4.2 and 4.3, there are 
also some interesting findings which are shared in common in the three PBN studies. 
First, even if the signalling networks that we investigated have several complex features 
such as feedback loop and crosstalk interactions, we found that all of them can be 
modelled within the PBN framework in a simplified manner. Second, our literature-derived 
PBN models can fit well to various sets of steady-state protein data. This finding applied to 
the models in physiological condition such as the apoptotic model in primary hepatocytes, 
as well as to the models in pathological contexts including the model of deregulated 
PDGF signalling in GIST and the model of deregulated L-plastin signalling in breast 
cancer cell lines. Lastly, the fitted PBN models can be used to assess the relevance of 
network interactions in the context of the study based on a given set of steady-state 
measurement. Practically, various approaches can be applied to indicate the relevance of 
interactions such as the knock-in of interactions (Chapter 4.1 and 4.2) or the knock-out of 
interactions (Chapter 4.3) with subsequent evaluation of the fitting costs. Also, the values 
of optimised selection probabilities in PBNs (considered as weights of interaction) can be 
used as indicators for relevance, i.e. the lower the value is, the less relevant the 
respective interaction becomes. In addition, the distributions of these parameters indicate 
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if the identified parameter values are robust against variations in the initial conditions 
(Chapter 4.1 and 4.2) and/or within the measured dataset (Chapter 4.3). 
 
 In Chapter 4.4.1, I demonstrated that detailed mechanistic models such as ODE-
based models are often used in the pipeline of pharmaceutical development. I presented a 
large and detailed ODE-based model of a literature-derived c-MET signalling network 
where I successfully fitted the model to the signalling profiles of 3 downstream signalling 
molecules over the time-course of 2 hours. Then, I integrated the inhibitory mechanism of 
a c-MET antibody OA-5D5 to the fitted c-MET signalling model and showed that the 
extended model predicted the changes of pAKT profile at different OA-5D5 concentrations 
correctly against wet-lab experimental data. Subsequently, I performed an in silico 
prediction by simulating the inhibitory effect of OA-5D5 on the signalling profiles of 3 
downstream signalling molecules in artificial cell lines where the number of c-MET 
receptors is varied from 10,000 to 1,000,000 molecules per cell. I compared the 
predictions from two experimental settings: pre-incubation of OA-5D5 prior to HGF 
stimulation versus co-incubation where I found that the inhibitory profiles on pMET and 
pAKT differ substantially. These results showed that detailed mechanistic models can be 
applied to identify the best experimental condition to demonstrate the effectiveness of the 
therapeutic agents of choice and also to compare the inhibitory profiles of multiple 
therapeutic agents. One remark to be mentioned is that the optimisation and analysis of 
this large-scale ODE-based model required large computational resources which are not 
always available and this limitation subsequently impeded the progression of 
pharmaceutical development to some extent. 
 
 As we demonstrated that the PBN framework can be applied to assess the 
relevance of network interactions, it can therefore be applied to perform a pre-selection of 
the network topology prior to detailed mechanistic modelling in order to lessen 
computational demands. In Chapter 4.4.2, we showed in a small example model with 10 
uncertain interactions that the network pre-selected by optPBN matched the minimal 
network topology of the ODE-based model still fitting well to experimental data. Such 
results demonstrated that PBN is a promising modelling framework to be further explored 
for contextualising network structures of mechanistic models in an actual pharmaceutical 
setting. 
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4.1. optPBN: an optimisation toolbox for probabilistic 
Boolean networks (Trairatphisan et al., 2014) 
 
Preface: A number of computational tools for the inference and analysis of 
biological networks in Boolean formalism were proposed but only a few of them extended 
their functionalities into a quantitative scale. In parallel, the computational time of the tools 
which allows for quantitative optimisation does not usually scale which poses a challenge 
for the analysis of large-scale biological models. 
 
To overcome such limitations, we developed a novel computational tool in the 
probabilistic Boolean network (PBN) framework which allows for capturing the change of 
molecular states quantitatively. Here we present optPBN, an optimisation and analytical 
toolbox for probabilistic Boolean networks that allows for determining selection 
probabilities in PBNs based on experimental data and prior knowledge. Subsequent 
analysis on optimised selection probabilities of PBNs in turn reveal new insights into 
biological systems such as the relevance of network interactions within the context of the 
study. Optimisation of large-scale networks can be performed on parallel computing 
infrastructures applying the grid-based version of the optPBN pipeline where the 
computational time can be scaled according to the available computational resources. 
 
 In this article, we present several toy models to illustrate the functionality of the 
optPBN toolbox including the selection of suitable Boolean rules in Boolean networks 
(BNs) and the identification of selection probabilities in PBNs. We compared the results 
from our tool to a Boolean network optimiser CellNOptimiser (http://www.cellnopt.org) 
where optPBN could identify the same network topology of BNs and it additionally offers 
quantitative optimisation. Lastly, we applied the grid-based version of the optPBN toolbox 
to optimise a large-scale Boolean network of apoptosis by (Schlatter et al., 2009) where it 
requires only several minutes to complete the task. A following analysis on the optimised 
parameters revealed that a novel interaction which was not included in the original 
network, i.e. the activation of NFκB by Caspase 8 (Imamura et al., 2004) is essential to be 
integrated in order to generate a contextualised apoptotic model for primary hepatocytes. 
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Abstract
Background: There exist several computational tools which allow for the optimisation and inference of biological networks
using a Boolean formalism. Nevertheless, the results from such tools yield only limited quantitative insights into the
complexity of biological systems because of the inherited qualitative nature of Boolean networks.
Results: We introduce optPBN, a Matlab-based toolbox for the optimisation of probabilistic Boolean networks (PBN) which
operates under the framework of the BN/PBN toolbox. optPBN offers an easy generation of probabilistic Boolean networks
from rule-based Boolean model specification and it allows for flexible measurement data integration from multiple
experiments. Subsequently, optPBN generates integrated optimisation problems which can be solved by various
optimisers. In term of functionalities, optPBN allows for the construction of a probabilistic Boolean network from a given
set of potential constitutive Boolean networks by optimising the selection probabilities for these networks so that the
resulting PBN fits experimental data. Furthermore, the optPBN pipeline can also be operated on large-scale computational
platforms to solve complex optimisation problems. Apart from exemplary case studies which we correctly inferred the
original network, we also successfully applied optPBN to study a large-scale Boolean model of apoptosis where it allows
identifying the inverse correlation between UVB irradiation, NFkB and Caspase 3 activations, and apoptosis in primary
hepatocytes quantitatively. Also, the results from optPBN help elucidating the relevancy of crosstalk interactions in the
apoptotic network.
Summary: The optPBN toolbox provides a simple yet comprehensive pipeline for integrated optimisation problem
generation in the PBN formalism that can readily be solved by various optimisers on local or grid-based computational
platforms. optPBN can be further applied to various biological studies such as the inference of gene regulatory networks or
the identification of the interaction’s relevancy in signal transduction networks.
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Introduction
The Boolean network (BN) modelling framework was first
introduced by Kauffmann in 1969 for the study of gene regulatory
networks [1]. It has been widely applied to analyse the dynamics of
different biological systems such as the gene regulatory network of
the yeast cell cycle [2], T-cell signalling [3], signal transduction in
the apoptotic pathway [4] and many more. For an overview see,
e.g., [5,6]. Despite its simplicity, the framework has been shown to
be capable of modelling large-scale biological networks and
providing meaningful biological interpretations, e.g., the attractors
can be correlated to different cellular states [7]. Nevertheless, BNs
only provide a very limited quantitative insight into biological
systems due to their inherent qualitative nature of state and time.
In 2002, the probabilistic Boolean network (PBN) modelling
framework was introduced by Ilya Shmulevich and colleagues for
the modelling of gene regulatory networks [8]. PBNs combine the
rule-based modelling of Boolean networks with uncertainty
principles as described by Markov chains [8,9]. The PBN
formalism allows multiple Boolean functions to be assigned to a
certain node with corresponding selection probabilities. This
assignment forms a collection of Boolean networks (so-called
constituent networks) that are being randomly chosen in accordance
with their selection probabilities throughout the course of a
simulation of the PBN. A constituent Boolean network determin-
ing the state transition of the PBN is randomly chosen at each
epoch in an instantaneously random PBN, while the transition
determining constituent Boolean network remains constant for a
period of time until a binary random variable asks for a switch in a
context-sensitive PBN [10]. Modelling with PBNs provides a
quantitative understanding of biological systems. For example,
interactive effects (so called influences) between certain genes [8] or
average activities of certain genes given by steady-state probabil-
ities [7] can be computed and expressed in quantitative terms.
Over the past years, PBNs have been widely applied to study
various biological systems. For instance, Yu et al. inferred a gene
regulatory network of the interferon pathway in macrophages
from time-course gene expression data via the calculation of
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Coefficient of Determination (CoD) to determine the selection
probability of each predictor function [11]. Using a similar
approach, Ma et al. inferred a brain connectivity network from
functional Magnetic Resonance Imaging (fMRI) data where the
influence of each brain compartment in patients with Parkinson’s
disease could be determined [12]. In recent years, Flo¨ttmann et al.
modelled the regulatory processes taking place during the
production of induced pluripotent stem cells by combining the
interplay between gene expression, chromatin modification, and
DNA methylation [13]. An extensive analysis on the PBN model
of Flo¨ttmann et al. suggests possible interventions on gene
regulation which might be further developed into clinical
applications. For more examples, see [6,14,15,16], where, among
others, PBN models for the pathogenesis of dengue viral infection
and the transcriptional programming during C. elegans develop-
ment, are discussed.
To facilitate the building of BN and PBN models as a
representation of biological systems, several computational tools
have been developed which can be applied for the optimisation
and inference of models in a Boolean formalism. For instance,
CellNetOptimiser (CellNOpt a.k.a. CNO) by Saez-Rodriguez et al. [17]
was used for the inference of a signal transduction network from
high-throughput sandwich immunoassay data [18]. Dynamic
Deterministic Effects Propagation Networks (DDEPN) by Bender et al.
allows for the reconstruction of signalling networks based on time-
course experimental data [19]. La¨hdesma¨ki and Shmulevich
introduced BN/PBN toolbox [20], a Matlab-based toolbox which
allows for the simulation, visualisation and analysis of BN and
PBN models. BN/PBN toolbox also provides a pipeline for network
inference in both the BN and PBN formalisms based on
experimental measurements such as microarray data. The network
inference process is performed via the calculation of the CoD by
exploring the error size of a given Boolean function (or so-called
predictor) compared to data. The state transition probabilities and
the influences that determine the interactive effect for each pair of
molecules (such as genes) are subsequently calculated. The BN/
PBN toolbox was initially designed for the inference and analysis of
gene regulatory networks [20]. However, it was also applied for
the study of different biological systems such as the brain
connectivity network as previously mentioned [12].
Based on the existing functionalities of the BN/PBN toolbox, we
introduce optPBN, a Matlab-based optimisation toolbox for
probabilistic Boolean networks. optPBN allows for a simple
generation of PBN models from rule-based Boolean modelling.
Prior biological knowledge such as known interactions in the
network, which was not considered in the original BN/PBN
toolbox, can additionally be integrated as inputs in terms of
Boolean rules. optPBN facilitates the incorporation of experimental
data to BN/PBN models in order to generate an integrated
optimisation problem which can subsequently be solved by various
optimisation solvers. In comparison to the BN/PBN toolbox,
optPBN extends the functionality by allowing the identification of
suitable Boolean rules in BNs and the determination of selection
probabilities in PBNs based on experimental data and prior
knowledge. Even though the optimisation pipeline of optPBN is
rather simple and straight-forward, the results generated from
optPBN retain meaningful qualitative and quantitative biological
interpretations which are in accordance with the observed
biological phenomena as captured in the experimental data.
In terms of functionality, optPBN can handle optimisation
problems of networks characterised by various complexities. We
offer a stand-alone version of optPBN toolbox which is suitable for
solving simple optimisation problems, e.g., for small networks. For
solving optimisation problems of complex biological networks such
as the Boolean model of apoptosis from Schlatter et al. which
comprises 86 nodes and 125 interactions [4], we also offer a grid-
based optimisation pipeline of optPBN toolbox that operates on a
large-scale computational platform such as the Grid’5000 [21].
Based on the results obtained from the optimisation of Schlatter’s
model in the PBN format, we quantitatively identified an inverse
correlation between UVB irradiation, nuclear factor kappa-B
(NFkB) and Caspase 3 activations, and apoptotic activity which
could not be demonstrated in the original article due to the
qualitative limitation of the Boolean network framework. In
addition, we were able to estimate the relevancy of a newly
introduced molecular interaction, i.e., the activation of NFkB by
Caspase 8, by considering the value of fitted parameter sets and
the sensitivity of parameters as indicated by parameter distribu-
tions.
Method and Implementation
Probabilistic Boolean networks
A probabilistic Boolean network (PBN) is a collection of Boolean
networks in which a constituent network governs the state (activity)
of a node (molecule) for a random period of time before another
randomly chosen constituent network takes over [7]. Formally, a
probabilistic Boolean network G(V ,F ) is defined by a set of
binary-valued nodes V~fx1,x2, . . . ,xng and a family of sets
F~fF1,F2, . . . ,Fng. For each i~1,2, . . . ,n the set Fi is
Fi~ff (i)1 ,f (i)2 , . . . ,f (i)l(i)g where f (i)j (1ƒjƒl(i)) is a possible Boolean
predictor function for the node xi and l(i) is the number of such
predictor functions. A realisation of the PBN at a given instant of
time is determined by a vector of predictor functions, where the ith
element of that vector contains the function selected at that time
point for xi. For a PBN with N realisations there are N possible
network transition functions f1, f2, . . . , fN of the form
fl~ff (1)l1 , f
(2)
l2
, . . . , f (n)ln g, l~1,2, . . . ,N, 1ƒljƒl(j), f
(i)
lj
[Fj and
j~1,2, . . . ,n. Each network transition function fl defines a
constituent Boolean network of the PBN. In this way the
realisations of the PBN can be identified with the constituent
Boolean networks.
Let c(i)j be the probability that the predictor f
(i)
j , 1ƒjƒl(i),
which is selected to determine the value of xi at the next time
instance. It follows that
Pl(i)
j~1 c
(i)
j ~1. The PBN is said to be
independent if the predictors for all nodes are selected independently
of each other. Assuming independence, there are N~Pni~1 l(i)
constituent Boolean networks of the PBN and the probability
governing the selection of a particular network is given by
Pr(fl)~cl~P
n
i~1 c
(i)
li
for all 1ƒlƒN. Two selection schemes are
possible: the selection of the constituent Boolean network takes
place at each consecutive time step (instantaneously random PBN)
or there is a random variable which governs whether the PBN is
updated in accordance with the current Boolean network or a
newly selected one (context-sensitive PBN). In both cases the
constituent network is chosen according to the selection probabil-
ities cj , 1ƒjƒN . For further details on PBN, we refer to [6,7]
which give a comprehensive overview on probabilistic Boolean
networks. An example of a PBN with three nodes is given in
Figure 1.
The example model consists of three nodes V= (N1,N2,N3) and
the functional classes F1= {f (N1)1 }, F2= {f
(N2)
1 }, and
F3= {f (N3)1 ,f
(N3)
2 }. N1 and N2 are inputs, where N1 activates
N3 while N2 partly inhibits N3 (40%). The respective truth table is
shown in Figure 1C. Once both N1 and N2 are activated (taking a
state value of 1), node N3 could either solely be under the
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influence of N1 with a probability of 0.6, resulting in the activation
of N3 that will take a state value of 1. Or, node N3 could also be
under the influence of both N1 and N2 with a probability of 0.4,
resulting in the inhibition of N3 that will take a state value of 0.
The probabilistic terms that correspond to the selection probabil-
ities (c(i)j ) for the Boolean predictor functions are indicated in the
truth table. We study this example in the context of instanta-
neously random PBNs and show three exemplary model
simulations in Figure 1D.
There are two constituent Boolean networks of the example
model given by the two different Boolean rules for node N3 shown
in Figure 1B. These two constituent networks are randomly chosen
at each time step of a simulation which for N1=N2=1 results in
flips of the state value of N3 between 0 and 1 as shown in
Figure 1D.
The dynamics of the PBN is governed by a Markov chain which
structure is presented in Figure 2. The nodes represent the states of
the system and the possible transitions between the states are
labelled with the respective transition probabilities. The graph of
the Markov chain consists of four disjoint parts referred to as A, B,
C, and D, respectively. There are four bottom strongly connected
components of the graph that correspond to four irreducible
subchains of the Markov chain: 000 (part A), 010 (part B), 101
(part C) and 110, 111 (part D). It follows that the Markov chain is
not ergodic.
With N1 and N2 set to 1, the dynamics of the resulting PBN is
given by part D of the Markov chain in Figure 2D which in fact is
an ergodic two-state Markov chain. The steady-state probability
for N3 to be active is 0.6. This value can be estimated by taking
the mean activity over a Monte-Carlo run as shown in Figure 1D.
The respective values obtained for 3 independent runs are 0.57,
0.62 and 0.52. In general, longer runs would result in a better
estimation of the steady-state probability value.
From a biological point of view, the steady-state probability of a
node being active can be interpreted as mean activity of the
respective molecule in a cell population normalised to the maximal
observed value. Let us assume that some a priori knowledge on the
model structure is given in the form of a set of constituent Boolean
networks, but the selection probabilities are unknown. The above
biological interpretation provides basis for considering inferring
the selection probabilities from measurement data from different
biological conditions (e.g., different ligand stimulations, mutants,
or inhibitor treatments). Once selection probabilities are inferred,
the relevancy of Boolean interactions can be determined by the
values of selection probability and the parameters sensitivity as
indicated by their distribution. Furthermore, selection probabilities
can be further used to calculate the influences, which reflect the
relative importance of parent molecules on the target molecules in
the resulting PBN [8].
optPBN pipeline
optPBN is a Matlab-based toolbox which operates under the
framework of the BN/PBN toolbox by La¨hdesma¨ki and Shmulevich
[20], see File S1 for the toolbox and File S2 for optPBN’s examples.
optPBN extends the existing functionalities of the original toolbox
by allowing 1) for an easy BN/PBN models generation procedure
allowing to incorporate prior knowledge, 2) for improved model
fitting to multiple experimental data, i.e., the optimisation of
selection probabilities for different experimental settings, 3) for a
subsequent statistical analysis of the optimised parameters, and 4)
for a fast computation on grid-based platforms. A simplified
pipeline of the optimisation process in optPBN is shown in Figure 3
and a detailed explanation of the pipeline and computational
scripts can be found in File S3.
The optPBN pipeline starts with the generation of a BN/PBN
model from a preliminary model structure which is usually derived
from literature. This step can be easily done by assigning different
Figure 1. An example model with the corresponding Boolean rules, truth table and model simulation results. [A] The example model
consists of 3 nodes with one activation edge and one partial inhibition edge. The weights of both edges are expressed as selection probability next to
the arrow. [B] Two representative Boolean rules were assigned with the corresponding selection probabilities (c(i)j ) to represent the example model in
PBN format. [C] The truth table of the example model demonstrates the state values according to different inputs. Once both inputs (N1 and N2) are
active, the output (N3) has a probability of being ON at 0.6 and of being OFF at 0.4 according to the selection probability of Boolean rules. [D] Three
separated Monte-Carlo simulations were performed on an instantaneously random PBN of the example model in Figure 1. The state values of N3 are
shown on the y-axis as a function of time. The mean of the N3 state values over 20 time steps is given on the upper right corner of each run.
doi:10.1371/journal.pone.0098001.g001
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Boolean interactions in a rule-based Boolean modelling format for
each molecule. This means, prior information is considered in
terms of a set of possible constituent Boolean functions. For each
molecule in a network, single or multiple Boolean functions with
the corresponding selection probabilities can be assigned to define
how often the respective Boolean function will be present in the
chosen constituent network. For unknown or uncertain interac-
tion(s), the selection probabilities of these Boolean rules can be
inferred later by optimisation to normalised experimental data.
In the next step, an optimisation problem is generated based on
the integration of the preliminary BN/PBN model structure and
experimental data. The description of each experimental condi-
tion (e.g., different ligand stimulations, mutants, or inhibitor
treatments) with its respective measurement data are defined as
separate modelling cases. The integration step is simplified by
applying the script rule2PBN to convert the rules and experimental
description of each modelling case into the BN/PBN toolbox’s
internal variables (see the documentation in [20] or File S3) and by
subsequently applying the script add2estim to collect and combine
multiple modelling cases into a single global data structure named
estim. Following this step, the script preprocessMultiExp derives only
essential information to generate a final integrated optimisation
problem which can subsequently be solved by different optimisa-
tion algorithms.
optPBN can be operated in two optimisation modes: ‘discrete’
and ‘continuous’. In the ‘discrete’ mode each Boolean network
from the pool of considered networks is assigned one of two
possible values: 0 or 1. Only Boolean networks with value 1 are
considered as constitutive Boolean networks of the inferred PBN,
each with equal selection probability. In the ‘continuous’ mode the
selection probabilities can be any numbers in the range from 0 to 1
with the only constraint that the sum of selection probabilities of
all constitutive Boolean networks of the inferred PBN is 1.
Additional details on the two optimisation modes can be found in
File S3.
To solve the integrated optimisation problem, two different sets
of optimisers are used in optPBN: 1) particle swarm optimisation
(PSO), pswarmSB [22], a global optimisation algorithm as described
in the Systems Biology Toolbox 2 (SBToolbox2) [23,24], and 2) the
evolutionary algorithm (EA) [25] which is integrated in the
population-based meta-heuristic optimisation framework Paradi-
sEO [26] coupled with a differential evolution algorithm (DE) [27].
We therefore offer two versions of optPBN: a stand-alone version
which uses pswarmSB and a grid-based version which uses the
coupled EA and DE algorithms. For additional details on the
pipeline of the grid-based version and the algorithms used, please
see File S4.
The stand-alone version of the optPBN toolbox (PSO-based) was
designed for solving simple optimisation problems, e.g., for small
networks, while the grid-based version (EA- and DE- based) was
customised to be implemented on a large-scale computational
platform such as the Grid’5000 [21] for solving complex
optimisation problems. The respective objective function of the
optimisation process in optPBN pipeline is to minimise the sum of
squared errors (SSE) between 1) molecular activities as represented
Figure 2. Structure of the dynamics of the example model. The
dynamics of the example PBN model presented in Figure 1 is governed
by a Markov chain. The graph of the Markov chain consists of four
disjoint parts as presented in [A], [B], [C], and [D], respectively. In each
graph, the nodes represent the states of the system and the possible
transitions between the states are labelled with the respective
transition probabilities. Four bottom strongly connected components
of the graph that correspond to four irreducible subchains of the
Markov chain are shown as follows: 000 [A], 010 [B], 101 [C] and 110,
111 [D].
doi:10.1371/journal.pone.0098001.g002
Figure 3. Optimisation pipeline of the optPBN toolbox. A
preliminary model structure is required as an input for the generation
of a PBN model. The generated PBN models from different experimental
conditions together with the corresponding measurement data are
subsequently combined to generate an integrated optimisation
problem which can be solved by various optimisation algorithms. Once
the optimisation algorithm(s) generate sufficient amount of good
parameter sets, a statistical analysis of the optimised parameter sets
(i.e., of PBN’s selection probabilities) is performed to indicate the
identifiability and the sensitivity of parameters through the consider-
ation on parameters’ distribution. The optPBN scripts used for each task
are given in parentheses.
doi:10.1371/journal.pone.0098001.g003
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by their steady-state probabilities and 2) measurement data in each
experimental condition. The interface for communication between
the integrated optimisation problem in BN/PBN toolbox’s internal
format and the optimisers, e.g., the conversion from sampled
parameter values to selection probabilities (c(i)j ) in PBN, is provided
in the script optfun with a set of adjustable parameters to customise
the optimisation process (see File S3).
During the optimisation process, we approximate the marginal
steady-state distribution of the output nodes by applying the two-
state Markov chain method as presented in the study of
Shmulevich et al. [28]. The ergodicity of the PBN’s underlying
Markov chain is ensured by the introduction of perturbations
controlled by a small perturbation parameter (p) as introduced by
Miranda and Parga [29]. The two-state Markov chain method is
subsequently applied to determine the number of simulation steps
to be discarded before reaching steady-state (‘burn-in period’, m0)
and the minimal number of time steps (N) required to estimate the
marginalised steady-state distribution at a pre-defined accuracy.
The accuracy of the steady-state approximation can be adapted by
adjusting the parameters (e, r, and s) as described by Raftery and
Lewis [30]. Note that the equations used for the calculation of m0
and N as presented in [28] and [30] contain two small errors. We
present the correct derivations of these two-state Markov chain
approach formulas in File S5 and we applied the correct formulas
in the optPBN pipeline accordingly.
Starting from an initial parameters setting (e.g. m0 = 0 and
N=100), we iteratively determine a new pair of values for m0 and
N from the estimated transition probabilities between the two
meta-states. If the new value for m0+N is greater than the previous
value, the model is simulated further in order to extend the
trajectory to the length given by the new value of m0+N. Then, the
transition probabilities are re-estimated from the last N states in
the trajectory and used to calculate new values for m0 and N. This
process is repeated until the new value for m0+N is not greater than
its previous value. Finally, the marginalised steady-state probabil-
ity is estimated with the frequency with which the corresponding
state in the two-state Markov chain was sampled within the N last
elements of the obtained trajectory.
We observed in the investigated case studies that at least 5,000
iterations of selection probability (c(i)j ) parameter sampling by
optimisers for small models (n,10) and at least 7,500 iterations for
large model (10,n,100) are sufficient to get a good fit and to
obtain representative parameter sets for further statistical analysis.
Note that this only holds for the investigated examples and cannot
be generalised for other large-scale models. Once the optimisation
process is finished, the best parameter set is reported and the
model can be re-simulated with the script evalCijAndSimulate in
order to check the quality of model fitting by comparing simulated
steady-state probability to measurement data (see detailed
explanation in File S3). Note that under the stochastic events of
constituent networks chosen during PBN simulations, the same
exact result might not be observed from the re-simulation.
Nevertheless, the differences of the results between each simulation
are expected to be minimal based on the assumption that the
approximation of the steady-state distribution with the two-state
Markov chain approach is rather accurate.
After checking model fitting, a representative set of parameters
which fit well to measurement data can be chosen for further
statistical analysis. The calculation of mean and standard deviation
(SD) of the selected set of parameters can be performed by
applying the script BestRunsStat. The mean of selection probabil-
ities from selected parameter sets indicates to some extent what are
the expected selection probabilities for the potential constitutive
Boolean networks in PBNs that fit the experimental data. In
parallel, the SD value gives an insight on the identifiability for each
parameter and parameters’ sensitivity can be assessed from
parameter distributions. These pieces of information in turn allow
for the estimation of the relevancy of Boolean interactions within
the context of the study.
Results and Discussion
In this section, four case studies with different levels of
complexity are presented to demonstrate the functionalities of
optPBN. We applied the optPBN pipeline, which approximates
marginalised steady-state distribution with simulation of ergodic
PBNs coupled with the two-state Markov chain method, to
generate the results in this section. The parameters for checking
steady-state convergence are set as follows: p= 0.001, r = 0.025,
e=0.01 and s = 0.95.
For each case study, we consider the best 500 parameter sets in
terms of the optimal cost to analyse the identifiability of the model
parameters and to perform subsequent statistical analyses. The
spread of the identified parameters for each case study is shown in
Figure 4. The scatter plots show that the obtained parameters are
clustered for the first three case studies. However, the parameters
in case study 4 are not always clustered. Therefore, we
demonstrated the result generated from the best run of each case
study which was marked as a red asterisk on Figure 4. A summary
of these results can be found in File S6.
Case study 1: optPBN allows for the identification of
suitable Boolean rule(s) in Boolean networks
With respect to optimising qualitative Boolean networks, optPBN
is capable of identifying a set of suitable Boolean rules from a user-
defined list of candidate rules based on experimental data. For this
task, optPBN is operated in the ‘discrete mode’ for which only 0
and 1 values for the selection probabilities are evaluated (see detail
in File S3).
In order to demonstrate the respective functionality of optPBN,
we use case study 1 (Figure 5) as an example. We pre-define a set
of five different Boolean rules to represent the potential influence
of PI3K and TNFa on NFkB as follows: connect PI3K and TNFa
activation with an OR gate (|), connect PI3K and TNFa
activation with an AND gate (&), has only an activation from
PI3K (PI), has only an activation from TNFa (TN), and has no
interactions from either PI3K or TNFa and output is fixed to 0
(Ø). We consider 4 experimental measurements of NFkB, each
with a configuration of the input nodes PI3K and TNFa. For each
individual measurement, we applied optPBN to determine which of
the pre-selected rules(s) is capable of explaining the experimental
data. The obtained results show that optPBN could identify the
correct Boolean rules. Then, we applied optPBN to all experimen-
tal measurements considered simultaneously. In this case, optPBN
identified the connection of PI3K and TNFa to NFkB with an
AND gate (&) as the only suitable Boolean rule which can explain
the complete set of experimental data. This case study shows that
optPBN can be applied for the inference of biological networks in
the Boolean formalism. The obtained results are summarised in
Table 1.
Case study 2: optPBN allows for the determination of
selection probabilities in probabilistic Boolean networks
In this theoretical case study, we consider the regulation of PIP3
by PI3Kand PTEN. We assume that this process can be modelled
with the network presented in Figure 1A, where the nodes N1, N2,
and N3 represent PI3K, PTEN, and PIP3, respectively. Nodes N1
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and N2 are the so-called input nodes, i.e., they are not influenced
by any node in the network and their values are determined by
explicit assignment. This makes that the underlying Markov chain
consists of four disjoint, non-communicating Markov subchains,
one for each of the four different assignments of values to the input
nodes.
Let us now assume that the model structure is only partially
known, i.e., it is known that PI3K activates PIP3, but there is no
certain information on whether PTEN activates or inhibits PIP3
and to what extent. Therefore, as a prior knowledge, we consider
four different Boolean rules that encode four potential signal flows
from PI3K and PTEN to PIP3 as follows: only activation from
PI3K (PI), only activation from PTEN (PT), activation from PI3K
and inhibition from PTEN (PI&,PT), and no interaction from
either PI3K or PTEN and output is 0 (Ø). Furthermore, four
experiments are performed, where various combinations of values
for PI3K and PTEN as the initial conditions are considered. As the
measured values of PIP3 we take the theoretical values of the
Figure 4. Scatter plots of a set of fitted parameters from all case studies. The distributions of selection probabilities from the best 500
parameter sets in term of optimal cost are shown in [A] for case study 1 (node NFkB), [B] for case study 2 (node PIP3). The dependency among
selection probabilities across two nodes are shown in [C] for case study 3 (nodes NFkB and ERK) and [D] for case study 4 (nodes NFkB and complex2).
The parameter values for the first 3 case studies form a single cluster which indicates that the respective parameters are identifiable. However, the
parameter which influences on NFkB (y-axis) seem to be identifiable in case study 4 but the parameter which influences on complex2 (x-axis) are
much sparser. Such observation raises an issue in term of parameters’ identifiability. Only the best parameter set from each case study (marked as a
red asterisk) was therefore used for further analysis and interpretation.
doi:10.1371/journal.pone.0098001.g004
Figure 5. Case study 1. [A] Case study 1 deals with a Boolean
network that consists of 3 nodes with an unknown Boolean interaction
from the two inputs. [B] The table contains artificial experimental data
from four different combinations of input states (Experiments ‘A’, ‘B’, ‘C’,
and ‘D’) of case study 1.
doi:10.1371/journal.pone.0098001.g005
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underlying Markov chain stationary probabilities determined by
the initial conditions. The partially known network structure and
the experimental data are shown in Figure 6. Now, we applied
optPBN to perform the optimisation in the ‘continuous mode’
where an extensive continuous parameter space (the interval from
0 to 1) is explored within the optimisation process to determine the
selection probabilities for the four different Boolean rules.
When performing optimisation, the values of the input nodes
are fixed to the values specified by the available experimental
conditions, one by one. For each experimental dataset only the
subchain determined by the experimental condition is considered.
In order to make the considered part of the underlying Markov
chain ergodic, perturbations are introduced which make the
considered subchain irreducible and aperiodic. In this way, the
considered part has a unique steady-state probability distribution
which can be estimated by the two-state Markov chain approach
independently of the choice of the initial state of a simulation. The
obtained steady-state probabilities are estimated and the squared
difference of the estimated value and the experimental value is
calculated. To get the final fit score, the squared differences from
all experimental conditions are added.
Two remarks are in place. First, it should be noted that the fit
quality of these experiments could be improved by increasing the
accuracy for the approximation of steady-state distribution, e.g.,
by adjusting the parameter ‘r’. Details on model fitting’s quality in
relationship to the accuracy parameter ‘r’ can be found in File S6.
Second, more importantly, the inference results heavily depend on
the experimental data. In this case study the set of experimental
data was comprehensive in the sense that it covered possible
assignments of values to the input nodes: by considering
experiments A, B, C, and D in Figure 6 part [B], all the four
non-communicating subchains of the Markov chain in Figure 2
are taken into account. If this is not the case, the inference may
result in wrong outcomes. According to the results of this case
study shown in Table 2, the selection probabilities inferred from all
experiments agree well with the selection probabilities of the
original network. However, when only experimental data from
experiments A and D were taken into account, the optimisation
inferred a PBN consisting of all four constituent Boolean networks
given by the rules ‘PI’, ‘PT’, ‘PI&,PT’,and ‘Ø’, with selection
probabilities 0.4602, 0.1344, 0.3607 and 0.0447, respectively.
In summary, this case study demonstrates that the optPBN
toolbox can be applied to infer selection probabilities from given
comprehensive data. Once the selection probabilities are obtained,
they can subsequently be used to estimate the relevancy of Boolean
interactions. In addition, they can also be used to determine the
influence between molecules as presented in [8].
Case study 3: optPBN generates comparable results to an
existing tool while having a broader functionality
To date, there are several computational tools which are
applicable for the optimisation of biological networks in the
Boolean formalism. One of the leading tools is CellNetOptimizer
(CellNOpt a.k.a. CNO) introduced by Saez-Rodriguez et al. [17].
CellNOpt was applied for building logic-based models of signal
transduction networks in different logic formalisms that are trained
against high-throughput proteomics data [18].
To illustrate and prove the functionalities of CellNOpt, the tool
was used to optimise a toy model based on a set of artificial
experimental data. The objective function of CellNOpt is based on
two components: 1) the mean squared error (MSE) deviation
between data and predicted states, and 2) a penalised term for
increasing model size (E`s) which is adjustable by a scaling factor
(a). By minimising a combination of these two terms, CellNOpt was
able to identify the Boolean interactions that correspond to
experimental data (see Figure S1).
To benchmark our newly developed toolbox, we applied optPBN
to optimise the compressed version of the toy model in Boolean
Table 1. Results from the optPBN toolbox for case study 1 compared to the original network.
Optimisation results
Exp|rules I & PI TN Ø
A 3 (0.2) 3 (0.2) 3 (0.2) 3 (0.2) 3 (0.2)
B 7 (0) 3 (0.33) 7 (0) 3 (0.33) 3 (0.33)
C 7 (0) 3 (0.33) 3 (0.33) 7 (0) 3 (0.33)
D 3 (0.25) 3 (0.25) 3 (0.25) 3 (0.25) 7 (0)
All (A to D) 7 (0) 3 (1) 7 (0) 7 (0) 7 (0)
Original network
Correct rule 7 (0) 3 (1) 7 (0) 7 (0) 7 (0)
The table shows the results of optimisation for four different individual datasets (A, B, C and D) and for the combined four datasets (All) compared to the original
network. Five different Boolean rules are applied as follows: connect PI3K and TNFa activation with an OR gate (|), connect PI3K and TNFa activation with an AND gate
(&), has only an activation from PI3K (PI), has only an activation from TNFa (TN), and has no interactions from either PI3K or TNFa and output is fixed to 0 (Ø). The symbol
‘3’ indicates that the respective rule can explain the measurement data while the symbol ‘7’ refers to the contrast observation. The results from the optPBN toolbox
divide the sum of probabilities, i.e. 1, by the number of correct result(s) in each experiment (given in parentheses) and they all correspond to the correct results.
doi:10.1371/journal.pone.0098001.t001
Figure 6. Case study 2. [A] Case study 2 deals with a probabilistic
Boolean network that consists of 3 nodes with an unknown type and
weight of interaction from PTEN to PIP3. [B] The table contains artificial
experimental data from four different combinations of input states
(Experiments ‘A’, ‘B’, ‘C’, and ‘D’) of case study 2.
doi:10.1371/journal.pone.0098001.g006
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formalism as presented in the original CellNOpt article [18], see also
Figure S1. The original toy model comprises 8 nodes. There are 2
input nodes which are TGFa and TNFa with two downstream
nodes that can be inhibited by inhibitors (PI3Ki and Rafi). The
presence of inhibitor is depicted in the input table with ‘2’ once it
is absent and with ‘+’ when it is present. The rest of the nodes are
considered as output nodes and are all measured. Here, we applied
optPBN to optimise the two unknown logic gates for NFkB and
ERK.
The original model structure with 6 different experimental
conditions were plugged into the optPBN pipeline in ‘discrete
mode’ as previously described for case study 1. optPBN is capable
of acquiring the same results as CellNOpt, i.e. to identify
‘NFkB=PI3K & TNFa’ and ‘ERK=Raf’ as the correct Boolean
rules. In addition, optPBN also identified the rule ‘ERK= -
Raf|NFkB’ as an additional solution that can also explain the
data from all experimental conditions (see Figure S1). We also
verified that both correct Boolean rules are independent as the
optimal costs after assigning these two rules one-at-a-time to be the
correct rule are highly similar.
Then, we extended the current study by applying optPBN for the
optimisation of a modified toy model based on a new set of
artificial data (case study 3) as shown in Figure 7. In this version,
we assumed that the weights of molecular activation and the
inhibitors’ efficacies are not absolute, resulting in a propagation of
signals in a non-discrete (continuous) manner. Once output nodes
can be activated by multiple molecules, i.e., NFkB can be activated
by PI3K and TNFa while ERK can be activated by Raf and
NFkB, we consider disjoint activating signals from both inputs
which are sum up to a full activation. When inhibitor is
additionally present, the activating signal is reduced proportionally
to the inhibitor’s efficacy.
Considering e.g. experiment D, both inputs are ON and there
are two unknown weights of activation from PI3K and TNFa
towards NFkB with the presence of PI3K-inhibitor treatment. If
we assume that the activating signal from PI3K is 70% and from
TNFa is 30% with the presence of PI3K-inhibitor that inhibits
PI3K signal at 70%, the signal for the activation on NFkB in this
experiment can be calculated from the sum of the remaining PI3K
signal after inhibition (100%270%=30%) multiplied by the
weight of PI3K’s activation (70%), resulted in the signal value of
0.3*0.7 = 0.21. This signal is then combined with the disjoint
activating signal from TNFa (30% or 0.3). The sum of activating
signals for NFkB node is therefore 0.51 in this experimental
setting.
To perform an optimisation study on this modified toy model,
optPBN was applied in the ‘continuous mode’ as previously
described for case study 2. The optimisation results as shown in
Table 3 are in a good agreement with the selection probabilities of
the original model.
In summary, the results from the two toy model studies
demonstrate that the optimised networks generated from CellNOpt
and optPBN are similar when operated in a discrete (qualitative)
optimisation mode. At the same time, optPBN offers an additional
functionality of a continuous (quantitative) optimisation mode to
identify selection probabilities which might yield additional insight
into the relevancy of interactions within the network.
Case study 4: optPBN allows for the optimisation of an
apoptotic network at scalable computational time and
for the estimation of interactions’ relevancy in a context-
specific manner
Optimisation of an apoptotic network in the PBN
framework. Schlatter et al. introduced a large-scale Boolean
network of apoptosis in hepatocytes that consists of 86 nodes and
125 interactions as shown in Figure 8. [4] The assigned Boolean
interaction for each molecule was derived from literature. After
the Boolean model was built, it was subsequently validated by
experimental data which were categorised into three discrete
values: no activity ‘0’, low activity ‘1’, and high activity ‘2’. The
analysis of Schlatter’s model was conducted in CellNetAnalyzer
(CNA), a Boolean network and constraint-based models analyser
which allows for the calculation of logical steady-states [31]. As the
original model structure comprises many feedback loops, 13
interactions were removed from the model in order to generate a
new model variant which delivers fixed point steady-states and
thus is compatible to be analysed in CNA. The analysis revealed
the effects from different cytokines stimulations and UVB
irradiations towards apoptosis in hepatocytes, but only in a limited
qualitative manner [4].
Based on the original study, we applied optPBN to optimise
Schlatter’s model in the PBN formalism. We converted the multi-
value Boolean model of apoptosis into a binary PBN model which
comprises 96 nodes and 106 interaction functions (‘initial apoptosis
model’). We used the selected set of Boolean interactions as
described in the original article with minimal modifications on a
few Boolean rules to make them suitable for modelling in the PBN
format (see File S2). Our initial aim is to optimise selection
probabilities of our PBN model in order to return the steady-state
probabilities of 3 output nodes, i.e., Apoptosis, Caspase 3 and
Table 2. Results from the optPBN toolbox for case study 2 compared to the original network.
Optimisation results
Exp|rules PI PT PI&,PT Ø
A,D 0.4602 0.1344 0.3607 0.0447
All (A to D) 0.6041 0 0.3959 0
Original network
Selection probabilities 0.6 0 0.4 0
The table shows the results of optimisation for two datasets: 1) containing measurement data from experiments A and D 2) containing all measurement data from
experiments A, B, C and D. Four different Boolean rules are applied as follows: only activation from PI3K (PI), only activation from PTEN (PT), activation from PI3K and
inhibition from PTEN (PI&,PT), and no interaction from either PI3K or PTEN and output is fixed to 0 (Ø). The selection probabilities inferred from all experiments agree
well with the selection probabilities of the original network. The dataset consisting of the measurement from only experiments A and D is insufficient to reconstruct the
original network.
doi:10.1371/journal.pone.0098001.t002
Optimising Probabilistic Boolean Networks
PLOS ONE | www.plosone.org 8 July 2014 | Volume 9 | Issue 7 | e98001  
Chapter 4.1: optPBN: an optimisation toolbox for PBN     71 | P a g e  
 
NFkB, which match the measurement data. We optimised the
selection probabilities of Boolean rules for 7 target nodes: IKK,
IkBa, IkBe, complex2, caspase8 and caspase3 (both at low and
high activities), which are connected to the 3 output nodes. This
results in the optimisation of 17 selection probabilities.
Next, pre-processing of the original measurement data on
hepatocytes for the three output nodes: Apoptosis, Caspase 3 and
NFkB, was performed by background subtraction and normalisa-
tion to the maximal value. Saturation of Caspase 3’s signals was
assumed in our study (see File S7). Then, the normalised
experimental data and the PBN model description were combined
into an integrated optimisation problem which was subsequently
solved with optPBN in ‘continuous mode’.
For this case study six different experimental conditions which
were experimentally validated are given. During optimisation six
subchains of the underlying Markov chain are considered, each
determined by fixing an input node’s value in accordance with the
experimental condition. The fixed value of the input node is not
perturbed, but all the other nodes can be perturbed, which makes
the subchain ergodic and in consequence having a unique steady-
state distribution. It should be noted that performing the
optimisation with use of a more rich set of experimental data,
i.e., for conditions which correspond to setting the input nodes to
different combinations of values, could provide more insight into
the network interactions.
Optimisation of a complex network at scalable
computational time. To evaluate the fitting cost during the
optimisation process, the marginalised steady-state probabilities
for activity of one molecule at a time for a set of output nodes
(Apoptosis, Caspase 3 and NFkB) needed to be estimated. As
previously presented in the description of the optPBN pipeline, this
was achieved by applying the two-state Markov chain approach
with the accuracy set to 0.025 (r = 0.025). Although the size of the
underlying Markov chain of the PBN is huge, i.e., 296 states, it
Figure 7. Modified toy model of Saez-Rodriguez et al. and corresponding artificial experimental data (case study 3). [A] The modified
toy model from Saez-Rodriguez et al. [18] is a probabilistic Boolean network that consists of 8 nodes with two unknown weights of Boolean
interactions for NFkB and ERK. [B] The table describes the states of inputs and inhibitor treatments for 6 experimental conditions. [C] The
corresponding normalised artificial experimental data of the experimental conditions as described in [B]. The 6 experimental conditions based on the
combination of stimulus and inhibitor treatments yield different readouts on four downstream molecules.
doi:10.1371/journal.pone.0098001.g007
Table 3. Results from the optPBN toolbox for case study 3 compared to the original network.
Optimisation results
Outputs NFkB ERK
Exp|rules PI TN RA NF
All (A to F) 0.708 0.292 0.603 0.397
Original network
Selection probabilities 0.7 0.3 0.6 0.4
The table shows the optimisation results for the dataset which combines all six experiments from A to F (All) in case study 3. Two different Boolean rules are applied for
NFkB and another two rules for ERK as follows: activation signal from PI3K (PI) or TNFa (TN) to NFkB, and activation signal from Raf (RA) or NFkB (NF) to ERK. The results
from the optimisation of modified toy model from Saez-Rodriguez et al. are corresponded with the correct results.
doi:10.1371/journal.pone.0098001.t003
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Figure 8. Boolean model of apoptosis by Schlatter et al. and normalised experimental data (case study 4). [A] The Boolean model of
apoptosis by Schlatter et al. [4] consists of 86 nodes with 125 Boolean interactions. The model was analysed with CellNetAnalyzer (CNA) to study the
correlations between 10 different inputs from different cytokines stimulations and UVB irradiations towards apoptosis. [B] The normalised
experimental dataset were generated based on the experimental data as presented in the original article (see details in File S7). The inverse
correlation between UVB irradiation, NFkB and P17 form of activated Caspase 3 (C3ap17) activations, and apoptotic activity is quantitatively observed
in the original measurement data.
doi:10.1371/journal.pone.0098001.g008
Table 4. Run-time analysis of grid-based optPBN pipeline.
Model Iterations Stand-alone version (1 core) Grid-based version (80 cores) Improvement (folds)
1 1000 305s (5m5s) 8s 38.1
5000 1093s (18m13s) 16s 68.3
2 1000 321s (5m21s) 9s 35.7
5000 1205s (20m5s) 16s 75.3
3 (modified model) 1000 1302s (21m42s) 18s 72.3
5000 6151s (1h42m31s) 39s 157.7
4 (extended structure) 1000 16783s (4h39m43s) 99s (1m39s) 169.5
5000 45503s (12h38m23s) 259s (4m19s) 175.7
The table shows the computational time of the optimisation process required by the grid-based version of optPBN pipeline operated on 80 cluster cores in comparison
to the one required by the stand-alone version running on a single local machine. The run-time analysis was performed on the four case studies for 1,000 and 5,000
parameter samplings to approximate the steady-state probability distribution of output nodes. The results reveal a remarkable reduction of the computational time
from 35 to 175 folds. Abbreviations: s = seconds, m=minutes, and h = hours.
doi:10.1371/journal.pone.0098001.t004
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turned out that in all three cases (Apoptosis, Caspase 3 and NFkB)
the two-state Markov chains were well-mixing: there were frequent
transitions between the two meta-states of the two-state Markov
chains that were considered on top of the underlying Markov
chain of 296 states. In consequence, the marginalised probabilities
could be estimated from trajectories of length less than 4000 (see
File S6). Given this, we were able to perform the optimisation task
in a feasible amount of computational time.
To confirm the accuracy of our results, we performed additional
analyses by fixing one set of selection probabilities (randomly
generated) and started the simulation from random initial
conditions as well as from the extreme cases where initial
conditions for all nodes are either zero or one. We found that
the variations between these 3 cases are minimal, all less than 0.01
(1%). Also, we generated another set of results with higher
accuracy (r = 0.01) where the number of required time steps is
increased approximately 6 folds. We found that the steady-state
distributions of output nodes which were estimated at the two
levels of accuracy (r = 0.025 and r = 0.01) are almost the same, i.e.,
they differ by less than 0.01 (1%) in all case. This indicates that the
chosen parameters lead to a good estimate of the steady-state
distribution of the considered model. We also performed the same
analysis multiple times for different parameter sets where we
obtained similar results. We present a comprehensive datasheet of
the analysis performed for one parameter set in File S8.
Due to the large size of the apoptotic network (Figure 8), the
stand-alone version of optPBN pipeline which runs on a standard
local computer (1 CPU Intel@2.99 GHz, 2 cores/CPU, 3.25 GB
RAM) is not suitable to solve the optimisation problem. Since the
optimisation required 12 hours of computational time to evaluate
approximately 5,000 parameter samples on a standard computer,
we applied the grid-based version of optPBN to solve this
optimisation problem on the Grid’5000 using 10 server machines
(1 server machine comprises 2 CPUs Intel@1.995 GHz, 4 cores/
CPU, 15 GB RAM, see detailed documentation on the installation
and execution of the grid-based pipeline in File S4 and File S9).
The optimisation process was operated in the ‘continuous mode’
on 80 parallel processing cores where the results were delivered in
a timely manner (approximately 10 minutes to evaluate 15,000
parameter samples). The run-time analysis of four case studies
reveals a reduction of computational time from 35 to 175 folds
when running the same optimisation tasks on Grid’5000 with 80
cores. More details on this analysis are shown in Table 4.
Approximation of steady-state distributions by optPBN
reveals more quantitative insight into biological data. For
comparison, the original results from Schlatter’s study (Orig.) and
the set of results from the optimisation of the ‘initial apoptosis
model’ by optPBN (Init.) are shown in Table 5. We were able to
identify a PBN model structure with a set of selection probabilities
that could match relatively well to the measurement data
quantitatively, while the results from the original model are only
limited to 0 and 1 value. The fitting costs of the original model and
of the ‘initial apoptosis model’ based on the calculation of SSE are
1.002 and 0.328, respectively. This indicates that the apoptosis
model in the PBN formalism fits the measurement data better.
In addition, the inverse correlation between the intensity of
UVB irradiation, the activations of NFkB and Caspase 3, and the
apoptotic activity were also identified in a quantitative manner.
Namely, a stronger UVB irradiation (i.e., UV2=600 £/m2.
UV1=300 £/m2) resulted in a stronger NFkB pathway activation
(0.3083 against 0.0023) but a weaker Caspase 3 activation (0.0016
against 0.9966) and a weaker apoptotic activity (0.4681 against
0.9920). In contrast, the original study of Schlatter et al. could only
identify this relationship in a limited qualitative manner [4].
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optPBN allows for an estimation of interactions’
relevancy in a context-specific manner. As can be seen in
Table 5, the fitted ‘initial apoptosis model’ (Init.) failed to explain
some of the experimental data. For instance, the fitting of NFkB in
a condition with a high concentration of Fas ligand stimulation
(FasL (2)) is not in a good agreement with the experimental
measurement (0.0198 against 0.32). This observation raises a
question whether the set of considered molecular interactions was
sufficient to model the context-specific apoptotic signalling in the
hepatocytes.
In fact, NFkB can also be activated through Caspase 8 with a
mechanism distinct from that of tumour necrosis factor alpha
(TNFa) for cytokine production as described in [32,33]. There-
fore, we modified the Boolean rules to take this information into
account and thereby derived a new model called ‘extended
apoptosis model’ (see detail in File S2). The results from the
optimisation on the ‘extended apoptosis model’ (Ext.) are shown in
Table 5. We found that the ‘extended apoptosis model’ fits the
experimental data better (cost of 0.199) than the ‘initial apoptosis
model’ (cost of 0.328) and the inverse correlation between UVB
intensity, NFkB and Caspase 3 activations, and apoptotic activity
is still preserved. In addition, we also found that the discrepancy
between the simulated model state and the measurement data of
NFkB in the FasL (2) experiment is decreased after the addition of
the new molecular interaction derived from literature.
In Figure 4, we presented the best 500 values for selection
probabilities c(NFkB)1 and c
(complex2)
1 in term of fitting cost. By taking
1-c(NFkB)1 and 1-c
(complex2)
1 , we could determine the values for the
selection probabilities c(NFkB)2 and c
(complex2)
2 respectively. The
mean and the SD values for these selection probabilities are given
in Table 6. These statistics were confirmed in 3 independent
optimisation runs with 500 best parameter sets considered in each
run (see File S2).
We found that the selection probability c(NFkB)2 for the Boolean
rule which represents the co-influence of Caspase 8 and nuclear
factor of kappa light polypeptide gene enhancer in B-cells inhibitor
alpha and epsilon (IkBa/IkBe) degradations on the activation of
NFkB obtained a mean value of 16% with SD of 2%. The non-
zero mean value indicates that this interaction is important to
explain the experimental data in the context of our study. Also, the
narrow distribution of the values of selection probability for this
Boolean rule suggests that the model is sensitive to this parameter.
Such information therefore highlights the relevancy of this newly
introduced interaction. In contrast, the distribution of the values of
the selection probability c(complex2)2 which describes the influence of
deubiquitinated form of receptor associated kinase 1 (RIPdeubi) on
the activation of TNF receptor-1 signalling complex 2 (complex2)
is more spread. This might suggest that the model is less sensitive
to this parameter. Therefore, the relevancy of this interaction in
the context of our study is still in question.
We tried to further investigate the influence of RIPdeubi on
complex2 by following the methodology as presented in [8].
However, we observed that, the required length of the trajectory to
estimate the joint distribution on the parent nodes of complex2 is
very long and therefore it is practically infeasible to perform this
analysis in a reasonable amount of time with the current
implementation of the optPBN toolbox. Thus, we further estimate
the relevancy of this interaction by considering the model topology
within the context of our study instead.
Considering the model topology as presented in [4], the Boolean
interaction in question represents positive signals on the activation
of complex2 by RIPdeubi via two sources (see Figure 8): 1) A
positive feedback loop from activated Caspase 8 (C8*) + unknown
proteins in type 2 apoptosis (P)Rtruncated Bid (tBid)RBaxRS-
macRRIPdeubiRcomplex2RC8*-complex2RC8*, and 2) The
positive signal from UVB radiation (UV)RBaxRsmacRRIPdeu-
biRcomplex2. According to the original study, the activation of
type 2 receptor (T2R) was only considered and experimentally
validated in the context of Jurkat cells, but not hepatocytes [4].
Therefore, the node P which is activated by T2R will never be
activated and the feedback loop as shown in 1) is not active in our
PBN model (which only fits to the hepatocyte data). In parallel, the
activation of complex2 by UVB (via RIPdeubi) requires the
presence of TNF receptor-1 signalling complex 1 (complex1). This
means the positive interaction in 2) will only be valid when TNF and
UVB co-stimulate. Nevertheless, this condition was not validated in
the original study [4] nor was constrained in the PBN model either.
Thus, the interactions on complex2 activation from 1) and 2) via
RIPdeubi as described are not relevant in the context of primary
hepatocyte. These interactions could therefore be removed from the
PBN model in our study.
We demonstrated that optPBN can be applied to determine the
selection probabilities in PBN which can subsequently be used to
estimate the relevancy of molecular interactions in the context of
study. Such information in turn leads to the generation of
computational models which could represent the dynamics of
biological networks in a context-specific manner.
Table 6. The distributions of fitted selection probabilities on the extended apoptosis model.
Molecule Functions Mean SD
NFkB = (,I_kBa|,I_kBe) 0.8354 0.0209
= (,I_kBa|,I_kBe)|(C8a|C8a_2) 0.1646 0.0209
complex2 = complex1 & FADD 0.8480 0.1105
= complex1 & FADD & RIP_deubi 0.1520 0.1105
The Boolean rules of two target molecules in the ‘extended apoptosis model’ and the parameter distributions of the top 500 fitted selection probabilities in terms of
optimal cost are shown. A low standard deviation (SD) value comparing to the corresponding mean value indicates that model is sensitive to the parameter of the
respective Boolean interaction. This information highlights the relevancy of the respective interaction within the context of study e.g., the case of nuclear factor kappa-B
(NkFB) activation by Caspase 8 (C8a or C8a_2) together with the absence of nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha and
epsilon (IkBa and IkBe) inhibitions. In contrast, a high value of standard deviation comparing to the mean value as seen in the case of TNF receptor-1 signalling complex
2 (complex2) activation by deubiquitinated form of receptor associated receptor kinase 1 (RIP_deubi) suggests that the model might not be sensitive to the respective
parameter in this study. The relevancy of this interaction within the context of apoptotic signalling in primary hepatocytes is therefore in question.
doi:10.1371/journal.pone.0098001.t006
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Conclusions
We present optPBN, a novel optimisation toolbox which
provides a simple yet comprehensive pipeline for the generation
of integrated optimisation problems in the PBN formalism which
can readily be solved by various optimisers on local or grid
computational platforms. The optPBN toolbox offers two modes of
optimisation, discrete and continuous, for the selection of
appropriate constituent Boolean networks for the PBN from the
pool of available choices and for the determination of selection
probabilities from experimental data, respectively. The two modes
can be applied for the optimisation and/or inference of the
networks in both qualitative and quantitative manner.
optPBN was tested and compared against existing optimisation
tools for the Boolean formalisms where optPBN delivers similar
results and it also offers quantitative optimisation. The updated
version of CellNOpt, CellNOptR, is also capable of handling
quantitative optimisation, but the respective Boolean models have
to be converted into fuzzy logic or ordinary differential equation
(ODE) modelling frameworks beforehand [17,34]. We also
demonstrated that optPBN allows for the optimisation of an
apoptotic network, leading to the generation of an optimised PBN
model with the corresponding selection probabilities that fit
experimental data. Such results do not only yield a better
quantitative insight into biological networks, they can also be
further used to evaluate interactions’ relevancy within the network
in a context-specific manner. Lastly, the computational time which
is a major limitation when dealing with complex optimisation
problems can be better handled by applying the grid-based
implementation of the optPBN optimisation pipeline.
Limitations
Even though optPBN offers many simple-to-use functionalities,
there are some limitations that come along with the simplicity of
the toolbox. First, our approach always requires prior knowledge
on the possible interactions between molecules which are given in
the form of potential constituent Boolean networks. There exist
approaches using Bayesian network with Boolean variables for
reconstructing biological networks which do not have this
limitation, see e.g., [35]. Second, the formulation of the rule-
based modelling has to be in a specific order when there is a
combination between parameter and constant value in the
assignment of different Boolean rules. For instance, given an
output which can be activated by an input (a parameter is assigned
to the rule) while it can also be inhibited by an inhibitor (the
constant value ‘0’ is assigned to the rule), the Boolean rule which
represents the activation by an input has to come first (see more
examples in the help section of the script rule2PBN in the optPBN
toolbox). Lastly, optPBN uses only one global data structure (estim)
to store and process all information of the network so that the
integrated optimisation problem can be solved simultaneously for
all experimental cases. This setting might not be applicable to
solve the optimisation problem where different parameter values
are expected for each experimental case (i.e., the optimisation of
local parameters). The optimisation of such local parameters is not
yet available in the current version of the toolbox.
Outlook
First, we aim to improve optPBN to be capable of optimising
local parameters. In addition, we plan to introduce the concept of
penalisation for increasing model size (E`s and a) as implemented in
CellNOpt and CellNOptR as a part of our objective function in order
to generate better results. Second, we foresee that other global
optimisation techniques, e.g., Simulated Annealing, Pattern
Search methods, or Mode Hopping Metropolis sampling could
be integrated into the optPBN pipeline. Third, the ambiguity of
Boolean rules formulation to properly represent biochemical
reactions is yet to be addressed. Lastly, we envisage many useful
applications from implementing the optPBN toolbox to study
biological systems such as the inference of gene regulatory
networks from microarray data and the identification of crosstalk
signalling’s relevancy in mammalian signal transduction networks
based on experimental data in a context-specific manner.
Software Availability and Requirements
– Project name: optPBN
– Project home page: http://sourceforge.net/projects/
optpbn
– Operating system(s): Platform independent
– Programming language: Matlab (and C++ for grid-based
version)
– Other requirements: BN/PBN Toolbox, Systems Biology
Toolbox 2 (with Message Passing Interface (MPI) and
ParadisEO for grid-based version)
– License: GNU GPL v3.0 (with CeCILL license required for
ParadisEO framework)
– Restrictions: no restrictions except for commercial use
Supporting Information
Figure S1 Compared results from optPBN and CellNOpt
on the original toy model of Saez-Rodriguez et al. [A] The
model structure of the original toy model of Saez-Rodriguez et al.
[18] is shown on the left panel. The experimental descriptions and
the corresponding artificial measurement data are shown in the
left and right tables respectively. [B] The results from CellNOpt
under a defined set of size penalty (0#a,0.23 and E`s = 0.58)
identifies the AND (&) gate for the connection between PI3K and
TNFa to NFkB. The interaction from Raf was identified as the
only factor that activates ERK. [C] The results from the
optimisation with optPBN toolbox in discrete mode are in a good
agreement with CellNOpt for NFkB. Furthermore, optPBN also
discovered the OR (|) gate for the connection between Raf and
NFkB to ERK as an additional solution.
File S1 Stand-alone version of optPBN toolbox. The
compressed zip file contains all scripts of optPBN toolbox in
stand-alone version. Also, it contains three scripts of optPBN
toolbox in grid-based version with the tag ‘_G5K.m’ for the
analysis of optimisation results obtained from the grid-based
pipeline which runs on a local computer. To install the stand-alone
version, a wrap-up script in Matlab (install.m) is provided for the
ease of installation. The installations of the BN/PBN toolbox [20]
and the optimisation toolbox of Systems Biology Toolbox 2
(SBtoolbox2) [24], which are required for the running of optPBN
toolbox, are also included in the wrap-up script. The grid-based
version of the optPBN toolbox is provided separately and can be
downloaded at https://sourceforge.net/projects/optpbn. It com-
prises all packages needed for running the algorithm on a cluster
or on a grid-based infrastructure. This includes the ParadisEO 1.1
framework (evolutionary algorithms and parallelisation support),
MPICH2, LibXML2, GSL, MCR and the optPBN grid-based
implementation in itself. A detailed description on the installation
and execution of the grid-based pipeline can be found in File S9.
(ZIP)
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File S2 Computational scripts of all examples and the
corresponding original result files. The compressed zip file
contains the optPBN optimisation pipeline in the form of Matlab
scripts (.m) for all examples used in this study (case study 1, case
study 2, toy models of Saez-Rodriguez et al., i.e. case study 3, and
Boolean model of apoptosis of Schlatter et al., i.e. case study 4).
For the results presented in this article, the integrated
optimisation problems of the first 3 case studies were optimised
by using the stand-alone version of the optPBN pipeline applying
particle swarm optimisation as the optimiser on a single local
machine. The last case study (Schlatter’s model, i.e. case study 4),
due to a complex optimisation problem, was optimised by using
the grid-based version of the optPBN pipeline applying a
combined differential evolution and evolutionary algorithms as
the optimisers on the Grid’5000. The corresponding results from
the optimisations of each model presented in the article are
included in a matrix format (.mat and .log) for further analysis on
the distributions of optimised parameters. A complete set of result
files for four case studies and the results from additional analysis
as presented in File S8 can be downloaded at https://
sourceforge.net/projects/optpbn.
(ZIP)
File S3 Manual of the optPBN toolbox. The PDF manual
provides a detailed description of the optPBN optimisation pipeline.
A step-by-step guideline on how to use the optPBN toolbox
together with the explanation of the core idea for each
computational script is provided in the document.
(PDF)
File S4 Grid-based pipeline of optPBN toolbox. The PDF
documentation provides a description on the grid-based pipeline of
the optPBN toolbox. It also describes a strategy to combine two
optimisation algorithms, evolutionary algorithm (EA) and differ-
ential evolution algorithm (DE), as a single optimiser. An
optimisation run on Grid’5000 is demonstrated as an example.
(PDF)
File S5 Derivations of the two-state Markov chain
approach’s formulas. The PDF documentation provides the
corrected derivations of the two-state Markov chain approach’s
formulas in relation to the derivations presented in the original
work of Raftery and Lewis [30]. The term l which refers to
1{a{b in the calculation of m0 should be replaced with lj j (i.e.,
1{a{bj j). In addition, W which denotes the standard normal
cumulative distribution function in the calculation of N should be
substituted with the inverse of its function, W21, after derivations.
(PDF)
File S6 Results of optPBN for four case studies. The
spread sheet provides a complete set of results generated from the
optPBN pipeline for the four case studies. Different numbers of
(selection probability) parameter samplings from optimisers and a
range of accuracy parameter ‘r’ from 0.01 to 0.05 are explored.
Computation time and quality of model fitting were reported for
both stand-alone and grid-based versions.
(XLSX)
File S7 Normalised and justified experimental data for
the study of apoptosis model from Schlatter et al. The
spread sheet provides a detailed description of the measurement
data that were used for the optimisation of the Boolean and
probabilistic Boolean models of apoptosis from Schlatter et al. The
pipeline on background subtraction and normalisation of exper-
imental data with the justification on the saturation of the signal
for p17 form of activated Caspase 3 is described in detail.
(XLS)
File S8 Analysis of the approximation of steady-state
distributions with different initial conditions and accu-
racies. The spread sheet presents the steady-state probability of
output nodes in case study 4 which are approximated by optPBN
applying a fixed set of selection probabilities (randomly generated)
with different sets of initial conditions. Three sets of initial
conditions (random, all zeros, and all ones) together with two levels
of accuracies (r = 0.025 and r = 0.01) were explored. Steady-state
probabilities of output nodes and parameters of two-state Markov
chain approach are shown. The differences of these values across
different sets of initial conditions and across two levels of
accuracies are also presented.
(XLS)
File S9 Installation guide for the grid-based pipeline of
optPBN and an execution example on Grid’5000. The PDF
documentation provides a list of commands to set-up the grid-
based version of the optPBN toolbox on a cluster or on a grid-based
infrastructure. An example set of commands to reserve resources
and to execute an optimisation task on Grid’5000 is also included.
(PDF)
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4.2. A Probabilistic Boolean Network Approach for the 
Analysis of Cancer-specific Signalling: a Case Study of 
Deregulated PDGF Signalling in GIST 
 
Preface: Different types of mathematical models in systems biology have been 
applied to study and analyse biological systems where each of them has distinct strong 
and weak points. For the analysis of signal transduction networks with quantitative steady-
state proteomic measurements, applying a qualitative modelling approach, such as 
Boolean network, usually fails to capture quantitative changes of molecules due to its 
inherent qualitative nature of state and time. In contrast, applying a quantitative method 
such as ODE-based models might need a richer set of data to identify kinetic parameters. 
Also, there might exist a large number of potential model variants which fit equally well to 
a single set of steady-state data when the majority of model structure is not yet known.  
 
Given the drawbacks of each modelling approach, we see probabilistic Boolean 
networks (PBNs), which can capture the quantitative changes of molecular states at 
steady-state and can deal with uncertainty within the network structure, as an alternative 
compromise. We previously demonstrated in (Trairatphisan et al., 2014) that the PBN 
approach could be applied to study and analyse an apoptotic signalling network in the 
physiological context of hepatocytes. In this article, we applied the same approach to 
model and analyse the deregulated PDGF signalling in the pathological context of GIST. 
An extensive set of steady-state protein profiles of PDGFRα mutants in combination with 
signalling inhibitors was generated and integrated with a literature-derived PDGF 
signalling network applying the tool optPBN. The derived context-specific PDGF signalling 
in GIST points out to the importance of some crosstalk interactions including the ones 
from PI3K to MAPK pathway and another one from PKC to MEK1,2. 
 
To evaluate our modelling results, we performed an additional set of experiments 
by inhibiting PI3K and PKC with signalling inhibitors and observing their crosstalk targets. 
The results revealed that PKC is independent of PDGFRα activation which is in contrast to 
the assumption applied to the initial model structure. We subsequently revised the model 
structure and integrated additional data into model training. The refined final model 
demonstrated that only the crosstalk interactions from PI3K towards MAPKs are essential. 
The refined model was also evaluated with a validation dataset for predictive power where 
it delivers very good predictions. 
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Abstract 
 
Signal transduction networks are increasingly studied with mathematical modelling 
approaches. Modelling the network behaviour with qualitative approaches, like Boolean 
networks, does not usually capture quantitative effects while applying detailed mechanistic 
modelling requires an extensive amount of data to infer the respective kinetic parameters. 
Probabilistic Boolean network (PBN) modelling might therefore be a promising 
compromise, as it allows capturing quantitative changes of molecular states at steady-
state with minimal parameterisation. PBN modelling so far has not been explored for 
studying signalling networks. 
 
We successfully applied the PBN approach to model and analyse the deregulated 
Platelet-Derived Growth Factor (PDGF) signalling pathway in Gastrointestinal Stromal 
Tumour (GIST). We experimentally determined a rich and accurate dataset of steady-
state profiles of selected downstream kinases of PDGF-receptor-alpha mutants in 
combination with inhibitor treatments. Applying the tool optPBN, we fitted a literature-
derived candidate network model to the training dataset consisting of single perturbation 
conditions. Model analysis suggested several important crosstalk interactions. The validity 
of these predictions was further investigated experimentally pointing to relevant ongoing 
crosstalk from PI3K to MAPK signalling in tumour cells. The refined model was evaluated 
with a validation dataset comprising multiple perturbation conditions. The model thereby 
showed excellent performance allowing to quantitatively predict the combinatorial 
responses from the individual treatment results in this cancer setting. 
  
We therefore propose the PBN approach as a promising method for analysing 
signal transduction networks, as it allows for modelling these networks in a simplified 
manner while still delivering quantitative predictions. The established optPBN pipeline is 
widely applicable to gain a better understanding of signalling network properties at steady-
state in a context-specific fashion. 
 
Keywords: probabilistic Boolean networks, Systems Biology, signal transduction networks, 
PDGF signalling, Gastrointestinal Stromal Tumour 
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Author summary 
  
 Probabilistic Boolean network (PBN) modelling is an alternative modelling 
approach which allows capturing quantitative changes of molecular states at steady-state 
with minimal parameterisation. PBN has been mainly applied to study gene regulatory 
networks in the context of uncertainty. In this research article, we applied PBN to model 
and analyse a cancer-specific signalling network with uncertain influences from crosstalk 
interactions. We demonstrated that PBN models can fit well to steady-state protein data. 
Subsequent modelling analysis revealed the importance of certain crosstalk interactions 
where the validity of these predictions was further investigated experimentally. The refined 
model was evaluated with a validation dataset where it showed very good predictive 
power. With its simplicity yet effectiveness of the PBN framework, we propose PBN 
modelling as an alternative approach for analysing signal transduction networks with 
steady-state measurements. The same analytical pipeline as presented in this article 
could also be applied for the study of other signalling pathways in order to gain a better 
understanding on their contextualised properties at steady-state. 
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Introduction 
 
Signal transduction networks are one of the core functional layers in cells. They 
conveys intra- and extra-cellular signals towards cellular regulators which modulate the 
expression of cellular phenotypes corresponding to the types and concentrations of the 
stimuli [1]. In general, a signal transduction network is a large and highly complex network 
comprising multiple intracellular signalling pathways such as mitogen-activated protein 
kinases (MAPK), phosphatidyl-inositide-3-kinases/AKT/mammalian-target-of-Rapamycin 
(PI3K/AKT/mTOR), and phospholipase C gamma/protein kinase C (PLCγ/PKC) pathways 
[2]. Also, there exist a number of crosstalk interactions between these signalling pathways 
which help to fine-tune signals and to preserve the whole networks’ integrity upon 
perturbations [3–5]. In a physiological condition, signals from various stimuli are optimally 
integrated and transduced to regulate cellular functions and to maintain homeostasis of 
cellular components [6]. Once the transfer processes of these signals are deregulated, the 
resulting aberrant signals often lead to abnormalities of cellular functions which were 
identified as the etiology of many diseases including neurodegenerative diseases, 
metabolic diseases, as well as cancers [7–9]. 
 
Gastrointestinal stromal tumours (GISTs) are the most common primary 
mesenchymal neoplasia of the gastrointestinal tract. These tumours commonly arise from 
gain of function mutations of type III receptor tyrosine kinases, i.e. KIT at 78-90% of the 
cases and platelet-derived growth factor alpha (PDGFRα) at 5-7% of the cases [10]. As 
constitutively active surface receptors, these mutated proteins are the most upstream 
components of the cellular signal transduction network. The first-line therapy for GISTs is 
surgical resection combined with administration of Imatinib mesylate, a tyrosine kinase 
inhibitor with activities against ABL, BCR-ABL, KIT, and PDGFRα/β.  The clinical outcome 
of the first-line therapy is mostly satisfactory with 35%-49% 9 years survival [11]. 
However, certain point mutations in GIST, e.g. an Aspartate (D) to Valine (V) mutation at 
amino acid 842 on the PDGFRA gene, were also shown to be associated with drug 
resistance [12]. Several hypotheses were proposed to explain the underlying molecular 
mechanisms of oncogenic PDGFRα-driven GIST formation such as the retention of 
oncogenic PDGFRα in intracellular compartments [13] or the deregulation of downstream 
oncogenic signalling pathways, see also [14]. Such hypotheses still require further 
investigation at the molecular level to understand how signals are transduced and 
processed mechanistically in this cancer setting. 
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 In recent years, various modelling approaches in Systems Biology were applied to 
model and analyse the properties of signal transduction networks in both physiological 
and pathological conditions. This includes Bayesian networks [15], Boolean networks [16], 
fuzzy logic models [17], ordinary differential equation (ODE)-based models [18], partial 
differential equation (PDE)-based models [19] and also stochastic models [20], to list only 
a few examples. Some modelling work also demonstrated the connections between the 
deregulation of signal transduction networks to the pathophysiology of diseases, e.g. in 
metabolic disease [21] and in cancers [22]. Even if there exist many modelling 
approaches for the study of signal transduction networks, each of them has certain 
advantages and disadvantages. Describing the connections between signalling molecules 
with conditional probabilities in Bayesian networks framework express their relationships 
quantitatively but such values could not explain the underlying regulatory mechanisms 
between molecules. Boolean networks could depict simple regulatory mechanisms of 
biochemical interactions with logic operators but the results are nonetheless strictly 
qualitative. More quantitative approaches such as fuzzy logic or ODE-based models 
provide additional mechanistic details of the networks on a continuous scale. However, 
they require an extensive amount of prior knowledge to define suitable mathematical 
formula and they also need an extensive set of experimental data in order to infer kinetic 
parameters.  
 
 Given the pros and cons of different modelling approaches, we envisage 
probabilistic Boolean network (PBN) modelling which allows capturing quantitative 
changes of molecular states at steady-state with minimal parameterisation as an 
alternative framework for modelling and analysis of signal transduction networks. Initially, 
PBN was introduced by Shmulevich et al. to model gene regulatory networks in the 
context of uncertainty [23]. With the assignment of probabilities on each interaction, PBN 
is capable to depict individual regulatory effects in a stochastic manner. The concept of 
PBN can also be applied to study other biological networks including metabolic networks 
and physiological networks, for a recent review see [24]. In terms of applications on signal 
transduction networks, Bayesian networks coupled with a probabilistic Boolean threshold 
function were used to infer the topology of the signal transduction network from 
experimental data [25]. Nevertheless, the concept of PBN as originally introduced by 
Shmulevich et al. has not been applied to model and analyse signal transduction networks 
so far. We therefore investigated the application of the original PBN concept as introduced 
in [23] to model and analyse a contextualised signal transduction network in a pathological 
condition with our tool optPBN [26]. As a case study, we investigated the deregulation of 
PDGF signalling in GIST. We demonstrate its excellent performance in modelling and 
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parameter fitting, as well as its predictive capacity, by correctly predicting combinatorial 
treatment results from individual stimulation measurements. 
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Materials and Methods 
 
Biological materials 
 
The PDGFRα-mutant proteins were generated based on the pLNCX2-PDGFRα 
wild-type expression plasmid generously provided by Prof. Andrius Kazlauskas (Boston). 
This sequence was cloned to pcDNA5/FRT/TO-vector (Invitrogen™) and the constitutively 
active oncogenic PDGFRα mutant occurring in GIST was generated by introducing the 
D842V point mutation (PDGFRα-D842V-wild type, “DV-WT”). Based on the PDGFRα-
D842V mutant, two PDGFRα-D842V-”knock-out” mutants were constructed by introducing 
tyrosine (Y) to phenylalanine (F) point mutations, i.e. Y720F (PDGFRα-D842V-Y720F, 
“DV-dMAPK”) and YY731/742FF (PDGFRα-D842V-YY731/742FF, “DV-dPI3K”) which 
have been shown to abrogate the recruitment of signalling molecules such as SHP2 and 
PI3K in the PDGFRα-wild type receptor, respectively. All point mutations were introduced 
using the QuikChange kit (Stratagene) following the manufacturer’s recommendations.  
 
For analysing the signalling behaviour of the mutant PDGFRα protein, an isogenic 
Flp-In™ cell line was constructed based on the Hek293 cell line which is naturally devoid 
of endogenous expression of PDGFRα/β proteins. As such, Hek293 cells were co-
transfected with the Flp-In™ target site vector (pFRT/lacZeo, Invitrogen™) and the 
regulatory vector (encoding Tetracycline repressor protein, pcDNA™6/TR/invitrogen) 
using the TransIT®-LT1 transfection reagent (Mirus) according to the manufacturer’s 
recommendations. Cell clones were selected by cultivation in presence of 10µg/ml 
Blasticidin and 100µg/ml Zeocin™ (both InvivoGen). Based on this isogenic parental cell 
line (“293FR”), stable cell lines were generated by site directed recombination by co-
transfecting the transgene expression plasmid (pcDNA5/FRT/TO-based) in combination 
with the Flp recombinase expression plasmid (pOG44, Invitogen). Stably transfected cells 
were selected and cultivated in presence of 100µg/ml Hygromycin and 10µg/ml Blasticidin 
[13]. 
 
Cell treatment and Western blot analysis  
 
Experiments were conducted by seeding 250,000 cells/well (12 well plate) in 
DMEM containing 10% FBS, 2% L-Glutamine, and 25mM HEPES on 12-well plates for 
24-30 hours. Then, growth media was exchanged and protein expression was induced by 
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adding 5ng/ml doxycycline (Sigma) under serum reduced (1% FBS) conditions for 14 
hours and for additional 3 hours under serum free (0% FBS) conditions. Pharmacological 
inhibition was performed by adding either 1µM of the PI3K inhibitor Wortmannin, 10µM of 
the MEK1,2 inhibitor U0126, 1µM of the pan-PKC inhibitor GF109203X, or 500nM for the 
PKC-α and PKC-β1 specific inhibitor Gö6976. Wortmannin and Gö6976 were purchased 
from Sigma-aldrich while GF109203X and U0126 were purchased from Calbiochem.  
 
Cells were lysed on the dish with 300µl 1x Lämmli buffer. Cellular proteins were 
subjected to SDS-PAGE, transferred to a nylon membrane (Amersham Hybond™-N/GE 
Healthcare by ThermoFisher Scientific), blocked with 10% BSA and probed with the 
respective antibodies. Alpha-tubulin was also probed as loading control. Phospho-specific 
antibodies against ERK1/2 (pThr202/pTyr204), PDGFRα (pTyr849)/β(pTyr857), AKT 
(pSer473) and PKC substrates (pSer) were purchased from Cell Signaling. Phospho-
specific antibodies for STAT5 (pTyr694) and PLCγ1 (pTyr783) were purchased from BD 
Biosciences. Antibodies against PDGFRα (C-20) were purchased from Santa Cruz 
Biotechnology®. Each gel was probed simultaneously against alpha-tubulin to allow 
compensation for loading variations (using either antibody DM1A/Santa Cruz 
Biotechnology® or PA1-38814/Pierce™). The secondary antibodies were coupled with 
IRdye, allowing imaging with the LI-COR Odyssey system. The relative intensities of 
Western blot images were quantified with Image Studio Lite version 4.0 using left-right 
and top-bottom background subtraction. The experiments were done in 3 biological 
replicates with 3 technical replicates on each Western blot. The calibrator sample was 
prepared from an early passage of DV-WT cell line induced by 5ng/ml doxycycline. 
 
Normalisation pipeline and datasets for modelling 
 
Starting from the obtained raw experimental data, a quality control step was 
applied by discarding 1) the data points overlapping with unspecific stains and 2) the data 
points with low signals due to blotting issues. Furthermore, data points with a 
corresponding tubulin signal of less than 20 percent compared to the maximal signal 
within the same blot were removed from the analysis due to low signal to noise ratio. 
 
The remaining data points were first normalised to tubulin (loading control) and 
then to a calibrator sample in order to correct for the differences across multiple blots. The 
normalised mean of technical triplicates from each biological replicate were pooled and re-
normalised to the maximal value to generate the final mean and standard deviation for the 
modelling task. 
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We divided the initial set of experimental data into two parts. The training dataset 
comprises 6 experimental conditions including negative control (all signals assumed to be 
zero), positive control (DV-WT) and 4 experimental conditions with single perturbations by 
YF point mutations (DV-dMAPK and DV-dPI3K) or signalling inhibitors (DV-WT-
Wortmannin and DV-WT-U0126). The validation dataset comprises the 4 remaining 
experimental conditions with combined perturbations.  
 
Literature-derived PDGF signalling network 
 
We built a mutant PDGF signalling network including the major downstream 
signalling pathways including MAPK, PI3K/AKT/mTOR, PLCγ/PKC pathways, as well as 
STAT5 as another prominent signalling target downstream of the oncogenic mutant (but 
not downstream of the wild-type receptor) [13]. Interactions and regulatory mechanisms 
were modelled according to well-established knowledge [27,28]. The recruitment sites of 
upstream signalling molecules to PDGFRα were previously described [29,30]. Among the 
three major downstream signalling pathways in PDGF signalling, there also exist a 
number of crosstalk interactions suggested by literature as listed in Table 1. In addition, 
apart from depicting the effects of inhibitors on their main targets, we also included the 
information on an off-target effect of Wortmannin on conventional PKC [31] which might 
be essential to explain the obtained signalling profiles in the context of GIST. 
 
Table 1. References for the investigated crosstalk interactions in the PDGF signalling 
network. 
Crosstalk number Descriptions References 
1 Ras -> PI3K (Rodriguez-Viciana et al., 1994) 
2 MEK1,2 -| Grb2SOS (Kolch, Calder, & Gilbert, 2005) 
3 PI3K -> Ras (C.-C. Wang et al., 2009) 
4 PI3K -> MEK1,2 (Grammer & Blenis, 1997) 
5 PIP3 -> GabSOS (Markevich et al., 2004) 
6 Akt -| GabSOS (Lynch & Daly, 2002) 
7 Akt -| Raf (Zimmermann & Moelling, 1999) 
8 PLCγ -> PI3K (Z. Wang & Moran, 2002) 
9 PKC -> MEK1,2 (Grammer & Blenis, 1997) 
 
The crosstalk interactions among MAPK, PI3K/AKT/mTOR and PLCγ/PKC pathways within PDGF 
signalling as suggested by literature are listed. The annotation ‘->’ refers to activation and the 
annotation ‘-|’ refers to inhibition. 
 
PBN description of PDGF signalling network 
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Based on the topology of the literature-derived PDGF signalling network, we built a 
corresponding PBN model which comprises 27 nodes (molecules) and 40 edges 
(interactions). Multiple interactions directing onto one node were usually modelled as 
separated Boolean rules with the corresponding selection probabilities. We applied the 
Boolean logic gate “OR” to combine non-exclusive inputs in the same class while 
inhibitions were represented by the “AND NOT” gate. Additionally, selection probabilities 
of the main pathways were assigned to be high with the flag “H”, while being fixed to low 
with the flag “L” for crosstalk interactions. This assignment will ensure that the boundary of 
selection probabilities for the interaction(s) with the flag “H” will always be higher 
compared to the interaction(s) with the flag “L”. This implementation is integrated in the 
latest version of the optPBN toolbox (version 2.2.3) available on 
http://sourceforge.net/projects/optpbn. The full set of model descriptions can be found in 
the Supporting Information: S1 File and the computational scripts of the PBN models, as 
well as the example of results are included in Supporting Information: S2 File. 
 
Optimisation 
 
We applied the grid-based version of the optPBN toolbox (version 2.2.3) to 
perform the optimisation [26]. 23 selection probabilities within the PBN models were 
optimised on the Grid’5000 infrastructure using 160 parallel cores (Intel CPU @2.50Ghz, 
16GB ram). 10,000 samples of parameter sets were evaluated by two optimisation 
algorithms, i.e. differential evolution (DE) and evolutionary algorithm (EA). Three rounds of 
optimisation were performed where the best fitting cost from DE algorithm was chosen for 
further analyses. 
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Results 
 
Incomplete inhibition and potential influence of crosstalk interactions were 
observed from experimental data 
 
We investigated the signalling profiles of three PDGFRα mutants, i.e. DV-WT, DV-
dMAPK and DV-dPI3K in combinatorial treatment with two signalling inhibitors, i.e. 
Wortmannin and U0126. According to the results from the Western blot investigation (Fig. 
1), the cell system and the signalling inhibitors functioned properly. We observed that 
PDGFRα transgenes were expressed exclusively upon doxycycline induction and that 
basal phosphorylation of the signalling molecules was very low. Also, phosphorylated 
PDGFRα (pPDGFRα) signals were found to be comparable between the different mutants 
(Fig. 1). This observation also applies to phosphorylated STAT5 (pSTAT5) signals. The 
phosphorylated PLCγ (pPLCγ) signals dropped in the DV-dMAPK mutant, indicating that 
the SHP-2 recruiting motif Y720 also affects PLCγ activation (see Fig. 1). In parallel, 
decreased activities of downstream signalling molecules, i.e. phosphorylated ERK1,2 
(pERK1,2) and phosphorylated AKT (pAKT) were observed in accordance to the inhibitory 
effects of YF mutants and the signalling inhibitors. These results indicate that the 
abrogation of recruitment sites by point mutations and the signalling inhibitors worked 
effectively on their primary targets. In addition, we found that neither the constructions of 
our cell system nor the inhibitor treatments used in the study affect the expression level of 
the investigated signalling components (see [13] and Supporting Information: S1 Figure). 
 
Among the inhibitory effects that we investigated, we observed that both 
Wortmannin and U0126 reduced the phosphorylation of their downstream signalling 
targets almost completely. In contrast, the DV mutants with additional YF point mutations 
delivered only partial inhibition, e.g. the signals of pERK1,2 and pPLCγ in DV-dMAPK 
mutants are only reduced by half. In parallel, some evidences of crosstalk interaction were 
observed in the dataset. For instance, inhibiting PI3K with Wortmannin also decreased the 
pERK1,2 signal in the MAPK pathway while inhibiting MEK1,2 with U0126 additionally 
increased the pAKT signal in the PI3K/AKT/mTOR pathway (Fig. 1B). It should be noted 
that the cross-regulation through Wortmannin inhibition is stronger than the one via 
U0126, with up to 39% decreased pERK1,2 signal versus up to 25% increased pAKT 
signal compared to the untreated conditions. Also, the cross-regulation by Wortmannin is 
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significant in 2 out of 3 mutants while the crossed inhibitory effect mediated by U0126 was 
significant only in the DV-WT condition (Fig. 1). 
 
Initial data integration in the PBN framework suggested important crosstalk 
interactions from candidate network 
 
We integrated this initial dataset into the literature-derived PBN model of PDGF 
signalling by applying the tool optPBN. The model structure and the splitting of datasets 
are shown in Fig. 2. Initially, we started with a model topology without any crosstalk 
interaction to explore if the model that contains only the major oncogenic pathways would 
already be sufficient to fit the training dataset. The results showed that the initial model 
fitted well to pPDGFR, pSTAT5 and pAKT data, but still could not capture the decrease of 
pERK1/2 signals after Wortmannin treatment. Also, we found that a model variant with all-
or-none inhibition could not fit well to either the pERK1/2 or the pPLCγ data (see 
Supporting Information: S2 Figure). 
 
Next, we investigated 9 model variants where the crosstalk interactions proposed 
in the literature (Table 1) were added one-at-a-time and optimisation was re-performed 
(Table 2).  
 
Table 2. Fitting costs of the initial model variants with and without crosstalk 
interactions. 
 
Crosstalk number Descriptions Fitting cost 
- No crosstalk 0.179 
1 Ras -> PI3K 0.174 
2 MEK1,2 -| Grb2SOS 0.190 
3 PI3K -> Ras 0.127 
4 PI3K -> MEK1,2 0.131 
5 PIP3 -> GabSOS 0.188 
6 Akt -| GabSOS 0.193 
7 Akt -| Raf 0.182 
8 PLCγ -> PI3K 0.188 
9 PKC -> MEK1,2 0.112 
 
The fitting cost from the initial PBN model without any crosstalk interaction was compared to the 
ones after adding crosstalk interactions one-at-a-time. The fitting cost is the sum of squared error 
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between the simulated values and the mean values of measurement data in 6 experimental 
conditions within the training dataset. The annotation ‘->’ refers to activation and the annotation ‘-|’ 
refers to inhibition. 
 
Only the positive crosstalk interactions from PI3K to Ras (Number 3), from PI3K to 
MEK1,2 (Number 4) and from PKC to MEK1,2 (Number 9) could further improve model 
fitting and allowed to distinguish the signal intensities of the DV-WT and DV-WT-
Wortmannin conditions (results not shown). 
 
Iterative experimental investigation and model refinement revealed that PKC 
activity is independent of PDGFRα activation and the crosstalk interactions from 
PI3K towards MAPK pathway being the most relevant 
 
To investigate the validity of these modelling results, we set-up an additional 
experiment by treating the DV-WT mutant with PKC inhibitors (Pan-PKC inhibitor 
‘GF109231X’ or conventional-PKC specific inhibitor ‘Gö6976’) thereby also probing for 
phosphorylated PKC (pPKC) substrates to investigate if the PKC inhibitors worked 
effectively (Fig. 3). 
 
While the PKC inhibitors exhibited a strong effect on their downstream primary 
target, the results showed that PKC activity is independent from PDGFRα activation. 
Considering the positive crosstalk interaction from PKC towards MEK1,2, we initially 
expected to observe decreased activities of pERK1,2 upon the reduction of pPKC 
substrates signals. However, we witnessed in contrary that the pERK1,2 signals increased 
after PKC-inhibitors treatments. Regarding the fact that our initial model assumed pPKC 
signals to be dependent on pPDGFR activation, we concluded that the crosstalk 
interaction from PKC towards MEK1,2 is not important in our cellular context. 
 
On the counterpart, we still observed that pERK1,2 signals were decreased upon 
Wortmannin treatment as previously shown in the initial set of experiments (Fig. 1 and Fig. 
3). This finding supported the validity of the positive crosstalk interactions from PI3K 
towards MAPK pathways. In addition, we saw that pAKT and pERK1,2 signals are 
significantly up-regulated following PKC-inhibitor treatment. On one hand, it could be an 
off-target effect of the two PKC inhibitors on the negative regulators of both oncogenic 
pathways. On other hand, the off-target effect might only be applied to PI3K/AKT/mTOR 
pathway while the changes in pERK1,2 signals were modulated by the positive crosstalk 
as suggested by the model.   
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Further model refinement by introducing basal PKC activity and by adding the 3 
data points from negative control, positive control and Wortmannin treatment conditions to 
the training dataset confirmed in the one-at-a-time crosstalk adding experiment (Table 3, 
see also Table 2 for comparison) that the crosstalk interactions from PI3K to MAPK 
pathway are the only relevant interactions which improve model fitting. We chose the 
refined model with the crosstalk from PI3K to MEK1,2 which has the best fitting cost as 
the final model for further analysis. 
 
Table 3. Fitting costs from the model variants with and without crosstalk 
interactions integrated after model refinement. 
 
Crosstalk number Descriptions Fitting cost 
- No crosstalk 0.181 
1 Ras -> PI3K 0.182 
2 MEK1,2 -| Grb2SOS 0.180 
3 PI3K -> Ras 0.152 
4 PI3K -> MEK1,2 0.139 
5 PIP3 -> GabSOS 0.188 
6 Akt -| GabSOS 0.189 
7 Akt -| Raf 0.192 
8 PLCγ -> PI3K 0.191 
9 PKC -> MEK1,2 0.184 
 
The fitting cost from the refined PBN model variants without crosstalk interaction was compared to 
the ones after adding crosstalk interactions one-at-a-time. The fitting cost is the sum of square 
error between the simulated values and the mean values of measurement data in 6 experimental 
conditions within the training dataset. The annotation ‘->’ refers to activation and the annotation ‘-|’ 
refers to inhibition. 
 
We found that the quality of plotted fitting results generated from the final model is 
very good when compared against the training dataset (Fig. 4) where similar results can 
be obtained from the model variant with the crosstalk from PI3K to Ras (results not 
shown). We checked that a model variant with both crosstalk interactions from PI3K to the 
MAPK pathway integrated could not further improve the fitting cost (results not shown), 
possibly due to redundancy. Either one of these two crosstalk interactions is sufficient to 
explain the signalling profiles of the cancer-specific deregulated PDGF signalling in GIST. 
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The final PBN model of deregulated PDGF signalling in GIST is highly predictive for 
combinatorial stimulations and it provides quantitative insights on signal flows. 
In order to evaluate the predictive power of the final PDGF model, we simulated 
the model with combined perturbations conditions integrating YF point mutations (dMAPK 
and dPI3K) with signalling inhibitors (Wortmannin and U0126) and compared the 
respective experimental data (validation dataset). The results are shown in Fig. 5. 
 
It was shown that our final PBN model predicts the molecular profiles of the 
combined perturbations conditions in the validation dataset accurately. 19 out of 20 data 
points in combined perturbation conditions were precisely predicted within the standard 
deviation of the experimental data. Also, the prediction on pSTAT5 in the DV-dPI3K-
U0126 condition is qualitatively captured correctly. We suspect that this data point could 
be an experimental outlier due to its distinctly low signal compared to the others on the 
same panel (see Fig. 1). Overall, this shows the excellent performance of the final PBN 
model on predicting combinatorial treatments. 
 
The model variant without any crosstalk interaction also returned a relatively good 
prediction, except in the experimental conditions where the necessary crosstalk 
interaction takes place (see Supporting Information: S3 Figure). For instance, the 
discrepancy can be observed in the DV-dPI3K-Wortmannin condition where pERK1,2 
signals were modulated by the crosstalk interaction from PI3K/AKT/mTOR pathway. 
 
Besides its predictive power, the final PBN model also summarises the quantitative 
signal flow within the deregulated PDGF signalling network in GIST by considering the 
weights of interactions represented by the optimised selection probabilities as shown in 
Fig. 6. 
 
 It demonstrates that, among multiple crosstalk interactions which were proposed in 
literature to be involved in the PDGF signalling pathway, only one crosstalk is necessary 
to explain the investigated experimental data in the context of GIST mutants in our cell 
system. Also, it is shown that the weight of the crosstalk interaction from PI3K to MEK1,2 
is not very strong (0.259) compared to the main pathway (0.741). In parallel, it is shown 
that the weight of basal PKC activity which is independent from the PDGFRα activation 
completely overrides the activation signals from inositol 1,4,5-trisphosphate (IP3), 
diacylglycerol (DAG), and calcium ion (Ca) (1.000 versus 0.000). The known inhibitory 
effects of inhibitor are also reported quantitatively, e.g. the effects of Wortmannin on its 
primary target PI3K (0.870) is stronger than the one on its off-target molecule PKC (0.113) 
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while U0126 has a very strong inhibitory effect on MEK1,2 (0.917) [5,37,38]. The complete 
list of the weights of the interactions from the final PBN model can be found in Supporting 
Information: S3 File. 
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Discussion 
 
Advantages of applying the PBN approach for analysing signal transduction 
networks 
  
In this research article, we demonstrated several advantages of applying the PBN 
approach for analysing signal transduction networks. First, we experimentally showed that 
the inhibitory effects of biological interventions do not work in an all-or-none fashion. Such 
data call for modelling approaches which can capture quantitative changes of signalling 
molecules where PBN approach serves the purpose well for capturing quantitative 
changes at steady-state. Second, we showed that a PBN model with minimal 
parameterisation is sufficient to explain the signalling profiles observed at steady-state. 
Hence, PBN might be a better candidate for modelling signal transduction networks with 
steady-state data compared to more quantitative approaches where additional information 
on prior knowledge and parameters might be needed.  Third, we demonstrated that we 
can study the importance of crosstalk interactions within the PBN framework by analysing 
the fitting quality after adding an individual interaction. Also, the weights of interaction can 
be derived quantitatively. Such results lead to the generation of new hypotheses on the 
importance of crosstalk interactions which can subsequently be tested experimentally. 
Lastly, we showed that we can predict the signalling profiles of combined perturbation 
experiments based on a PBN model which was only trained on single perturbation 
experiments. This might be a promising idea for future studies to assess the effects of 
combinatorial perturbations or drugs treatments by performing in silico prediction on PBN 
models prior to wet-lab experiments.  
 
Unresolved issues and open questions from the study 
  
There are a couple of unresolved issues and open questions from the study. First, we 
observed in our initial experimental that pAKT was up-regulated after U0126 treatment 
(significant in DV-WT mutant). Some evidences were shown that MEK1,2 inhibition can 
lead to AKT up-regulation but it was only demonstrated in breast and lung cancer models 
[39,40]. In addition, this observation was not significant in the other two mutants in our 
initial set of experiment.  Second, Wortmannin was shown to potentially inhibit MEK1 
(MKK1) [38] and this interaction could replace the need of crosstalk interactions to fit our 
datasets (results not shown). However, the study is based on in-vitro kinase assays so the 
threshold for the inhibitory effect might differ substantially comparing to our cell-based 
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experiments. Furthermore, other studies failed to detect this potential inhibitory effect of 
Wortmannin on MEK1 [37] and [41]. Lastly, we found that the model variant without any 
crosstalk interaction also has a relatively good predictive power. One might argue that we 
do not need to investigate the importance of crosstalk interactions nor to include them in 
the model. However, we still believe that crosstalk interaction is an essential element that 
could not be left out from the models of signal transduction networks. To support our 
argument, we showed in Fig. 5 that at least one essential crosstalk interaction is required 
in the model to explain the observed signalling profiles. In addition, recent literature 
supports the role of crosstalk interactions in providing a compensatory mechanism within 
signal transduction networks which was proven to be an important factor for the discovery 
and design of therapeutic agents as well [42]. 
 
Technical issues, limitations, and outlook on PBN modelling 
  
There are some technical issues and limitations on the current implementation of 
PBN modelling that should be noted. For instance, the assignment of Boolean rules in our 
PBN model was still performed manually. Hence, the rules might be inconsistent between 
different modellers. Also, the assignment of importance on main pathways over crosstalk 
interactions might be biased, especially once dealing with less well-studied signalling 
pathways. On the technical side, optPBN generated results based on an approximation of 
the steady-state distributions. The approximation error might not be negligible for certain 
examples and the respective parameters (precision and number of optimisation rounds) 
would have to be tuned accordingly. In addition, even if the grid-based pipeline of optPBN 
can generate optimisation results in an acceptable timeframe, large computational 
resources are needed to perform the calculation. This might consider to be a rate-limiting 
step in the workflow once there is a limited amount of computational resources. This issue 
also posts a big challenge for analysing larger signalling networks in the future. 
 
To account for these issues and limitations, we foresee several potential 
improvements to be implemented in the optPBN toolbox. First of all, we plan to build a 
standardised pipeline for converting network interactions into PBN model structures. Such 
pipeline should eliminate the variability of PBN modelling among different modellers. In 
terms of computation, a recent PBN simulation tool on Java called “ASSA-PBN” was 
developed which allows for a more precise steady-state approximation and for faster 
calculations [43]. These features of ASSA-PBN could be integrated into the optPBN 
framework in order to improve the efficiency and accuracy of the results. As for an outlook 
into future applications, we envisage that the same analytical pipeline as presented here 
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could also be applied to study the properties of different signalling networks at steady-
state. Furthermore, since PBN is also widely used to model gene regulatory networks, it is 
possible to build multi-scale models which connect the two functional layers within the 
PBN framework in order to get more comprehensive insights. 
 
Conclusion 
 
We demonstrated a novel pipeline for modelling and analysing signal transduction 
networks with the PBN approach. By integrating normalised measurement data at steady-
state into an a priori model topology derived from literature using the tool optPBN, we 
could generate a PBN model which fits well to signalling data at steady-state 
quantitatively. An additional experiment was performed to investigate the validity of 
predicted crosstalk interactions. After a new round of experimental and modelling work, 
we generated a final PBN model of the PDGF signalling network contextualized for GIST 
with a high predictive power for predicting the combinatorial treatments from the individual 
stimulation measurements. Such model could be further used to guide and reduce the 
number of experimental conditions to be investigated in the lab. In addition, the analytical 
pipeline we presented could also be used to study and analyse other signal transduction 
networks. 
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Supporting information 
S1 Figure | Expression level of signalling molecules in PDGFRα mutants. 
A panel of PDGFRα-D842V mutants with YF point mutations in a separated set of 
experiment is shown. The experiments were performed following the same protocol as 
described in Materials and Methods. We observed that different constructions of mutants, 
including the Y720F and YY731/742FF mutants in our study, did not affect the expression 
level of the signalling molecules that we investigated. 
 
S2 Figure | Compared fitting quality of the initial PBN variants with all-or-none 
inhibition versus with partial inhibition. 
Model simulations from two initial PBN model variants, one with all-or-none inhibition and 
another with partial inhibition, were compared against the training dataset in 6 
experimental conditions. The model variant with all-or-none inhibition could not be fitted to 
the data points of pPLCγ and pERK1,2 in DV-dMAPK condition while the model variant 
with partial inhibition fitted well to these data points. Nevertheless, the latter model still 
could not distinguish the differences in pERK1,2 signals comparing between DV-WT and 
DV-WT-Wortmannin conditions. 
 
S3 Figure | Predictive power of the final PBN model versus the model variant 
without crosstalk. 
Model simulations from the final model and the refined model variant without any crosstalk 
interaction were compared against the validation dataset in 4 experimental conditions. 
Both model variants have very good predictive power on most of the experimental 
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conditions. Nevertheless, the refined model variant without any crosstalk interaction could 
not accurately predict the change of pERK1,2 signal in DV-dPI3K-Wort condition which is 
modulated via crosstalk signalling. 
 
S1 File | Model description of the PDGF signalling network in PBN format. 
This document provides a detailed description of the PBN models of PDGF signalling 
presented in our study. The model descriptions are divided into 3 sections: 1) The core 
model structure with major intracellular signalling pathways, 2) The integration of crosstalk 
interactions proposed in literature, and 3) The final model structure after integrating data 
from the additional experiment. Small examples within the computational scripts are also 
included in each section to illustrate how each type of network interaction can be coded in 
the PBN format. 
 
S2 File | Computational scripts of the PBN models and the result files from the 
modelling studies. 
This compressed zip file comprises the following elements from modelling study: 1) PBN 
model descriptions in the form of computational scripts, 2) Examples of result file from 
grid-based computation, and 3) Saved model structures for grid computation. Instructions 
on how to further analyse the result files and how to re-perform the optimisation are 
included.  
 
S3 File | Weights of interaction of the final PBN model. 
This spreadsheet provides a list of Boolean interactions in the final PBN model together 
with the mean and standard deviation of the optimised selection probabilities, i.e. weights 
of interaction, generated from the best 500 parameter sets of the optimisation. Very low 
standard deviations of the optimised weights (all < 0.025) indicate the high consistency of 
the optimisation result. 
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[A] An example set of raw data from Western blot experiments is shown in Fig. 1A. Three 
PDGFRα mutants containing the D842V point mutation were investigated. One mutant contains 
no additional YF point mutation, i.e. wild type (DV-WT) while the other two contain either Y720F 
(DV-dMAPK) or YY731/742FF (DV-dPI3K) point mutations which abrogate the recruitment sites 
of upstream signalling molecule for MAPK and PI3K/AKT/mTOR pathways, respectively. These 
experimental conditions were combined with the treatment with two signalling inhibitors, i.e. 
Wortmannin (W) [1 µM], which mainly inhibits PI3K, and U0126 (U) [10 µM], which mainly inhibits 
MEK1,2. Doxycycline is used to induce the transcription of the constitutively phosphorylated 
PDGFRα mutants. The experiment was performed in 3 biological replicates with 3 technical 
replicates. The signals from the calibrator sample (C) derived from the induced DV-WT cell line in 
an early passage were applied to calibrate relative intensities between Western blots. [B] The 
summarised quantified Western blot data are shown in Fig. 1B. The signals were normalised 
against tubulin and subsequently calibrated by the calibrator signals. The normalised mean of 
technical triplicates from each biological replicate were pooled and re-normalised to the maximal 
value to generate the final mean and standard deviation values for modelling task. The 
significances between two data points were assessed with the Student’s T-test; p-value < 0.05 
(*) and p-value < 0.01 (**). 
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[A] The model structure of the literature-derived PDGF signalling is shown in Fig. 2A. The 
constitutive activity of mutated PDGFRα (mPDGFR) is inducible by doxycycline (DOX). 
Downstream of mPDGFR includes 3 canonical intracellular signalling pathways: MAPK, 
PI3K/AKT/mTOR and PLCγ/PKC pathways as well as regulatory mechanisms on PDGFRα. In 
addition, we included, STAT5, which was shown to be rather activated by oncogenic PDGFRα 
mutants (Bahlawane et al., 2015). SHP2, PI3K and PLCγ, marked with asterisks, are the targets 
of YF mutants. The basal activities of PTEN and PDK were represented by bPTEN and bPDK, 
respectively. Four signalling inhibitors, i.e. Wortmannin, U0126, GF109231X (GF109), and 
Gö6976, and their targets are also depicted. The phosphorylation state of five downstream 
signalling molecules, i.e. PDGFRα, STAT5, PLCγ, ERK1,2 and AKT were used as read-outs. 
There were 9 crosstalk interactions proposed in literature (numbered 1-9) that might be involved 
in PDGF signalling. Note that the phosphorylation of PKC substrates (PKC) was also included as 
a read-out in the additional experiment (Fig. 3) and the read-out nodes with multiple inputs, i.e. 
PDGFRα, PLCγ, PKC and AKT are also optimised. [B] The quantified Western blot data from 9 
experimentally-investigated conditions together with a negative control condition were applied for 
modelling task. Experimental data were split into a training set (single perturbation plus positive 
and negative controls) and a validation dataset (combinatorial perturbations). 
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This experiment was performed by Dr. Christelle Bahlawane 
(Figure 3A), the quantification of Western blot images was 
performed by P. Trairatphisan (Figure 3B). 
[A] An example set of raw data from the additional Western blot experiment to investigate the 
validity of modelling results are shown in Fig. 3A. The PDGFRα mutant with D842V point 
mutation (DV-WT) was investigated. Two additional signalling inhibitors, i.e. PKC-α and PKC-β1 
specific inhibitor Gö6976 and pan-PKC inhibitor GF109203X together with the detection of 
phosphorylated PKC (pPKC) substrates were included. Six experimental conditions were 
assigned, i.e. negative control without doxycycline induction (ND), positive control with 
doxycycline induction but without inhibitor treatment (-), doxycycline induction with the treatment 
of Gö6976 (Gö) [500nM], of GF109203X (GF) [1µM], of Wortmannin (W) [1µM] and of combined 
Gö6976 and Wortmannin (Gö/W) [500nM/1µM]. The experiment was performed in 3 biological 
replicates with 3 technical replicates. [B] The summarised quantified data from the additional 
Western blot experiment are shown in Fig. 3B. Data were normalised against tubulin, then the 
mean values of technical triplicates from each biological replicates were pooled and re-
normalised to maximal values. The significances between two data points were assessed with 
the Student’s T-test; p-value < 0.05 (*) and p-value < 0.01 (**). 
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The mean and standard deviation (SD) of ten simulated values generated from the final PBN 
model (black stars [mean] and error bars [SD] on top) were compared against the experimental 
data from the training dataset (multi-coloured squares [mean] and error bars [SD] on bottom). Six 
experimental conditions as labelled on the x-axis are in the following order: DV-WT (WT[-]), DV-
WT-Wortmannin (WT[W]), DV-WT-U0126 (WT[U]), DV-dMAPK (dM[-]), DV-dPI3K (dP[-]), and 
negative control (no doxycycline induction, ND). 
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The mean and standard deviation of ten simulated values from the final PBN model (black stars 
[means] and error bars [SD] on top) were compared against the experimental data from the 
validation dataset (multi-coloured squares [mean] and error bars [SD] on bottom). Five molecules 
as labelled on the x-axis in four experimental conditions are in the following order: pSTAT5, 
pPDGFRα, pPLCγ, pERK1,2 and pAKT. 
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A quantitative overview of the signal flow in the final PBN is shown. The weights of interaction as 
represented by the optimised selection probabilities in PBN model were classified into 5 
categories: very low (< 0.1), low (0.1 to 0.3), medium (0.3 to 0.7), high (0.7 to 0.9), and very high 
(> 0.9) where the sizes of arrow were adjusted accordingly. The crosstalk interactions which are 
not necessary in the context of GIST were replaced with dotted grey arrows. 
 
Chapter 4.3: A PBN study on L-plastin signalling in breast cancer cell lines   109 | P a g e  
 
4.3. A comparative study of L-plastin signalling in breast 
cancer cell lines with a probabilistic Boolean approach 
Manuscript title: L-plastin Ser5 phosphorylation in breast cancer cells and in vitro is 
mediated by RSKs, the downstream effectors of the MAPK-ERK pathway 
 
Preface: Cell invasion and metastasis is one of the ultimate hallmarks that cancer 
cells need to acquire to be able to spread their colonies into adjacent and distant tissues 
(Hanahan & Weinberg, 2000, 2011). This cellular process is principally governed by the 
changing expressions of actin-binding proteins such as cofilin, filamin, fastin and L-plastin 
and these proteins were found to be over-expressed in several types of cancer. 
 
 To uncover a novel therapeutic target which could impede the metastatic process, 
an investigation on the controlling mechanisms of actin-binding proteins at the molecular 
level is required. In this study, we comparatively investigated the L-plastin signalling in 
four breast cancer cell lines with different invasive capacities using a combined 
experimental and modelling approach. A large panel of experimental conditions combining 
the activators and inhibitors of the L-plastin signalling were initially investigated where 
several hypotheses on network interaction were formulated. Then, these hypotheses were 
incorporated into a literature-derived L-plastin signalling model via the MAPK-ERK 
pathway as additional edges. The integrated model was subsequently optimised by an 
improved version of the optPBN toolbox to investigate the relevance of the hypothesised 
interactions observed from the data and to compare the differences of signalling paths 
between non-invasive and invasive cell lines. 
 
 According to the optimisation results, only two hypothesised interactions, i.e. PKC 
activating PKA and ribosomal protein S6 kinase (RSK) activating L-plastin were shown to 
be relevant in all four cancer cell lines. The validity of these interactions was also 
confirmed by 100 rounds of bootstrapping. This finding points out to RSK as the key 
regulator for controlling the phosphorylation of L-plastin, and possibly, for controlling 
invasion and metastasis. In addition, comparative analyses of the identified selection 
probabilities revealed that the activities of PKA in invasive cancer cell lines are depended 
on 8-bromo-cAMP stronger than in the non-invasive ones while the crosstalk between 
PKA towards PKC might only exist in invasive cell lines. These findings allow researchers 
to identify more targets to further design novel therapeutic agents. 
 
Remark: Only Figure 5 and result on modelling part were contributed by P. Trairatphisan. 
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Abstract 
 
Deregulated cell migration and invasion, which are hallmarks of metastatic cancer 
cells, are correlated to structural and functional alterations of the actin cytoskeleton which 
is regulated by numerous actin-binding proteins. Among these, the actin-bundling protein 
L-plastin, initially detected in leukocytes, is ectopically expressed in several solid tumours 
and is often considered as a metastatic marker. Phosphorylation of L-plastin on residue 
serine 5 (Ser5) has been shown to activate L-plastin and to be crucial for invasion and 
metastasis formation. Here, we investigate the signalling pathway leading to L-plastin 
phosphorylation using four breast cancer cell lines. Whole genome microarray analysis 
comparing cell lines with different invasive capacities and corresponding variations in L-
plastin Ser5 phosphorylation level revealed that genes of the ERK/MAPK pathway are 
differentially expressed. In line, in vitro kinase assays showed that ERK/MAPK pathway 
downstream kinases RSK1 and RSK2 are able to directly phosphorylate L-plastin on 
Ser5. In parallel to a knockdown approach, activation and inhibition studies of signalling 
molecules of the ERK/MAPK pathway, followed by computational modelling analysis, 
confirmed that RSK is an important activator of L-plastin in all four studied cell lines. 
Finally and rounding up our study, RSK knockdown significantly impaired migratory and 
invasive capacities of a selected invasive cell line, thus consolidating RSK as a promising 
therapeutic target in certain invasive carcinomas. Altogether, our data provide substantial 
evidence that the ERK/MAPK pathway is involved in L-plastin Ser5 phosphorylation in 
breast cancer cells with its downstream kinases RSK1 and RSK2 being able to directly 
phosphorylate L-plastin on Ser5. 
 
 
Keywords 
L-plastin 
Ser5 phosphorylation 
Mitogen-activated protein kinase 
Ribosomal S6 kinase 
Epidermal growth factor receptor 
Invasion 
Breast cancer 
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Abbreviations 
MAPK  Mitogen-activated protein kinase 
RSK1  Ribosomal protein S6 kinase alpha-1 
RSK2  Ribosomal protein S6 kinase alpha-3 
MSK1  Ribosomal protein S6 kinase alpha-5 
MEK  Dual specificity mitogen-activated protein kinase kinase (MAPKK) 
ERK  Extracellular signal regulated kinase (MAPK3) 
RAF  RAF proto-oncogene serine/threonine-protein kinase 
EGFR  Epidermal growth factor receptor 
EGF  Epidermal growth factor 
PMA  Phorbol 12-myristate 13-acetate 
PKC  Protein kinase C 
PKA  Protein kinase A 
DEG  Differentially expressed gene 
SDE  Significantly differentially expressed 
IPA  Ingenuity Pathway Analysis 
FC  Fold change 
FDR  False discovery rate 
TBS  Tris-buffered saline  
MT  Mutant 
WT  Wild type 
SEM  Standard error of the mean 
Chapter 4.3: A PBN study on L-plastin signalling in breast cancer cell lines   113 | P a g e  
 
Introduction 
 
Tumor cell migration and invasion are largely dependent on actin cytoskeleton changes 
[41], which are under the control of a large panel of actin-binding proteins such as cofilin, 
α-actinin, filamin, fascin or the plastins [41, 44]. In this context, our previous studies have 
shown that the actin-bundling protein L-plastin regulates the turnover of the actin filaments 
in vitro and in vivo in addition to its crosslinking activities [1]. Although L-plastin is typically 
expressed in haematopoietic cells where it plays a role in the immune response (reviewed 
in [35]), it is also frequently ectopically expressed in carcinoma cells (reviewed in [45]). 
Here L-plastin localises to actin-rich structures such as focal adhesions, filopodia and 
membrane ruffles which are involved in adhesion, signalling or locomotion [4, 21]. 
 
L-plastin activity has been shown to be increased following phosphorylation on residue 
serine 5 (Ser5) in vitro and in vivo. In leukocytes, phosphorylation of L-plastin is part of the 
immune response [23, 33]. Moreover, F-actin-binding and -bundling activities of L-plastin 
are increased upon Ser5 phosphorylation and this phosphorylation is required for its 
efficient targeting to focal adhesions [21]. Most interestingly, recent findings have 
demonstrated that L-plastin Ser5 phosphorylation is crucial for in vitro invasion [21, 28] 
and in in vivo metastasis formation [42]. Distinct protein kinases have been reported to 
play a role in L-plastin Ser5 phosphorylation depending on the cell type and environment. 
Candidate kinases include protein kinase A (PKA) [21, 33, 55], protein kinase C (PKC) [1, 
16, 22, 24, 32, 37, 38] and phosphoinositide 3-kinase (PI3K) [24, 37]. Nevertheless, the 
detailed signalling pathway(s) leading to L-plastin Ser5 phosphorylation remain(s) to be 
resolved. 
 
Besides the deregulation of the actin cytoskeleton, also the deregulation of signalling 
pathways is an important feature of many cancers. Breast cancers as well as other 
cancers frequently display an upregulation of members of the epidermal growth factor 
family [9]. The epidermal growth factor receptor (EGFR) (also called HER1) and its 
relatives HER2, HER3 and HER4 are known as oncogenic drivers in various cancers, 
including lung cancer [34], breast cancer [5] and glioblastoma [30, 31, 54]. Particularly 
EGFR and HER2 are mutated to constitutively active forms in a large number of epithelial 
tumors. Signalling pathways downstream of these receptors which are frequently 
deregulated in cancer are the Ras/Raf/MEK/ERK (MAPK) and the PTEN/PI3K/AKT/mTOR 
pathways (for review see [20] and [14]).   
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In this study, we have investigated the signalling pathways leading to L-plastin Ser5 
phosphorylation in cancer cells and we have provided evidence that the ERK/MAPK 
pathway is crucial for L-plastin Ser5 phosphorylation. In vitro kinase assays have revealed 
that phosphorylation of L-plastin residue Ser5 can be directly mediated by the MAPK-
activated protein kinases RSK1 and RSK2 which may provide a useful therapeutic target 
in the future. 
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Materials and Methods 
 
Cell Culture 
SK-BR-3 and BT-20 cells were grown in Mc Coy’s 5A and EMEM (Eagle's minimal 
essential medium) media respectively and MCF7 and MDA-MB-435S cells were grown in 
RPMI (Roswell Park Memorial Institute) medium. All media were supplemented with 10% 
fetal bovine serum, 2 mM of L-glutamine and 100 units/ml of penicillin and streptomycin. 
Cells were grown at 37°C under 5% CO2 atmosphere. All cells were bought from or 
authentified by ATCC (American Type Culture Collection, Manassas, VA, US). 
 
Antibodies and Reagents 
Mouse monoclonal IgG1 against L-plastin (LPL4A.1, MA5-11921) was purchased from 
Thermo Scientific (Erembodegem, Belgium). Rabbit polyclonal anti-Ser5-P antibody 
recognising specifically  L-plastin phosphorylated at Ser5 was raised against a peptide 
encoding L-plastin residues 2-17 in which Ser5 was phosphorylated 
(ARGS(P)VSDEEMMELREA) (characterised in [21]). Rabbit polyclonal antibodies against 
RSK1 (sc-231) or RSK2 (#9340) were purchased from Santa Cruz Biotechnology (Santa 
Cruz, Heidelberg, Germany)  and Cell Signalling Technology (Leiden, Netherlands) 
respectively.  Phorbol 12-myristate 13-acetate (PMA), epidermal growth factor (EGF), 8-
Bromo-cAMP, H89 and PP2  were obtained from Sigma-Aldrich (Diegem, Belgium), 
GF109203X, SL0101 and BI-D1870 from Calbiochem Merck Millipore (Nothingham, UK) 
and PD98059 from Cell Signalling Technology (Leiden, Netherlands). 
 
Treatment of Cells with Pharmacological Agents 
Cells were treated with PMA at a concentration of 0.1 µM for 1 hour, with EGF at 1 ng/ml 
for 15 minutes, with  GF109203X at 1 µM for 3 hours, with H89 at 50 µM for 1 hour, with 
PP2 at 10 µM for 1 hour, with PD98059 at 10 µM for 1 hour, with BI-D1870 at 5 µM for 30 
minutes, with SL0101 at 80 µM for 4 hours. In case of combined treatment with activators 
and inhibitors, the incubation with the inhibitor was performed before the incubation with 
the activator. For serum starvation prior to EGF treatment, cells were cultured in the 
absence of serum for 24 hours.  
 
Microarrays 
RNA extraction was performed using Trizol reagent. RNA quality and concentration were 
evaluated spectroscopically using a NanoDrop 2000c instrument (Thermo Scientific, 
Erembodegem, Belgium). RNA integrity was subsequently analysed on an Agilent 2100 
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Bioanalyser (Agilent Technologies, Palo Alto, CA, USA). Only good quality RNA with 
integrity numbers > 9 was used in this study. Transcriptome profiling assays were 
performed using the Affymetrix Human GeneChip 1.0 ST arrays (Affymetrix, Santa Clara, 
CA, USA). Briefly, 250 ng of total RNA was reverse transcribed into cDNA, then 
transcribed into cRNA and labeled into biotinylated cRNA using the GeneChip WT PLUS 
Reagent kit (Affymetrix) according to the manufacturer’s standard protocols (P/N 4425209 
Rev.B 05/2009 and P/N 702808 Rev.6). Labeled cRNA products were randomly 
fragmented and hybridised onto Affymetrix GeneChips. Upon hybridisation, arrays were 
washed and stained using the Affymetrix GeneChip WT Terminal Labeling and 
Hybridisation kit, before being scanned using a GeneChip Scanner 3000. CEL files 
containing hybridisation raw signal intensities were imported into the Partek GS software 
(Partek, St. Louis, MO, USA) using Partek default options. Resulting expression data 
(transcript cluster level) were imported into R statistical environment for further analysis. 
Transcript clusters with no chromosome location were removed. Quality of the data was 
assessed through boxplot, relative log expression and Pearson’s correlation. For 
differential expression analysis, LIMMA was used to compare gene expression between 
different conditions, according to author’s recommendations [LIMMA User’s Guide section 
9.5]. Resulting p-values were adjusted for false discovery rate with Benjamini and 
Hochberg’s FDR [7] and transcript clusters with FDR < 0.05 and absolute FC ≥ 1.5 were 
considered as significantly differentially expressed (SDE). The Ingenuity Pathway Analysis 
(IPA) software (Ingenuity Systems, Redwood City, CA, USA, www.ingenuity.com) was 
used for transcript cluster mapping which led to the identification of differentially 
expressed genes (DEGs) and for data mining, including functional analyses and gene 
network reconstruction. Right-tailed Fisher’s exact test was used to calculate a p-value for 
functional enrichment analysis (threshold: -log(p-value) > 1.301). Microarray expression 
data are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under the 
accession number E-MTAB-3487. 
 
Kinase screening 
A phosphorylation prediction algorithm, Kinase substrate predictor version 2.0 (KSPv2) 
from KINEXUS Bioinformatics Corporation (Vancouver, Canada), identified the 50 best 
scored candidate kinases for L-plastin phosphorylation on residue Ser5, out of which 43 
were subsequently screened by KINEXUS. The following peptides corresponding to the L-
plastin N-terminus and comprising residue Ser5 were chosen to be used in the kinase 
assays:  ARGSVSDEERR (WT) and ARGSVADEERR (MT), both starting with an N-
acetylalanine  
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(taking into account co-translational modifications described by the UniProtKB/Swiss-Prot 
database), as well as native MARGSVSDEERR (M-WT) and MARGSVADEERR (M-MT), 
both still comprising the initial methionine residue. The substitution of residue Ser7 by an 
alanine was done in order to be able to distinguish between Ser5 and Ser7 
phosphorylation and to exclude false positives. The addition of two arginine residues (R) 
at the C-terminal end of the peptides was meant to ensure the adhesion of the peptides to 
the capture phosphocellulose filter paper following the kinase assay, and placed far 
enough away from the Ser5 site so as not to affect the kinase recognition of this site. 
Briefly, L-plastin peptides were mixed with individual protein kinases in the presence of [γ-
33P] ATP for 20-40 minutes, depending on the protein kinase tested. The assay was 
terminated by spotting 10 µl of the reaction mixture onto a multiscreen phosphocellulose 
P81 plate. After removing unreacted [γ-33P] ATP from the reaction, radioactivity was 
quantified in a scintillation counter. 
 
In vitro kinase assays 
10 µg of recombinant L-plastin were incubated with 100 ng of recombinant kinase (RSK1, 
RSK2 or MSK1) obtained from SignalChem (Richmond, British Columbia, Canada) in a 
reaction volume of 25 µl according to the manufacturer’s protocol. Following an incubation 
of 15 minutes at 30°C, Laemmli buffer was added, the samples were boiled at 100°C for 5 
minutes and then analysed by immunoblotting. 
 
Immunoblotting 
Cells were lysed in situ in ice-cold lysis buffer (50 mM Tris-HCL pH 7.5, 150 mM NaCl, 
0.1% SDS, , 5 mM EDTA, 1% Nonidet P-40, 1% Triton X-100, 1% Na-deoxycholate, 1 mM 
Na3VO4, 10 mM NaF, 100 µM leupeptin, 100 µM E64D) containing a cocktail of protease 
inhibitors (Roche Diagnostics GmbH, Howald, Luxembourg). Lysates were cleared by 
centrifugation at 13200 rpm for 15 minutes at 4°C. The total protein concentration was 
determined using the Bradford assay (Bio-Rad, Temse, Belgium). Protein separation was 
performed by SDS-PAGE gel electrophoresis under reducing conditions and proteins 
were then transferred onto nitrocellulose membranes by semi-dry transfer. The 
membranes were saturated with 1% BSA in Tris-buffered saline (TBS) 1x buffer 
supplemented with Tween 0.1% for 1 hour at RT, then incubated with primary antibodies 
overnight at 4°C and with secondary antibodies coupled to a fluorescent dye for 1h at RT. 
Antibody incubations were followed by membrane washings with TBS 1X buffer 
supplemented with Tween 0.1%. Signal intensities were detected by the Odyssey infrared 
image system (Licor, Westburg, Leusden, Netherlands). For quantification, the ratio 
between the intensities obtained for phosphorylated L-plastin (or phosphorylated PKA 
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substrates) versus total L-plastin was determined and then normalised to the mean of all 
the values obtained in one experiment to account for experimental variability. After scaling 
to the highest signal, graphical representations show means and standard deviations. 
Statistical significance was determined by an unpaired T-test with Welch’s correction. 
P<0.05 was considered significant. 
 
siRNA knockdowns 
Small interfering RNA against RSK-1 (Hs_RPS6KA1_10) and RSK-2 (Hs_RPS6KA3_5) 
were purchased from Qiagen GmbH (Venio, Netherlands). 60 nM of siRNA was 
transfected using Lipofectamine® 2000 (Life Technologies, Gent, Belgium) according to 
the manufacturer’s protocol. 
 
Invasion and migration assays 
Cancer cell lines were seeded in collagen I-coated (200 µg/ml) 96-well plates (Essen 
Imagelock, Essen Bioscience, Hertfordshire, UK). At appoximately 90% confluence, a 
wound was scratched across each well with the Cellplayer 96-well woundmaker (Essen 
Bioscience). (For siRNA knockdown, cells were transfected with siRNA 24 h before the 
wound was scratched.) To study invasion, cells were covered with collagen I (1.5 mg/ml) 
diluted in cell culture medium. To study migration, cell culture medium was added to the 
cells. Wound confluence was monitored with the Incucyte LiveCell Imaging System 
(Essen Bioscience) by measuring cell confluence every 3 hours for a total of 72 hours. 
The graphs depict means from three biological replicates each with at least five technical 
replicates +/- standard error of the mean (SEM).  
 
** The following paragraph is written by P.Trairatphisan 
Modelling  
The literature-derived model topology of the L-plastin signalling including the interactions 
between src, PKC, PKA and the ERK/MAPK pathway were described as Boolean rules 
with corresponding selection probabilities in the probabilistic Boolean network (PBN) 
framework (see review in [52]). The experimental data obtained for ratios of 
phosphorylated L-plastin versus total L-plastin (P-LPL/LPL) and phosphorylated PKA 
substrates versus total L-plastin (P-PKAsubstrates/LPL) from the four cell lines were used 
for model contextualization. Normalisation of western blot data was performed as 
described above in the immunoblotting section. Data generated from different 
experimental sets were normalised to the calibrator PMA, subsequently pooled and scaled 
to the maximal value. We applied an improved version of the optPBN toolbox [51] to 
optimise the selection probabilities of the L-plastin signalling model in the PBN format. 
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Optimisation was performed on a stand-alone machine (Intel CPU Xeon @3.50GHz, 
16GB Ram) for the different model variants based on random initial conditions. 
Bootstrapping was performed by randomly sampling 100 artificial data sets based on 
mean and standard deviation as acquired from our experimental datasets. Optimisation 
was subsequently performed 100 times to identify the distribution of the identified 
selection probabilities. 
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Results 
 
Invasive breast cancer cell lines display higher baseline L-plastin Ser5 
phosphorylation than non-invasive breast cancer cell lines 
The four breast cancer cell lines MCF7, SK-BR-3, BT-20 and MDA-MB-435S chosen as a 
working model for this study were carefully selected in order to cover different 
clinicopathological features [25, 27, 47] with the main prerequisite being the expression of 
our protein of interest L-plastin. It is noteworthy however, that considerable doubt had 
been raised about the origin of the cell clone MDA-MB-435S. Indeed evidence was 
provided that MDA-MB-435S cells and the M14 melanoma cell line are genetically 
identical, which was confirmed by microsatellite analysis [18, 40]. Even though the correct 
origin of the two cell lines is still under debate, the most recent findings strongly suggest 
that both cell lines may be of breast origin, which substantiates our selection [10, 19]. For 
this study the invasive phenotype of the chosen breast cancer cell lines is of particular 
importance, with MCF7 and SK-BR-3 being considered as non- or merely weakly invasive 
cell lines in contrast to  BT-20 and MDA-MB-435S which have been described as invasive 
cell lines [29, 39, 49, 60]. By performing in vitro scratch wound assays (Essen BioScience 
CellPlayer™) we reassessed the invasive capacities of our four cell lines. In line with the 
literature, our results confirmed that MCF7 and SK-BR-3 cells are only weakly invasive 
whereas invasiveness was considerably increased in BT-20 and highly increased in MDA-
MB-435S cells (Fig. 1a). Since a correlation between the invasive capacity of melanoma 
cells and the phosphorylation state of L-plastin on residue Ser5 has been suggested 
before [28], we continued by investigating L-plastin Ser5 phosphorylation in the four 
breast cancer cell lines. To this end, we used an antibody recognising specifically L-
plastin phosphorylated on residue Ser5 (anti-Ser5-P antibody) raised and characterised 
by our group [1, 21, 22]. Although the L-plastin expression level is higher in the invasive 
as compared to the non-invasive cell lines, our results clearly show high baseline L-plastin 
Ser5 phosphorylation in the invasive cell lines BT-20 and MDA-MB-435S as compared to 
absent or extremely weak phosphorylation in the non-invasive cell lines MCF7 and SK-
BR-3 (Fig. 1b).  
 
The ERK/MAPK pathway is enriched in DEGs when comparing breast cancer cells 
with differential Ser5 L-plastin phosphorylation 
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Whole genome microarray analysis was performed to detect differences in signal 
transduction pathways leading to differential L-plastin Ser5 phosphorylation in non-
invasive breast cancer cells with low baseline Ser5 phosphorylated L-plastin, versus 
invasive breast cancer cells, with constitutively Ser5 phosphorylated L-plastin. In addition, 
we treated the two non-invasive cell lines with phorbol-12-myristate-13-acetate (PMA), as 
this treatment had been shown previously to increase L-plastin Ser5 phosphorylation in 
MCF7 cells [1]. As expected, PMA treatment led to a considerable increase in L-plastin 
Ser5 phosphorylation in both cell lines MCF7 and SK-BR-3 as compared to their 
respective untreated control. (Fig. 2 left). In order to perform microarray analysis, total 
RNA was isolated from triplicate cultures and microarray data were obtained using 
Affymetrix technologies. Lists of differentially expressed transcript clusters were 
established as described in the materials and methods section and transcript cluster 
mapping was performed with IPA. For the comparison of PMA-treated versus untreated 
controls, we thus obtained a first list of DEGs for MCF7 and a second for SK-BR-3 cells. 
For the comparison of our two model invasive and two model non-invasive cancer cell 
lines, we obtained another four lists of DEGs (Fig. 2 right), the intersection of which was 
retained as the third list of DEGs to be analysed. Taking the intersection of the 4 lists 
enabled us to focus on the genes that are differentially expressed between all 
comparisons of invasive versus non-invasive cells, thus setting a stringent filter. At the 
end, a detailed analysis using Ingenuity Pathway Analysis® (IPA) was performed with the 
three lists of DEGs described above. The three lists of differentially expressed genes can 
be found in electronic supplementary material (ESM_List1, ESM_List2 and ESM_List3). 
 
A heatmap based on the four sample sets obtained with the untreated four cell lines and 
integrating the differentially expressed transcript clusters of the intersection of the 4 
corresponding lists shows that the vast majority of these genes are regulated in opposite 
directions depending on the invasive capacities of the cell line (ESM_Fig1). Thus the 
DEGs of the intersection clearly partition the cell lines into two distinct groups: invasive 
and non-invasive. 
 
Most importantly, in order to assess a difference in signalling pathways in the compared 
conditions, we focused on canonical signalling pathways in IPA. For each of the 3 
comparisons of interest, IPA revealed a list of canonical signalling pathways 
(ESM_CP_List1, ESM_CP_List2, ESM_CP_List3) from which we selected those that were 
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significant (P-value ≤ 0.05) and thus enriched by genes that are significantly differentially 
expressed. Interestingly, we identified 3 canonical signalling pathways that were common 
to the 3 lists: ERK/MAPK Signalling, Role of Osteoblasts, Osteoclasts and Chondrocytes 
in Rheumatoid Arthritis and UVA-Induced MAPK Signalling (Fig. 2). These results suggest 
an involvement of one or more of these pathways in L-plastin Ser5 phosphorylation. 
 
RSK1 as well as RSK2 specifically phosphorylate residue Ser5 of recombinant full-
length L-plastin in vitro 
L-plastin peptides were synthesised and screened for Ser5 phosphorylation by 43 
candidate kinases identified using the phosphorylation prediction algorithm, Kinase 
substrate predictor version 2.0 (KSPv2) from KINEXUS Bioinformatics Corporation 
(Vancouver, Canada). In addition to PKA, which was previously shown to be able to 
phosphorylate L-plastin Ser5 in vitro [21, 55], our screening identified RSKs as well as 
MSK1 as candidate kinases for phosphorylating this residue. As shown in Table 1, these 
kinases led to high radioactivity counts for the wild type L-plastin peptide (WT) as well as 
for the Ser7-to-alanine mutated peptide (MT), both peptides being devoid of the initiator 
methionine and acetylated on the N-terminal alanine, thus taking into account information 
about co-translational modifications of L-plastin described by the UniProtKB/Swiss-Prot 
database. The WT peptide displayed higher counts for the named kinases than the MT 
peptide, indicating that phosphorylation occurs not only at residue Ser5, but also at Ser7. 
However, notably  Ser7 phosphorylation is not required for Ser5 phosphorylation by the 
investigated kinases and, importantly, the same kinases appear in the top positions for 
both peptides. Validation experiments as well as experiments with the WT and MT 
peptides still containing the initiator methionine were performed and showed similar 
rankings (data not shown). 
 
As the in vitro kinase assays performed on L-plastin peptides identified RSK1, RSK2 and 
MSK1 as candidate kinases (Table 1), we also tested these kinases for their ability to 
phosphorylate recombinant full-length L-plastin on residue Ser5 in vitro. As shown in 
Figure 3, both RSK1 and RSK2 were able to strongly phosphorylate L-plastin on residue 
Ser5 while MSK1 was merely able to induce a weak L-plastin Ser5 phosphorylation.  
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Table 1 For in vitro kinase assays on L-plastin peptides, the peptides were mixed with 
individual protein kinases in the presence of [γ-33P] ATP for 20-40 minutes, depending on 
the protein kinase tested. The assay was terminated by spotting 10 µl of the reaction 
mixture onto a multiscreen phosphocellulose P81 plate. After removing unreacted [γ-33P] 
ATP from the reaction, radioactivity was quantified in a scintillation counter. 
Ranking Kinases Counts (cpm) Kinases Counts (cpm) 
  *ARGSVSDEERR 
(WT) 
 *ARGSVADEERR 
(MT) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
RSK2 
PKAca 
RSK1 
MSK1 
RSK3 
PKAcb 
RSK4 
PKAcg 
SGK3 
SGK2 
PRKG2 
PKCh 
p70S6Kb 
AURORA B 
STK33 
PKCq 
VRK1 
116698 
109766 
101952 
86947 
71917 
54673 
45174 
40167 
32646 
32129 
29921 
29273 
19894 
12688 
9990 
9671 
9054 
RSK1 
PKAca 
MSK1 
RSK2 
PKAcb 
PKAcg 
RSK3 
PRKG2 
RSK4 
SGK2 
SGK3 
STK33 
PKCh 
AURORA B 
PRKG1 
PRKX 
DCAMKL1 
55774 
53986 
53254 
48800 
34148 
33572 
32917 
26041 
22477 
22249 
20290 
10761 
10007 
9696 
9110 
8113 
5899 
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18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
PRKX 
PRKG1 
CAMK1b 
VRK2 
CAMK4 
PKCe 
DCAMKL2 
MNK1 
DCAMKL1 
NDR 
PKCd 
PIM2 
SGK1 
NDR2 
MSK2 
IKKe 
AKT1 
ASK1 
PIM3 
p70S6K 
AKT3 
AKT2 
PIM1 
CK2a2 
8310 
8189 
8126 
7876 
6955 
6779 
5726 
5718 
5437 
5072 
4597 
4405 
4243 
3821 
3741 
3437 
3257 
3241 
2732 
2454 
2196 
2142 
892 
892 
VRK1 
VRK2 
MNK1 
PKCe 
CAMK4 
DCAMKL2 
p70S6Kb 
CAMK1b 
NDR 
PKCq 
IKKe 
NDR2 
ASK1 
SGK1 
PKCd 
AKT1 
p70S6K 
PIM2 
PIM3 
AKT3 
AKT2 
MSK2 
PIM1 
AURORA C 
5745 
5470 
5430 
5053 
4668 
4447 
4242 
3996 
3797 
3589 
3422 
3284 
2771 
2540 
2329 
1920 
1911 
1813 
1537 
1460 
1242 
1005 
922 
663 
Chapter 4.3: A PBN study on L-plastin signalling in breast cancer cell lines   125 | P a g e  
 
42 
43 
AURORA C 
CHK1 
588 
176 
CHK1 
CK2a2 
256 
44 
*N-terminal alanine is acetylated 
 
The ERK/MAPK pathway and its downstream RSK kinases are involved in L-plastin 
Ser5 phosphorylation in breast cancer cells 
The two newly identified prime candidate kinases capable of L-plastin Ser5 in vitro 
phosphorylation, RSK1 and RSK2, are downstream effectors of the ERK/MAPK pathway. 
In addition, the results of our microarray experiments have also pointed to a potential 
involvement of the ERK/MAPK pathway in L-plastin Ser5 phosphorylation. Altogether 
these findings prompted us to further investigate the role of the ERK/MAPK pathway in L-
plastin Ser5 phosphorylation. In a first step, we inhibited selected signaling molecules of 
this pathway and we showed that PKC inhibition with the widely used pan-PKC inhibitor 
GF109203X, MEK1/MEK2 inhibition with PD98059 as well as RSK inhibition with BI-
D1870 decreased baseline L-plastin Ser5 phosphorylation in invasive cells (Fig. 4a). In a 
second step, we took advantage of the fact that the ERK/MAPK pathway is one of the 
major signalling pathways stimulated upon binding of various growth factors to the 
corresponding receptor tyrosine kinases. Knowing that the EGFR/ErbB family, a 
prominent receptor tyrosine kinase family, plays a key role in normal and malignant breast 
development [15] and is capable to trigger cell migration through ERK/MAPK pathway 
signalling [50], we checked for EGFR expression in our four model cell lines. As 
previously decribed by others [43, 47], both SK-BR-3 and BT-20 cells expressed high 
levels of EGFR, whereas for MCF7 and MDA-MB-435S cells the expression was very low 
to absent (ESM_Fig2a). As expected, stimulation with EGF as a key EGFR binding ligand 
did not increase L-plastin phosphorylation in the two EGFR-negative cell lines MCF7 and 
MDA-MB-435S, even when stimulated with high EGF concentrations (ESM_Fig2b). 
However, EGF treatment highly increased L-plastin Ser5 phosphorylation in SK-BR-3 and 
BT-20 cells at all tested concentrations (ESM_Fig2b). We have shown previously that 
treatment with the phorbol ester PMA, a well-known activator of PKCs which has also 
been described to activate the ERK/MAPK pathway [3, 8, 26], was able to induce L-plastin 
Ser5 phosphorylation in MCF7 [1] and SK-BR-3 cells (Fig. 2). Accordingly, PMA treatment 
of the two invasive cell lines BT-20 and MDA-MB-435S, displaying already high baseline 
L-plastin Ser5 phosphorylation, was able to further increase this phosphorylation level 
(Fig. 4b). Importantly, preincubation with inhibitors of the ERK/MAPK pathway impaired L-
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plastin phosphorylation upon PMA or EGF stimulation in all tested cell lines (Fig. 4b). To 
exclude off-target effects, we confirmed our results with a second RSK inhibitor, SL0101, 
which impaired EGF-triggered L-plastin phosphorylation in SK-BR-3 and BT-20 cells and 
decreased baseline L-plastin phosphorylation in invasive cell lines (data not shown). 
Interestingly, the strongest decrease of L-plastin Ser5 phosphorylation was obtained for 
the combined inhibition of RSK and PKC (Fig. 4b). And finally, Trametinib, a clinical MEK 
inhibitor approved by the US Food and Drug Administration (FDA) for melanoma 
treatment (trade name Mekinist), clearly reduced L-plastin Ser5 phosphorylation in 
invasive cell lines and prevented an EGF-triggered increase in L-plastin Ser5 
phosphorylation (Fig. 4c). Altogether these results point to a major involvement of the 
ERK/MAPK signalling pathway in L-plastin Ser5 phosphorylation. 
 
** The following section, Table 2, and Table 3 are contributed by P.Trairatphisan  
Modelling of the L-plastin signalling pathway with probabilistic Boolean networks 
The signalling pathways leading to L-plastin Ser5 phosphorylation are not clearly 
understood and, so far, it was assumed that the identity of the protein kinase responsible 
for this phosphorylation event depends on the cell type and environment. In addition to 
reports on the involvement of PKA [21, 33, 55] and PKC [1, 16, 22, 24, 32, 37, 38], our 
results presented here highlight a role of RSK kinases in this process. In order to get a 
better quantitative understanding of the signalling pathways upstream of L-plastin Ser5 
phosphorylation, we applied the optPBN toolbox to further study and analyse these 
pathways in the probabilistic Boolean network (PBN) framework [51]. We built a PBN 
model which represents the network topology of signalling pathways upstream of L-plastin 
Ser5 phosphorylation based on literature information and own findings (Fig. 5a). Our 
model is mainly focused on the ERK/MAPK pathway (downstream of the EGFR) and 
includes src, PKC and PKA kinases which are known to interact with this pathway. Then, 
we fitted the PBN model to an extensive dataset comprising activation and inhibition of 
various network nodes which modulate the signals towards the two measured output 
nodes, i.e. L-plastin Ser5 phosphorylation and PKA substrate phosphorylation in four 
breast cancer cell lines. To this end, we took into account the described off-target effects 
of the inhibitors GF109203X and H89 on RSK [2, 11]. As a result, we obtained a model 
which explained well our experimental data for all four cell lines as shown in Figure 5b.  
As we found RSK kinases to be essential for L-plastin Ser5 phosphorylation, the fitted 
PBN model was used to investigate whether RSK kinases have more influence on L-
plastin in the four cell lines than PKA and PKC. In addition, we checked whether the 
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crosstalk interactions between PKC and PKA suggested in the literature [48, 59] are 
important to modulate the signal transduction within the L-plastin signalling pathway. We 
therefore applied an in silico knock-out approach where we removed an interaction from 
the model one-at-a-time and checked if the removal affected the fitting quality. Five 
interactions situated in close proximity to our output nodes were analysed, i.e. RSKàL-
plastin, PKCàL-plastin, PKAàL-plastin, PKCàPKA and PKAàPKC (Table 2). We found 
that removing the interactions RSKàL-plastin and PKCàPKA led to a dramatic increase 
of the model fitting costs in all four cell lines, meaning that the networks missing one of 
these two interactions fitted our experimental data less well. The individual knock-out of 
the other three interactions only led to minor changes in fitting costs, suggesting that none 
of these three interactions is necessary to explain our experimental data. 
We then proceeded by examining the optimised selection probability (weight) of each 
interaction and their distributions obtained via bootstrapping (see Methods section). A 
subset of the obtained weight distributions of the interactions is shown in Table 3. All 
weights can be found in electronic supplementary material (ESM_Fig3). Strikingly, in all 
four cell lines, the activation of L-plastin by RSK is largely predominant as compared to its 
activation by PKC or PKA. In addition, the weights attributed to the investigated 
interactions indicate that in all 4 cell lines the crosstalk appears to be directed from PKC to 
PKA rather than from PKA to PKC. The relatively low standard deviations on the weights 
ensured that these findings are robust against experimental variation in the dataset. 
 
Table 2 The fitting costs of model variants after removing individual interactions were 
compared to those of the initial model structure prior to removal. The fitting cost is the sum 
of squared error between simulated state values and the mean values of the experimental 
data. 
 MCF7 SK-BR-3 BT-20 MDA-MB-435S 
Initial model 0.2298 0.2942 0.2961 0.3126 
RSK -> LPL removed 0.7872 1.0344 0.6921 1.2369 
PKC -> LPL removed 0.2298 0.2942 0.2962 0.3126 
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PKA -> LPL removed 0.2318 0.2942 0.2966 0.3126 
PKC -> PKA removed 0.7163 0.4520 0.4245 0.4622 
PKA -> PKC removed 0.2298 0.2942 0.3045 0.3452 
 
Table 3 The distributions of identified weights obtained via bootstrapping are shown for 
the five interactions under investigation in the four cell lines shown as mean and (standard 
deviation). 
  MCF7 SK-BR-3 BT-20 MDA-MB-435S 
RSK -> LPL 0.888 (0.081) 1.000 (0.000) 0.948 (0.070) 1.000 (0.000) 
PKC -> LPL 0.004 (0.023) 0.000 (0.000) 0.025 (0.058) 0.000 (0.000) 
PKA -> LPL 0.108 (0.073) 0.000 (0.000) 0.027 (0.023) 0.000 (0.000) 
PKC -> PKA 0.407 (0.060) 0.236 (0.049) 0.262 (0.059) 0.252 (0.093) 
PKA -> PKC 0.072 (0.112) 0.005 (0.017) 0.256 (0.189) 0.204 (0.068) 
 
Combined RSK1 and RSK2 knockdown decreases L-plastin Ser5 phosphorylation 
and impairs migration and invasion in breast cancer cells 
Altogether, we provide evidence that RSK kinases are involved in L-plastin Ser5 
phosphorylation by in vitro kinase assays, by inhibition with two different RSK inhibitors as 
well as by computational modelling. To consolidate our findings, we simultaneously 
knocked down RSK1 and RSK2 by an siRNA approach, which resulted in an important 
decrease of L-plastin Ser5 phosphorylation in our four breast cancer cell lines (Fig. 6a). 
Even though phosphorylation was not completely abolished, our data clearly reveal an 
important role for RSKs in L-plastin Ser5 phosphorylation in all four model cell lines. Some 
RSK1 and RSK2 protein was still expressed after knockdown and may account for the 
remaining L-plastin phosphorylation. 
Finally, we investigated the effect of RSK knockdown on migration and invasion in MDA-
MB-435S. This cell line was selected as it has the highest invasive capacity as shown in 
Figure 1a. In vitro scratch wound assays (Essen BioScience CellPlayer™) revealed that 
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the combined knockdown of RSK1 and RSK2 considerably slowed down both migration 
and invasion of MDA-MB-435S cells (Fig. 6b), whereas cell proliferation remained largely 
unaffected (data not shown).  
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Discussion  
 
In our former studies we have shown that phosphorylation of L-plastin on residue Ser5 
plays a critical role for L-plastin activation [1, 21]. In this study, we have unraveled a major 
signalling pathway responsible for L-plastin Ser5 phosphorylation in cancer cells. We have 
revealed the involvement of the ERK/MAPK pathway with its downstream target kinases 
RSK1 and RSK2 being able to directly phosphorylate L-plastin on Ser5. In line with 
previous studies showing L-plastin Ser5 phosphorylation to be crucial for cell invasion and 
metastasis formation [21, 28, 42], we have consolidated in our model an involvement of 
RSK1 and RSK2 in cancer cell invasion. 
 
In this study, we chose to take a microarray-based gene expression profiling approach in 
order to correlate conditions and cell lines presenting differential L-plastin Ser5 
phosphorylation levels with patterns of changes in gene expression. In the context of the 
cofilin pathway in breast cancer invasion and metastasis [56], the authors have pointed 
out that not only individual genes, but whole pathways with differential regulation and 
activity states of the corresponding molecules should be taken into account for phenotype 
interpretation. Similarly, in our study the whole genome microarray analysis approach 
allowed us to identify three canonical pathways enriched in DEGs, namely ERK/MAPK 
Signalling, Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis 
and UVA-Induced MAPK. In addition, the in vitro kinase assays carried out in parallel 
using L-plastin peptides identified the ERK/MAPK pathway downstream kinases RSK1 
and RSK2 as the most prominent candidate kinases for L-plastin Ser5 phosphorylation. 
These findings together with a previous report describing L-plastin as a MAP kinase 
pathway regulated protein (Lewis, TS, 2000), prompted us to proceed to an in depth 
investigation of this pathway, whose deregulation has been described in a large subset of 
human breast cancers [57].  
 
Several approaches were taken to unravel the involvement of the ERK/MAPK pathway 
with its downstream kinases RSK1 and RSK2 in the L-plastin Ser5 phosphorylation event. 
To trigger this pathway we stimulated the cells with EGF or with PMA, both described as 
activators of the ERK/MAPK pathway. Evidence for a direct involvement of the 
ERK/MAPK pathway downstream kinases RSK1 and RSK2 in L-plastin Ser5 
phosphorylation was provided, based both on a siRNA knockdown approach and on the 
use of two different RSK inhibitors BI-D1870 and SL0101, thus reducing the risk that the 
inhibitor-dependent phosphorylation decrease  is due to off-target effects. Indeed, BI-
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D1870 and SL0101 appear to have only one common off-target, Aurora B [6], which 
showed considerably weaker potency in phosphorylating L-plastin peptides than RSK1 or 
RSK2 as shown by the in vitro kinase assays from KINEXUS (Table 1). In line and most 
importantly, the two kinases RSK1 as well as RSK2 were able to directly phosphorylate 
the recombinant L-plastin protein on residue Ser5 in an in vitro kinase assay. Further 
evidence for the importance of the ERK/MAPK pathway comes from the data obtained 
with the MEK inhibitor PD98059 as well as with the clinically used inhibitor Trametinib 
(trade name Mekinist). Moreover, our finding that L-plastin phosphorylation can be 
mediated by RSK upon activation of the ERK/MAPK pathway was confirmed by our 
computational model which suggests that RSK is the most important activator of L-plastin 
in all 4 cell lines. Our PBN modelling approach proved to be a useful tool to integrate the 
information from literature together with our vast experimental dataset, in particular 
because signalling tends to occur in complex networks.  
 
Although our results provide strong evidence for a role of the ERK/MAPK pathway with 
the downstream kinases RSK1 and RSK2 being able to directly phosphorylate L-plastin 
on residue Ser5, they do not rule out that L-plastin Ser5 phosphorylation can also be 
mediated by other pathways. So far, only PKA has been reported to directly phosphorylate 
L-plastin in vitro [21, 55], whereas other kinases such as PKCδ, catalytic domain of PKC, 
casein kinase II, Pak1, protein kinase B, M2K, M3K and p38-regulated/activated protein 
kinase failed to directly phosphorylate L-plastin in vitro [24, 55]. In cells, by contrast, 
distinct protein kinases have been reported to play a role in triggering L-plastin 
phosphorylation depending on the cell type and environment. Most frequent are reports of 
the involvement of PKA [21, 33, 55] and PKC [1, 16, 22, 24, 32, 37, 38]. PI3K has also 
been reported to play a role in L-plastin phosphorylation in human neutrophils [24, 37], but 
not in T lymphocytes [16]. Even though an siRNA knockdown approach was successful in 
reducing L-plastin Ser5 phosphorylation for PKCδ [1, 22] and PKCβII [38], it has to be 
considered that most studies were based on activation and/or inhibition studies. Strikingly, 
all inhibitors used to demonstrate the involvement of PKA and PKC (H89, GF109203X, 
Gö6976 and Ro-31-8220) in L-plastin phosphorylation also strongly inhibit RSK2 [2, 11]. 
Moreover, PMA, used as a PKC activator, does not only activate PKC but has also been 
shown to activate the ERK1/2 module either through PKC and c-Src or through RasGRP 
[3, 8, 26]. Finally, the effect of the PKA activator cAMP on the ERK1/2 module appears to 
depend on the cellular context since cAMP has been demonstrated to stimulate ERK in a 
B-Raf dependent manner or to suppress ERK signalling in many cells through its ability to 
target C-Raf (reviewed in [13]). In the present study we have demonstrated a clear and 
direct activity of RSK1 and RSK2 kinases in L-plastin phosphorylation, supported by a 
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modelling approach. A potential involvement of the previously described kinases, PKA, 
PKC and PI3K, cannot be ruled out, although, in our model, PKA and PKC appear to play 
a more indirect role in L-plastin activation than RSK. This result is in line with previous 
findings of Hagi et al., who reported that cAMP stimulation was not able to trigger L-plastin 
Ser5 phosphorylation in macrophage [17]. Regarding a potential involvement of PI3K, 
future studies, which were out of the scope of the present work, have to be dedicated to 
the investigation of the PTEN/PI3K/AKT/mTOR pathway in mediating L-plastin Ser5 
phosphorylation. 
 
RSKs have been described as versatile regulators controlling migration and invasion 
downstream of  ERK/MAPK activation (reviewed in Sulzmaier and Ramos, Cancer 
Research, 2013), by altering the transcription of many genes involved in EMT, by 
regulating cell adhesion through phosphorylation events with subsequent integrin activity 
modulation and/or by remodeling the actin cytoskeleton. In this context, RSK2 expression 
has been correlated to the expression of the actin-bundling protein Fascin-1 in tumor 
samples from HNSCC patients and to filopodia formation in cancer cells (Li D, JBC, 
2013), suggesting that the RSK2-CREB pathway increases proinvasive and prometastatic 
capacities. Interestingly, RSK1 has been described to phosphorylate a further actin-
bundling protein, filamin A [36], on residue Ser2152 [58], a site required for membrane 
ruffling [53]. In our study, both RSK1 and RSK2 were able to phosphorylate the actin-
binding protein L-plastin and combined knockdown of the two isoforms led to a significant 
decrease in cell migration and invasion. The identification of L-plastin as a target of RSK 
kinases consolidates a role for RSK in the regulation of the actin cytoskeleton. Our results 
extend the findings of Doehn and colleagues, who investigated the effects of RSK1 and 
RSK2 on migration and invasion in epithelial breast cells and who showed that combined 
knockdown of RSK1 and RSK2 or RSK inhibition suppressed the ERK pathway 
dependent induction of promotile and proinvasive genes [12]. We suggest that the effect 
of RSK knockdown on the promotile/invasive capacities of cancer cells may also be due, 
in part, to the decrease of L-plastin Ser5 phosphorylation upon RSK knockdown. The link 
between L-plastin Ser5 phosphorylation and the motile capacities of cells may consist in 
the improved capacity of the phosphorylated form to regulate the actin cytoskeleton.  
 
Overall, our results show the first evidence, to our knowledge, of the involvement of the 
ERK/MAPK pathway in L-plastin Ser5 phosphorylation. These findings corroborate Ser5 
phosphorylated L-plastin as a molecular marker for invasive carcinomas with deregulated 
ERK/MAPK pathway  signaling. Furthermore, our identification of the signalling molecules 
leading to L-plastin Ser5 phosphorylation consolidates them as potential targets for cancer 
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therapies as L-plastin phosphorylation has been shown to promote metastasis and 
invasion [21, 28, 42]. As opposed to MEK and Raf, RSKs are not “global regulators” and 
thus their inhibition by therapeutic drugs may have less severe side effects. Knowing that 
RSKs are overexpressed in approximately 50% of human breast cancer tissues [46], this 
kinase family can be considered as a highly promising therapeutic drug target in certain 
invasive carcinomas. 
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Electronic supplementary material 
 
ESM_Fig1 Heatmap of differentially expressed transcript clusters between invasive and 
non-invasive cell lines. BT-20 and MDA-MB-435S were successively compared to MCF7 
and to SK-BR-3. FDR and absolute FC thresholds of 0.05 and 1.5 were used to select 
differentially expressed features and expression profiles of 1858 transcript clusters 
detected in the four comparisons are depicted in the figure as heatmap. Transcript 
clusters are shown in rows and samples (triplicates for each cell line) in columns. Row 
and column orders were determined by hierarchical clustering and colors represent 
transcript cluster expression level as z-score. 
 
ESM_Fig2 Analysis of EGF-dependent L-plastin Ser5 phosphorylation. a EGF receptor 
(EGFR) is expressed in SK-BR-3 and BT-20 breast cancer cell lines. Cell extracts were 
subjected to immunoblot analysis using antibodies specific for the EGFR and β-actin, 
used as a loading control. b Cells were stimulated with different EGF concentrations as 
indicated and cell extracts were subjected to immunoblot analysis using antibodies 
specific for Ser5 phosphorylated  L-plastin (P-LPL) and total L-plastin (LPL). 
 
ESM_Fig3 Optimised interactions’ weights for the L-plastin signalling network. 
Bootstrapping was performed by randomly sampling 100 artificial data sets based on 
mean and standard deviation as acquired from the wet lab experiments. Optimisation was 
subsequently performed 100 times to identify the distribution of the identified selection 
probabilities. Means and standard deviations of the interactions’ weights were compared 
among the four cell lines. 
 
ESM_ListDEG1 List of differentially expressed genes between MCF7+PMA and MCF7 
identified by whole genome microarray analysis using Affymetrix Human GeneChip 1.0 ST 
arrays. 
ESM_ListDEG2 List of differentially expressed genes between SK-BR-3+PMA and SK-
BR-3 identified by whole genome microarray analysis using Affymetrix Human GeneChip 
1.0 ST arrays. 
ESM_ListDEG3 List of differentially expressed genes, between invasive and non-invasive 
breast cancer cells (intersection of comparisons BT-20 vs MCF7, MDA-MB-435S vs 
MCF7, BT-20 vs SK-BR-3 and MDA-MB-435S vs SK-BR-3), identified by whole genome 
microarray analysis using Affymetrix Human GeneChip 1.0 ST arrays. 
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ESM_CP_List1 List of canonical pathways identified by IPA for the comparison of 
MCF7+PMA and MCF7. 
ESM_CP_List2 List of canonical pathways identified by IPA for the comparison of SK-BR-
3+PMA and SK-BR-3. 
ESM_CP_List3 List of canonical pathways identified by IPA for the comparison of BT-20 
vs MCF7, MDA-MB-435S vs MCF7, BT-20 vs SK-BR-3 and MDA-MB-435S vs SK-BR-3. 
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Fig. 1 High baseline L-plastin Ser5 phosphorylation in highly invasive versus low baseline 
L-plastin Ser5 phosphorylation in non- or weakly invasive breast cancer cell lines. 
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High baseline L-plastin Ser5 phosphorylation in highly invasive versus low baseline L-plastin 
Ser5 phosphorylation in non- or weakly invasive breast cancer cell lines. a Four breast cancer 
cell lines were seeded in collagen I-coated (200 µg/ml) 96-well plates (Essen Imagelock, Essen 
Bioscience). At appoximately 90% confluence, a wound was scratched across each well with the 
Cellplayer 96-well woundmaker (Essen Bioscience). Cells were covered with collagen I (1.5 
mg/ml) diluted in growth medium. Wound confluence was monitored with the Incucyte LiveCell 
Imaging System (Essen Bioscience) by measuring cell confluence every 3 hours over a total 
period of 72 hours. The graphs depict means +/- SEM from three biological replicates with at 
least 5 technical replicates. b Cell extracts were subjected to immunoblot analysis using 
antibodies specific for Ser5 phosphorylated  L-plastin (anti-Ser5-P antibody, P-LPL) and total L-
plastin (LPL) and signals were analysed using the Odyssey infrared image system 
(Licor,Westburg). 
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Fig. 2 MAPK pathways among the top canonical pathways for the 3 comparisons of 
interest. 
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MAPK pathways among the top canonical pathways for the 3 comparisons of interest. Whole 
genome microarray analysis revealed significantly differentially expressed transcript clusters 
between the indicated conditions. The lists 1-3 were mapped and analysed by Ingenuity Pathway 
Analysis which revealed 3 canonical pathways that were ranked over the treshold of -log(p-val) ≥ 
1.3010 common to the 3 comparisons.   
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Fig. 3 RSK1 and RSK2 are able to directly phosphorylate L-plastin Ser5 in vitro. 
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RSK1 and RSK2 are able to directly phosphorylate L-plastin Ser5 in vitro. 10 µg of recombinant 
full-length L-plastin were incubated with 100 ng of recombinant kinase and with 50 µM of ATP in 
a reaction volume of 25 µl according to the manufacturer’s protocol. Samples were incubated for 
15 minutes at 30°C. Following incubation, Laemmli buffer was added, the samples were boiled at 
100°C for 5 minutes and analysed by immunoblot visualising Ser5 phosphorylated L-plastin (P-
LPL) and total L-plastin (LPL). 
 
144 | P a g e   Chapter 4.3: A PBN study on L-plastin signalling in breast cancer cell lines 
 
Fig. 4 Involvement of the ERK/MAPK pathway in L-plastin Ser5 phosphorylation in breast 
cancer cells. 
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Involvement of the ERK/MAPK pathway in L-plastin Ser5 phosphorylation in breast cancer cells. 
(a) Invasive cell lines exhibiting high baseline L-plastin Ser5 phosphorylation were treated with 
inhibitiors of selected signalling molecules of the ERK/MAPK pathway GF109203X (GF), 
PD98059 (PD) and BI-D1870 (BID). Subsequent to inhibitor treatment, residual L-plastin Ser5 
phosphorylation was determined by immunoblot analysis. For quantification, the ratio between 
the intensities obtained for phosphorylated L-plastin (P-LPL) versus total L-plastin (LPL) was 
determined and then normalised to the mean of all the values obtained in one experiment to 
account for experimental variability. After scaling to the highest signal, graphical representations 
show means and standard deviations. Statistical significance was determined by an unpaired T-
test with Welch’s correction. *P<0.05, **P<0.01 and ***P<0.001 (b) Cells were preincubated with 
inhibitors of the ERK/MAPK pathway and then stimulated with EGF (for the two EGFR 
expressing cell lines) or PMA (for the four cell lines). L-plastin Ser5 phosphorylation was 
quantified as described under (a). (c) Cells were treated with Trametinib with or without 
subsequent EGF stimulation and L-plastin Ser5 phosphorylation was quantified as described 
under (a). For each immunoblot shown, samples were run on the same gel, but for BT-20 shown 
under (a) and MDA-MB-435S shown under (b), bands were cut and put in another order for 
representative purposes. 
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** Figure 5 is prepared by P.Trairatphisan  
Fig. 5 Literature-derived and experiment-based L-plastin signalling network and model 
fitting results. 
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Literature-derived and experiment-based L-plastin signalling network and model fitting results. (a) 
A candidate network for the signalling pathways upstream of L-plastin phosphorylation was built 
based on literature information and own findings. The network interactions were analysed by 
applying a probabilistic Boolean network approach taking into account cell line specific 
immunoblot-based quantifications of phosphorylated L-plastin and phosphorylated PKA 
substrates. Various conditions were tested in the four cell lines MCF7, SK-BR-3 (SK), BT-20 
(BT), MDA-MB-435S (MDA) including activation by EGF, PMA or 8-Bromo-cAMP (8Br) and/or 
inhibition by GF109203X(GF), H89, PP2, PD98059 (PD) or BI-D1870 (BID). (b) PBN model fitting 
results in comparison to experimental data for the various tested conditions. Coloured bars 
indicate the conditions tested for the individual cell lines. For quantification, the ratio between the 
intensities obtained for phosphorylated L-plastin (P-LPL) respectively phosphorylated PKA 
substrates (P-PKAsubstrates) versus total L-plastin (LPL) was determined and normalised to the 
mean of all the values obtained in one experiment to account for experimental variability. Data 
generated from different experimental sets were normalised to the calibrator PMA, subsequently 
pooled and scaled to the highest signal (of each respective graph). Means of ten simulated 
values from the PBN model (black stars) were compared against the experimental data (multi-
coloured squares [mean] and error bars [SD]).  
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Fig. 6 Combined RSK1 and RSK2 knockdown decreases L-plastin Ser5 phosphorylation 
and impairs migration and invasion in breast cancer cells. 
(a)
MCF7 (+PMA)   SK-BR-3 (+EGF)           BT-20     MDA-MB-435S
1        0.62 1        0.31 1        0.70 1        0.48
1        0.441        0.561        0.42 1        0.60
1        0.52 1        0.25 1        0.51 1        0.44
P-LPL
LPL
RSK1
β-actin
RSK2
β-actin
scrambled siRNA
RSK1+2 siRNA
+           -   
-            +
+           -   
-            +
+           -   
-            +
+           -   
-            +
(b)
0
20
40
60
80
100
120
0 20 40 60 80
W
ou
nd
 co
nﬂ
ue
nc
e 
(%
)
Time (h)
Migration upon RSK knockdown
0
20
40
60
80
100
120
0 20 40 60 80
W
ou
nd
 co
nﬂ
ue
nc
e 
(%
)
Time (h)
Invasion upon RSK knockdown
scrambled siRNA
RSK1+2 siRNA
scrambled siRNA
RSK1+2 siRNA
0                      20                     40                     60                      80 0                      20                     40                     60                      80
 
Combined RSK1 and RSK2 knockdown decreases L-plastin Ser5 phosphorylation and impairs 
migration and invasion in breast cancer cells. A siRNA against RSK1 and RSK2 or scrambled 
siRNA were transfected in the four cancer cell lines as indicated and L-plastin Ser5 
phosphorylation, RSK1 and RSK2 expression were assessed by immunoblot analysis 72 hours 
post transfection. Non-invasive cell lines were treated with EGF or PMA as indicated. b MDA-MB-
435S cells were seeded in collagen I-coated (200 µg/ml) 96-well plates (Essen Imagelock, Essen 
Bioscience) and transfected with siRNA against RSK1 and RSK2 or with scrambled siRNA. After 
24 hours, a wound was scratched across each well with the Cellplayer 96-well woundmaker 
(Essen Bioscience). To study invasion, cells were covered with collagen I (1.5 mg/ml) diluted in 
cell culture medium. To study migration, cell culture medium was added to the cells. Migration 
and invasion were monitored by measuring wound confluence every 3 hours for a total of 72 
hours with the Incucyte LiveCell Imaging System (Essen Bioscience). The graph depicts means 
+/- SEM from three biological replicates each including at least 11 technical replicates. Efficient 
knockdown of RSK1 and RSK2 as well as efficient decrease of L-plastin Ser5 phosphorylation 
were confirmed by immunoblot analysis (data no shown). 
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4.4. Potential applications of PBNs in pharmaceutical 
industry 
4.4.1 Detailed mechanistic models and their applications in pharmaceutical industry 
 
In the drug discovery process, various strategies are applied to identify novel 
therapeutic targets including target-based screening, phenotypic screening, modification 
of natural substances and biologic-based approaches (Swinney & Anthony, 2011). In 
recent years, pharmaceutical industry started to apply computational approaches in 
systems biology to aid the drug discovery process via performing model-based data 
integration approaches to identify and explore the molecular mechanism of action of 
therapeutic agents (Iskar, Zeller, Zhao, van Noort, & Bork, 2012). Merrimack 
Pharmaceuticals (Boston, MA, USA, http://merrimackpharma.com) is one of the leading 
pharmaceutical companies which applies modelling approaches in systems biology known 
as Network Biology for the discovery and assessment of therapeutic agents which are 
tailored for the treatments on different types of cancers. 
 
In this sub-chapter, I present a modelling study which I performed during my 
internship at Merrimack to demonstrate how quantitative mechanistic modelling can be 
applied to analyse the properties of a therapeutic agent in a pharmaceutical setting. Here, 
we focused on the study of c-MET signalling which is one of the important signalling 
pathways that drives tumour growth, proliferation and metastasis in many cancer types. 
To get a better understanding on the dynamics and the other properties such as the 
sensitivity of molecules in this signalling pathway, we built a mechanistic ODE-based 
model of c-MET signalling based on a literature-derived model topology. Then, we 
performed an optimisation against a training dataset which comprises the read-out from c-
MET and downstream signalling molecules in response to hepatocyte growth factor (HGF) 
stimulation from 0.037nM to 9nM over the course of 2 hours on the ACHN (renal cancer) 
cell line. Once we obtained the model with optimised parameters that fits well to the data, 
the model was subsequently used to assess the effectiveness of a therapeutic agent. 
 
To start building a dynamical model of c-MET signalling, we derived a set of ODEs 
based on the network topology as proposed in literature (Schoeberl et al., 2009, 2002). 
The network topology of the receptor level and the downstream signalling pathways is 
shown in Figure 3. The c-MET signalling model consists of 109 species, 141 parameters 
and 104 reactions which include detailed interactions and regulations of c-MET receptor 
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(MET) and downstream intracellular signalling pathways, i.e. MAPK and PI3K/AKT/mTOR 
pathways with their crosstalks. Apart from fitting the model to experimental data, prior 
knowledge from literature such as the HGF-cMET affinity (Kd), the fraction of internalised 
c-MET to total c-MET, the fraction of degraded c-MET to total c-MET and the minimal ratio 
of phosphorylated c-MET were integrated as additional soft constraints. The optimisation 
was performed by applying a modified version of particle swarm algorithms (confidential) 
to identify the corresponding parameter values. The plotted results from the optimisation 
in time-course and dose-response representations are shown in Figure 4 and Figure 5. 
 
 
 
 
Figure 3. Network topology of the literature-derived c-MET signalling network. A) upstream 
signalling pathway at the c-MET receptor level with parameter names. B) downstream 
signalling pathways including MAPK and PI3K/AKT/mTOR pathways with their crosstalk 
interactions. The dashed arrows in A and B link the upstream signalling pathway to the 
downstream signalling pathway. 
A 
B 
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Figure 4. Plotted optimisation results of c-MET signalling model after HGF stimulation at 
concentrations from 0.037nM to 9nM over the course of two hours in time-course 
representation. Error-bars depict experimental data and solid-lines depict model 
simulations. 
 
150 | P a g e      Chapter 4.4: Potential applications of PBNs in pharmaceutical industry 
 
 
 
 
Figure 5. Plotted optimisation results of c-MET signalling model after HGF stimulation at 
concentrations from 0.037nM to 9nM over the course of two hours in dose-response 
representation. Error-bars depict experimental data and solid-lines depict model 
simulations. 
 
pMET 
pERK 
pAKT 
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As shown in Figure 4 and Figure 5, we identified a set of parameters that fit well to 
the training set of time-course experimental data which comprises phosphorylated c-MET 
(pMET), phosphorylated ERK1,2 (pERK) and phosphorylated AKT (pAKT) at different 
HGF concentrations. In addition, we checked that the prior knowledge from literature in 
the form of soft constraints were all fulfilled. For instance, after stimulating the cells with 
9nM HGF, the fraction of internalised c-MET to total c-MET is predicted to 17.05% after 2 
hours which is in a good agreement with literature which suggested a fraction between 15-
30%. Also, we found that the predicted fraction of degraded internalised c-MET to total c-
MET is 68.22% in the same experimental setting while literature suggest a fraction of 70-
80% (see visualised comparisons in Figure 6). Hence, we are ensured that we obtained a 
good dynamical model of c-MET signalling with integrated prior knowledge where it can 
be further used for the discovery of therapeutic target, e.g. by performing a sensitivity 
analysis, and for designing the optimal properties of therapeutic targets by performing in 
silico simulations (Schoeberl et al., 2009). 
 
 
 
Figure 6. Internalisation and degradation rates of c-MET from model simulation compared 
against prior knowledge in literature. Note: The total number of c-MET receptor in the model 
is 129,000 molecules per cell. Upper row: total number of internalised c-MET (N. Li, Xiang, 
Dokainish, Ireton, & Elferink, 2005), Lower row: total number of degraded internalised c-MET 
(Abella et al., 2005). 
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In the next step, we investigated how a detailed quantitative ODE-based model 
can be applied to analyse the efficiency of a therapeutic agent. For the treatment of 
cancers that arose from the deregulation of c-MET receptor and its ligand, multiple 
strategies could be applied, see (Cecchi, Rabe, & Bottaro, 2010). One of the treatment 
options is to use a target-specific antibody against c-MET to block the binding between 
receptors and ligands. This mechanism of action prevents the auto-phosphorylation of the 
receptor which in turn reduces (or eliminates) the signals towards downstream signalling 
molecules. In this demonstrative example, we introduced OA-5D5, a one-armed 
humanized IgG1 monoclonal antibody against c-MET receptor (formerly under 
development by Roche/Genentech as MetMAb) (Merchant et al., 2013) as a subject of 
study to analyse how the properties of this antibody could affect the change of signalling 
patterns in downstream signalling pathways by applying the optimised c-MET signalling 
model that we previously built. 
 
First, we examined if the optimised model of c-Met signalling is predictive for OA-
5D5 to ensure that the model will be compatible for the analysis of this antibody. To 
investigate this, we performed an experiment by pre-incubating OA-5D5 at different 
concentrations from 1pM to 1µM for 2 hours on 3 human cancer cell lines which are A549 
(adenocarcinomic alveolar epithelial cells), H2170 (squamous cell carcinoma of lung) and 
SW-620 (metastasised colorectal adenocarcinoma). Then, the cells were treated with 
HGF at 1nM for 10 minutes and pAKT was measured as a read-out. On the modelling 
part, the inhibitory mechanism and measured kinetic parameters of OA-5D5 were 
incorporated into the optimised c-MET signalling model. Subsequently, a target 
engagement prediction was performed by simulating the model in the experimental 
conditions as performed in wet-lab experiment and compare it to the experimental data. 
The results of model prediction are shown in Figure 7. 
 
 
 
Figure 7: Model predictions of OA-5D5 (MetMAb) inhibitory effects on phosphorylated AKT 
(pAKT) at different concentrations in A549, H2170 and SW620 cell lines (from left to right). 
Red error bars depict the experimental data and blue lines depict model simulations. 
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As shown in Figure 7, the simulated results matched very well to the experimental 
data. These results confirmed that the integrated c-Met signalling model with OA-5D5 
inhibitory mechanism can accurately predict the changes of downstream signalling 
molecules. Therefore, this predictive c-MET model could then be further used to perform 
in silico predictions in order to investigate biological phenomena once the systems 
properties or the experimental conditions are altered. To demonstrate an example, we 
performed in silico simulations in two experimental conditions which are 1) Pre-incubate 
OA-5D5 (1pM-1µM) for 120 minutes and stimulate with 1nM of HGF for 10 minutes, and 
2) Co-incubate OA-5D5 (1pM-1µM) together with 1nM of HGF for 120 minutes, with the 
levels of c-MET varied from 10,000 to 1,000,000 molecules per cell. The predicted results 
on 3 signalling molecules including pMET, pERK1,2 and pAKT are shown in Figure 8. 
 
  
   
   
 
Figure 8. In silico predictions of molecular activities in the c-MET signalling pathway when 
c-MET is varied from 104 to 106 molecules per cell. The predictions were performed by pre-
incubating OA-5D5 (MetMAb) for 2 hours followed by 1nM HGF stimulation for 10 minutes 
(top row) or by co-incubation of OA-5D5 (MetMAb) and 1nM HGF (bottom row) for 2 hours. 
 
As demonstrated in Figure 8, the inhibitory effects of OA-5D5 are relatively 
different comparing the two experimental conditions. Low concentration of OA-5D5 at 1nM 
can totally inhibit the pMET signal when having pre-incubated the cells with antibodies 
while up to 50% of pMET were still active at this concentration once OA-5D5 and HGF 
pMET pERK pAKT 
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were co-incubated. In contrary, pMET and pAKT signals could be decreased up to 40% 
once HGF was co-incubated with OA-5D5 at a very low concentration, e.g. at 1pM, while 
there was no inhibitory effect if the antibody was pre-incubated at this concentration. 
These results demonstrate that the detailed mechanistic model of c-MET signalling can 
serve as a tool to explore the effectiveness of therapeutic targets in various experimental 
conditions which in turn facilitates future experimental planning to obtain desirable 
outcomes. 
 
 From this modelling study, there is one important remark that should be 
mentioned, i.e. the set of kinetic parameters which were used to assess the effectiveness 
of OA-5D5 was identified from only one round of model optimisation. In a practical way, 
multiple rounds of optimisation should be performed and a large set of kinetic parameter 
values from the fitted models should be analysed for their distributions. These values will 
indicate whether the obtained parameter values are identifiable. In the presenting case, 
the optimisation has to be performed on an in-house computational cluster due to the 
large size and the high complexity of the model. However, the cluster is a shared resource 
for a group of modellers who work on different projects. Therefore, only a few rounds of 
optimisation were performed on the c-MET signalling model according to the availability of 
the cluster. In parallel, in silico simulations to assess the effectiveness of OA-5D5 (Figure 
8) which were performed on a local standard computer also took a few hours per condition 
which is considered to be impractical. To summarise, the large models’ size, the high 
complexity of the models, and the limited computational resources, are the main limiting 
factors which impede the advancement of modelling work in a pharmaceutical setting that 
need to be resolved. 
 
Apart from the application of a quantitative mechanistic model on analysing the 
properties of therapeutic targets as demonstrated, different types of quantitative models 
can also be applied in a pharmaceutical setting. For instance, the bioavailability of drugs 
can be analysed in pharmacokinetic/pharmacodynamics (PK/PD) models (Roy et al., 
2013). Also, partial differential equation (PDE)-based models can be applied to predict the 
changes of drug’s concentration over time and over the distance from tumour cores (Graff 
& Wittrup, 2003). These examples therefore additionally highlighted the broad applications 
of quantitative models in systems biology in a pharmaceutical setting. 
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4.4.2 A PBN-based approach for network pre-selection 
 
As demonstrated in Chapter 4.4.1, detailed mechanistic ordinary differential 
equation (ODE)-based and partial differential equation (PDE)-based models are mainly 
applied for the discovery and assessment of therapeutic targets in a pharmaceutical 
setting. Nevertheless, the basic ground of these advanced mathematical models still relied 
on the model of cellular signal transduction network which is a pre-requisite element for 
understanding the signal flow at the molecular level. In general, the required 
computational resources and optimisation time for ODE-based models of signalling 
networks are considerably high as mentioned in Chapter 4.4.1. One of the major causes 
for such high computational time is the large size of networks. The number and complexity 
of ODEs normally grows according to the number of included molecules and interactions 
which are derived from evidence in literature. However, these interactions are typically not 
exclusive for the specific experimental settings of interested, e.g. for specific cell lines or 
for specific intracellular signalling pathways downstream of certain receptor tyrosine 
kinases. To select a suitable network topology with a “brute-force” approach by examining 
all combinations of potential interactions in the ODE-based framework will take 
unbearable time to perform. This issue therefore calls for a fast and reliable approach to 
pre-select the suitable network topology prior to building detailed mechanistic models 
which could in turn boost the speed of pharmaceutical discovery and development. 
 
Based on the performance of the PBN framework on the study of signal 
transduction networks as shown in Chapter 4.1, 4.2 and 4.3, we foresee that PBN could 
also be used to pre-select a suitable network topology based on the experimental data at 
steady-state. By analysing the selection probabilities of an optimised PBN model, one 
could determine if certain reactions can be removed. The closer the value gets close to 
zero, the more likely the corresponding interaction does not influence the signal flow in the 
network. Following this concept, one could perform an iterative optimisation pipeline to 
successively remove unnecessary interactions until only core interactions which are 
necessary to explain experimental data remain in the model. 
 
To explore if the PBN approach can actually be applied for pre-selecting a suitable 
model topology before starting with detailed mechanistic modelling of a network. We built 
a small example model comprising 11 nodes and 15 edges with artificial steady-state 
measurement data as shown in Figure 9. Among the 15 edges, 5 are assigned as 
canonical interactions, i.e. core interactions, while the other 10 interactions (with the prefix 
‘kx’) remained uncertain if they are necessary to be included. Then, we applied optPBN to 
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perform the optimisation and it shows that only five out of ten uncertain interactions have 
optimised weights which are not close to zero (Table 1). These interactions with the 
corresponding weights are essential to be integrated into the model in order to explain the 
measurement data. The other five interactions with identified weights close to zero could 
be excluded from the model without any impact on the quality of model fitting. The low 
standard deviations from multiple parameter sets (best 500 sets were used) also ensured 
that the optimised parameters are clustered together. The contextualised model topology 
by optPBN with optimised weights is shown in Figure 10. 
 
 
Figure 9: The network topology of a small example model with steady-state measurements.  
 
Table 1: Fitting cost, optimisation time and parameter distributions generated by optPBN. 
The interactions with optimised weights close to zero are shown in red, otherwise, in green. 
Mean fitting costs 0.0062 
Optimisation time Stand-alone (1 core): 4051 seconds         
Grid’5000 (40 cores): 166 seconds 
500 Parameters Mean SD 
kx1 1.000 0.002 
kx2 0.996 0.012 
kx3 0.000 0.002 
kx4 0.004 0.012 
kx5 0.000 0.000 
kx6 0.000 0.004 
kx7 0.499 0.005 
kx8 0.016 0.028 
kx9 0.791 0.031 
kx10 0.193 0.037 
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Figure 10: [Left] The contextualised network topology of the small example model with 
optimised weights as identified by optPBN. The sizes of arrows are adjusted according to 
the optimised weights. [Right] Plotted simulation results. The experimental data are 
presented as green error bars and the simulated values of the optimised model are shown 
as blue stars with red arrow bars. 
 
Next, we evaluate if the core network topology pre-selected by optPBN can be 
used for the building of a detailed mechanistic ODE-based model that fits to the 
measurement data. Based on the initial network topology with only 5 canonical (core) 
interactions, we added combinations of 0 to 10 interactions picked from the pool of 
uncertain ‘kx’ interactions and applied the law of mass action to derive a total of 1024 
ODE-based model variants. Then, we performed the optimisation of these model variants 
applying the Systems Biology Toolbox 2, SBtoolbox2 (Schmidt & Jirstrand, 2006). The 
results from the optimisations in terms of fitting costs and computational time are shown in 
Figure 11A and 11B, respectively. 
In Figure 11A, it is shown that the fitting costs vary in the range of 0 to 0.6. Among 
them, the initial model variant which contains only canonical interactions without any 
additional uncertain ‘kx’ interaction (depicted as Pick0) could not fit to the data and has 
the highest fitting cost. In parallel, adding more uncertain ‘kx’ interactions into the initial 
model variant (depicted as Pick1, Pick2, …, depending on the number of added 
interactions) improved the fitting costs as some essential interactions are added to the 
model. Interestingly, we found that the model variant with 5 uncertain ‘kx’ interactions 
(Pick5) which exactly overlaps to the list of essential interactions as identified by optPBN 
(see Table 1 and Figure 10) has the lowest fitting cost. Hence, this result demonstrates 
that the contextualised network topology identified by optPBN matches the minimal 
topology of the ODE-based model that fits well to the same set of measurement data. 
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Figure 11. Fitting costs and computational time of the 1024 ODE-based model variants. A) 
Fitting cost (left: overview, right: zoomed-in with cost <0.06 [left part of the dotted line]). B) 
Computational time (left: overview, right: zoomed-in with time <50 seconds [left part of the 
dotted line]). The red circles highlight the fitting cost and computational time of the ODE-
based model variant with the same network topology as the one contextualised by optPBN. 
 
In terms of computational time as shown in Figure 11B, we observed that the 
model variants required from a few seconds up to 500 seconds to perform parameter 
identifications in the ODE framework. We also found that the model variant with 5 selected 
interactions which overlaps with the optPBN results returned the best fitting cost in just 
only 27 seconds while the total optimisation time for all model variants is 57840 seconds 
(about 16 hours). This finding demonstrates that the network pre-selection by optPBN 
could guide modellers to directly identify the essential set of reactions for building a 
detailed mechanism model in a reasonable timeframe. Such pipeline might be able to 
replace the trail-and-error selection of uncertain interactions in the ODE framework which 
requires much higher computational time once steady-state data is available. This will be 
further explored in follow-up studies. 
 
A
B
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Chapter 5 
DISCUSSION AND PERSPECTIVES 
 
Molecular signatures of deregulated signal transduction networks at steady-state 
reflect sustained aberrant cellular phenotypes in diseases. 
 One of the principal goals of every living organism is to survive and to maintain its 
well-being. After exposures to internal and external changes in the cellular environment, 
e.g. changes in temperature, in nutritional sources, or in genetic integrity, the 
corresponding regulatory mechanisms have to operate in an efficient and effective 
manner in order to maintain homeostasis or ‘balanced state’ of the cell. Failures of these 
regulations range from systemic to molecular levels and often lead to various types of 
diseases, such as neurodegenerative diseases, metabolic diseases, and cancers. 
 
 Upon perturbations, ‘signals’ are transduced via intracellular signalling cascades 
towards multiple cellular components in order to adapt cellular phenotypes corresponding 
to the type and intensity of perturbators. At the molecular level, cells receive signals 
through the binding of ligands to signalling receptors which in turn transduce, integrate, 
modulate, and spread signals towards successive functional units including genes, 
mRNA, proteins, and metabolites. Even if there exist various kinds of cellular processes 
downstream of the signal transduction networks such as gene transcription, mRNA 
translation, or enzymatic conversion of metabolites, these processes as well as their 
regulatory mechanisms can also be viewed as a single integrated signalling network that 
transfers signals to communicate and regulate multiple cellular components in an 
orchestrated fashion in order to achieve the same ultimate goal, to maintain cellular 
integrity and homeostasis (Gonçalves et al., 2013). The schematic of interconnections and 
regulations among cellular components is depicted in Figure 12. 
 
On pathological perturbations in cancer biology, molecular perturbations which 
lead to carcinogenic transformation are usually under a tight control by multiple types of 
cellular regulation, e.g. DNA excision and repair, cell cycle arrest or senescence, as well 
as apoptosis. Generally, a short-term perturbation, e.g. an acquisition of a thymine-dimer 
after strong UV light exposure will be rapidly corrected by the photolyase or excision 
enzyme with no observable change in the phenotype (Kao, Saxena, Wang, Sancar, & 
Zhong, 2005). However, certain types of perturbations such as the acquisition of the 
D842V point mutation on PDGFRα does not have specified repairing mechanism and 
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could eventually lead to a permanent change in cellular responses, e.g. the over-
proliferation and increased survival of mesenchymal cells as found in GISTs. The 
signatures of these permanents changes can be detected at the molecular level such as 
the changes of gene expression or an increase in the pool of active signalling proteins 
and/or enzymes in metabolism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Schematic of the interconnections and regulations among signalling, gene 
regulation and metabolism, adapted from (Gonçalves et al., 2013). 
 
As the regulations of cells upon perturbations are dynamic, the signatures of 
cellular responses will evolve overtime until the perturbations are subsided or until the 
cells reach a new equilibrium or so-called ‘steady-state’. Measuring the changes of 
molecular signatures at an early time point might be beneficial once the precise time point 
of perturbation is known, e.g. in an in vitro experiment. However, in the context of long-
term developing diseases such as cancers, it might be more sensible to observe the 
changes of molecular signatures at steady-state which correlate more to the expressed 
and sustained pathological phenotypes. Even if some dynamical changes such as 
oscillation might be observed at steady-state, it is more likely that the averaged measured 
molecular profiles will still be higher (or lower) compared to the physiological condition 
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without perturbation. In addition, clinical data from patients’ records are also likely to be 
steady-state measurements in nature. Hence, studying deregulated signal transduction 
networks based on steady-state measurements does not only reveal the aberrant 
regulatory mechanisms at the molecular level but it also elucidates the corresponding 
changes of phenotypes as clinically observed in patients. 
 
PBN as a suitable framework for modelling signal transduction networks with 
steady-state measurement. 
 To get a better understanding of the dynamics and other properties of signal 
transduction networks which are often deregulated in many types of disease, various 
modelling approaches in systems biology were increasingly applied in recent years. As 
previously stated in the Chapter 1.3.4., each modelling approach has its own advantages 
and disadvantages. Therefore, one has to balance and choose the suitable approach 
according to the research question and to the type and amount of available data. 
 
For the study of signal transduction networks with steady-state measurements, we 
demonstrated that PBN is one of the suitable modelling frameworks to study and analyse 
the properties of the system at the equilibrium state. PBN can be applied to depict 
interactions within signalling networks with simplified Boolean rules while it could still 
express molecular state-values in a quantitative scale at steady-state. Modelling signal 
transduction networks with strictly qualitative modelling approaches such as the original 
Boolean networks or Petri nets does not require extensive prior knowledge but these 
models could not express quantitative measures neither because of their qualitative 
nature. On the other hand, modelling the systems with more quantitative approaches such 
as fuzzy logic models or ODE-based models is considered to be too detailed for fitting to 
steady-state data. More importantly, the system dynamics as obtained from quantitative 
models might not always be accurate as there might exist multiple model variants that are 
able to fit the same set of steady-state measurements. Also, the problem with 
unidentifiability of kinetic parameters commonly occurs due to the limited amount of data. 
In parallel, the fitting time for detailed mechanistic models is usually higher than the one of 
PBN. Hence, in terms of application and efficiency, PBNs seem to be a more suitable 
modelling approach to fit steady-state data where quantitative details are expected to be 
derived from the model. 
 
In a mathematical view, both BN and PBN were generally designed to study the 
properties of networks at steady-state, e.g. in the form of attractors or steady-state 
distributions. The mathematical foundation to calculate or approximate steady-state 
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distributions are well-established which allows for a comparison of these steady-state 
properties to steady-state data from biological experiments (Shmulevich et al., 2003). 
Even if it is also possible to study network properties at steady-state with ODE-based 
models, the simulated trajectories of molecular states have to be long enough to ensure 
that there will be no change in the state-value at the time point which is considered to 
reach steady-state. When there exist multiple steady-states, a high number of repeated 
simulations with different initial conditions are also required to discover all possible 
steady-states. These situations often require longer simulation time and it is considered to 
be impractical for the study of large-scale networks 
 
PBN models of signal transduction networks with simplified Boolean rules are able 
to fit steady-state data proteomic data and return quantitative biological insights. 
 In this dissertation, we demonstrated the applications of PBN on the study of 3 
signalling networks including the apoptotic network in primary hepatocytes, deregulated 
PDGF signalling in GIST, and comparative L-plastin signalling in non-metastatic and 
metastatic breast cancer cell lines. An important remark from the 3 studies is that many 
types of interactions within signalling networks can be modelled with simplified Boolean 
rules. It was known that different types of biochemical reactions take place in signalling 
networks, e.g. phosphorylation, dephosphorylation as well as proteasomal degradation via 
ubiquitination. Nevertheless, we demonstrated that all of these reactions can be simply 
depicted with the AND, OR and NOT gates in a set of Boolean rules within PBN which in 
turn allows for the approximation of steady-state distributions that fit to normalised 
experimental data. This observation also indicates that detailed mechanistic models are 
not always required for the quantitative study of signal transduction networks. 
 
 In the first PBN study on an apoptotic network in primary hepatocytes, we showed 
that we can derive a PBN from an established Boolean network which in turn allows us to 
obtain additional quantitative information from the existing set of experimental data. 
Besides breaking multiple mechanisms of regulation on signalling molecules from one 
original Boolean rule into multiple Boolean rules with the corresponding selection 
probabilities, we only modified the Boolean rules of two additional signalling molecules in 
order to obtain a PBN model that fitted well to the observed measurement data of two 
downstream signalling molecules and of apoptotic phenotype. This finding demonstrated 
that the original apoptotic network derived from literature can also be used as a starting 
model topology for PBN modelling. In addition, this study also showed that the PBN 
approach is applicable for the modelling and optimisation of large-scale networks, e.g. 
with 96 nodes and 105 interactions (Trairatphisan et al., 2014). By applying the grid-based 
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pipeline of optPBN, the optimisation task can be performed in less than an hour while a 
network of similar size, e.g. the c-MET signalling network in the ODE framework required 
at least several hours to identify a desirable set of kinetic parameters. 
 
 In the second example, we demonstrated that PBN can be used to study a 
deregulated PDGF signalling in GIST. Similar to the study of the apoptotic signalling 
network in a physiological condition in primary hepatocytes, PBN can also be applied to 
study an aberrant signalling networks in a pathological context such as in cancers. In this 
study, we showed once again that we can derive a network topology from literature as a 
set of simplified Boolean rules in a PBN model which fitted well to a large set of steady-
state experimental data. In addition, we could observe in this example that the core model 
topology of the PDGF signalling network in PBN formalism with only linear interactions in 
each intracellular signalling pathway could fit and predict the measurement data relatively 
well. However, it was also shown that an essential crosstalk interaction is still required to 
fit the data points where the influences from the cross regulations between downstream 
signalling cascades take place. Such finding gives a clue that most of the signals in 
aberrant PDGF signalling networks in GIST might actually be linearly transduced with only 
minimal fine-tuning between downstream signalling cascades. Hence, targeting the 
signalling molecules in the canonical pathways might have a higher impact on the 
treatment of GIST compared to focusing on shutting down crosstalk interactions. 
 
 In the last study, we demonstrated that we could apply the PBN approach to 
perform a comparative study of L-plastin signalling profiles in multiple non-metastatic and 
metastatic breast cancer cell lines. Similar to the previous examples, we could fit a 
literature-derived PBN model of L-plastin signalling with simplified Boolean rules to an 
extensive set of measurement data at steady-state. The interesting remark on this study is 
that we could apply a single PBN model topology to fit up to 4 breast cancer cell lines 
where a different set of selection probabilities, which are considered as interaction 
weights, was identified for each cell line. These results allowed us to directly compare how 
the signals flow in each cell line and also to identify the regulatory mechanisms that these 
cancer cell lines have in common, e.g. the positive crosstalk from PKC towards PKA and 
the positive connectivity from RSK towards L-plastin. In addition, signal flow comparison 
can be performed based on the phenotypes of cell lines such as the role of 8-bromo-
cAMP on the activation of PKA is slightly stronger in the invasive cancer cell lines (BT-20 
and MDA-MB-435S) while the basal activities of PKA in these cell lines are slightly weaker 
than the ones in non-invasive cell lines (MCF7 and SK-BR-3). The comparative 
observations as derived from the weights of interactions might be useful to guide towards 
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the targets of intervention which control the metastatic process in breast cancers. The 
detections and inhibitions of these targets might subsequently be further developed into 
diagnostic approaches or therapeutic agents such as drugs or biomarkers which are 
beneficial for breast cancer patients in the future. 
 
PBN can cope with uncertainty in a literature-derived network topology in an 
effective and efficient manner. 
 In the 3 PBN models as demonstrated previously, each of them has a substantial 
amount of interactions from literature where their optimised selection probabilities are 
close to zero. This implies that these interactions can be excluded without decreasing the 
fit quality, or in another word, these interactions are not necessary to be included in the 
models in order to explain the measurement data within the context of the study. For 
instance, the crosstalk interaction from deubiquitinated receptor associated receptor 
kinase-1 (RIP-deubi) towards the formation of TNF-receptor-α1 signalling complex 2 was 
shown to be inessential in the context of apoptotic signalling in primary hepatocyte with 
single ligand or ultra-violet-B (UVB) stimulation. In the second PBN study, we 
demonstrated that a majority of crosstalk interactions which were proposed in literature 
within the context of PDGF signalling were not required to explain the steady-state 
proteomics data that we investigated. Lastly, we showed that the crosstalk interactions 
from PKC and PKA towards L-plastin which were proposed and validated in different 
experimental settings can indeed be excluded within the context of our four breast cancer 
cell lines. The results from these 3 PBN studies point to the same trend that the network 
topologies derived from comprehensive literature reviews tend to be larger than the 
minimal topology that are required to fit the data. 
 
 Even if the starting model topologies of the PBN examples that we explored 
contain a certain number of unnecessary interactions, we demonstrated that they could 
still fit well to the data without sacrificing a major portion of optimisation time. In return, the 
optimised PBN model with unnecessary interactions integrated also pointed out whether 
the interactions in question are indeed essential or not by expressing the importance in 
terms of selection probabilities. Such findings allow us to rapidly identify the core 
regulatory mechanisms that govern the investigated networks in a contextualised manner. 
 
Applying PBN for studying multiple signalling networks in cancers. 
 According to the concept of cancer signalling pathways which elicits the acquisition 
of the cancer hallmarks as introduced by Hanahan and Weinberg (Hanahan & Weinberg, 
2000, 2011), it was demonstrated that the deregulation of different intracellular signalling 
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pathways contributes to distinct cancer phenotypes. For instance, deregulated MAPK 
pathway usually leads to cell over-proliferation while aberrant PI3K/AKT/mTOR pathway 
often promotes cell survival via inhibiting pro-apoptotic proteins. These two intracellular 
signalling cascades can be activated by a wide range of signalling receptors such as 
cytokine receptors, integrins, as well as a large family of receptor tyrosine kinases. To 
comprehensively understand the signal transduction process in cancers, one should 
therefore aim to model and analyse a large-scale signalling network comprising multiple 
signalling pathways as depicted in Figure 1 which will subsequently allow for designing 
therapeutic agents that could suppress multiple cancer hallmarks at once. 
 
 In recent years, there has been some effort to build mathematical models of 
multiple signalling pathways for the discovery and assessment of therapeutic targets. The 
aim of these models is to facilitate the design of therapeutic agents which inhibit multiple 
receptor tyrosine kinases (RTKs) and prevent resistance mechanisms at the same time. 
Some examples of these therapeutic agents include MM-141, a bi-specific monoclonal 
antibody which targets both ErbB3 and IGF-1 receptors to shut down the signals in 
PI3K/AKT/mTOR pathway effectively (Fitzgerald et al., 2014), and MM-111, a bi-specific 
monoclonal antibody against HER2 and ErbB3 receptors that inhibits the signals in both 
MAPK and PI3K/AKT/mTOR axes (Kirouac et al., 2013). Given that the downstream 
signalling cascades of these RTKs and other RTKs such as PDGFR and EGFR are 
similar, the model topology of RTK signalling could be shared where it can be used to fit 
experimental data across various RTKs and to explore the therapeutic effects of different 
antibodies. 
 
In this dissertation, we showed that PBN can be used to model and analyse 
signalling networks in cancer, i.e. the deregulated PDGF signalling in GIST and the 
deregulated L-plastin signalling in breast cancer cell lines. Hence, our PBN models could 
also be applied for the study of other cancer-related signalling pathways as stated above. 
In addition, it should also be possible to apply PBN to integrate the signals from multiple 
RTKs into a single model which will provide a broader picture on how different RTKs 
interplay with each other to integrate intracellular signals towards cancer phenotypes. 
Such integrative models will open up an opportunity to predict the effects of combinatorial 
treatments from therapeutic targets which is similar to the prediction of effects from 
combined perturbation conditions as shown in the PDGF signalling study. 
 
Complete the loop of regulations: multi-scale modelling with PBN. 
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 As previously illustrated in Figure 12, multiple cellular processes such as gene 
regulation, signal transduction, and metabolism, work together in an orchestrated fashion 
to regain homeostasis upon perturbations. For instance, signals are transduced from 
extracellular ligands towards transcription factors to regulate gene expression which in 
turn controls the translation of signalling proteins and metabolic enzymes. Therefore, 
modelling only one cellular process at a time might be insufficient to understand the global 
regulatory processes which are all connected. To date, there are several systems biology 
studies which proposed novel integrative modelling approaches to combine the 
mathematical descriptions of multiple cellular processes into a single multi-scale model. 
Some examples include the whole cell model of Mycobacterium Genitalium (Karr et al., 
2012) and the integrated generalised Boolean-based signalling and/or gene regulatory 
network with a kinetic ODE-based model of metabolic network (Ryll et al., 2014). These 
two examples illustrate an initiative for building a mechanistic multi-scale model which 
comprehensively represents cellular regulations and responses at different functional 
layers as well as at the whole cell level. 
 
Following the initiative on multi-scale modelling, we also consider PBN as an 
alternative modelling approach for building a multi-scale model. In a simplified view, PBN 
could serve as the mainstream modelling approach. First of all, PBN is well-studied in the 
context of gene regulatory networks. As we demonstrated in this dissertation that PBN 
could also be applied to model signal transduction networks, the integration of these two 
functional layers within the PBN framework should not pose any issue. In parallel, the 
connection between the gene regulatory network in Boolean formalism and the metabolic 
networks in the constrained-based modelling (CBM) formalism with probabilities was 
already established in PROM, a probabilistic regulation of metabolism framework 
(Chandrasekaran & Price, 2010). Hence, connecting the first two functional layers in the 
PBN framework with a metabolic network in CBM format should also be possible. As a 
final outcome, we expect to see an integrated PBN model of gene regulatory and signal 
transduction networks connecting to a constraint-based model of metabolism which yields 
quantitative prediction at the level of metabolites based on the changes in gene 
expression or in the proteomic profile. 
 
 On a contrast view, we anticipate that PBN models can also be generalised into a 
detailed kinetic model which could subsequently be integrated into a quantitative multi-
scale model following a similar methodology as proposed by (Ryll et al., 2014). Currently, 
an approach to transform PBN into a detailed mechanistic model, e.g. into an ODE-based 
framework, was not yet established. Nevertheless, we envisage that the Boolean logic 
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gates within PBN can be generalised into the fuzzy logic or ODE-based frameworks as 
proposed in (Wittmann et al., 2009) so the conversion of PBNs to ODE-based models 
seems to be feasible. Once the Boolean logic gates were transformed into algebraic 
equations, the integration of generalised PBN-based gene regulatory and signalling 
models into a mechanistic ODE-based model of metabolic network should be relatively 
straight-forward. Even if this pipeline of model integration is not entirely new, we expect 
that the final multi-scale model derived from generalised PBNs should still provide more 
quantitative information comparing to one derived from the generalised Boolean networks 
as proposed by (Ryll et al., 2014).  
 
Potential applications of the PBN approach in a pharmaceutical setting. 
Nowadays, a number of pharmaceutical companies apply a systems biology-
based approach to discover potential therapeutic targets and to design the properties of 
therapeutic agents with mathematical models. Among them, Merrimack Pharmaceuticals 
(Boston, MA, USA) is one of the leading pharmaceutical companies which applies a 
quantitative systems biology approach called Network biology to analyse the dynamics 
and other properties of deregulated signal transduction networks of different RTKs that 
are involved in the pathogenesis of cancers. Generally, quantitative mechanistic models of 
signal transduction networks, e.g. the ones in an ODE-based framework, are required to 
decipher quantitative signal transfers within signalling cascades which allow for the 
assessment of therapeutic targets as demonstrate in Chapter 4.4.1. With respect to this 
requirement, fine details of molecular interactions in multiple steps were derived into a 
large set of differential equations to precisely depict the mechanisms of signal 
transduction processes within the signalling networks of interest. Such detailed 
assignment often leads to an explosion of the model size and of the number of kinetic 
parameters which consequently requires more computational time and resources for the 
optimisation as well as more data to precisely infer kinetic parameters.  
 
As we demonstrated and discussed earlier, we discovered in our PBN examples 
that large and comprehensive network topologies derived from literature often contain 
unnecessary interactions which are not required to fit the observed data. The large size of 
networks is one of the factors that leads to a high computational demand and this is a 
common problem across all modelling frameworks including the ODE-based models. To 
account for this problem, we believe that the optimisation of large ODE-based models can 
be performed much faster once the interactions in the network which do not fit to the 
context of study are removed. In this regard, we need an efficient approach to 
contextualise the network topology based on the experimental data prior to the modelling 
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of detailed mechanistic models. As demonstrated in Chapter 4.1, 4.2 and 4.3, the 
analyses of the optimisation results from optPBN could help to identify non-essential 
interactions within the network in a fast and effective manner. Therefore, we consider that 
PBN is one of the modelling frameworks that has a high potential to be applied for such 
efficient network contextualisation tasks. 
 
We demonstrated in a small example model that the network topology pre-
selected by optPBN indeed corresponded to the minimal ODE-based model counterpart 
that still fits well to experimental data (see Chapter 4.4.2). This is a proof-of-concept 
example to demonstrate the application of PBN on network pre-selection which would 
save time in pharmaceutical research compared to directly performed trail-and-error 
combinatorial tests within detailed modelling frameworks. Nevertheless, it should be noted 
that this still needs to be further explored in an actual pharmaceutical setting. 
 
 Another potential application of PBN in a pharmaceutical setting is a quick 
screening of combinatorial effects from multiple therapeutic agents. We showed in 
Chapter 4.2 that we can predict the signalling profiles of combined perturbation 
experiments based on the PBN model with optimised parameters inferred from a set of 
single perturbation experiments within the PBN framework. We envisage that a similar 
concept can be applied in a pharmaceutical setting. Once the individual effects of multiple 
therapeutic agents were depicted as a set of Boolean rules, these mechanisms of action 
can be translated into the model descriptions in optPBN which allows for an efficient in 
silico simulation in the setting where the individual effect from each therapeutic agent is 
integrated. The results from optPBN might thereby allow to predict the combinatorial 
effects of multiple therapeutic agents in a fast and effective manner.  
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Challenges and outlooks: 
Applying the PBN approach to depict non-linear relationships within signal 
transduction networks. 
 Even if we demonstrated that we could apply PBN models to fit the proteomic 
profiles of several signalling networks where linear relationships and additive effects were 
shown, we should not exclude from our consideration the evidences of non-linear 
relationships in signal transduction networks such as non-competitive inhibitions or 
synergistic effects as previously shown in literature. An example of non-linear 
relationships in literature includes a synergistic effect on the expression of Intercellular 
adhesion molecule-1 (ICAM-1) in response to a combinatorial treatment of stem cell factor 
(SCF) and TNFα on human leukemic mast cell-1 (Tsang, Wong, Ip, & Lam, 2005). To 
account for non-linear relationships in the BN framework, a combination of fundamental 
Boolean logic gates AND, OR and NOT was proposed to represent the mechanisms of 
complex interactions (R.-S. Wang et al., 2012). It was also shown that a large combination 
of Boolean operators can be applied to depict non-linear behaviours such as complex 
patterns in cryptography (Sarkar & Subhamoy, 2000) which was applied in computer 
sciences and engineering. Since PBN also applies Boolean logic gates to model the 
interactions within the framework, we therefore anticipate that complex biochemical 
interactions with non-linear relationships could also be represented by combinations of 
Boolean operators as shown in the examples from computer sciences. 
 
In the original concept of Boolean networks, the AND gate can be applied to 
connect multiple components which are absolutely required together in a reaction such as 
the formation of protein complexes from subunits. In parallel, the OR gate can be applied 
when only one from multiple components is sufficient for the execution of a reaction such 
as the activation of proteins that have multiple catalytic sites. Combined with the concept 
of selection probabilities in PBN, we could demonstrate in Chapter 4.1 and 4.2 that many 
complex mechanisms of interaction within the networks can be depicted by the 
combination of Boolean logic gates which operate on their targets at certain probabilities. 
Nevertheless, certain non-linear relationships such as synergy is still beyond the capacity 
of the original PBN framework to account for this positive connectivity. Such problem 
could be accounted by normalising all signals by the maximal synergised signal to obtain 
the maximal probability of one, then introduce additional parameters to specifically add the 
synergistic effects towards to the target nodes. This proposed method still needs to be 
tested if it will work properly on a real dataset from biological experiments. 
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A perspective on the optimisation of PBN models with time-course data 
 So far, we have demonstrated that PBN is a suitable approach for modelling of 
signal transduction networks with steady-state measurements. However, in many 
biological studies, time-course data are generated to observe dynamical changes of 
signalling molecules over the course of experiments. Generally, the original Boolean 
network and its variants including PBN are not meant to be studied in the context of 
dynamical time because of their discrete-time nature. Nevertheless, we would like to 
discuss here the possibilities to take advantage of time-course data for the modelling and 
analyses of signal transduction networks within the PBN framework. 
  
 In previous studies, there were some efforts to correlate time steps in Boolean 
networks to the “snapshot” dynamics of signalling networks at several time points. For 
instance, Saez-Rodriguez et al. built a logical T-cell receptor signalling network 
considering two different time-scales to represent the early and late processes of T-cell 
receptor activation (Saez-Rodriguez et al., 2007). Similarly, the model topology of the 
large-scale Boolean model of apoptosis by Schlatter et al. was separated into several sub-
models at different time points which corresponded to the expected dynamics of signalling 
networks and feedback regulations in an actual time-scale (Schlatter et al., 2009). Both of 
these examples demonstrated that it is possible to build Boolean networks that fit to 
cellular phenotypes at different time-scales. A similar methodology could be applied in the 
PBN framework as well. 
 
Optimisation of large-scale models in the PBN framework. 
 In Chapter 4.1, we demonstrated that optPBN was successfully applied to optimise 
a large-scale PBN model of apoptosis with 96 nodes in a timely manner. However, the 
optimisation of more comprehensive networks such as an integrated signal transduction 
network in cancer, e.g. as shown in Figure 1, or a multi-scale model of comprehensive 
cellular processes, e.g. as shown in Figure 12, would require either more computational 
resources or faster algorithms to solve the optimisation problems efficiently. As the 
cluster-based or grid-based computational resources are generally shared by a large 
number of users in the community, these resources might not always be available in time 
of need. Therefore, more efforts should be emphasized on advancing the efficiency and 
effectiveness of the optimisation pipelines and algorithms rather than relying only on a 
“brute-force” approach with the usage of large computational resources. 
 
 Currently, we foresee that the problem on limited computational resources and an 
inefficient optimisation pipeline can be tackled by two different approaches. The first 
Chapter 5: Discussion and perspectives    171 | P a g e  
 
approach is to improve the implementation of the already well-established PBN 
framework, e.g. in an alternative programming language. In general, Matlab is an efficient 
modelling language to process computational tasks in matrix form. However, the 
simulation task in optPBN which is based on the calculation of molecular state trajectories 
stored in vectors did not take full advantage of Matlab. In addition, the BN/PBN toolbox, 
on which the optPBN toolbox is based on, comprises a bundle of connected Matlab scripts 
which are inefficient in terms of computation. Based on such limitation, our collaborators 
at the Computer Science and Communications Research Unit at the University of 
Luxembourg developed ASSA-PBN, a Java-based toolbox which allows for the simulation 
of PBN models in a highly efficient manner (Mizera, Pang, & Yuan, 2015). In the current 
implementation, ASSA-PBN could perform PBN simulations with a trajectory length of 
more than one million time steps on a standard computer in a timely manner while the 
longest length that optPBN can simulate in the same timeframe is no longer than a few 
ten thousands time steps. 
 
From a technical view, as the calculation of influences from parent nodes to a 
target node which was introduced in (Shmulevich et al., 2002) might require the 
calculation of joint distributions, the required lengths of a trajectory to reach steady-state 
with a desired accuracy are generally much longer than the ones computed for the 
independent marginal distribution of each node as assumed in the optPBN study. Also, 
decreasing the error range of approximated steady-state distributions on the accuracy 
parameter ‘r’ also increases the required lengths of the trajectory in a substantial 
proportion. As previously stated, the increased trajectory lengths in PBNs could be 
handled efficiently by ASSA-PBN. Therefore, the implementation of ASSA-PBN opens up 
a possibility to obtain more accurate PBN results and to obtain more detailed features 
such as influence values which in turn describe the impact of the changes on parent 
nodes towards their target nodes. 
 
 In terms of limitation, ASSA-PBN still needs an input generated from the optPBN 
toolbox which combines the model descriptions in Boolean rules and experimental data 
into an optimisation problem. Hence, ASSA-PBN still partly relies on the functionality of 
the optPBN toolbox. Future work will be to establish a PBN construction pipeline from 
Boolean rules within the ASSA-PBN framework and also to provide a user-friendly 
interface for the Java-based tool. Regarding the computation, the implementation of 
parallel computing in the ASSA-PBN framework on a cluster-based or grid-based 
infrastructure is yet to be implemented. A parallelisation on a general-proposed graphic 
processing unit (GPU) as introduced by (Bosnacki, Odenbrett, Wijs, Ligtenberg, & Hilbers, 
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2012) is also an interesting approach to maximise the computational power on a standard 
local machine. 
 
The second approach to account for the problem of limited computational 
resources and an inefficient optimisation algorithm is to explore an alternative form of PBN 
representation where the optimisation problems in the respective form can be solved more 
efficiently. Recently, we developed a new efficient optimisation tool called FALCON, a 
Fast ALgorithm for COntextualisation of Networks, based on the concept of optPBN. 
FALCON takes two input files, i.e. a simple list of network interactions and a list of 
experimental conditions with the corresponding measurement data. Only two types of 
simplified interactions were considered in FALCON, i.e. activation and inhibition. The 
Boolean logic gates ‘AND’ and ‘OR’ can be assigned to combine multiple inputs (optional). 
Such simple input format should eliminate the inconsistency when deriving network 
interactions either from a list of biochemical interactions or from a network graph. Once 
the model descriptions were derived, we applied a Matlab solver to fit models to 
experimental data and to optimise the parameter values in an efficient way. Please note 
that we refrain from providing detailed descriptions on the methodology of FALCON in this 
dissertation as we would like to explore the possibility to commercialise this software in 
the near future. 
 
To evaluate the performance of the new tool, we applied FALCON to perform the 
optimisation of the deregulated PDGF signalling model in GIST and of the L-plastin 
signalling model in the BT-20 cell line on a standard PC (1 core) and we compared the 
results against the ones obtained from the grid-based pipeline of optPBN on Grid’5000 
(160 cores). The comparative results are shown in Table 2. 
 
Table 2: Compared fitting costs and optimisation time between optPBN versus FALCON 
Model 
optPBN 
On Grid’5000 (160 cores) 
FALCON 
On standard PC (1 core) 
Time Improvement 
per core (folds) 
Fitting cost Time Fitting cost Time 
PDGF 0.1806 937s 0.1566 17s 8819 
L-plastin 0.2765 2395s 0.2996 34s 11271 
 
As shown in Table 2, the time improvement of FALCON over optPBN is up to 
10,000 fold for realistic case studies. Not only that the computational time is significantly 
improved, we showed that it is also possible to run FALCON on a standard PC to solve 
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the complex optimisation problems of the PDGF and L-plastin signalling pathways while 
this task is not practical for the optPBN pipeline. 
 
In summary, we demonstrated that the PBN approach can be applied to study the 
steady-state properties of signal transduction networks. Also, it allows for network 
contextualisation prior to the building of mechanistic models based on steady-state data 
with promising future applications in pharmaceutical industry. In the near future, once the 
integrated optPBN/ASSA-PBN and FALCON pipelines are mature enough both in terms of 
mathematical foundation and applications, it might be worth to perform a benchmarking to 
compare the efficiency and effectiveness of the two approaches and to explore large-
scale applications in pharmaceutical industry. Once these tools will indeed operate 
effectively and efficiently in an actual pharmaceutical setting, we hope that they will be 
valuable computational tools which contribute to the advancement of translational 
sciences from molecular biology towards clinical medicine. 
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7.1 Selected supplementary information of Chapter 4.1  
Results from the optPBN pipeline for four case studies
*Note: Disc. = Discrete mode, Cont. = Continuous mode, Ext. = Extended model structure, Init. = Initial model tructure
iter. = iterations, Apo. = Apotosis, Delta = difference between steady-state distributions and measurement data
nsteps = length of simulated two-state Markov chain trajectory used to estimate the steady-state probablities
Stand-alone version (Optimiser: Particle swarm algorithm, PSO)
Case study (Model) Approach
Pswarm iter. r Time (s) nsteps C2(NFkB) Delta
0.05 129 101 1 (&) 0
0.025 305 101 1 (&) 0
0.01 1578 382 1 (&) 0
0.05 627 101 1 (&) 0
0.025 1093 101 1 (&) 0
0.01 5841 382 1 (&) 0
Pswarm iter. r Time (s) nsteps C2(NFkB) Delta C1(ERK), C3(ERK) Delta
0.05 357 101 1 (&) 0 0.5 (|), 0.5 (Lt) 0
0.025 2194 101 1 (&) 0 0.5 (|), 0.5 (Lt) 0
0.01 5451 382 1 (&) 0 0.5 (|), 0.5 (Lt) 0
0.05 1761 101 1 (&) 0 0.5 (|), 0.5 (Lt) 0
0.025 3011 101 1 (&) 0 0.5 (|), 0.5 (Lt) 0
0.01 25064 382 1 (&) 0 0.5 (|), 0.5 (Lt) 0
Pswarm iter. r Time (s) nsteps C1(N3), C3(N3) Delta
0.05 150 408 0.6045, 0.3955 0.0045
0.025 321 1514 0.6087, 0.3913 0.0087
0.01 1351 10612 0.6090, 0.3910 0.009
0.05 659 438 0.6237, 0.3763 0.0237
0.025 1205 1444 0.6041, 0.3959 0.0041
0.01 7968 10357 0.5979, 0.4021 0.0021
Pswarm iter. r Time (s) nsteps C1(NFkB), C2(NFkB) Delta C1(ERK), C2(ERK) Delta
0.02 906 433 0.6934, 0.3066 0.0066 0.5477, 0.4523 0.0523
0.01 1302 1861 0.6990, 0.3010 0.001 0.6122, 0.3878 0.0122
0.005 8802 10534 0.6968, 0.3032 0.0032 0.5868, 0.4132 0.0132
0.02 4384 543 0.6992, 0.3008 0.0008 0.6532, 0.3468 0.0532
0.01 6151 1861 0.7078, 0.2922 0.0078 0.6028, 0.3972 0.0028
0.005 48747 10403 0.7016, 0.2984 0.0016 0.6046, 0.3954 0.0046
Pswarm iter. r Time (s) nsteps Simulated (Apo.) Delta Simulated (NFkB) Delta
376 0.0027 (vs 0) 0.0027 0.0053 (vs 0) 0.0053
1505 0.4133 (vs 0.63) 0.2167 0.2970 (vs 0.32) 0.023
1725 0.0017 (vs 0) 0.0017 0.5843 (vs 1) 0.4157
1667 0.0012 (vs 0.1) 0.0988 0.6029 (vs 0.98) 0.3771
815 0.7963 (vs 1) 0.2037 0.0025 (vs 0.26) 0.2575
2029 0.2617 (vs 0.49) 0.2283 0.4421 (vs 0.46) 0.0179
457 0.0066 (vs 0) 0.0066 0.0022 (vs 0) 0.0022
1346 0.6218 (vs 0.63) 0.0082 0.2117 (vs 0.32) 0.1083
549 0 (vs 0) 0 0.9271 (vs 1) 0.0729
1630 0.0006 (vs 0.1) 0.0994 0.7571 (vs 0.98) 0.2229
101 0.9406 (vs 1) 0.0594 0.0099 (vs 0.26) 0.2501
1819 0.4766 (vs 0.49) 0.0134 0.3090 (vs 0.46) 0.151
Cij Cost -> 0.1939 Value
C1
(NFkB) 0.7982
C2
(NFkB) 0.2018
C1
(complex2) 0.7517
C2
(complex2) 0.2483
Cij Cost -> 0.2681 Mean S.D.
C1
(NFkB) 0.8036 0.0433
C2
(NFkB) 0.1964 0.0433
C1
(complex2) 0.669 0.0739
C2
(complex2) 0.331 0.0739
NF_kB = ( ~I_kBa | ~I_kBe )
NF_kB = ( ~I_kBa | ~I_kBe ) | ( C8a | C8a_2 )
complex2 = ( complex1&FADD )
complex2 = ( complex1&FADD&RIP_deubi )
Best run
Mean (500/5000 runs)
Model 4 (Cont./Ext.)
NF_kB = ( ~I_kBa | ~I_kBe )
NF_kB = ( ~I_kBa | ~I_kBe ) | ( C8a | C8a_2 )
complex2 = ( complex1&FADD )
complex2 = ( complex1&FADD&RIP_deubi )
5000
1000
ergodic PBN and two-state Markov chain
Sum Delta (2 nodes) = 1.8484  ; SSE (3 nodes) = 0.7527
Sum Delta (2 nodes) = 0.9944  ; SSE (3 nodes) = 0.2138
45503
16783
0.025
0.025
Model 1 (Disc.)
Model 3 (Cont.)
1000
5000
1000
5000
1000
5000
1000
5000
Model 3 (Disc.)
Model 2 (Cont.)
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Grid-based version (Optimisers: Differential evolution [DE] + Evolutionary algorithm [EA], 80 cores)
Run-time analysis (Table 4)
Case study (model) G5K iter. r
1000
5000
1000
5000
1000
5000
1000
5000
Optimisation results of case study 4
Case study (model) G5K iter.
r Time (s) nsteps Simulated (Apo.) Delta Simulated (NFkB) Delta
880 0.0054 (vs 0) 0.0054 0.0027 (vs 0) 0.0027
919 0.717 (vs 0.63) 0.087 0.1501 (vs 0.32) 0.1699
817 0.0063 (vs 0) 0.0063 0.8481 (vs 1) 0.1519
1667 0.0018 (vs 0.1) 0.0982 0.8723 (vs 0.98) 0.1077
119 0.9868 (vs 1) 0.0132 0.0033 (vs 0.26) 0.2567
1366 0.4914 (vs 0.49) 0.0014 0.2932 (vs 0.46) 0.1668
80 cores
Cij Cost -> 0.176 Value
C1
(NFkB) 0.8544
C2
(NFkB) 0.1456
C1
(complex2) 1
C2
(complex2) 0
Cij Cost -> 0.1994 Mean S.D.
C1
(NFkB) 0.8354 0.0209
C2
(NFkB) 0.1646 0.0209
C1
(complex2) 0.848 0.1105
C2
(complex2) 0.152 0.1105
r Time (s) nsteps Simulated (Apo.) Delta Simulated (NFkB) Delta
880 0 (vs 0) 0 0.0168 (vs 0) 0.0168
608 0.9208 (vs 0.63) 0.2908 0.0198 (vs 0.32) 0.3002
815 0.0028 (vs 0) 0.0028 0.8873 (vs 1) 0.1127
1723 0.002 (vs 0.1) 0.098 0.7889 (vs 0.98) 0.1911
101 0.992 (vs 1) 0.008 0.0023 (vs 0.26) 0.2577
1494 0.4681 (vs 0.49) 0.0219 0.3083 (vs 0.46) 0.1517
80 cores
Cij Cost -> 0.2668 Value
C1
(complex2) 0.7524
C2
(complex2) 0.2476
Cij Cost -> 0.2869 Mean S.D.
C1
(complex2) 0.8351 0.1114
C2
(complex2) 0.1649 0.1114
Pooled Grid-based results from 3 separated runs (Extended structure of Model 4)
Cij  Cost -> 0.2043 Mean S.D.
C1
(NFkB) 0.831 0.0304
C2
(NFkB) 0.169 0.0304
C1
(complex2) 0.7899 0.1716
C2
(complex2) 0.2101 0.1716
Mean (500*3 runs)
NF_kB = ( ~I_kBa | ~I_kBe )
NF_kB = ( ~I_kBa | ~I_kBe ) | ( C8a | C8a_2 )
complex2 = ( complex1&FADD )
complex2 = ( complex1&FADD&RIP_deubi )
NF_kB = ( ~I_kBa | ~I_kBe )
NF_kB = ( ~I_kBa | ~I_kBe ) | ( C8a | C8a_2 )
complex2 = ( complex1&FADD )
complex2 = ( complex1&FADD&RIP_deubi )
complex2 = ( complex1&FADD )
complex2 = ( complex1&FADD&RIP_deubi )
Sum Delta (2 nodes) = 1.4517 ; SSE (3 nodes) = 0.3275
0.025
634
0.025 580
Grid-based (80 cores)
15000
15000
NF_kB = ( ~I_kBa | ~I_kBe )
NF_kB = ( ~I_kBa | ~I_kBe ) | ( C8a | C8a_2 )
complex2 = ( complex1&FADD )
complex2 = ( complex1&FADD&RIP_deubi )
Best run
Mean (500/7500 runs)
Model 4 (Cont./Ext.)
Model 4 (Cont./Init.)
Mean (500/7500 runs)
complex2 = ( complex1&FADD )
complex2 = ( complex1&FADD&RIP_deubi )
Best run
1093s (18m13s)
321s (5m21s)
8s
16s
9s
Improvement (folds)
38.1
68.3
35.7
Pooled Model 4 (Ext)
Model 1
Model 2
Model 3 (Cont.)
Model 4 (Cont./Ext.)
39s
99s (1m39s)
259s (4m19s)
1205s (20m5s)
1302s (21m42s)
6151s (1h42m31s)
16783s (4h39m43s)
0.025
16s
45503s (12h38m23s)
Sum Delta (2 nodes) = 1.0672 ; SSE (3 nodes) = 0.1987
75.3
72.3
157.7
169.5
18s
175.7
Stand-alone (1 core)
305s (5m5s) 
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Supporting Information File S1:  
Model description of the PDGF signalling network in PBN format 
 
  
This document provides a detailed description of the PBN models of PDGF signalling which are 
presented in the manuscript. The model descriptions are separated into 3 parts as follows: 
1) The core model structure with major intracellular signalling pathways 
2) The integration of crosstalk interactions which were proposed in literature 
3) The refined model structure after integrating data from additional experiment 
Please note that we applied the annotation ‘->’ to depict an activating interaction and ‘-|’ to 
depict an inhibitory interaction. 
 
Part 1: The core model structure with major intracellular signalling pathways 
 We built a core model structure of PDGF signalling comprising PDGFRα and its regulatory 
mechanisms together with the major downstream signalling pathways including MAPK, 
PI3K/AKT/mTOR, PLCγ/PKC pathways as well as STAT5. The core model topology is shown below: 
 
 
 
 From the top, we depicted the induction of PDGFRα-transgene by doxycycline (DOX) in our 
cell system. The regulatory mechanisms of mutated PDGFRα (mPDGFR, represented as ‘PDGFR’ in the 
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model) are governed by cytoplasmic phosphatase (PPX), protein tyrosine phosphatase shp2 (SHP2) 
and proteosomal degradation via ubiquitination promoted by c-Cbl (cCbl). The network topology of 
downstream signalling pathways comprises as follows: 
- MAPK pathway (SHP2 -> Grb2SOS/GabSOS -> Ras -> Raf1 -> MEK1,2 (MEK12) -> ERK1,2 
(ERK12)) 
- PI3K-AKT-mTOR pathway (PI3K -> PIP3 -> PDK -> AKT <-> mTOR) with basal activity of PTEN 
(bPTEN) inhibiting PIP3 and basal activity of PDK (bPDK) activating PDK. Note that PIP3 can 
also directly activate Akt. 
- PLCg-PKC pathway (PLCg -> IP3_DAG_Ca -> PKC) 
- STAT5 
According to this model topology, we formulated the model descriptions with Boolean rules 
as follows: 
=== PDGFR activation and regulatory mechanisms === 
% DOX:   rules=[rules; {'DOX = 1','1','C'}];                         
% PPX:   rules=[rules; {'PPX = ~PDGFR','1','C'}]; 
% cCbl:   rules=[rules; {'cCbl = PDGFR','1','C'}]; 
% PDGFR:  rules=[rules; {'PDGFR = DOX','1','D'}]; 
rules=[rules; {'PDGFR = DOX & ~cCbl','1','D'}]; 
rules=[rules; {'PDGFR = DOX & ~PPX','1','D'}]; 
rules=[rules; {'PDGFR = DOX & ~SHP2','1','D'}]; 
 
=== MAPK pathway === 
% SHP2:  rules=[rules; {'SHP2 = PDGFR','1','C'}]; 
% Grb2SOS:  rules=[rules; {'Grb2SOS = SHP2','1','C'}];  
% GabSOS:  rules=[rules; {'GabSOS = SHP2','1','C'}]; 
% Ras:   rules=[rules; {'Ras = Grb2SOS | GabSOS','1','C'}]; 
% Raf1:   rules=[rules; {'Raf1 = Ras','1','C'}]; 
% MEK12:  rules=[rules; {'MEK12 = MEK12_induce','1','C'}]; 
% MEK12_induce: rules=[rules; {'MEK12_induce = Raf1','1','C'}]; 
% ERK12:  rules=[rules; {'ERK12 = MEK12','1','C'}]; 
 
=== PI3K-AKT-mTOR pathway === 
      % PI3K_PDGFR:  rules=[rules; {'PI3K_PDGFR = PDGFR','1','C'}];             
      % prePI3K:  rules=[rules; {'prePI3K = PI3K_PDGFR','1','C'}]; 
      % PI3K:   rules=[rules; {'PI3K = prePI3K','1','C'}]; 
% bPTEN:   rules=[rules; {'bPTEN = 1','1','C'}]; 
% PIP3:   rules=[rules; {'PIP3 = PI3K','1','D'}]; 
rules=[rules; {'PIP3 = PI3K & ~bPTEN','1','D'}]; 
% bPDK:  rules=[rules; {'bPDK = 1','1','C'}]; 
% PDK:   rules=[rules; {'PDK = PIP3','1','D'}]; 
rules=[rules; {'PDK = bPDK','1','D'}]; 
% Akt:   rules=[rules; {'Akt = PIP3','1','D'}]; 
rules=[rules; {'Akt = PDK','1','D'}]; 
rules=[rules; {'Akt = MTOR','1','D'}]; 
% MTOR:  rules=[rules; {'MTOR = Akt','1','C'}]; 
 
       === PLCg-PKC pathway === 
      % PLCg:   rules=[rules; {'PLCg = PDGFR','1','C'}]; 
% IP3_CaIon_DAG: rules=[rules; {'IP3_CaIon_DAG = PLCg','1','C'}]; 
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% PKC_induce:  rules=[rules; {'PKC_induce = IP3_CaIon_DAG','1','C'}];             
    % PKC:   rules=[rules; {'PKC = PKC_induce','1','C'}]; 
        
        === STAT5 === 
% STAT5:  rules=[rules; {'STAT5 = PDGFR','1','C'}]; 
 
 Based on these assigned Boolean rules, there are a few important observations. First, the flags 
‘C’ and ‘D’ at the end of the Boolean rules are defined to correlate with the terms ‘Constant’ and 
‘Default’ respectively.  Once the flag ‘C’ is used, it means that the selection probability of that Boolean 
rule will be constant and the corresponding node (molecule) will not be optimised so all rules for this 
node need to have the flag ‘C’ then. This flag is exclusively applied for the nodes with only one input 
as the probability of activating or inhibiting such nodes have to be 1. In parallel, when a node has more 
than one incoming interaction, multiple Boolean rules can be assigned for such node and the 
respective node is typically optimised. The flag ‘D’ can be assigned throughout multiple Boolean rules 
on a single node to give a full boundary of the selection probability from 0 to 1 during the 
optimisation.1 With this flag assigned, each regulatory mechanism as coded in different Boolean rule 
will have an equal chance to dominate the other. In general, this assignment is defined once the 
influence from each interaction is unclear. For instance, the activation of Akt can be mediated by PIP3, 
PDK and mTOR but there is no prior information nor assumption whether one specific source of signal 
will be stronger than the others. 
 
 Another observation that should be noted is some molecules, i.e. MEK1,2, PI3K and PKC have 
intermediate nodes. These nodes represent the intermediate steps of signal transduction processes 
where multiple activating and inhibiting interactions take place. On the last observation on the 
inhibitory mechanisms, we applied 2 types of single perturbation to the system, i.e. additional YF point 
mutations to abrogate recruitment sites on the PDGFRα (dMAPK and dPI3K) and signalling inhibitors 
(Wortmannin and U0126) in the initial experiment. Based on our experimental observations and 
literature information, we found that the abrogation of tyrosine residue Y720F in dMAPK mutant also 
affects the binding of pPLCg to PDGFRα while Wortmannin has an additional off-target on PKC apart 
from inhibiting PI3K. To account for these inhibitory mechanisms without adding more nodes, we 
repeated the same Boolean rule for the activating interaction once and we set the second Boolean 
rule as 0 once the targeted molecule is inhibited. To illustrate our methodology, we provide an 
example of Boolean rules for the D842V-PDGFRα mutant without YF point mutation or signalling 
inhibitor (DV-WT) compared to the Boolean rules of D842V-PDGFRα-dMAPK mutant and Wortmannin 
treatment (DV-dMAPK-Wort.) as follows: 
 
 === DV-WT === 
            % SHP2:  rules=[rules; {'SHP2 = PDGFR','1','D'}]; 
                rules=[rules; {'SHP2 = PDGFR','1','D'}];                         
             % MEK12:  rules=[rules; {'MEK12 = MEK12_induce','1','D'}]; 
                rules=[rules; {'MEK12 = MEK12_induce','1','D'}];                                     
             % PI3K_PDGFR:  rules=[rules; {'PI3K_PDGFR = PDGFR','1','D'}]; 
                rules=[rules; {'PI3K_PDGFR = PDGFR','1','D'}];                         
             % prePI3K:  rules=[rules; {'prePI3K = PI3K_PDGFR','1','C'}]; 
                                                             
1 If the sum of optimised selection probabilities from multiple Boolean rules is larger than 1, the selection 
probability of each Boolean rule will be normalised to the sum of all probabilities in order to ensure that the sum 
of the selection probabilities will be 1. 
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             % PI3K:   rules=[rules; {'PI3K = prePI3K','1','D'}]; 
                rules=[rules; {'PI3K = prePI3K','1','D'}]; 
             % PLCg:   rules=[rules; {'PLCg = PDGFR','1','D'}]; 
                rules=[rules; {'PLCg = PDGFR','1','D'}]; 
             % PKC:    rules=[rules; {'PKC = PKC_induce','1','D'}]; 
                rules=[rules; {'PKC = PKC_induce','1','D'}]; 
 
 === DV-dMAPK-Wort. === 
            % SHP2:  rules=[rules; {'SHP2 = PDGFR','1','D'}]; 
                rules=[rules; {'SHP2 = 0','1','D'}]; % effect of dMAPK                         
             % MEK12:  rules=[rules; {'MEK12 = MEK12_induce','1','D'}]; 
                rules=[rules; {'MEK12 = MEK12_induce','1','D'}];                                     
             % PI3K_PDGFR:  rules=[rules; {'PI3K_PDGFR = PDGFR','1','D'}]; 
                rules=[rules; {'PI3K_PDGFR = PDGFR','1','D'}];                         
             % prePI3K:  rules=[rules; {'prePI3K = PI3K_PDGFR','1','C'}]; 
             % PI3K:   rules=[rules; {'PI3K = prePI3K','1','D'}]; 
                rules=[rules; {'PI3K = 0','1','D'}]; % effect of Wortmannin 
             % PLCg:   rules=[rules; {'PLCg = PDGFR','1','D'}]; 
                rules=[rules; {'PLCg = 0','1','D'}]; % effect of dMAPK 
             % PKC:    rules=[rules; {'PKC = PKC_induce','1','D'}]; 
                rules=[rules; {'PKC = 0','1','D'}]; % effect of Wortmannin 
 
 As demonstrated, the second rules of SHP2 and PLCg were changed to 0 to account for the 
inhibitory effect of dMAPK while the second rules of PI3K and PKC were also set to 0 to take the 
inhibitory effect of Wortmannin into consideration. A similar assignment was applied to the second 
rule of PI3K_PDGFR in order to account for the dPI3K effect, and it was also applied to the second rule 
of MEK12 in order to account for U0126 inhibition. With the methodology for the assignment of 
Boolean rules as demonstrated, we were able to generate the model structures of PDGF signalling 
which could represent the six experimental conditions within the training dataset and we 
subsequently applied them to perform model fitting accordingly. 
 
Part 2: The integration of crosstalk interactions which were proposed in literature 
 After we tried to fit the core model topology to the training dataset, we discovered that the 
model fitted to the data relatively well but there were still a few data points where could not be fitted. 
We hypothesise that a certain number of crosstalk interactions is required to explain all data points. 
Therefore, we built 9 additional model variants by adding the crosstalk interactions which were 
proposed in the literature to the core model topology one-at-a-time and we re-performed the 
optimisation on the model variants to the training dataset. The types and targets of the crosstalk 
interactions in the 9 model variants are shown as follows: 
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In terms of the implementation in the PBN model, one interaction was added to the core 
model topology (Part 1) for each model variant. For instance, the model variant with crosstalk number 
9 (PKC -> MEK12) has the following Boolean rules: 
% MEK12_induce: rules=[rules; {'MEK12_induce = Raf1','1','H'}]; 
rules=[rules; {'MEK12_induce = PKC','1','L'}]; 
  
Note that another set of flags ‘H’ and ‘L’ were used. As previous mentioned in the manuscript, 
we consider that the signals flow through canonical pathways stronger than flowing pass crosstalk 
interactions. Hence, we assign the flag ‘H’ (High) for the canonical interaction Raf1 -> MEK12 and the 
flag ‘L’ (Low) for the crosstalk interaction PKC -> MEK12. This assignment ensure that the boundary of 
the interaction(s) with the flag ‘H’ will always have higher selection probability compared to the 
interaction(s) with the flag ‘L’.  
 Among the pool of all model variants, one of the complex model variants that should be 
mentioned is the model variant with crosstalk number 1 (Ras -> PI3K). In this model variant, we 
introduce a new node called ‘PI3K_crosstalk’ coded as “rules=[rules; {'PI3K_crosstalk = Ras','1','C'}];” 
to account for this crosstalk interaction. Previously, we had the node ‘PI3K_PDGFR’ which represents 
PI3K signal after the activation by PDGFR. To integrate the signals, the successive node ‘prePI3K’ was 
assigned to represent PI3K signals which receive the inputs both from PDGFR and from crosstalk 
interaction(s) as depicted in following Boolean rules: 
             % prePI3K:  rules=[rules; {'prePI3K = PI3K_PDGFR','1','H'}]; 
                rules=[rules; {'prePI3K = PI3K_crosstalk','1','L'}]; 
  
Note that the information on canonical pathway versus crosstalk interaction is also applied 
here with the flags ‘H’ and ‘L’. Subsequently, the integrated signals of PI3K in ‘prePI3K’ node can 
further be inhibited by Wortmannin by setting the second rule of ‘PI3K’ node to 0 as explained above. 
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Part 3: The refined model structure after integrating data from the additional experiment 
After we performed the additional experiment (Figure 3) and we found that PKC activity is 
independent of the activation from PDGFRα, we added the node ‘bPKC’ to account for the basal 
activity of PKC with the following Boolean rules:  
% PKC_induce:  rules=[rules; {'PKC_induce = IP3_CaIon_DAG','1','D'}]; 
rules=[rules; {'PKC_induce = bPKC','1','D'}]; 
 
The updated model topology with the additional information on two new PKC inhibitors 
(GF109 and Gö6976) is shown in the figure below: 
 
 
  
Note that even if we performed an additional experiment with the two new PKC inhibitors, 
we only took the information from the experimental conditions which overlapped with the ones in 
the training dataset for modelling. With this regard, we only included pPKC substrates data on 
negative control, positive control (DV-WT) and DV-WT-Wortmannin conditions into the training 
dataset for final model refinement. 
After we fitted the refined model to the updated training dataset, we also performed an in 
silico analysis to investigate the importance of crosstalk interactions which were described in Step 2. 
This analysis revealed that only crosstalk interactions number 3 (PI3K -> Ras) or number 4 (PI3K -> 
MEK1,2) are important to fit the training dataset. Then, we proceeded with the final PBN model, i.e. 
the refined model plus the crosstalk interaction number 4 (PI3K -> MEK1,2) to evaluate the predictive 
power of the model. We found that the final model could predict the signalling profiles in the 
combined perturbation conditions within the validation dataset accurately. Hence, we concluded that 
our final PBN model is highly predictive. 
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7.4 Joint publication: Probabilistic model checking of the PDGF signalling 
pathway (Yuan et al., 2012) 
 
Preface: In this research article, we applied the probabilistic model checker PRISM 
to analyse the platelet-derived growth factor (PDGF) signalling pathway. We converted a 
literature-derived PDGF signalling network from an interaction graph into a reaction-based 
ODE model using the law of mass action and we shortly discuss on the translation from 
kinetic rates into stochastic rates. Parameter sensitivity analysis was performed to ensure 
that the qualitative system dynamics are robust against perturbations on parameter 
values. 
 
 Once biochemical interactions and stochastic parameters were derived, they were 
represented as a continuous-time Markov chain (CTMC) model which is compatible to be 
analysed in PRISM, a probabilistic model checker for stochastic models. Several research 
objectives were defined to be analysed thereby, i.e. to analyse the dynamics of PDGF-
induced signalling, to analyse the influence of crosstalk interactions, and to analyse the 
importance of individual reactions. These objectives were practically specified as 
observing properties in PRISM where several properties were subsequently derived, e.g. 
the dynamical probabilities of certain molecules to be activated over certain time points or 
the long-run (steady-state) probabilities of certain molecules to be in an active state. The 
‘node’ and ‘edge’ knock-out model variants were generated and analysed where the 
changing activities of downstream signalling molecules (MEK1,2 & AKT) were observed. 
 
 Lastly, we also compared the dynamical and steady-state results from stochastic 
verification versus ODE simulation. Surprisingly, we found that the long-run probability of 
AKT can be largely differed between the two approaches in an isolated reciprocal positive 
feedback structure. We identified that the state values of molecules in the ODE framework 
will always be multiplied up within a positive-feedback loop which leads to very high 
steady-state values even if the parameter values are small. In contrast, the long-run 
probabilities in the CTMC model are proportionally reduced according to the stochastic 
parameter values as analysed by PRISM (see Figure 14 in the article). This finding 
highlights the importance of choosing an appropriate modelling framework which should 
correspond to the observations on the biological systems of interest. 
 
Remark: The building and analysis of the ODE-based model and the comparison between 
the results from CTMC and ODE-based models were performed by P. Trairatphisan. 
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Probabilistic Model Checking of
the PDGF Signaling Pathway?
Qixia Yuan1,2, Panuwat Trairatphisan3, Jun Pang1??,
Sjouke Mauw1, Monique Wiesinger3, and Thomas Sauter3
1 Computer Science and Communications, University of Luxembourg, Luxembourg
2 School of Computer Science and Technology, Shandong University, China
3 Life Sciences Research Unit, University of Luxembourg, Luxembourg
Abstract. In this paper, we apply the probabilistic symbolic model checker PRISM
to the analysis of a biological system – the Platelet-Derived Growth Factor (PDGF)
signaling pathway, demonstrating in detail how this pathway can be analyzed in
PRISM. Moreover, we compare the results from verification and ODE simula-
tion on the PDGF pathway and demonstrate by examples the influence of model
structure, parameter values and pathway length on the two analysis methods.
1 Introduction
Biological systems consist of components, which interact to influence each other and
therefore the whole system’s behavior. The field of systems biology aims to under-
stand such complex interactions. Due to the similarity between biological systems and
complex distributed/reactive systems studied in computer science [2], modeling and an-
alyzing techniques developed in the field of formal methods can be applied to biological
systems as well [3]. Due to efficient verification techniques, formal methods can ana-
lyze large systems exhibiting complex behaviors – this process is typically supported
by automatic computer tools. This potentially gives formal methods an advantage, as in
silico experiments are much easier to perform than in vitro experiments for the aim of
analyzing and understanding biological systems. During the last decade, there has been
a rapid and successful development in applying formal methods to systems biology –
new formalisms are developed for systems biology to create models for biological phe-
nomena, new algorithms and tools are specially designed and tailored for the analysis
of such models (e.g., see [4–6]).
In this paper, we explore the usage of model checking for biological systems. Model
checking is referred to as the automatic process of checking whether a system model
satisfies a given specification (expressed as a temporal logic formula), by exhaustively
exploring all possible executions of the system. This differs from simulation-based tech-
niques, which only study a subset of the executions. More specifically, we focus on the
probabilistic (or stochastic) model checking approach [7, 8], first introduced by Hart,
? An extended abstract appears in the proceedings of CompMod 2011 [1]. The first two authors
made equal contributions to this work.
?? Corresponding author.
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Sharir and Pnueli [9], as biological systems usually have complicated stochastic behav-
iors. This technique is well-established and widely used for ascertaining the correct-
ness of real-life systems, including distributed systems and communication protocols.
In probabilistic (or stochastic) model checking, systems are normally represented by
Markov chains or Markov decision processes. Properties of the models are expressed
in quantitative extensions of temporal logics. In the literature, depending on the models
used, usually probabilistic model checking has its focus on discrete-timeMarkov chains
(DTMCs), while stochastic model checking deals with continuous-time Markov chains
(CTMCs). Stochastic verification, in particular, has gained notable success in analyzing
probabilistic systems including biological signaling pathways (e.g., see [10, 11]).
The stochasticity which occurs in biological signaling pathways can considerably
affect the changes of biological processes. For instance, the stochasticity of initial con-
ditions of caspases enzymes in the separatrix region can influence the cells to escape
or enter apoptotic process [12]. In this paper, we use the probabilistic model checker
PRISM [11] to yield a better understanding of the Platelet-Derived Growth Factor
(PDGF) signaling pathway. PDGF, described approximately 30 years ago as a major
mitogenic component of whole blood [13], is a growth factor that regulates cell growth
and division. It promotes angiogenesis and also preserves vascular integrity through the
recruitment of pericytes to endothelial tubes. Clinical studies reveal that aberrant ex-
pression of PDGF and its receptor is often associated with a variety of disorders such as
atherosclerosis, fibroproliferative diseases and most importantly, neoplasia [13]. Dereg-
ulation of the PDGF signaling pathway plays a critical role in the development of many
types of human diseases such as gastrointestinal stromal tumor and hypereosinophilic
syndrome [14, 15, 13, 16, 17]. Based on intensive literature review, we have built the
PDGF signal transduction model in ODE (Ordinary Differential Equation) format. The
essential part of the PDGF signaling pathway contains the coupling of PDGF ligand
to its receptor PDGFR, the negative regulatory mechanism on PDGFR and the activa-
tion of two main downstream signaling pathways, i.e., MAPK (Mitogen-Activated Pro-
tein Kinase) and PI3K/Akt pathways. In addition, there also exist positive and negative
crosstalk interactions between different downstream signaling pathways (more details
on the PDGF signaling pathway can be found in Sect. 3). In our study of the PDGF
pathway, there are three main goals: (1) to analyze the dynamics of PDGF induced
signaling, (2) to analyze the influence of the crosstalk reactions and (3) to analyze the
importance of individual reactions/molecules on downstream signaling molecules. The
first two can be used to check whether the constructed signaling pathway is consistent
with respect to biological data, while the last one can lead us to some prediction. We
have achieved these goals by stochastic verification using PRISM.
Moreover, we present the differences of the results obtained from ODE simulation
and stochastic verification on the PDGF pathway, and demonstrate by examples the
influence of model structure, parameter values and pathway length on the two analysis
methods. In particular, we show that the two methods can predict the results differently,
especially when parameter values are small.
Related work. There exists a large body of work on applying formal techniques to the
analysis of biological systems. We focus on the use of PRISM and probabilistic model
2
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checking in the literature, and other studies on the modeling and analysis of the PDGF
pathway.
Calder et al. [18] perform a case study on the the RKIP inhibited ERK pathway
using PRISM. Interestingly, they present a result stating that with a small number of
molecules simulation results of their stochastic CTMC model and the corresponding
ODE model are comparable. In this paper, we show that this result holds for the PDGF
signaling pathway even with only one instance for each molecule (see Sect. 6). In [19],
PRISM is used to study the MAPK cascade where a small subset of the MAPK path-
way was modeled. The authors explain how the biological pathway can be modeled in
PRISM and how this enables the analysis of a set of quantitative properties. In principle,
these studies are correlated to our work as both ERK pathway and MAPK cascade are
among the main components in the PDGF signaling pathway. However, the work [18]
focuses on the molecules in the ERK pathway, which is a part of the MAPK pathway,
and the results from [19] only cover the analysis for a subset of the long MAPK path-
way. In our study, we investigate a more general representation of the MAPK pathway
in PDGF signaling. Thus, these make the direct comparison of these studies to the re-
sults from our PDGF signaling pathway’s analysis infeasible.
Pronk et al. [20] apply PRISM to the biological problem of codon bias. They show
that the results obtained from the quantitative analysis in PRISM agree with the bio-
logical literature. Ribosome kinetics and aa-tRNA competition are modeled as CTMCS
analyzed in PRISM [21]. In [22], Kwiatkowska et al. use PRISM to analyze the FGF
(Fibroblast Growth Factor) signaling pathway. Although only a model corresponding
to a single instance of the pathway is built, it is still rich enough to explain the roles
of the components in the pathway and how they interact. The tunable activation thresh-
old hypothesis of T Cells is studied through computational modeling of T cell signaling
pathways in PRISM [23], and the authors demonstrate tuning and synergy. Jha et al. [24]
present the first algorithm for performing statistical model checking using Bayesian se-
quential hypothesis testing and test the algorithm on the FGF signaling pathway and
several others. More recently, Lio` et al. use PRISM to diagnose the emerging of bone
pathologies [25].
In addition, there are a few papers which apply the traditional methods in Systems
Biology to study the PDGF signaling pathway. Zhang et al. [26] model the survival
signaling in large granular lymphocyte leukemia, which is partly related to the PDGF
signaling, using a Boolean model of the network’s dynamics. Wang et al. [27] model
the crosstalk interaction between MAPK and PI3K/Akt pathways in ODE format. The
experimental data and the evidence of crosstalk reaction from [27] also partly contribute
to the model structure and the justification of the reactions in our work.
Outline of the paper. In Sect. 2, we give an overview of probabilistic model checking
and the tool PRISM. Sect. 3 describes the PDGF signaling pathway. In Sect. 4, we build
a model in PRISM for the PDGF signaling pathway and describe several properties of
the model that we are interested in. Our verification results are given in Sect. 5. In
Sect. 6, we compare stochastic verification and ODE simulation by investigating the
influence of model structure, parameter values and pathway length. Finally, we draw
the conclusions of this paper and discuss some future work in Sect. 7.
3
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2 Probabilistic Model Checking and PRISM
We briefly introduce stochastic verification and the model checker – PRISM [11].
2.1 CTMC and CSL
Probabilistic model checking is a variant of model checking, which aims at analyz-
ing the correctness of finite state systems with a focus on quantitative aspects. Model
checking of a system requires two inputs: a formal description of the system, which is
usually given in a high-level modeling formalism (e.g., Petri nets or process algebra)
and a specification of the system properties, which is usually given as temporal logic
(e.g., CTL or LTL) formulas. After accepting the two inputs, a model checking tool
then can verify whether the system satisfies the desired properties and give counter-
examples if the system does not satisfy a certain property, by exploring all possible
behaviors of the system exhaustively. As the word “probabilistic” indicates, probabilis-
tic model checking focuses on systems with stochastic behaviors. Instead of asking the
model checker “will the molecule become active in the end?”, we can ask “what is the
probability of the molecule being active at the steady state?” or “what is the probability
of the molecule being active at time instant t?”. In probabilistic model checking, sys-
tems are normally represented by Markov chains or Markov decision processes. In this
paper, we use continuous-time Markov chains (CTMCs) to build the signaling pathway
models and stochastic verification for thesis anlyses.
A CTMC can model both (continuous) real time and probabilistic choice by assign-
ing rates at transitions between states. The formal definition of a CTMC is given as
follows.
Definition 1. Let R 0 denote the set of non-negative reals and AP be a fixed finite set
of atomic propositions. A CTMC is a tuple (S,R, L) where:
– S is a finite set of states;
– R : S ⇥ S ! R 0 is a transition rate matrix;
– L : S ! 2AP is a labeling function which associates each state with a set of atomic
propositions.
The transition rate matrix R assigns rates to each pair of states, which are used as
parameters of the exponential distribution. A transition can occur between two states
s and s0 if R(s, s0) > 0, and the probability of the transition being triggered within
t time-units equals to 1   eR(s,s0)·t. If R(s, s0) > 0 for more than one state s0, the
first transition to be triggered determines the next state. Therefore, the choice of the
successor state of s is probabilistic. The time spent in state s before any such transition
occurs is exponentially distributed withE(s) =
P
s02S R(s, s
0). Hence, the probability
of moving to state s0 is R(s,s
0)
E(s) , i.e., the probability that the delay of going from s to s
0
“finishes before” the delays of any other outgoing transition from s. A path in a CTMC
is a sequence   in the form of s0t0s1t1 · · · with R(si, si+1) > 0 and ti 2 R 0 for all
i   0. The amount of time spent in si is denoted by ti.
For a CTMC, we consider two types of state probabilities: transient probability
is related to a state in the CTMC at a particular time instant, and steady probability
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describes the state of the CTMC in a long run. If we denote the state of the CTMC at
time t as X(t), the transient probability at time t is the probability that the CTMC is in
state s at time t, i.e., ps(t) = Pr{X(t) = s}. Intuitively, the steady-state probability
for being at state s is then defined as
ps = lim
t!1 ps(t).
Corresponding to CTMC models, we use Continuous Stochastic Logic (CSL) to
specify properties of built models. CSL, originally introduced by Aziz et al. [28], pro-
vides a powerful means to specify both path-based and traditional state-based perfor-
mance measures on CTMCs.
Definition 2. The syntax of CSL is given as follows:
  ::= true | a | ¬  |   ^   | P⇠p[ U I ] | S⇠p[ ]
where a is an atomic proposition, ⇠2 {<,, , >}, p 2 [0, 1], and I is an interval of
R>0.
CSL formulas are evaluated over the states of a CTMC. CSL includes the standard
operators from propositional logic: true (satisfied in all states); atomic propositions
(a is true in states which are labelled with a); negation (¬  is true if   is not); and
conjunction ( 1^ 2 is true if both  1 and  2 are true). Other standard boolean operators
such as disjunction ( 1 _  2 ⌘ ¬(¬ 1 ^ ¬ 2)) and implication ( 1 )  2 ⌘ ¬ 1 _
 2) can be derived from these in the usual way. CSL also includes two probabilistic
operators, P and S, both of which include a probability bound ⇠ p. A formula P⇠p[ ]
is true in a state s if the probability of the path formula  being satisfied from state s
meets the bound ⇠ p. A path formula evaluates to either true or false for a single path
in a model. In this paper, we use a simple type of the path formula, F I  ⌘ trueU I ,
called an eventual formula, which is true for a path   if   eventually becomes true for
some time instant t 2 I . Particularly, if the time interval is set to zero, e.g. F [t,t] ,
the formula is true for a path   if   becomes true at time instant t. The S operator is
used to specify steady-state behavior of a CTMC, i.e., its behavior in the long-run or
equilibrium. More precisely, S⇠p[ ] asserts that the steady-state probability of being in
a state satisfying  meets the bound ⇠ p. We refer the reader to the papers [29, 7, 8] for
model checking algorithms for computing steady-state probabilities.
2.2 The model checker PRISM
PRISM [11] is a model checking tool developed at the universities of Birmingham
and Oxford. It allows one to model and analyze systems containing stochastic behav-
iors. PRISM supports three kinds of models: discrete-time Markov chains (DTMCs),
continuous-time Markov chains (CTMCs) and Markov decision processes (MDPs).
Analysis is performed through model checking such systems against properties writ-
ten in the probabilistic temporal logics PCTL if the model is a DTMC or an MDP, or
CSL in the case of a CTMC, as well as their extensions for quantitative specifications
and costs/rewards.
5
Chapter 7.4: Probabilistic model checking of the PDGF signalling pathway   201 | P a g e  
 
In PRISM a model consists of a number of modules that contain variables and can
interact with each other. The values of the variables at any given time constitute the
state of the module, and the local states of all modules decide the global state of the
whole model. The behavior of a module, normally the changes in states which it can
undergo, is specified by a set of guarded commands of the form:
[a] g ! r : u;
a is an action label in the style of process algebra, which introduces synchronization
into the model. It can only be performed simultaneously by all modules that have an
occurrence of action label a. If a transition does not have to synchronize with other
transitions, then no action label needs to be provided for this transition. The symbol
g is a predicate over all the variables in the system. A guarded command g ! r : u
means that if the guard g is true, the system is updated according to u with rate r,
which is corresponding to the transition rate of CTMC. A transition updates the value
of variables by giving their new value of the form x0 = expr, where x is a variable and
its primed version x0 refers to the value of x in the next state, expr is an expression built
on the unprimed variables. If an update does not contain x0 = ..., then the value of the
variable x remains unchanged.
PRISM models can be augmented with information about rewards (or equivalently,
costs). The tool can analyze properties which relate to the expected values of these
rewards. A CTMC in PRISM can be augmented with two types of rewards: state reward
associated with states which are accumulated in proportion to the time spent in the
state, and transition reward associated with transitions which are accumulated each
time the transition is taken. CSL is extended with quantitative costs/rewards as well,
which is quite useful in analyzing the quantitative properties of a biological system, by
introducing the R operator:
R ::= R⇠r[I=t] | R⇠r[Ct] | R⇠r[F ] | R⇠r[S]
where ⇠2 {<,, , >}, r, t 2 R 0 and   is a CSL formula. Intuitively, a state s sat-
isfies R⇠r[I=t] if from s the expected state reward at time instance t meets the bound
⇠ r; a state s satisfies R⇠r[Ct] if the expected reward accumulated up until t time
units past satisfies ⇠ r; a state s satisfies R⇠r[F ] if from s the expected reward ac-
cumulated before a state satisfying   is reached meets the bound ⇠ r; and a state s
satisfies R⇠r[S] if from s the long-run average expected reward satisfies ⇠ r.
It is often useful to take a quantitative approach – computing the actual probability
that some behavior of a model is observed, rather than just verifying whether or not
the probability is above or below a given bound. Hence, PRISM allows the P and S
operators in CSL to take the following form: P=?[ ] and S=?[ ].
3 The PDGF Signaling Pathway
3.1 Biology of the PDGF signaling pathway
Cell signaling is part of a complex system in cellular communication. It allows the
cells to activate a large number of signaling molecules and to regulate their activity. In
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order to transfer a regulatory signal upon reception of a triggering stimulus, the signal
is transformed into a chemical messenger within the signaling cell, e.g., via transfer of
a phosphate group (phosphorylation) [30]. For further details on cell signaling see, for
example, [31, 30].
Platelet-Derived Growth Factor (PDGF), described approximately 30 years ago as
a major mitogenic component of whole blood [13], is a growth factor that regulates cell
growth and division. By binding to its receptor (PDGFR), it regulates many biological
processes such as migration, survival and proliferation [32]. PDGFR is a receptor tyro-
sine kinase, which in general transfers upstream signals to many downstream signaling
pathways by phosphorylation. Up to now, five pairs of PDGF which can be formed as
a molecule that can bind with its receptor to form a complex (or so called ‘ligand’)
are known, PDGF-AA, -AB, -BB, -CC, -DD, interacting with three different types of
PDGFR complexes, PDGFR-↵↵, -↵  and -  . Each of the PDGFR subtypes has a dif-
ferent affinity to the different PDGF ligands [33].
After PDGFRs couple with their respective ligands, phosphorylation of the recep-
tor at specific tyrosine residues will occur, thus enabling binding of signaling enzymes
including Src, phosphatidylinositol 3 kinase (PI3K), phospholipase C  (PLC ) and
SHP2 in the MAPK pathway at specific binding sites. The recruitment of these sig-
naling enzymes to PDGFR is mediated via an intrinsic SH2 domain. The translocation
of PI3K and PLC  to the plasma membrane also increases their accessibility to their
respective substrates. Moreover, recent findings suggest that PDGFR also has potential
binding sites for CrkL [34], which will activate Rap1 to positively influence c-Raf in
the MAPK pathway [35], for Signal Transducer and Activator of Transcription (STAT),
which might regulate the signal in parallel to the JAK-STAT pathway [36] and also for
cCbl, which promotes ubiquitination of PDGFR. cCbl is also considered to be one of
the negative regulatory molecules in PDGF signal transduction [37].
3.2 Model structure of the PDGF signaling pathway
Based on intensive literature reviews, we have built a PDGF signal transduction model
in ODE format which consists of 17 molecules (see Fig. 1). The model consists of the
main parts from the PDGF signaling pathway including the coupling of PDGF ligand
to PDGFR, the negative regulatory feedbacks on PDGFR and the activation of two main
downstream signaling pathways, the MAPK and PI3K/Akt pathways, with the crosstalk
interactions between the two pathways. The scope of our model with 17 nodes is suf-
ficient to capture the main dynamic behavior of the PDGF signaling pathway which is
further analyzed in PRISM.
Fig. 1 describes how signals are transduced in the PDGF pathway by activating or
deactivating specific downstream pathways signaling molecules. In this model, there are
three inputs, viz. PDGFL (PDGF ligand), bPTEN, and bPDK. PDGFL is the node which
represents the upstream molecule activating the whole network. PPX, and bPTEN are
nodes which represent phosphatase enzymes in the cytoplasm that negatively regulate
their targets. Lastly, bPDK, standing for basal activity of PDK, is the node that con-
stantly gives a basal additional input to PDK node. This node is always active in order
to activate the survival pathway to counteract apoptotic signaling and keep the cell sur-
vive at a basal level. There are three different types of arrows in the network: blue
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Fig. 1. The extracted PDGF signaling pathway (blue arrows: main pathway, green arrows: positive
crosstalk, red arrows: negative regulatory)
arrows, green arrows and red arrows. The blue arrows represent the main activating in-
teractions, indicating the two main downstream signaling pathways in the network. The
MAPK pathway covers SHP2, Grb2SOS, Gab2SOS, Ras, c-Raf and MEK12. These
molecules play a major role in the cellular proliferative circuit [38]. The PI3K/Akt path-
way covers the molecules PI3K, PIP3, PDK, bPTEN, bPDK and Akt. In addition, this
pathway closely interacts with the MTOR node which represents the mTOR pathway
through positive feedback regulation. Both of these pathways play a major role together
in the viability circuit of the cells [38]. The green arrows represent positive crosstalk
interactions to the molecules the arrows point to. Lastly, the red arrows represent either
negative crosstalk interactions or other negative regulatory interactions. The molecules
will become active after they have been activated by either blue or green arrows. In
contrary, the molecules will become inactive after they have been deactivated by the
red arrows or the basal phosphatase activities in the cell (not shown in the figure).
PDGFR can be activated by PDGFL. The active PDGFR in turn activates three down-
stream molecules which are SHP2, PI3K and cCbl. Both SHP2 and cCbl assert
a negative feedback to PDGF making it inactive. The three blue arrows connecting
PDGFR to these downstream signaling molecules, so called mutant arrows, are the
targets of system interventions both experimentally and computationally. The experi-
mental intervention can be performed by introducing a point mutation from tyrosine to
phenylalanine at the specific recruitment site for the downstream signaling enzyme, for
8
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instance, Y720F for SHP2 recruitment site, YY731/742FF for PI3K recruitment site,
and Y1018F for cCbl recruitment site, leading to the loss of signal capacity of the re-
spective signaling pathway [39–41]. Thus, the result of computational simulation such
as the relative activities at the steady state of downstream signaling molecules from
these respective mutants can be validated experimentally in biological laboratories.
After the upstream signaling molecules, SHP2 and PI3K, have been activated, they
transfer the signal via the phosphorylation process to downstream signaling molecules.
In the MAPK pathway, the process starts from the transfer of the signal from SHP2
to Grb2SOS and Gab2SOS. Then, the two molecules in turn transfer the signal to
H-Ras, c-Raf, and MEK12, respectively. There is also a negative feedback regulation
from MEK12 to Grb2SOS to modulate the signal in this pathway. In the PI3K/Akt
pathway, the signal transfer starts from PI3K to PIP3 which then in turn activates
PDK and Akt. PIP3 can be deactivated by the phosphatase enzyme PTEN (represented
as bPTEN) and the node PDK can get additional input from the basal activity of itself
(represented as bPDK). At the downstream part of the PI3K/Akt pathway, the node Akt
can be activated by either PDK or PIP3 and it also forms a positive feedback loop with
the mTOR pathway which was represented as the MTOR node.
In addition to the activation and regulation within each pathway, there are also sev-
eral crosstalk reactions between the two pathways. These are the positive crosstalk reg-
ulations from PI3K to MEK12, from PIP3 to Gab2SOS, and a positive feedback loop
between PI3K and H-Ras. In parallel, there are also negative regulations from Akt to
Gab2SOS and c-Raf. These crosstalk reactions modulate the signals between the two
pathways to generate a robust network.
Fig. 2 contains the list of model reactions. Each molecule is simplified to be in two
states, either inactive or active (indicated by the suffix act in the figure). All the re-
actions except for reactions 9, 10 and 11 describe the molecules changing between the
two states; while reactions 9, 10 and 11 indicate the basal production, the basal degra-
dation and the internalization following activation of PDGFR. For instance, reaction 2
describes that an active PPX gives a negative feedback to PDGFR, making it inactive.
3.3 Conversion of the interaction graph to a reaction-based ODE model
Generally, we can generate a set of biochemical reactions to represent the interactions
for each molecule based on the interaction graph presented in Fig. 1. Nevertheless, the
strengths of both activation/phosphorylation and inhibition/dephosphorylation interac-
tions for each molecule are different. Therefore, during the conversion process of an
interaction graph to biochemical reactions, a consistent procedure is applied to deter-
mine the biochemical reactions as well as the parameter values. In this section we will
explain this procedure in some detail.
In our study, we assigned the parameter set based on the knowledge derived from the
literature (e.g., [14, 15, 13, 16, 17]) and our own experimental observation of PDGFR↵
mutant. We also obtained the information that the time constants of the MAPK and
PI3K/Akt pathways are comparable as shown in [27]. The experimental data in [27]
shows that the time for the MAPK pathway to activate ERK12 (the molecule below
MEK12) and the time for the PI3K/Akt pathway to activate Akt are highly similar.
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a. PDGFR and PPX
1) PDGFL + PDGFR! PDGFR act + PDGFL kon
2) PDGFR act + PPX act! PDGFR + PPX act koff1
3) PDGFR act + SHP2 act! PDGFR + SHP2 act koff2
4) PDGFR act + cCbl act! PDGFR + cCbl act kubi
5) PDGFR act + PPX act! PPX + PDGFR act koffppx
6) PDGFR act + cCbl! cCbl act + PDGFR act k1
7) PDGFR act + SHP2! SHP2 act + PDGFR act k5
8) PDGFR act + PI3K! PI3K act + PDGFR act k6
9) ! PDGFR kbasal
10) PDGFR! kbasal
11) PDGFR act! kdeg
b. SHP2, Grb2SOS and Gab2SOS
12) SHP2 act + Grb2SOS! Grb2SOS act + SHP2 act k52
13) SHP2 act + Gab2SOS! Gab2SOS act + SHP2 act k522
14) SHP2 act! SHP2 kp5
15) Grb2SOS act + H-Ras! H-Ras act + Grb2SOS act k53
16) Grb2SOS act! Grb2SOS kp52
17) MEK12 act + Grb2SOS act! Grb2SOS + MEK12 act kcross1
18) Gab2SOS act + H-Ras! H-Ras act + Gab2SOS act k532
19) Gab2SOS act! Gab2SOS kp522
20) PIP3 act + Gab2SOS! Gab2SOS act + PIP3 act kcross2
21) Akt act + Gab2SOS act! Gab2SOS + Akt act kcross3
c. H-Ras, c-Raf and MEK12
22) H-Ras act + c-Raf! c-Raf act + H-Ras act k54
23) H-Ras act! H-Ras kp53
24) PI3K act + H-Ras! H-Ras act + PI3K act kcross4
25) H-Ras act + PI3K! PI3K act + H-Ras act kcross9
26) c-Raf act + MEK12! MEK12 act + c-Raf act k55
27) c-Raf act! c Raf kp54
28) Akt act + c-Raf act! c-Raf + Akt act kcross6
29) MEK12 act! MEK12 kp55
30) PI3K act + MEK12! MEK12 act + PI3K act kcross7
d. PI3K, PIP3 and PDK
31) PI3K act + PIP3! PIP3 act + PI3K act k62
32) PI3K act! PI3K kp6
33) PIP3 act + PDK! PDK act + PIP3 act k63
34) PIP3 act + Akt! Akt act + PIP3 act k64
35) PIP3 act + bPTEN! PIP3 + bPTEN kp62
36) bPDK + PDK! PDK act + bPDK k632
37) PDK act + Akt! Akt act + PDK act k642
38) PDK act! PDK kp63
e. Akt, cCbl, MTOR, bPTEN and bPDK
39) MTOR act + Akt! Akt act + MTOR act k643
40) Akt act + MTOR! MTOR act + Akt act k644
41) Akt act! Akt kp64
42) cCbl act! cCbl kp1
43) MTOR act! MTOR kp642
Fig. 2. List of biochemical reactions in the PDGF signaling pathway ODE model with respective
parameters in tab-separated format
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All parameters are assigned as relative values in the range of zero to one, compared
to the sum of all positive reaction rates around the respective molecule. We believe
that this assignment could still capture the real reaction rates on the same molecule.
Moreover, these parameter values should be able to represent the rates which are com-
parable to another signaling pathway as the time constants between the two signaling
pathways are relatively similar. In general, we follow Kwiatkowska et al.’s work [10,
11] on translating kinetic rates to stochastic rates. Namely, for first-order (non-binary)
reactions they take the stochastic rate to be the kinetic rate; for binary reactions, assum-
ing that the kinetic rate is given in terms of molar concentrations, the stochastic rate
can be obtained by dividing by the product of the volume and Avogadro’s number [42].
In the case of bimolecular reactions (second order) modeled by the standard law of
mass action as used in our paper (e.g., reactions 2-8), the kinetic rate and the stochastic
rate are equal if the states are normalized to the maximal value (as done in our paper),
according to the conversion of mole in chemistry.
To assign the parameter set, the reaction rate of that respective reaction is equal to
one if only one molecule which activates the respective node is present. For example,
the node SHP2 is solely activated by PDGFR once PDGFR is active (PDGFR act). Thus,
the biochemical reaction for the activation of the node SHP2 is generated as follow:
PDGFR act + SHP2
k5 ! SHP2 act + PDGFR act
SHP2 will only be activated by PDGFR act. Therefore, the respective parameter k5 is
assigned to 1.0. This rule is also applied to all nodes which have only one positive inter-
action on the interaction graph such as cCbl or MTOR. Apart from this, the activity of
the node SHP2 is also under the influence of the activities of cytoplasmic phosphatase
enzymes which dephosphorylate the active form of SHP2 (SHP2 act) resulting in the
dephosphorylated/inactive state (SHP2). This is represented in the following biochem-
ical reaction:
SHP2 act
kp5  ! SHP2
From biological observation, the reaction rate of the phosphorylation process is sig-
nificantly higher than the rate of the dephosphorylation process [43]. In our study, it
is assumed that the sum of the dephosphorylation strength for each molecule by cy-
toplasmic phosphatase enzymes in general is roughly 10% compared to the maximal
phosphorylation strength. Therefore, parameter kp5, as well as all kp-parameters which
represent the constant parameters for the dephosphorylation process, are all set to 0.1.
In this case, we can derive an ODE for the SHP2 act node as follows:
d/dt(SHP2 act) = k5 ⇥ PDGFR act ⇥ SHP2   kp5 ⇥ SHP2 act
In another case, if there is more than one positive interaction on a single node in
the interaction graph, we assume that the sum of all activation parameters is equal to
one. In this situation, we additively consider the strength of each interaction according
to their interaction strengths derived from the literature, without considering synergistic
effects. These interaction strengths are then considered in term of relative values which
have been assigned to each parameter accordingly. In general, the reaction rate of the
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canonical pathway (the main pathway of activation) is always higher than the rate of
other additional inputs such as crosstalk reactions or basal activities. For instance, node
PDK can be activated by node PIP3 with an interaction strength of 90%, while it can
also be activated by node bPDK which represents the basal activity of PDK by 10%. In
this case, two biochemical reactions of PDK node activation are generated as follows:
PIP3 act + PDK
k63  ! PDK act + PIP3 act
bPDK + PDK
k632   ! PDK act + bPDK
In this case, parameter k63 has been assigned to 0.9 while parameter k632 has been
assigned to 0.1, according to their interaction strengths as mentioned. When also con-
sidering the dephosphorylation rate, we could derive an ODE for the PDK act node as
follows:
d/dt(PDK act) = k63⇥ PIP3 act ⇥ PDK + k632 ⇥ bPDK ⇥ PDK
  kp63 ⇥ PDK act
The same rule is also applied to nodes with the same type of interaction such as H-Ras
or Akt.
In the most complex case, in the situation that there are both positive and negative
interactions on a single node, special consideration and assignment are applied. First,
we separate the positive and negative interactions and we consider only the strength of
all positive interactions as a sum value of one. Then, we consider the proportion of neg-
ative interaction to deactivate/dephosphorylate the molecule in addition to the activities
from cytoplasmic phosphatase enzymes with the parameter values according to their
inhibition strengths. To give an example, node Gab2SOS is activated by two nodes
which are SHP2 with a strength of 80% and PIP3 with strength 20%, according to
the maximal activation strength. Node Gab2SOS is also deactivated by node Akt with
strength 20% and by cytoplasmic phosphatase enzymes with strength 10%, according
to the maximal activation. All biochemical reactions which are related to the changing
states of the Gab2SOS node are shown as follows:
SHP2 act +Gab2SOS
k522   ! Gab2SOS act + SHP2 act
PIP3 act +Gab2SOS
kcross2     ! Gab2SOS act + PIP3 act
Akt act +Gab2SOS act
kcross3     ! Gab2SOS + Akt act
Gab2SOS act
kp522    ! Gab2SOS
As already mentioned, the parameters for the positive interactions from SHP2 and
PIP3 are firstly considered and they have been assigned to each reaction with a sum of
1.0. In this case, parameter k522 is assigned to 0.8 and parameter kcross2 is assigned to
0.2. Then, the additional negative interaction from Akt is considered and the respective
parameter is assigned. Thus, parameter kcross3 is assigned to 0.2. Lastly, the basal de-
phosphorylation activity from cytoplasmic phosphatase enzymes which is represented
by parameter kp522 is assigned to 0.1. In this case, an ODE is derived for Gab2SOS act
node as follows:
d/dt(Gab2SOS act) = k522 ⇥ SHP2 act ⇥Gab2SOS   kp522 ⇥Gab2SOS act
+ kcross2 ⇥ PIP3 act ⇥Gab2SOS
  kcross3 ⇥ Akt act ⇥Gab2SOS act
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After we applied this procedure to convert the interaction graph to a biochemical
reaction-based ODE model, we obtained a set of biochemical reactions as well as the
respective parameter set for our modeling analysis in PRISM.
3.4 Sensitivity analysis of the derived ODE model
As mentioned in Sect. 3.3, the parameter set which has been derived from the inter-
action graph integrated with knowledge from the literature and our own experimental
observations might not fully correlate to the actual biological system. Nevertheless, the
dynamic behavior of the system is still conserved in the model structure. In this sec-
tion, we present the results from the sensitivity analysis to confirm the validity of this
statement.
After we obtained the ODEmodel from the interaction graph, we imported the ODE
model into Matlab using Systems Biology Toolbox 2 [44] where a global parameter sen-
sitivity analysis with the FAST method is integrated [45]. The analysis was performed
by perturbing all parameter values to observe how the state values would differ based on
the perturbation. The perturbation scale used in this analysis is one order of magnitude
(for instance, from 1 to 10 or to 0.1).
Fig. 3. Sensitivity analysis of the derived ODE model for some selected parameters
In Fig. 3, we see that some states are sensitive to the change of specific parameters.
For instance, PI3K act is sensitive to k6 and Ras act is sensitive to kp53. In parallel,
we observe that there is no state, except for PPX act, which is sensitive to the change
of kcross4. In contrast, there are also many states which are sensitive to a change of a
single parameter. For example, kon, which is the parameter involved with the activation
of PDGFR by PDGF ligand and in turn activates the whole system, contributes to the
changes of many activated form of molecules in the model when this parameter value is
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perturbed. Based on this study, we identified the sensitive pairs of states and parameters
such as PI3K act which is sensitive to k6, Ras act which is sensitive to kp53 and most
of the molecules in activated states which are all sensitive to kon. In addition, we also
identified the insensitive pairs, such as Ras act which is insensitive to kcross4.
Next, we challenged the system by increasing and decreasing selected parameter
values from each pair up to 50%. For instance, the original kon parameter value of 1
was perturbed to 1.5 and 0.5, respectively. Then, the states trajectories of the respective
molecules were plotted to observe the change of systems behavior according to the
changes of the corresponding parameter values (see Fig. 4, 5 and 6).
(a) PI3K act concentration when k6 changes
from 25% to 50% (original k6 = 0.85)
(b) Ras act concentration when k6 changes from
25% to 50% (original kp53 = 0.1)
Fig. 4. Sensitivity analysis of PI3K act concentration vs. k6 and Ras act concentration vs. kp53
From the results in Fig. 4, we observe the changes of the steady state values of
PI3K act and Ras act which are related to changes of parameter values of k6 and kp53
accordingly. Nevertheless, we still see that the dynamic change of the molecules which
are reflected by the shapes of the figures remained mostly the same. The same observa-
tion can be made for Fig. 5 where the kon parameter is perturbed and the state changes
of PDGFR act, SHP2 act, PI3K act, MEK12 act and Akt act are observed. Here, we
see that PDGFR act is activated slower and weaker (when kon = 0.5), or faster and
stronger (when kon = 1.5), according to the kon values. Nevertheless, the dynamic
changes (shape of the figures) as well as the steady state values of PDGFR act, up-
stream molecules (SHP2 act and PI3K act) and downstream molecules (MEK12 act
and Akt act) were not drastically changed. Moreover, the order of steady state val-
ues of these molecules is still preserved (Akt act > MEK12 act > PI3K act >
SHP2 act > PDGFR act), even though the parameter value has been perturbed up to
50%. In parallel, when we plotted the state change of Ras act after the perturbation on
kcross4, little changes are observed as shown in Fig. 6, because Ras act is insensitive
to the change of this parameter. According to these results, we find that the decision to
normalize the reaction rates in the interval between 0 and 1 is sensible to observe the
dynamic changes of the systems which have been conserved within the model structure.
14
 
210 | P a g e   Chapter 7.4: Probabilistic model checking of the PDGF signalling pathway 
 
Fig. 5. Sensitivity analysis of the concentrations of PDGFR act, SHP2 act, PI3K act,MEK12 act
and Akt act vs. kon
Fig. 6. Sensitivity analysis of Ras act concentration when kcross4 changes from 25% to 50%
(original kcross4 = 0.05)
4 Modelling and Property Specifications in PRISM
4.1 PRISM model
We now describe in detail how to build a PRISMmodel for the PDGF signaling pathway
as presented in the previous section. Though our model represents a single instance of
the signaling pathway, meaning there can be at most one element of each molecule,
we believe it is still rich enough to explain the roles of the molecules in the pathway
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and how they interact with each other as shown in the literature [22]. In the single
instance model, a molecule’s steady state, which is expressed as a probability in PRISM,
potentially corresponds to the molecule density in the biological experiments.
module PDGFR
PDGFR : [0..2] init 0; //0 – inactive; 1 – active; 2 – degraded
[] PDGFL & PDGFR=0! kon : (PDGFR’=1);
[bkoff1] PDGFR=1! koff1 : (PDGFR’=0);
[bkoff2] PDGFR=1! koff2 : (PDGFR’=0);
[bkubi] PDGFR=1! kubi : (PDGFR’=0);
[bkoffppx] PDGFR=1! koffppx : (PDGFR’=1);
[bk1] PDGFR=1! k1 : (PDGFR’=1);
[bk5] PDGFR=1! k5 : (PDGFR’=1);
[bk6] PDGFR=1! k6 : (PDGFR’=1);
[] PDGFR=0! kbasal : (PDGFR’=2); //PDGFR degraded
[] PDGFR=2! kbasal : (PDGFR’=0);
[] PDGFR=1! kdeg : (PDGFR’=2); //PDGFR act degraded
endmodule
(a) PRISM module for PDGFR
module PPX
PPX : [0..1] init 1;
[bkoff1] PPX=1! (PPX’=1);
[bkoffppx] PPX=1! (PPX’=0);
endmodule
(b) PRISM model for PPX
rewards
“PDGFRactive”
PDGFR=1:1;
endrewards
(c) PRISM rewards
Fig. 7. PRISM modules and rewards
Each of the nodes (or molecules) of the pathway in Fig. 1, except for the PDGFL, is
represented by a separate PRISM module. Since PDGFL, bPTEN and bPDK remain the
same after the reactions they are involved in, we set them as constant boolean values
true. Fig. 7(a) and Fig. 7(b) show the modules for PDGFR and PPX. In each of the
modules, the status of the molecule is represented by a variable with the same name as
the module. The variables can have values of either 0 or 1 (PDGFR is an exception, be-
cause it can have value 2 since it can degrade), corresponding to the two states, inactive
and active, of a molecule. Each command in the PRISM module represents a reaction
in Fig. 2. Interactions of multiple molecules are implemented by the synchronization
between modules. More precisely, the same label is given to the commands which re-
quire synchronization in PRISM modules. For example, in Fig. 7(a) and Fig. 7(b), there
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are commands with label bkoff1 in both of the modules PDGFR and PPX. The two
commands are used to model the reaction (2) in Fig. 2, which involves both PDGFR and
PPX. It guarantees that the two commands (corresponding to one reaction) can only
occur when both guards are satisfied. The reaction rate is assigned by the command in
module PDGFR and hence the reaction rate of the command in module PPX is omitted.
We have modeled all the 17 molecules in 14 PRISM modules (PDGFL, bPTEN and
bPDK are modeled as a constant).
As mentioned in Sect. 2.2, PRISM models can be augmented with information
about rewards. We construct rewards to calculate the time for a molecule being ac-
tive. Fig. 7(c) shows the rewards for calculating the active state of PDGFR. Each time
PDGFR is in its active state, one is added to the total time of PDGFR being active. Sim-
ilarly, we build rewards structures for other molecules as well, including SHP2, Ras,
MEK12, PIP3 and Akt.
4.2 Property specifications
As stated in the introduction, the three main goals for this study are: (1) to analyze
the dynamics of PDGF induced signaling, (2) to analyze the influence of the crosstalk
reactions as defined in Sect. 3, and (3) to analyze the importance of individual reactions
on downstream signaling molecules. For the first goal, we study the signal transduction
properties of each mutant by removing the mutant arrows one by one and examining
how the states of each molecule change accordingly at different time instances. We also
examine the total time for each molecule being active. Moreover, it is interesting to
study the activities of each molecule at the steady state as well. For the second goal,
we do the comparison of probabilities for molecules to be active between different
mutants by removing each of the crosstalk reactions. For the last one, we study how the
steady state probabilities of molecule MEK12 and Akt change when a certain reaction
is removed.
Below we list the properties of the PRISM model that we have analyzed to achieve
our goals. Here, we use only the molecule PDGFR to illustrate the specification of the
properties expressed as CSL formulas.
– P=?[F [t,t]PDGFR = 1 ]
The probability that the molecule PDGFR is active at time instant t.
– R{“PDGFRactive”}=? [C <= t]
The expected time of PDGFR being active by time t. It refers to the reward structure
“PDGFRactive” as defined in Fig. 7(c).
– S=?[ PDGFR = 1 ]
The long-run probability that PDGFR is active.
5 Verification Results
We use PRISM to construct the PDGF model described in Sect. 4.1 and analyze the set
of properties listed in Sect. 4.2. We describe how to achieve our goals as explained in
Sect. 1 in the following subsections.
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5.1 Analyzing the dynamics of PDGF induced signaling
For the first goal to analyze the dynamics of PDGF induced signaling, we first develop
a base model representing the system, in which all the reactions in Fig. 2 are included.
Subsequently, we obtain the mutant models by removing the mutant arrows (as men-
tioned in Sect. 3) one by one. More precisely, we have developed four models in this
experiment including the base model corresponding to the WildType condition. The
second one, called SHP2Mutant, is obtained by removing the mutant arrow pointing
to SHP2. The third and the fourth ones are PI3KMutant and cCblMutant. Fol-
lowing the same process, we remove the mutant arrows pointing to PI3K and cCbl
separately in the last two models. The three removed mutant arrows correspond to the
reactions (7), (8) and (6) in Fig. 2. For each model, we compute the probability of each
molecule being active at time instance t, which is summarized in Fig. 8.
(a) PDGFR (b) SHP2
(c) Ras (d) PIP3
(e) MEK12 (f) Akt
Fig. 8. PRISM verification results: Probabilities for molecules being active
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Fig. 8 shows the probability of 6 out of the 17 molecules namely PDGFR, SHP2,
Ras, PIP3, MEK12, and Akt. The 6 molecules are chosen according to their positions
in the signaling pathway. We can see from Fig. 8(a) that cCbl affects PDGFRmore than
the other two molecules (SHP2 and PI3K). This is due to strong negative feedback
(red arrow) from cCbl to PDGFR in Fig. 1. There is also a negative feedback from
SHP2 to PDGFR. However, the reaction rate of the negative feedback from cCbl is 7
times as large as the one from SHP2, hence cCbl can affect PDGFR more than SHP2.
In contrast, there would be no effect of PI3KMutant to PDGFR as there is neither
a direct regulatory signal from PI3K on PDGFR nor indirect regulation through the
molecule which can regulate PDGFR such as SHP2 or cCbl. Apart from this, the red
curve in Fig. 8(d) shows that not only PIP3 in PI3KMutant is less active than in other
conditions, but also the time of it becoming active is delayed. In biological experiments,
this delay is not observed. This is due to the fact that there is another molecule PLCg
giving a fast positive crosstalk to PI3K. This interaction is outside of the scope of the
PDGF model we consider here.
If we focus on the light blue curves in Fig. 8(a) – Fig. 8(f), we can see that cCbl has
much impact on PDGFR but little impact on the other molecules. This is because after
PDGFR activates SHP2 and PI3K, the states of the other molecules are determined by
SHP2 and PI3K. Furthermore, from the green curve of Fig. 8(b), Fig. 8(c) and Fig. 8(e),
we see that SHP2 has great effect on the status of the molecules on the MAPK pathway.
However, the more downstream the molecule is, the less prominent the effect becomes
(the effect to MEK12 is less than that to Ras). Due to the influence of the positive
feedback from PI3K and PIP3, the molecules in the MAPK pathway can also become
active without SHP2, which is the result from positive crosstalk interactions. Besides,
the red curves of Fig. 8(d) and Fig. 8(f) show that the influence of PI3K to the molecules
in the PI3K/Akt pathway is still present due to the positive feedback from Ras.
We analyze the long-run probability of the molecules being active after PDGFL
stimulation (shown in Tab. 1). The result demonstrates the activities of each molecule
in this model in WildType condition. In the table, we observe that the two downstream
signaling molecules, MEK12 and Akt, have high long-run probabilities, i.e., 0.77 and
0.82, respectively. This is sensible in the real biology as these two signaling molecules
should be at sufficiently high concentrations after PDGF ligand activation in order to
push the cell toward proliferation and to keep the cell survive from apoptotic process.
In addition, we also observe high steady state probabilities on PDK and MTOR which
might be a result from the accumulative effect from the basal activity and the positive
feedback loop, in addition to the activation from PDGF ligand. In the mutants situations,
we expect to observe different steady state probability of each molecule which would
then affect the cell fate decision differently in each condition.
PRISM supports reward properties (see Sect. 4). Fig. 9 shows the expected time of
six molecules being active by time instant t. These six molecules are the same as in
Fig. 8. All the six curves tend to be linear after time instant 12, which shows that the 6
molecules start to be in a steady state after time instant 12.
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Molecule Probability Molecule Probability
PDGFR 0.22 Grb2SOS 0.55
SHP2 0.45 Ras 0.72
Gab2SOS 0.53 MEK12 0.77
c-Raf 0.63 PIP3 0.72
PI3K 0.62 Akt 0.82
PDK 0.83 MTOR 0.84
cCbl 0.47 PPX 0
Table 1. PRISM verification results: Steady state probabilities of molecules
5.2 Analyzing the influence of the crosstalk reactions
For the second goal, to analyze the influence of the crosstalk reactions, the experi-
ment is also performed as in silico genetics. After developing the base model, we get
the model variants by removing one crosstalk arrow at a time. In total, there are four
positive crosstalk reactions (green arrows) and two negative crosstalk reactions (red ar-
rows pointing from Akt). In this analysis, we focus on the positive crosstalk from Ras
to PI3K and the negative crosstalk from Akt to c-Raf. More precisely, we develop
three models in this experiment. The first one is the base WildType model with all
reactions included. The second one is the RasPI3KMutant model, in which the pos-
itive feedback from Ras to PI3K is removed. The last one is the Aktc-RafMutant
model, in which the negative feedback from Akt to c-Raf is removed. After build-
ing the three models, we analyzed the influence of the two crosstalks by comparing the
WildType model to the two mutant models, respectively.
Fig. 9. PRISM verification results: Expected time of being active by time t
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(a) Positive crosstalk from Ras to PI3K (b) Negative crosstalk from Akt to c-Raf
Fig. 10. PRISM verification results: Influence of crosstalks
Fig. 10 shows the results of the comparison. In both sub-figures, we compare the
molecules which are directly related to the crosstalk arrows and the molecules at the
end of the related main signaling pathways. In Fig. 10(a), we compare in each model
the probabilities for molecules PI3K and Akt being active, which is at the end of
the PI3K/Akt pathway; while in Fig. 10(b) we have chosen the molecules c-Raf and
MEK12, which is at the end of the MAPK pathway. The dark blue and green curves
in Fig. 10(a) show how the green arrow influences the status of PI3K. If there is no
positive crosstalk, the probability of PI3K being active (green curve) becomes smaller.
The two curves are coincident for a time period because the molecule Ras needs some
time to become active before it can activate PI3K. The red and light blue curves show
that the influence of the positive feedback on Akt is smaller than that on PI3K. Just like
the situation in Fig. 8(b), Fig. 8(c) and Fig. 8(e), the more downstream the molecules
are, the smaller the influence becomes. The results in Fig. 10(b) are similar: the dark
blue and green curves show that the influence the negative crosstalk gives to Ras is
significant; while the positive crosstalk has little influence on MEK12.
5.3 Analyzing the importance of individual reactions
For the last goal to analyze the importance of individual reactions on downstream sig-
naling molecules, we compute the steady state probabilities of Akt and MEK12 in 31
different models (called an edge knockout study), each of which is obtained by removing
one reaction from the wildtype model. For example, the ‘PIP3-Gab2SOS’ model
is obtained by removing reaction No. 20 in Fig. 2). The results are shown in Fig. 11. In
parallel to the edge knockout study, we have also computed the steady state probabil-
ity of Akt and MEK12 in 17 different models (called a node knockout study), each of
which is obtained by removing all related interactions around each node. For instance,
the interactions between PDGFR, H-Ras, PIP3 and MEK12 to PI3K are all omitted in
the ‘PI3K-KO’ model. The results are shown in Fig. 12. By adding a horizontal and a
vertical line through the dot of the wildtype model, we divide these figures into four ar-
eas. Apparently, the dots in different areas show that the removed reactions/nodes have
different influences on the steady state probabilities of Akt and MEK12. For instance,
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Fig. 11. PRISM verification results: Steady state probabilities of Akt and MEK12 in different
edge knockout models
Fig. 12. PRISM verification results: Steady state probabilities of Akt and MEK12 in different
node knockout models
the reactions (corresponding to the dots) in area 3 can decrease the steady state proba-
bilities of both Akt and MEK12, while those in area 1 can increase both probabilities.
The reactions in area 2 can decrease the steady state probability of Akt and increase
the one of MEK12; while reactions grouped in area 4 lead to the opposite effect. For
those dots lying on the horizontal line, the corresponding removed reactions have little
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impact on the steady state probability of MEK12. Similarly, the reactions on the vertical
line have little impact on Akt.
Comparing the two studies, the node knockout study is more relevant to biologi-
cal observations, which could be observed under the kinase inhibitor treatment scheme.
For instance, the ‘PI3K-KO’ model represents the cell system which has been treated
with PI3K inhibitors such as Wortmannin or LY294002 drugs [46]. Moreover, these
observations have biological implications as well. Akt and MEK12 are downstream
molecules in the signal transduction process that regulate different cellular functions.
The signal from Akt keeps the cells to survive from apoptosis and the signal from
MEK12 regulates the cells’ growth and proliferation. In cancer, both of these two main
pathways (see Fig. 1) are more active so they drive the cells to keep growing and divid-
ing in an uncontrolled manner. Therefore, if we could find the targets to control these
two signaling molecules to be at a desirable level, it would be beneficial for cancer
therapeutic development.
6 Comparing Stochastic Verification and ODE Simulation
In general, stochastic verification and ODE simulation produce comparable results, e.g.,
see [18]. To compare these approaches for the PDGF signaling pathway, we have con-
ducted some ODE simulations as well, where the normalized initial concentrations of
the molecules are set either to 0 or 1. Moreover, we have only one instance of each
molecule in the PRISM model. Thus, we would expect that the steady state probabil-
ities obtained from PRISM stochastic verification are comparable to the steady state
values (concentrations) obtained from ODE simulation.
Two particular results are shown in Fig. 13(a) and Fig. 13(b), which correspond to
Fig. 8(a) and Fig. 8(c). We can see that the dynamic behavior of the two molecules,
PDGFR and Ras, are similar between the two methods. However, considerable quanti-
tative differences have been observed between the two methods in the node knockout
study as shown in Tab. 2. For instance, the difference of the steady state probabili-
ties/values for Akt is roughly 0.18 in the PDGFR-KO and PI3K-KO scenarios.
Model Akt (PRISM) Akt (ODE) MEK12 (PRISM) MEK12 (ODE)
WildType 0.8217 0.8993 0.7660 0.8849
PDGFR-KO 0.3979 0.5748 0 0
PPX-KO 0.8217 0.8993 0.7660 0.8849
MEK12-KO 0.8245 0.8993 0 0
PI3K-KO 0.3979 0.5748 0.6918 0.8724
Table 2. Steady state probabilities (PRISM verification) and steady state values (ODE simula-
tions) of Akt and MEK12
In order to better understand the source of these differences, we investigated the
possible role of different model structures, parameter values, and pathway length. The
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(a) PDGFR (b) Ras
Fig. 13. ODE simulation results: Concentrations of molecules over time
prototypical model structures that we analyzed comprise a negative feedback loop as
shown in Fig. 14(b) and Fig. 15(b), a positive feedback loop as shown in Fig. 14(c),
and a linear chain (cascade) of molecules as shown in Fig. 15(a) and Fig. 15(b). Each
molecule, except from the input node ‘A’, has two states active and inactive, to resemble
the PDGF model. The impact of different parameter values was investigated by varying
parameter ‘k’ in Fig. 14(c).
According to Fig. 14(d) and Fig. 15(c), we find that model structures with positive
or negative feedbacks only have a minor contribution to the differences between the
steady state probabilities from PRISM verification and steady state values from ODE
simulation. Moreover, long-chain negative feedback loops which are generally present
in biological systems, e.g., as shown in Fig. 15(b), do not cause such high differences
either. On the other hand, when we consider the model with a positive feedback loop in
Fig. 14(c), the differences between the two methods highly increase once the parameter
values for the input node vary (see Fig. 14(e)). We observe that the decrease of param-
eter k in the model in Fig. 14(c) is correlated to the increase of the differences between
the two methods. The steady state probabilities (PRISM verification) and steady state
values (ODE simulation) for nodes B1 and B2 of the model in Fig. 14(c) with differ-
ent k values are presented in Fig. 14(f) and Fig. 14(g). We can observe that the steady
state probabilities from PRISM verification change drastically with different k values
for both nodes, while the steady state values from ODE simulation do not change that
much. This is essentially due to the different ways to compute steady state probabilities
for CTMCs [47, 29] and to compute steady state values for ODE [48].
Thus, we see that in our setting the difference between the two methods mainly
depends on parameter values and to some extent also on the model structure which
correlates to the findings in the PDGF model. Here, we observed large differences e.g.
for Akt in the PDGFR-KO conditions in the node knockout study as shown in Tab. 2.
Under this condition Akt is activated only by PDK (from bPDK) and positive feedback
from MTOR with a low parameter value of 0.1. This leads to a larger difference between
the two methods, in contrast to the wild-type situation with larger parameter values.
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This was in addition verified by analyzing model structures and parameters equal to the
positive feedback loop in the PDGF model (which is not detailed in this paper).
In conclusion, we have demonstrated by examples the impact of specific parameter
values and model structure on the differences between ODE simulation and stochas-
tic verification. It has been stated that the reason for these differences might be that
the approach based on verification leads to more accurate results when the number of
molecules is small [49]. Nevertheless, the influence of different parameter values needs
to be addressed in future research.
7 Conclusion and Future Work
In this paper, we have given a detailed description of using the probabilistic model
checker PRISM to study the PDGF signaling pathway. Based on intensive literature re-
views, we have built a PDGF signal transduction model in ODE format consisting of 17
molecule species and we converted it for the analysis in the probabilistic model checker
PRISM. We have analyzed the dynamics of PDGF induced signaling, the influence of
crosstalk reactions in the signaling pathway and the importance of individual reactions
on downstream signaling molecules. Our experimental results show that stochastic ver-
ification can provide us with a good understanding of the PDGF signaling pathway,
especially the result discussed in the end of Sect. 5.3 potentially can give rise to better
behavior prediction of the pathway.1
Furthermore, we have also investigated the differences of the results of the two
analysis methods, ODE simulation and stochastic verification (PRISM) as discussed in
Sect. 6. We have demonstrated that the two methods can predict the results differently,
especially when parameter values are small. Such results will bring more insights to
determine which method is more suitable for the analysis of biological systems.
Nevertheless, as indicated at the end of Sect. 3, our model is not intended to be
fully accurate. The reaction rates, especially the crosstalk reaction rates, are based on
literature reviewing and are only relative values. Currently, experiments in a biological
laboratory are performed to get more precise values for these reaction rates. We hope
techniques like parametric verification for Markov chains (e.g., [50–52]) can help to
synthesize values which are consistent with the lab experimental results.
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